PMID-sentid Pub_year Sent_text compound_name comp_offset prot_official_name organism prot_offset 33317571-1 2020 As a widely recognized standard regimen, R-CHOP (rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone) is able to cure two-thirds patients with diffuse large B cell lymphoma (DLBCL), and the remaining patients suffer from refractory or relapsed disease due to resistance to R-CHOP and fare poorly. Prednisone 112-122 DNA damage inducible transcript 3 Homo sapiens 43-47 32791510-2 2021 METHODS: This study included postdocetaxel patients with mCRPC treated with abiraterone acetate combined with prednisone (AA + P) who had experienced prostate-specific antigen (PSA) progression. Prednisone 110-120 kallikrein related peptidase 3 Homo sapiens 150-175 33323828-1 2020 Although the first-line rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone regimen (R-CHOP) substantially improved outcomes for patients with diffuse large B-cell lymphoma (DLBCL), 40% of the patients suffered from relapsed/refractory disease and had poor survival outcomes. Prednisone 87-97 DNA damage inducible transcript 3 Homo sapiens 109-113 33384022-2 2020 Treatment in the front-line setting is most often cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) or CHOP-like regimens, which are effective in B cell lymphomas, but in TCL are associated with a high failure rate and frequent relapses. Prednisone 98-108 DNA damage inducible transcript 3 Homo sapiens 110-114 33230132-2 2020 The standard treatment is the CHOP chemotherapy protocols that include cyclophosphamide, doxorubicin, vincristine and prednisone, where the majority of dogs achieve complete/partial response; however, it is very important to predict non-responsive cases to improve treatment and to develop new targeted therapies. Prednisone 118-128 DNA damage inducible transcript 3 Homo sapiens 30-34 33343957-10 2020 He was immediately started on prednisone 30 mg BID for a diagnosis of e-cigarette or vaping product use-associated lung injury (EVALI) and started showing clinical improvement. Prednisone 30-40 BH3 interacting domain death agonist Homo sapiens 47-50 31248333-3 2020 We present a case of a 41-year-old woman with a stable living-related kidney transplant maintained on an immunosuppressive regimen of cyclosporine, mycophenolate mofetil, and prednisone, who was subsequently diagnosed with a metastatic lobular breast carcinoma and papillary thyroid cancer and started palbociclib, a time-dependent CYP3A inhibitor. Prednisone 175-185 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 332-337 33269174-3 2020 Recent studies have demonstrated a potential benefit with combination of dose-adjusted rituximab, etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin (DA-REPOCH) in comparison to standard combination chemotherapy with cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) in ABC DLBCL patients. Prednisone 109-119 DNA damage inducible transcript 3 Homo sapiens 296-300 33011537-3 2020 Compounds 7-10 and 12 showed inhibitory effects on NF-kappaB/AP-1 activation and compounds 7-9 were subsequently confirmed to suppress the secretion of both IL-1beta and TNF-alpha in LPS-stimulated THP-1 cells more significantly than the prednisone used as a positive control. Prednisone 238-248 interleukin 1 alpha Homo sapiens 157-165 33262946-16 2020 Lower FOXO1 expression was associated with prednisone and cyclophosphamide resistance. Prednisone 43-53 forkhead box O1 Mus musculus 6-11 33011537-3 2020 Compounds 7-10 and 12 showed inhibitory effects on NF-kappaB/AP-1 activation and compounds 7-9 were subsequently confirmed to suppress the secretion of both IL-1beta and TNF-alpha in LPS-stimulated THP-1 cells more significantly than the prednisone used as a positive control. Prednisone 238-248 tumor necrosis factor Homo sapiens 170-179 31957527-0 2020 Efficacy of leflunomide combined with prednisone for the treatment of PLA2R-associated primary membranous nephropathy. Prednisone 38-48 phospholipase A2 receptor 1 Homo sapiens 70-75 32713039-0 2020 Complete remission of refractory pemphigus vulgaris in a Chinese patient with mutated NUDT15 by combination of minimal doses of azathioprine and prednisone. Prednisone 145-155 nudix hydrolase 15 Homo sapiens 86-92 31957527-1 2020 Objective: To evaluate the clinical efficacy and safety of leflunomide (LEF) combined with prednisone for the treatment of PLA2R-associated primary membranous nephropathy (PMN) and changes in anti-PLA2R antibody titers after treatment.Methods: Sixty patients with nephrotic syndrome, biopsy-proven MN and anti-PLA2R antibody positivity were included in this study conducted from December 2017 to February 2019. Prednisone 91-101 phospholipase A2 receptor 1 Homo sapiens 123-128 33076829-7 2020 RESULTS: Dexamethasone suppressed the level of IL-5 and IL-13 mRNA within Th2 cells with ~ 10-fold higher potency than prednisolone (the active form of prednisone). Prednisone 152-162 interleukin 5 Homo sapiens 47-51 33193831-10 2020 During abiraterone plus prednisone treatment, 65% of patients had a >=50% prostate-specific antigen decline, and quality of life remained appreciably high. Prednisone 24-34 kallikrein related peptidase 3 Homo sapiens 74-99 32584596-6 2020 Airway TL1A was assessed in sputum from subjects with mild asthma and subjects with prednisone-dependent severe eosinophilic asthma.Measurements and Main Results: There was a significant increase in sputum DR3+ ILC2s 24 hours after allergen challenge, and DR3 expression on ILC2s was upregulated by IL-2, IL-33, or TSLP in vitro. Prednisone 84-94 tumor necrosis factor receptor superfamily, member 25 Mus musculus 206-209 31801390-6 2020 Most anti-HMGCR Ab-positive NM patients had high titres of anti-HMGCR (83%) and a history of statin exposure (78%), along with severe muscle weakness, high creatine kinase (CK) levels (90% >= 5000 IU/L), a paucity of other organ manifestations, and the need for immunosuppression with prednisone and methotrexate, but generally favourable outcomes. Prednisone 285-295 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 10-15 32584596-6 2020 Airway TL1A was assessed in sputum from subjects with mild asthma and subjects with prednisone-dependent severe eosinophilic asthma.Measurements and Main Results: There was a significant increase in sputum DR3+ ILC2s 24 hours after allergen challenge, and DR3 expression on ILC2s was upregulated by IL-2, IL-33, or TSLP in vitro. Prednisone 84-94 tumor necrosis factor (ligand) superfamily, member 15 Mus musculus 7-11 32730183-1 2020 PURPOSE: Immunochemotherapy with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) has become standard of care for patients with diffuse large B-cell lymphoma (DLBCL). Prednisone 96-106 DNA damage inducible transcript 3 Homo sapiens 110-114 33050327-6 2020 DHEA-S was significantly lower before the 12th IVMP pulse and after oral prednisone (p = 0.015 and p = 0.00002, respectively) in comparison to evaluation before therapy. Prednisone 73-83 sulfotransferase family 2A member 1 Homo sapiens 0-6 33050327-7 2020 DHEA-S levels were below the reference range in one and three patients before the 12th IVMP pulse and after prednisone therapy, respectively. Prednisone 108-118 sulfotransferase family 2A member 1 Homo sapiens 0-6 33091357-1 2020 The integration of rituximab (R) into cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) by Coiffier and colleagues was the first, and last, successful modification of this backbone regimen, which has endured now for almost 20 years. Prednisone 86-96 DNA damage inducible transcript 3 Homo sapiens 98-102 32042095-3 2020 In current study, we aimed to explore the association between gene networks and overall survival (OS) of DLBCL patients treated with CHOP-based chemotherapy (cyclophosphamide combination with doxorubicin, vincristine and prednisone). Prednisone 221-231 DNA damage inducible transcript 3 Homo sapiens 133-137 32998908-7 2020 Our case provides evidence for early and aggressive treatment of MDA-5 dermatomyositis with a combination of weight-based prednisone, MMF and IVIg. Prednisone 122-132 interferon induced with helicase C domain 1 Homo sapiens 65-70 32658627-2 2020 The preferred treatment is abbreviated rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) and radiation therapy. Prednisone 98-108 DNA damage inducible transcript 3 Homo sapiens 112-116 32766857-1 2020 Rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) is the standard treatment of diffuse large B-cell lymphoma (DLBCL). Prednisone 59-69 DNA damage inducible transcript 3 Homo sapiens 73-77 32847118-6 2020 Biopsy revealed primary cutaneous PTCL-NOS, treated successfully with cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) plus etoposide combination chemotherapy. Prednisone 118-128 DNA damage inducible transcript 3 Homo sapiens 130-134 32785240-7 2020 In addition, the treatments with PBMT (p = 0.0005), PBMT plus prednisone (p = 0.0048) and PBMT plus NSAID (p = 0.0021) increased dystrophin gene expression compared to placebo-control group. Prednisone 62-72 dystrophin, muscular dystrophy Mus musculus 129-139 32246174-0 2020 The glucocorticoids prednisone and dexamethasone differentially modulate T cell function in response to anti-PD-1 and anti-CTLA-4 immune checkpoint blockade. Prednisone 20-30 cytotoxic T-lymphocyte associated protein 4 Homo sapiens 123-129 31142476-0 2020 Analysis of IL-6 measurement in patients with GCA treated with tocilizumab should consider concomitant treatment with prednisone. Prednisone 118-128 interleukin 6 Homo sapiens 12-16 32246174-8 2020 In addition, co-treatment of PD-1 + Jurkat cells with prednisone and/or dexamethasone with anti-PD-1 before stimulation significantly reduced SHP-2 phosphorylation, indicative of increased T cell function. Prednisone 54-64 protein tyrosine phosphatase non-receptor type 11 Homo sapiens 142-147 32648457-1 2020 BACKGROUND: The CHOP regimen comprising cyclophosphamide, doxorubicin, vincristine, and prednisone is a basic chemotherapeutic regimen for diffuse large B cell lymphoma (DLBCL). Prednisone 88-98 DNA damage inducible transcript 3 Homo sapiens 16-20 32722779-2 2020 Conventional chemotherapies such cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) and hyperfractionated cyclophosphamide, vincristine, doxorubicin, dexamethasone alternating with high-dose cytarabine and methotrexate (CVAD) have been commonly used for the BPDCN treatment until a recent study showed promising outcomes in patients treated with SL-401 (Tagraxofusp). Prednisone 81-91 DNA damage inducible transcript 3 Homo sapiens 93-97 32744028-9 2020 The protein and mRNA levels of TRPC6, STIM1, and Orai1 were partially, but significantly suppressed by prednisone or WHF treatment. Prednisone 103-113 transient receptor potential cation channel, subfamily C, member 6 Rattus norvegicus 31-36 32744028-9 2020 The protein and mRNA levels of TRPC6, STIM1, and Orai1 were partially, but significantly suppressed by prednisone or WHF treatment. Prednisone 103-113 stromal interaction molecule 1 Rattus norvegicus 38-43 32744028-9 2020 The protein and mRNA levels of TRPC6, STIM1, and Orai1 were partially, but significantly suppressed by prednisone or WHF treatment. Prednisone 103-113 ORAI calcium release-activated calcium modulator 1 Rattus norvegicus 49-54 32802528-5 2020 Intravenously administered alemtuzumab, a monoclonal antibody against the CD52 antigen, successfully reduced leukemia cells in peripheral blood; however, intrathecal treatment with methotrexate, cytarabine, and prednisone had a limited effect on the CNS involvement. Prednisone 211-221 CD52 molecule Homo sapiens 74-78 32651429-2 2020 Canine diffuse large B cell lymphoma shows a relatively good response to treatment with multi-agent cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy; however, the 2-year survival rate is as low as 20%. Prednisone 148-158 DNA damage inducible transcript 3 Homo sapiens 160-164 32417940-2 2020 Progression or relapse of FL within 2 years (so-called POD24) after diagnosis is associated with a poor outcome for patients treated with R-CHOP (rituximab plus cyclophosphamide, doxorubicin, vincristine, prednisone) in clinical trials. Prednisone 205-215 DNA damage inducible transcript 3 Homo sapiens 140-144 32278674-0 2020 Comparative Efficacy of Bortezomib, Melphalan, and Prednisone (VMP) With or Without Daratumumab Versus VMP Alone in the Treatment of Newly Diagnosed Multiple Myeloma: Propensity Score Matching of ALCYONE and VISTA Phase III Studies. Prednisone 51-61 neurensin 1 Homo sapiens 63-66 32606309-4 2020 BCL2 expression of 332 patients (221 patients for the training set and 111 patients for the validation set) with newly diagnosed DLBCL who received R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone) were analyzed using the tumor-specific automated quantitative analysis (AQUA) scoring method based on multiplex immunofluorescence. Prednisone 215-225 BCL2 apoptosis regulator Homo sapiens 0-4 32606932-12 2020 Conclusion: ADT combined with 6 cycles of docetaxel + prednisone chemotherapy benefits patients diagnosed with high-burden mHSPC in terms of the OS, PFS of PSA and radiographic, and the ratio of PSA falling to 0.2 ng/mL. Prednisone 54-64 kallikrein related peptidase 3 Homo sapiens 156-159 32606932-12 2020 Conclusion: ADT combined with 6 cycles of docetaxel + prednisone chemotherapy benefits patients diagnosed with high-burden mHSPC in terms of the OS, PFS of PSA and radiographic, and the ratio of PSA falling to 0.2 ng/mL. Prednisone 54-64 kallikrein related peptidase 3 Homo sapiens 195-198 32505213-1 2020 BACKGROUND: Rituximab (R) plus cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) is the current standard therapy for diffuse large B cell lymphoma (DLBCL). Prednisone 79-89 DNA damage inducible transcript 3 Homo sapiens 91-95 32581567-0 2020 Association Between CYP17A1, CYB5A Polymorphisms and Efficacy of Abiraterone Acetate/Prednisone Treatment in Castration-Resistant Prostate Cancer Patients. Prednisone 85-95 cytochrome b5 type A Homo sapiens 29-34 32196814-9 2020 These recently characterized KMT2A fusions have been described exclusively in infant and pediatric leukemia cases where the incidence varies vary according to leukemia subtype, are considered high-risk, with a high incidence of central nervous system involvement, poor response to initial prednisone treatment, and poor event free survival. Prednisone 289-299 lysine methyltransferase 2A Homo sapiens 29-34 32612387-4 2020 Patients and Methods: The expressions of PD-L1 and miR-34a were examined by IHC and qRT-PCR in 109 patients who were diagnosed with GDLBCL and were treated with rituximab plus cyclophosphamide, doxorubicin, prednisone vincristine and prednisone chemotherapy (R-CHOP) from January 2010 to December 2018. Prednisone 207-217 CD274 molecule Homo sapiens 41-46 32612387-4 2020 Patients and Methods: The expressions of PD-L1 and miR-34a were examined by IHC and qRT-PCR in 109 patients who were diagnosed with GDLBCL and were treated with rituximab plus cyclophosphamide, doxorubicin, prednisone vincristine and prednisone chemotherapy (R-CHOP) from January 2010 to December 2018. Prednisone 234-244 CD274 molecule Homo sapiens 41-46 32278674-1 2020 INTRODUCTION: Bortezomib, melphalan, and prednisone (VMP) is the standard of care for transplant-ineligible newly diagnosed multiple myeloma. Prednisone 41-51 neurensin 1 Homo sapiens 53-56 32538049-8 2020 Moreover, the level of serum miR-145 in prednisone poor responders was significantly lower than that in prednisone good responders. Prednisone 40-50 microRNA 145 Homo sapiens 29-36 32538049-8 2020 Moreover, the level of serum miR-145 in prednisone poor responders was significantly lower than that in prednisone good responders. Prednisone 104-114 microRNA 145 Homo sapiens 29-36 31903560-0 2020 Prednisolone/prednisone as adrenocorticotropic hormone alternative for infantile spasms: a meta-analysis of randomized controlled trials. Prednisone 13-23 proopiomelanocortin Homo sapiens 27-54 32555697-3 2020 The purpose of this study is to retrospectively analyze PV and PF patient sera to better understand the relationship between anti-AChR and -TPO Abs to disease activity and DSG reactivity between patients treated with prednisone and steroid sparing agents (SSA; n = 22) or prednisone and rituximab (n = 21). Prednisone 217-227 thyroid peroxidase Homo sapiens 140-143 31806154-7 2020 All TNF-alpha inhibitor treated patients demonstrated meaningful benefit, as assessed by changes in advanced imaging, echocardiographic measures of cardiac function, and prednisone use. Prednisone 170-180 tumor necrosis factor Homo sapiens 4-13 32320120-11 2020 Prednisone dose predicted nocturnal DBP index and DBP load (r2 = .40, P = .024 and r2 = .178, P = .02). Prednisone 0-10 D-box binding PAR bZIP transcription factor Homo sapiens 36-39 32320120-11 2020 Prednisone dose predicted nocturnal DBP index and DBP load (r2 = .40, P = .024 and r2 = .178, P = .02). Prednisone 0-10 D-box binding PAR bZIP transcription factor Homo sapiens 50-53 32187361-11 2020 The identification of both good and poor risk subtypes in patients treated with R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone) clearly show the clinical value of the approach, confirming the need for a consensus classification. Prednisone 147-157 DNA damage inducible transcript 3 Homo sapiens 82-86 32369480-2 2020 This study aims to compare the impact on beta-cell function and insulin resistance of prednisone 40 mg between adults with newly diagnosed T2DM and healthy adults. Prednisone 86-96 insulin Homo sapiens 64-71 32250167-1 2020 While combination of rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP) cures most patients with diffuse large B-cell lymphoma (DLBCL), those with high-risk international prognostic index disease have inferior survival. Prednisone 79-89 DNA damage inducible transcript 3 Homo sapiens 93-97 32052895-10 2020 Comparing delta cycle threshold values after treatment among drugs, cyclosporine was significantly different than prednisone (IL-2 and IFN-gamma both P < .001), with cyclosporine more suppressive than prednisone. Prednisone 114-124 interleukin 2 Canis lupus familiaris 126-130 32052895-11 2020 CONCLUSIONS AND CLINICAL IMPORTANCE: Prednisone and cyclosporine both affected expression of IL-2 and IFN-gamma, suggesting that both have the ability to influence results when utilizing pharmacodynamic monitoring of cyclosporine treatment. Prednisone 37-47 interleukin 2 Canis lupus familiaris 93-97 32052895-9 2020 Similarly, least squares means before treatment for IL-2 (1.55 [1.07-2.02] DeltaCt) and IFN-gamma (2.62 [2.32-2.92] DeltaCt) values were significantly lower (both P < .001) than values after treatment (3.55 [3.06-4.00] and 5.22 [4.92-5.52] DeltaCt, respectively) with prednisone. Prednisone 268-278 interferon gamma Canis lupus familiaris 88-97 32052895-11 2020 CONCLUSIONS AND CLINICAL IMPORTANCE: Prednisone and cyclosporine both affected expression of IL-2 and IFN-gamma, suggesting that both have the ability to influence results when utilizing pharmacodynamic monitoring of cyclosporine treatment. Prednisone 37-47 interferon gamma Canis lupus familiaris 102-111 31786803-0 2020 Analysis of brain metabolites by gas chromatography-mass spectrometry reveals the risk-benefit concerns of prednisone in MRL/lpr lupus mice. Prednisone 107-117 Fas (TNF receptor superfamily member 6) Mus musculus 125-128 32112707-5 2020 In a small sample size, etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab (EPOCH-R) achieved better outcomes than a regimen of rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP). Prednisone 35-45 DNA damage inducible transcript 3 Homo sapiens 231-235 32346376-9 2020 Moreover, the short-term antibiotics or FMT before onset inhibited the therapeutic efficiency of prednisone on lupus from 9 to 13 weeks old of MRL/lpr mice. Prednisone 97-107 Fas (TNF receptor superfamily member 6) Mus musculus 147-150 32248659-5 2021 The primary endpoint, prednisone-free remission, was defined as the absence of relapse through week 52 and normalization of the ESR and CRP. Prednisone 22-32 C-reactive protein Homo sapiens 136-139 32295216-8 2020 In Vk*MYC mice, addition of iron dextran or ferric carboxymaltose to the bortezomib-melphalan-prednisone (VMP) regimen increased the therapeutic response and prolonged remission without causing evident toxicity. Prednisone 94-104 neurensin 1 Mus musculus 106-109 32045360-8 2020 Results: In CRPC patients, administration of AAP (1000 mg/day AA with prednisone and medical castration) lowered all four 11-oxygenated androgens to below the lower limits of quantitation (<0.1-0.3 nmol/L), equivalent to 64-94% reductions from baseline. Prednisone 70-80 serpin family F member 2 Homo sapiens 45-48 32416674-9 2020 The mRNA expression levels of ICAM-1 and VCAM-1 were significantly reduced in the prednisone group and RPR group compared with the model group (P <0.05 or P <0.01). Prednisone 82-92 intercellular adhesion molecule 1 Mus musculus 30-36 32210951-11 2020 Indeed, an effect of prednisone on miR-146a expression was demonstrated in vitro on peripheral blood cells. Prednisone 21-31 microRNA 146a Homo sapiens 35-43 31871140-8 2020 A significant CS sparing effect of IFN-K was observed from W28 onwards, with a 24% prednisone daily dose reduction at W36 in IFN-K compared with PBO (p=0.0097). Prednisone 83-93 interferon kappa Homo sapiens 35-40 31871140-8 2020 A significant CS sparing effect of IFN-K was observed from W28 onwards, with a 24% prednisone daily dose reduction at W36 in IFN-K compared with PBO (p=0.0097). Prednisone 83-93 interferon kappa Homo sapiens 125-130 31943234-8 2020 Decreased expression of the glucocorticoid receptor (NR3C1alpha) may play a role in conferring resistance to prednisone in dogs with lymphoma. Prednisone 109-119 nuclear receptor subfamily 3 group C member 1 Canis lupus familiaris 28-51 31902733-4 2020 Our findings demonstrate good outcomes following induction treatment with R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone), suggesting that these cases can be treated as DLBCL rather than primary central nervous system lymphoma, obviating the need for more aggressive and toxic approaches. Prednisone 141-151 DNA damage inducible transcript 3 Homo sapiens 76-80 31624373-3 2020 Multivariate analysis demonstrated that CD9 positivity independently predicted inferior survival outcomes, and could be applied with established prognostic features, including prednisone response and cytogenetic status, to refine patient stratification. Prednisone 176-186 CD9 molecule Homo sapiens 40-43 31557340-0 2020 Rapid Discontinuation of Prednisone in Kidney Transplant Recipients from At-Risk Subgroups: An OPTN/SRTR Analysis. Prednisone 25-35 optineurin Homo sapiens 95-99 32010435-3 2020 Here, we investigated the combination of the WEE1 inhibitor, AZD1775, with cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) and radiation therapy (RT), with the aim of improving first-line treatment. Prednisone 122-132 WEE1 G2 checkpoint kinase Sus scrofa 45-49 31940809-2 2020 Despite this, the standard therapeutic approach is still immunochemotherapy (rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone-R-CHOP), which allows a 60% overall survival (OS) rate, but up to 40% of patients experience relapse or refractory (R/R) disease. Prednisone 140-150 DNA damage inducible transcript 3 Homo sapiens 153-157 32416674-9 2020 The mRNA expression levels of ICAM-1 and VCAM-1 were significantly reduced in the prednisone group and RPR group compared with the model group (P <0.05 or P <0.01). Prednisone 82-92 vascular cell adhesion molecule 1 Mus musculus 41-47 32416674-10 2020 Meanwhile, the immunohistochemistry expressions of ICAM-1 and VCAM-1 expressed in the kidney were significantly reduced in the prednisone group and RPR group (P <0.01 or P <0.05). Prednisone 127-137 intercellular adhesion molecule 1 Mus musculus 51-57 32416674-10 2020 Meanwhile, the immunohistochemistry expressions of ICAM-1 and VCAM-1 expressed in the kidney were significantly reduced in the prednisone group and RPR group (P <0.01 or P <0.05). Prednisone 127-137 vascular cell adhesion molecule 1 Mus musculus 62-68 32416674-11 2020 However, The mRNA expression level and the immunohistochemistry expressions of PECAM-1 expressed in the kidney were reduced in each treatment group (prednisone group and RPR group), but these differences were not significant (P >0.05). Prednisone 149-159 platelet/endothelial cell adhesion molecule 1 Mus musculus 79-86 31887117-13 2019 The expressions of occludin and E-cadherin were increased but zonulin decreased (P < 0.05 for each) in IBD dogs following prednisone therapy. Prednisone 125-135 occludin Canis lupus familiaris 19-27 31887117-13 2019 The expressions of occludin and E-cadherin were increased but zonulin decreased (P < 0.05 for each) in IBD dogs following prednisone therapy. Prednisone 125-135 cadherin 1 Canis lupus familiaris 32-42 31852157-11 2019 INTERVENTIONS: The current first-line treatment for diffuse large B-cell lymphoma is the cyclophosphamide, adriamycin, vincristine, prednisone (CHOP) protocol. Prednisone 132-142 DNA damage inducible transcript 3 Homo sapiens 144-148 31868632-1 2019 BACKGROUND: Six cycles of R-CHOP (rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone) are the standard treatment for aggressive B-cell non-Hodgkin lymphoma. Prednisone 97-107 DNA damage inducible transcript 3 Homo sapiens 28-32 31818069-10 2019 Case 2 was treated with 4 cycles of rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP) therapy after surgery and attained partial remission, and was then treated with apatinib and ibrutinib, and remained stable 18 months after initial diagnosis. Prednisone 94-104 DNA damage inducible transcript 3 Homo sapiens 108-112 31852847-4 2019 We reasoned that intermittent prednisone administration in dystrophic mice would alter muscle epigenomic signatures, and we identified the coordinated action of the glucocorticoid receptor, KLF15 and MEF2C as mediators of a gene expression program driving metabolic reprogramming and enhanced nutrient utilization. Prednisone 30-40 Kruppel-like factor 15 Mus musculus 190-195 31852847-4 2019 We reasoned that intermittent prednisone administration in dystrophic mice would alter muscle epigenomic signatures, and we identified the coordinated action of the glucocorticoid receptor, KLF15 and MEF2C as mediators of a gene expression program driving metabolic reprogramming and enhanced nutrient utilization. Prednisone 30-40 myocyte enhancer factor 2C Mus musculus 200-205 31777548-0 2019 Effects of cyclophosphamide combined with prednisone on TNF-alpha expression in treatment of patients with interstitial lung disease. Prednisone 42-52 tumor necrosis factor Homo sapiens 56-65 31777548-1 2019 Effects of cyclophosphamide combined with prednisone on TNF-alpha expression in the treatment of patients with interstitial lung disease (ILD), and its clinical significance were investigated. Prednisone 42-52 tumor necrosis factor Homo sapiens 56-65 31777548-10 2019 In conclusion, cyclophosphamide combined with prednisone is effective and safe in the treatment of ILD without severe adverse reactions, reducing TNF-alpha expression level, and therefore is worthy of clinical application. Prednisone 46-56 tumor necrosis factor Homo sapiens 146-155 31655496-0 2019 Development and validation of a method to confirm the exogenous origin of prednisone and prednisolone by GC-C-IRMS. Prednisone 74-84 guanylate cyclase 2C Homo sapiens 105-109 31535408-0 2019 Role of glucocorticoid signaling in urothelial tumorigenesis: Inhibition by prednisone presumably through inducing glucocorticoid receptor transrepression. Prednisone 76-86 nuclear receptor subfamily 3 group C member 1 Homo sapiens 115-138 31535408-5 2019 Using the in vitro system with MCA-SVHUC cells, we screened 11 GR ligands, including DEX, and found significant inhibitory effects of PRED on their neoplastic transformation. Prednisone 134-138 nuclear receptor subfamily 3 group C member 1 Homo sapiens 63-65 31535408-6 2019 The effects of PRED were restored by a GR antagonist RU486 in GR-positive MCA-SVHUC cells, while PRED failed to inhibit the neoplastic transformation of GR knockdown cells. Prednisone 15-19 nuclear receptor subfamily 3 group C member 1 Homo sapiens 39-41 31535408-6 2019 The effects of PRED were restored by a GR antagonist RU486 in GR-positive MCA-SVHUC cells, while PRED failed to inhibit the neoplastic transformation of GR knockdown cells. Prednisone 15-19 nuclear receptor subfamily 3 group C member 1 Homo sapiens 62-64 31535408-6 2019 The effects of PRED were restored by a GR antagonist RU486 in GR-positive MCA-SVHUC cells, while PRED failed to inhibit the neoplastic transformation of GR knockdown cells. Prednisone 15-19 nuclear receptor subfamily 3 group C member 1 Homo sapiens 62-64 31535408-7 2019 Significant decreases in the expression levels of oncogenes (c-Fos/c-Jun) and significant increases in those of a tumor suppressor UGT1A were seen in MCA-SVHUC-control cells (vs GR-short hairpin RNA) or PRED-treated MCA-SVHUC-control cells (vs mock). Prednisone 203-207 UDP glucuronosyltransferase family 1 member A complex locus Homo sapiens 131-136 31535408-10 2019 These findings suggest that PRED could prevent urothelial tumorigenesis presumably via inducing GR transrepression. Prednisone 28-32 nuclear receptor subfamily 3, group C, member 1 Mus musculus 96-98 31601523-1 2021 BACKGROUND: Cross resistance between androgen-receptor targeting therapies (ARTs) (abiraterone acetate plus prednisone [ABI+P] or enzalutamide [ENZ]) for treatment of metastatic castration-resistant prostate cancer (mCRPC) may affect responses to second ART (ART2). Prednisone 108-118 androgen receptor Homo sapiens 37-54 31314918-1 2019 OBJECTIVES: R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone) is the standard therapy for patients with previously untreated diffuse large B-cell lymphomas (DLBCL). Prednisone 75-85 DNA damage inducible transcript 3 Homo sapiens 14-18 31251343-1 2019 We compared treatment outcomes between rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) chemotherapy alone with R-CHOP followed by consolidative radiation therapy (RT) in diffuse large B-cell lymphoma (DLBCL). Prednisone 98-108 DNA damage inducible transcript 3 Homo sapiens 112-116 31554355-12 2019 Dexamethasone, in combinationwith L-asparaginase, despite having no difference in causing hyperglycemia, has an increased risk of changing BGLcompared to prednisone. Prednisone 154-164 asparaginase and isoaspartyl peptidase 1 Homo sapiens 34-48 31531960-0 2019 Circulating interleukin-6 as a biomarker in a randomized controlled trial of modified-release prednisone vs immediate-release prednisolone, in newly diagnosed patients with giant cell arteritis. Prednisone 94-104 interleukin 6 Homo sapiens 12-25 31531960-8 2019 CONCLUSION: Our study suggests that elevated levels of IL-6 in new GCA are better suppressed by MR prednisone compared with IR prednisolone. Prednisone 99-109 interleukin 6 Homo sapiens 55-59 31452347-8 2019 After eight cycles of rituximab-cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) chemotherapy, the lymphoma was cured clinically, and his interstitial lung disease (ILD) had improved. Prednisone 80-90 DNA damage inducible transcript 3 Homo sapiens 94-98 31129156-11 2019 These findings suggested that SAA exerted podocyte-protection against MCD injury through PPARgamma/Angptl4 and Nrf2/HO-1 pathways, and combined with low-dose prednisone possessed a significant anti-proteinuria and therapeutic effects in MCD rats. Prednisone 158-168 angiopoietin-like 4 Rattus norvegicus 99-106 31129156-11 2019 These findings suggested that SAA exerted podocyte-protection against MCD injury through PPARgamma/Angptl4 and Nrf2/HO-1 pathways, and combined with low-dose prednisone possessed a significant anti-proteinuria and therapeutic effects in MCD rats. Prednisone 158-168 NFE2 like bZIP transcription factor 2 Rattus norvegicus 111-115 31129156-11 2019 These findings suggested that SAA exerted podocyte-protection against MCD injury through PPARgamma/Angptl4 and Nrf2/HO-1 pathways, and combined with low-dose prednisone possessed a significant anti-proteinuria and therapeutic effects in MCD rats. Prednisone 158-168 heme oxygenase 1 Rattus norvegicus 116-120 31310030-3 2019 Using SRTR data, we studied outcomes associated with prednisone-free maintenance immunosuppression (rapid discontinuation of prednisone-RDP). Prednisone 53-63 negative elongation factor complex member E Homo sapiens 136-139 31651849-4 2019 The influence of mycophenolic acid (MPA) derivatives and prednisone on p70S6 kinase phosphorylation in CD4-positive cells was examined in liver transplant patients and healthy controls (HCs). Prednisone 57-67 CD4 molecule Homo sapiens 103-106 31453850-5 2019 We report a case of a statin-naive paraneoplastic anti-HMGCR myopathy, who unlike other reported cases, responded to a single dose of 1000 mg of intravenous rituximab and subsequent chemoradiation therapy for an underlying lung cancer, despite failing to completely respond to prior high-dose oral prednisone and methotrexate. Prednisone 298-308 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 55-60 31107754-5 2019 The lesions were decreased in both size and metabolism on follow-up PET/CT 2 months after treatment with prednisone. Prednisone 105-115 solute carrier family 6 member 10, pseudogene Homo sapiens 72-76 31462891-14 2019 Early intervention strategies by rational combination of Bcl-2 blockage may constitute a promising new treatment option to GC-resistant ALL and significantly improving the chances of treating poor prednisone responders. Prednisone 197-207 BCL2 apoptosis regulator Homo sapiens 57-62 31813863-7 2019 In summary, rats treated with methotrexate + prednisone can achieve high level of Tregs and low level of Th17 cells and IL-17. Prednisone 45-55 interleukin 17A Rattus norvegicus 120-125 31335477-15 2019 Prolonged survival is obtainable with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP)-like in elderly Chinese patients in all age groups, indicating that the R-CHOP-like regimen should be considered for this population, even for those aged 70 years or older. Prednisone 97-107 DNA damage inducible transcript 3 Homo sapiens 111-115 31335477-15 2019 Prolonged survival is obtainable with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP)-like in elderly Chinese patients in all age groups, indicating that the R-CHOP-like regimen should be considered for this population, even for those aged 70 years or older. Prednisone 97-107 DNA damage inducible transcript 3 Homo sapiens 191-195 30689468-1 2019 Combination of rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP) is regarded as standard care for diffuse large B-cell lymphoma (DLBCL) and upfront intensification of therapy is still controversial. Prednisone 73-83 DNA damage inducible transcript 3 Homo sapiens 87-91 31206316-4 2019 RESULTS: Of 650 patients, the 93 patients (14.3%) who received >= 10 mg of prednisone at the time of immunotherapy initiation had shorter median progression-free survival (mPFS) and median overall survival (mOS) times than patients who received 0 to < 10 mg of prednisone (mPFS, 2.0 v 3.4 months, respectively; P = .01; mOS, 4.9 v 11.2 months, respectively; P < .001). Prednisone 75-85 Moloney sarcoma oncogene Mus musculus 207-210 31206316-4 2019 RESULTS: Of 650 patients, the 93 patients (14.3%) who received >= 10 mg of prednisone at the time of immunotherapy initiation had shorter median progression-free survival (mPFS) and median overall survival (mOS) times than patients who received 0 to < 10 mg of prednisone (mPFS, 2.0 v 3.4 months, respectively; P = .01; mOS, 4.9 v 11.2 months, respectively; P < .001). Prednisone 75-85 Moloney sarcoma oncogene Mus musculus 320-323 31575843-8 2019 Prednisone use was associated with lower ET-1 levels. Prednisone 0-10 endothelin 1 Homo sapiens 41-45 31543772-3 2019 We present a case of newly diagnosed Graves" thyrotoxicosis following a successful R-CHOP (Rituximab, Cyclophosphamide, Doxorubicine, Vincristine and Prednisone) treatment in a patient with concurrent abdominal and thyroid diffuse large B-cell lymphoma (DLBCL). Prednisone 150-160 DNA damage inducible transcript 3 Homo sapiens 85-89 31360632-1 2019 Patients of clinically amyopathic dermatomyositis associated with rapidly progressive interstitial pneumonia (CADM-RFIP) with positive anti-MDA5 antibody usually presents rapid deterioration and traditional therapy such as cyclophosphamide combined with high-dose prednisone pulse therapy shows no clear benefit at whiles. Prednisone 264-274 interferon induced with helicase C domain 1 Homo sapiens 140-144 31575843-11 2019 These increased levels of ET-1 are associated with inflammation and smoking and reduced by prednisone intake. Prednisone 91-101 endothelin 1 Homo sapiens 26-30 31280230-7 2019 Among 125 patients receiving CHOP (doxorubicin, cyclophosphamide, vincristine, prednisone)-like regimens, complete response and complete control were increased in patients receiving triple antiemetics, compared to those with double antiemetics. Prednisone 79-89 DNA damage inducible transcript 3 Homo sapiens 29-33 31002839-5 2019 Both prednisone and bovine serum albumin were incorporated into the printed pill, but while most of the prednisone was released depending on the ratio between the two complementary pre-polymers, only 40% of the bovine serum albumin was released from the pill. Prednisone 104-114 albumin Homo sapiens 27-40 31305432-7 2019 INTERVENTION: The patient was treated with 6 courses of rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP). Prednisone 119-129 DNA damage inducible transcript 3 Homo sapiens 133-137 31516154-4 2019 He was managed by the oncologist with R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone) regimen which alleviated his symptoms considerably after completion of three cycles and was under follow-up. Prednisone 105-115 DNA damage inducible transcript 3 Homo sapiens 40-44 31165299-12 2019 The anti-IL-6 receptor tocilizumab was, therefore, administered with a rapid improvement of her active psoriatic arthritis that remained dependent on low prednisone dosage. Prednisone 154-164 interleukin 6 Homo sapiens 9-13 30996113-9 2019 The PAI-1 rs1799768 mutation had a protective effect on the SONFH risk prednisone-use and renal transplant populations. Prednisone 71-81 serpin family E member 1 Homo sapiens 4-9 30679323-9 2019 AF4-MLL expression retained its prognostic significance when analyzed in a Cox model adjusting for risk stratification according to the Interfant-06 protocol based on age at diagnosis, white blood cell count and response to prednisone. Prednisone 224-234 AF4/FMR2 family member 1 Homo sapiens 0-3 30679323-9 2019 AF4-MLL expression retained its prognostic significance when analyzed in a Cox model adjusting for risk stratification according to the Interfant-06 protocol based on age at diagnosis, white blood cell count and response to prednisone. Prednisone 224-234 lysine methyltransferase 2A Homo sapiens 4-7 31191526-7 2019 PTX3 concentration correlated with disease activity, acute phase reactants and prednisone dose. Prednisone 79-89 pentraxin 3 Homo sapiens 0-4 30996113-5 2019 There were significant correlations between the ABCB1 rs1045642 mutant and SONFH in the prednisone-use and methylprednisolone/prednisone-use populations. Prednisone 88-98 ATP binding cassette subfamily B member 1 Homo sapiens 48-53 30996113-5 2019 There were significant correlations between the ABCB1 rs1045642 mutant and SONFH in the prednisone-use and methylprednisolone/prednisone-use populations. Prednisone 126-136 ATP binding cassette subfamily B member 1 Homo sapiens 48-53 30996113-7 2019 For ApoB rs693, mutation increased the incidence of SONFH in prednisone-use and methylprednisolone/prednisolone-use populations and renal transplant patients. Prednisone 61-71 apolipoprotein B Homo sapiens 4-8 30996113-8 2019 For ApoB rs1042031, mutation increased the risk of SONFH in the prednisone-use population. Prednisone 64-74 apolipoprotein B Homo sapiens 4-8 30911862-5 2019 Treating MRL/lpr mice with prednisone (5 mg/kg) from the age of 8 weeks decreased anti-cardiolipin and anti-N-methyl-D-aspartate (NMDA) receptor antibody titres in the brain, reduced the weight of lymph nodes, and prolonged the floating latency in the forced swim test. Prednisone 27-37 Fas (TNF receptor superfamily member 6) Mus musculus 13-16 30850381-2 2019 Here, we report a phase 1b study investigating dose escalation of the BCL2 inhibitor, venetoclax, in combination with rituximab or obinutuzumab and cyclophosphamide, doxorubicin, vincristine, and prednisone (R-/G-CHOP) chemotherapy in B-cell NHL. Prednisone 196-206 BCL2 apoptosis regulator Homo sapiens 70-74 31124417-4 2019 Results: An association between the genotype tuberculoid of polymorphism ABCB1 3435C>T (rs1045642; p = 0.02) and prednisone dose was found in the recessive model. Prednisone 113-123 ATP binding cassette subfamily B member 1 Homo sapiens 73-78 30737835-2 2019 Since prednisone is known to induce the cytochrome P450 iso-enzyme CYP3A4, which is the main metabolizing enzyme of docetaxel in the liver, a potential drug-drug interaction may occur. Prednisone 6-16 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 67-73 31118928-0 2019 Alterations of the Gut Microbiota Associated With Promoting Efficacy of Prednisone by Bromofuranone in MRL/lpr Mice. Prednisone 72-82 Fas (TNF receptor superfamily member 6) Mus musculus 107-110 30663866-5 2019 After prednisone treatment, TNFalpha production was significantly reduced after stimulation with PMA/I or LPS compared to pre-treatment. Prednisone 6-16 tumor necrosis factor Canis lupus familiaris 28-36 30716510-5 2019 Five-weeks of prednisone treatment in Mdx mice decreased cortical bone thickness and area (p < 0.001), with a large increase in endocortical osteoclasts that were significantly improved by PTH treatment (p < 0.001). Prednisone 14-24 parathyroid hormone Mus musculus 192-195 30716510-8 2019 Prednisone improved grip strength and endurance of treadmill running, which were maintained and further improved, respectively, in co-treated Mdx mice. Prednisone 0-10 dystrophin, muscular dystrophy Mus musculus 142-145 30716510-5 2019 Five-weeks of prednisone treatment in Mdx mice decreased cortical bone thickness and area (p < 0.001), with a large increase in endocortical osteoclasts that were significantly improved by PTH treatment (p < 0.001). Prednisone 14-24 dystrophin, muscular dystrophy Mus musculus 38-41 31014429-6 2019 The prednisone good response group had significantly lower S100A8 protein and mRNA levels than the prednisone poor response group (P<0.01). Prednisone 4-14 S100 calcium binding protein A8 Homo sapiens 59-65 30302533-6 2019 Mdx mice treated with prednisone had improved muscle function that was not changed by pamidronate treatment. Prednisone 22-32 dystrophin, muscular dystrophy Mus musculus 0-3 30992670-1 2019 Objective: To compare cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) and CHOP plus etoposide (CHOPE) with regard to outcomes including efficacy and safety for patients with peripheral T-cell lymphoma (PTCL). Prednisone 70-80 DNA damage inducible transcript 3 Homo sapiens 82-86 30988678-5 2019 The aim of the present study was to compare the expression level of miR-146a in plasma-derived exosomes of responsive DLBCL patients (response to R-CHOP (Rituximab, and Cyclophosphamide, Hydroxydaunorubicin, Oncovine and Prednisone)), refractory DLBCL patients (resistant to R-CHOP), patients receiving R-CHOP, and healthy donors. Prednisone 221-231 microRNA 146a Homo sapiens 68-76 30302533-8 2019 Both 2 and 6 week pamidronate treatment increased cortical thickness and bone area compared to prednisone-treated Mdx mice, however, only 2 week pamidronate treatment improved the strength of cortical bone compared to that of glucocorticoid-treated Mdx mice. Prednisone 95-105 dystrophin, muscular dystrophy Mus musculus 114-117 30868028-3 2019 Usual chemotherapy regimen for DLBL is rituximab, cyclophosphamide, hydroxydaunorubicin, oncovin and prednisone (R-CHOP). Prednisone 101-111 DNA damage inducible transcript 3 Homo sapiens 115-119 32395171-4 2020 We present a patient who developed an acute inflammatory optic neuropathy shortly after a self-taper of oral prednisone while being treated with adalimumab for RA, and discuss the challenge of deciding whether or not to halt anti-TNF therapy. Prednisone 109-119 tumor necrosis factor Homo sapiens 230-233 30307363-5 2019 She was treated with cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) chemotherapy which was complicated by prolonged pancytopenia, without response. Prednisone 68-78 DNA damage inducible transcript 3 Homo sapiens 80-84 30551418-8 2019 At first, we found that lncRNA HOXA-AS2 was highly expressed both in prednisone insensitive ALL cell lines and patient samples. Prednisone 69-79 HOXA cluster antisense RNA 2 Homo sapiens 31-39 30417470-4 2019 Retrospective comparison between recurrent and cognate primary tissues showed that the number of TRA-1-60-positive cells from rituximab, cyclophosphamide, hydroxydaunorubicin, vincristine, and prednisone (R-CHOP)-treated FL had increased relative to primary tissue, a finding corroborated by assays on different rituximab-treated FL cell lines, FL-18 and DOHH2, wherein TRA-positive cell numbers increased over 10-fold compared to the untreated sample. Prednisone 193-203 phospholipid scramblase 4 Homo sapiens 97-102 30358904-7 2019 Post-treatment with prednisone and azathioprine, her serum calcium and magnesium normalized, as did her CaSR antibody titre and antibody-mediated stimulation of ERK1/2 phosphorylation and IP accumulation. Prednisone 20-30 mitogen-activated protein kinase 3 Homo sapiens 161-167 30606932-2 2019 While liposomal doxorubicin has been used as an effective treatment for KS patients, the cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) regimen used for PEL patients was reported to have 1-year survival rates of less than 40%. Prednisone 137-147 DNA damage inducible transcript 3 Homo sapiens 149-153 30451720-15 2019 In conjunction with other therapies (salicylates, mesalamine sulfasalazine and prednisone), G-CSF ameliorates inflammatory bowel symptoms, but doses must be limited because it increases spleen size associated with abdominal pain. Prednisone 79-89 colony stimulating factor 3 Homo sapiens 92-97 30593393-14 2019 Prednisone + tamoxifen combination achieved complete response in 1 case (RF-IgG4RD), partial response in 1 IRF; in 1 IRF case, disease remained stable and 1 did not respond. Prednisone 0-10 tripartite motif containing 63 Homo sapiens 107-110 30593393-14 2019 Prednisone + tamoxifen combination achieved complete response in 1 case (RF-IgG4RD), partial response in 1 IRF; in 1 IRF case, disease remained stable and 1 did not respond. Prednisone 0-10 tripartite motif containing 63 Homo sapiens 117-120 30588323-7 2018 Among patients receiving >7.5 mg/day corticosteroids at baseline, significantly more SRI responders had reductions in prednisone dose to <=7.5 mg/day than non-responders. Prednisone 122-132 sorcin Homo sapiens 89-92 30788202-10 2018 The patient was treated with six courses of CHOP-R (cyclophosphamide, doxorubicin, vincristine, prednisone, and rituximab). Prednisone 96-106 DNA damage inducible transcript 3 Homo sapiens 44-48 30501868-2 2018 Multiple retrospective studies of R-CHOP (rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone or prednisolone) have shown a worse outcome in patients with MYC rearrangement (alone or with rearrangement of BCL2 or BCL6, or both) than in patients without MYC rearrangement, and suggest improved outcomes after more intensive treatment. Prednisone 105-115 MYC proto-oncogene, bHLH transcription factor Homo sapiens 177-180 30217438-7 2018 Moreover, in comparison to the 6 months preceding the beginning of treatment with mepolizumab, after 24 weeks of anti-IL-5 therapy significant decreases were detected with regard to exacerbation numbers (from 3.64 +- 1.86 to 1.0 +- 0.78; p < 0.001) and oral intake of prednisone (from 24.11 +- 10.36 mg/day to 1.78 +- 3.82 mg/day). Prednisone 271-281 interleukin 5 Homo sapiens 118-122 30101910-1 2018 Objective Although R-CHOP (rituximab, cyclophosphamide, vincristine, doxorubicin, and prednisone) is a standard therapy for diffuse large B-cell lymphoma (DLBCL), the optimal dose for elderly patients remains unclear. Prednisone 86-96 DNA damage inducible transcript 3 Homo sapiens 21-25 30509237-6 2018 The AA + prednisone group had significantly longer median PSA PFS (10.3 vs 3.0 months, P < 0.001), rPFS (13.9 vs 3.9 months, P < 0.001), and OS (23.3 vs 17.5 months, P = 0.016) than the prednisone-alone group. Prednisone 9-19 kallikrein related peptidase 3 Homo sapiens 58-61 30472108-3 2018 Even though the combination of rituximab, cyclophosphamide, doxorubicine, vincristine and prednisone (R-CHOP) is considered standard therapy for DLBCL, management of elderly patients remains challenging. Prednisone 90-100 DNA damage inducible transcript 3 Homo sapiens 104-108 30420888-1 2018 Objectives: To assess the correlation between prednisone and methotrexate (MTX) treatment duration and dosage with the TST induration diameter of the TST reaction among rheumatoid arthritis (RA) patients. Prednisone 46-56 thiosulfate sulfurtransferase Homo sapiens 119-122 30124473-7 2018 Prednisone initiated alongside ART in selected patients with CD4 less than 100 cells/mul reduced the risk of paradoxical TB-IRIS by 30% in a recent randomized-controlled trial (RCT) and was not associated with significant adverse effects. Prednisone 0-10 CD4 molecule Homo sapiens 61-64 30536331-2 2018 MATERIALS AND METHODS: Based on the established inclusion and exclusion criteria, studies of prednisone induced test in evaluating the prognosis of childhood acute lymphoblastic leukemia were electronically searched from January 1990 to November 2016 using Pubmed, Embase, The Cochrane Library, Web of Science, WanFang, VIP, and CNKI database. Prednisone 93-103 vasoactive intestinal peptide Homo sapiens 320-323 30536331-6 2018 RESULTS: Meta-analysis showed that after complete prednisone induced test in children, 5y-EFS, 8y-EFS adverse reactions, persistent remission and relapse were statistically significant differences between the prednisone good response (PGR) and prednisone poor response (PPR). Prednisone 209-219 PPR1 Homo sapiens 270-273 30536331-6 2018 RESULTS: Meta-analysis showed that after complete prednisone induced test in children, 5y-EFS, 8y-EFS adverse reactions, persistent remission and relapse were statistically significant differences between the prednisone good response (PGR) and prednisone poor response (PPR). Prednisone 209-219 PPR1 Homo sapiens 270-273 27990763-9 2018 Plasma FAP was lower in RA patients receiving prednisone (P = 0.001) or leflunomide (P = 0.04), but higher with biologic agents (P = 0.01). Prednisone 46-56 fibroblast activation protein alpha Homo sapiens 7-10 30420888-1 2018 Objectives: To assess the correlation between prednisone and methotrexate (MTX) treatment duration and dosage with the TST induration diameter of the TST reaction among rheumatoid arthritis (RA) patients. Prednisone 46-56 thiosulfate sulfurtransferase Homo sapiens 150-153 30420888-5 2018 We compared TST reaction size between the following three groups: RA patients with current prednisone treatment, RA prednisone naive patients, and healthy individuals. Prednisone 91-101 thiosulfate sulfurtransferase Homo sapiens 12-15 30420888-5 2018 We compared TST reaction size between the following three groups: RA patients with current prednisone treatment, RA prednisone naive patients, and healthy individuals. Prednisone 116-126 thiosulfate sulfurtransferase Homo sapiens 12-15 30131546-13 2018 CONCLUSIONS: In selected clinical stable mCRPC patients with limited disease progression on AA + P, a steroid switch from prednisone to dexamethasone can lead to PSA and radiological responses. Prednisone 122-132 kallikrein related peptidase 3 Homo sapiens 162-165 29966970-1 2018 BACKGROUND: Aberrant microRNA (miRNAs) have recently been proposed as important regulators in acquiring resistance to cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) in diffuse large B-cell lymphoma (DLBCL). Prednisone 166-176 DNA-damage inducible transcript 3 Mus musculus 178-182 30344307-2 2018 The phase II SWITCH trial showed that further prostate-specific antigen (PSA) responses can be obtained in a subset of patients when prednisone was switched to dexamethasone at progression. Prednisone 133-143 kallikrein related peptidase 3 Homo sapiens 46-77 30340554-1 2018 BACKGROUND: Rituximab plus combination chemotherapy with cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) is broadly accepted as standard for the treatment of diffuse large B-cell lymphoma (DLBCL). Prednisone 105-115 DNA damage inducible transcript 3 Homo sapiens 119-123 30048718-3 2018 The model is shown to recapitulate prostate-specific antigen measurement data from three clinical trials for metastatic castration-resistant prostate cancer patients treated with 1) prednisone, 2) mitoxantrone and prednisone and 3) docetaxel and prednisone. Prednisone 182-192 kallikrein related peptidase 3 Homo sapiens 35-60 30048718-3 2018 The model is shown to recapitulate prostate-specific antigen measurement data from three clinical trials for metastatic castration-resistant prostate cancer patients treated with 1) prednisone, 2) mitoxantrone and prednisone and 3) docetaxel and prednisone. Prednisone 214-224 kallikrein related peptidase 3 Homo sapiens 35-60 30048718-3 2018 The model is shown to recapitulate prostate-specific antigen measurement data from three clinical trials for metastatic castration-resistant prostate cancer patients treated with 1) prednisone, 2) mitoxantrone and prednisone and 3) docetaxel and prednisone. Prednisone 214-224 kallikrein related peptidase 3 Homo sapiens 35-60 29688882-5 2018 RESULTS: Both androgen receptor-axis-targeted therapies (ARATs), abiraterone acetate plus prednisone and enzalutamide, are funded by provinces in the pre-and post-chemotherapy setting, however, sequential ARAT use is not funded. Prednisone 90-100 androgen receptor Homo sapiens 14-31 30125216-12 2018 CONCLUSION: Baseline corticosteroid use of >= 10 mg of prednisone equivalent was associated with poorer outcome in patients with non-small-cell lung cancer who were treated with PD-(L)1 blockade. Prednisone 58-68 CD274 molecule Homo sapiens 181-188 30190020-4 2018 Rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) is a highly effective but potentially neurotoxic regimen. Prednisone 59-69 DNA damage inducible transcript 3 Homo sapiens 73-77 30076934-5 2018 Locally administered SAA-BTL was found to significantly improve fracture callus formation and micro-architecture with accelerated mineralization rate in callus when compared to the dose equivalent SAA, non-targeting SAA liposome (SAA-NTL) or no treatment on a prednisone-induced delayed fracture union mouse model. Prednisone 260-270 serum amyloid A cluster Mus musculus 21-24 30252855-14 2018 Median prednisone intake of the CAT-only group was 141.33 mg/month. Prednisone 7-17 catalase Homo sapiens 32-40 30295242-6 2018 The significant differences were found between CD45- and CD45+ in WBC counts when being firstly diagnosed (Z=6.845, P<0.01), risk stratification (chi2=8.260, P<0.05) and prednisone poor responder (chi2=18.420, P<0.01). Prednisone 176-186 protein tyrosine phosphatase receptor type C Homo sapiens 47-51 30313105-6 2018 The patient was treated with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP).Neurological symptoms improved with R-CHOP. Prednisone 88-98 DNA damage inducible transcript 3 Homo sapiens 102-106 30313105-6 2018 The patient was treated with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP).Neurological symptoms improved with R-CHOP. Prednisone 88-98 DNA damage inducible transcript 3 Homo sapiens 146-150 30252855-21 2018 Rituximab significantly reduces the monthly prednisone requirement among CAT-resistant pemphigus vulgaris patients to levels on par with CAT-responsive patients. Prednisone 44-54 catalase Homo sapiens 73-76 30338042-0 2018 Lenalidomide combined with low-dose cyclophosphamide and prednisone modulates Ikaros and Aiolos in lymphocytes, resulting in immunostimulatory effects in lenalidomide-refractory multiple myeloma patients. Prednisone 57-67 IKAROS family zinc finger 3 Homo sapiens 89-95 29674443-3 2018 Treatment in the front-line setting is most often cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) or CHOP-like regimens, which are associated with a high failure rate and frequent relapses. Prednisone 98-108 DNA damage inducible transcript 3 Homo sapiens 110-114 30235659-10 2018 When the first-line therapy of cyclophosphamide combined with prednisone is not enough to eradicate the inhibitor, especially for a higher inhibitor titer, anti-CD20 monoclonal antibody could play an important role. Prednisone 62-72 keratin 20 Homo sapiens 161-165 31949844-0 2018 Expression of hypoxia-inducible factor-1a predicts benefit from rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone in diffuse large B-cell lymphoma. Prednisone 127-137 hypoxia inducible factor 1 subunit alpha Homo sapiens 14-41 31949844-2 2018 However, HIF-1alpha was suggested to predict improved survival in Western patients with diffuse large B-cell lymphoma (DLBCL) under rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) treatment. Prednisone 195-205 hypoxia inducible factor 1 subunit alpha Homo sapiens 9-19 30172345-1 2018 BACKGROUND: Immunochemotherapy with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) is a standard front-line treatment for follicular lymphoma. Prednisone 95-105 DNA damage inducible transcript 3 Homo sapiens 109-113 29674443-14 2018 Anthracycline-containing regimens, mostly cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP), are considered the standard of care, although the best first-line approach remains to be defined. Prednisone 90-100 DNA damage inducible transcript 3 Homo sapiens 102-106 29380942-2 2018 Lomustine, vincristine, procarbazine, and prednisone (LOPP) has been evaluated as a rescue, with encouraging results; however, resistance to vincristine is likely in patients relapsing on CHOP/CEOP, and this agent may enhance LOPP toxicity without improving efficacy. Prednisone 42-52 DNA damage inducible transcript 3 Homo sapiens 188-192 29199519-1 2018 High-grade B cell lymphoma with MYC and BCL2 rearrangements (double hit) has a poor prognosis with standard R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone). Prednisone 171-181 BCL2 apoptosis regulator Homo sapiens 40-44 30071836-4 2018 CASE PRESENTATION: We present a patient with a history of Mantle cell lymphoma and treatment with R-CHOP (rituximab, doxorubicine, vincristine, cyclofosfamide, prednisone), with a meningo-encephalitis, who was treated for a suspected lymphoma relapse. Prednisone 160-170 DNA damage inducible transcript 3 Homo sapiens 100-104 29252084-1 2018 High-dose glucocorticoids such as prednisone are combined with cytotoxic chemotherapy in the R-CHOP or dose adjusted R-EPOCH regimens used for non-Hodgkin lymphoma (NHL). Prednisone 34-44 DNA damage inducible transcript 3 Homo sapiens 95-99 30147970-5 2018 The patient was treated with two cycles of rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) which was complicated by progressive heart failure requiring substitution of liposomal doxorubicin. Prednisone 106-116 DNA damage inducible transcript 3 Homo sapiens 120-124 29630978-0 2018 The IMAAGEN Study: Effect of Abiraterone Acetate and Prednisone on Prostate Specific Antigen and Radiographic Disease Progression in Patients with Nonmetastatic Castration Resistant Prostate Cancer. Prednisone 53-63 kallikrein related peptidase 3 Homo sapiens 67-92 29630978-15 2018 CONCLUSIONS: In patients with high risk, nonmetastatic, castration resistant prostate cancer treatment with abiraterone acetate plus prednisone demonstrated a significant 50% or greater prostate specific antigen reduction with encouraging results for the secondary end points, including the safety of 5 mg prednisone. Prednisone 133-143 kallikrein related peptidase 3 Homo sapiens 186-211 29750632-2 2018 We assessed whether PET can guide therapy in patients who are treated with cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP). Prednisone 123-133 DNA damage inducible transcript 3 Homo sapiens 135-139 28844372-1 2018 BACKGROUND: Enzalutamide and abiraterone acetate plus prednisone, which target the androgen receptor axis, have expanded the treatment of advanced prostate cancer. Prednisone 54-64 androgen receptor Homo sapiens 83-100 29065744-1 2018 Activated B-cell-like (ABC) diffuse large B-cell lymphoma (DLBCL) is associated with worse survival after standard rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (RCHOP) chemoimmunotherapy compared to germinal center B-cell-like (GCB) subtype. Prednisone 174-184 ATP binding cassette subfamily B member 6 (Langereis blood group) Homo sapiens 0-21 29065744-1 2018 Activated B-cell-like (ABC) diffuse large B-cell lymphoma (DLBCL) is associated with worse survival after standard rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (RCHOP) chemoimmunotherapy compared to germinal center B-cell-like (GCB) subtype. Prednisone 174-184 ATP binding cassette subfamily B member 6 (Langereis blood group) Homo sapiens 23-26 28937334-7 2018 First, by reanalysing data of a randomized clinical trial comparing the efficacy of prednisone vs. placebo in patients with chronic liver cirrhosis, we demonstrate the utility of treating patients with a prothrombin level higher than 89%. Prednisone 84-94 coagulation factor II, thrombin Homo sapiens 204-215 29963517-2 2018 The R-CHOP therapy [rituximab (R), cyclophosphamide, hydroxy-doxorubicin, vincristine, and prednisone] is a popular and recommended regimen for primary therapy, prescribed by several treatment guidelines for WM. Prednisone 91-101 DNA damage inducible transcript 3 Homo sapiens 6-10 30294531-4 2018 Interferon-alpha2a (IFN-alpha2a) was then given along with low-dose oral prednisone (10 mg/day), and the uveitis responded well to this therapy. Prednisone 73-83 interferon alpha 2 Homo sapiens 0-18 29545450-10 2018 RESULTS: In patients, HCQ plus prednisone treatment inhibited IL-17 production, gene expression, and Th17 cell differentiation. Prednisone 31-41 interleukin 17A Homo sapiens 62-67 29545450-14 2018 Moreover, miR-590 was increased in patients treated with HCQ plus prednisone. Prednisone 66-76 microRNA 590 Homo sapiens 10-17 29627619-10 2018 The IL-18/TWEAK mRNA ratio reflecting the Th-1/Th-2 local equilibrium was significantly reduced (0.29 versus 0.10, p = .004), through very significant increase of TWEAK expression, in patients who were subsequently pregnant under prednisone. Prednisone 230-240 interleukin 18 Homo sapiens 4-9 29627619-10 2018 The IL-18/TWEAK mRNA ratio reflecting the Th-1/Th-2 local equilibrium was significantly reduced (0.29 versus 0.10, p = .004), through very significant increase of TWEAK expression, in patients who were subsequently pregnant under prednisone. Prednisone 230-240 TNF superfamily member 12 Homo sapiens 10-15 29627619-10 2018 The IL-18/TWEAK mRNA ratio reflecting the Th-1/Th-2 local equilibrium was significantly reduced (0.29 versus 0.10, p = .004), through very significant increase of TWEAK expression, in patients who were subsequently pregnant under prednisone. Prednisone 230-240 TNF superfamily member 12 Homo sapiens 163-168 29554376-12 2018 Elevated hs-cTnI predicted all CVE risk independent of demographics, cardiac risk factors and prednisone use (P = 0.03). Prednisone 94-104 troponin I3, cardiac type Homo sapiens 12-16 29886462-11 2018 Administration of Pim-1 inhibitor and prednisone resulted in inhibition of T-bet mRNA expression (P<0.05), but only prednisone could inhibit T-bet protein expression (P>0.05). Prednisone 119-129 T-box 21 Mus musculus 144-149 29886462-10 2018 Administration of Pim-1 inhibitor and prednisone resulted in suppression of GATA3, RORgammat expression, and the increase of Foxp3 expression (P<0.05). Prednisone 38-48 GATA binding protein 3 Mus musculus 76-81 29950212-6 2018 RESULTS: The D8-SRP test showed that among 269 ALL children, 240(89.22%) cases displayed prednisone poor response (PPR); the 3-year EFS rate in predrisone good response(PGR) group was significantly higher than that in PPR group(P<0.05). Prednisone 89-99 PPR1 Homo sapiens 115-118 29716630-2 2018 Chemo-immunotherapy with rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone (R-CHOP) is the current first-line treatment. Prednisone 80-90 DNA damage inducible transcript 3 Homo sapiens 94-98 29886462-10 2018 Administration of Pim-1 inhibitor and prednisone resulted in suppression of GATA3, RORgammat expression, and the increase of Foxp3 expression (P<0.05). Prednisone 38-48 forkhead box P3 Mus musculus 125-130 29886462-11 2018 Administration of Pim-1 inhibitor and prednisone resulted in inhibition of T-bet mRNA expression (P<0.05), but only prednisone could inhibit T-bet protein expression (P>0.05). Prednisone 38-48 T-box 21 Mus musculus 75-80 29761908-7 2018 Regarding first-line induction, a shift from R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone) to R-bendamustine was observed over time, as well as a decline in radiotherapy. Prednisone 108-118 DNA damage inducible transcript 3 Homo sapiens 47-51 28967708-9 2018 Evidence for the desired pharmacological effect (glucocorticoid receptor antagonism) was demonstrated by the ability of CORT125134 to prevent several effects of the glucocorticoid receptor agonist prednisone. Prednisone 197-207 nuclear receptor subfamily 3 group C member 1 Homo sapiens 49-72 28967708-9 2018 Evidence for the desired pharmacological effect (glucocorticoid receptor antagonism) was demonstrated by the ability of CORT125134 to prevent several effects of the glucocorticoid receptor agonist prednisone. Prednisone 197-207 nuclear receptor subfamily 3 group C member 1 Homo sapiens 165-188 29250742-0 2018 A randomized phase 2 study of a HSP27 targeting antisense, apatorsen with prednisone versus prednisone alone, in patients with metastatic castration resistant prostate cancer. Prednisone 74-84 heat shock protein family B (small) member 1 Homo sapiens 32-37 29557616-6 2018 The biopsy confirmed CD1a+ proliferation; it was treated with prednisone and vinblastine with favorable evolution. Prednisone 62-72 CD1a molecule Homo sapiens 21-25 29674626-3 2018 We aimed to do a systematic review and meta-analysis on the relationships between overexpression MYC and/or BCL2 and DLBCLs treated with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP). Prednisone 196-206 MYC proto-oncogene, bHLH transcription factor Homo sapiens 97-100 29731965-10 2018 In this study, the presence of both TP53 mutation and 17p/TP53 deletion, but not the individual variants, was associated with poor prognosis in DLBCL patients after treatment with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP) or similar regimens. Prednisone 238-248 tumor protein p53 Homo sapiens 36-40 29731965-10 2018 In this study, the presence of both TP53 mutation and 17p/TP53 deletion, but not the individual variants, was associated with poor prognosis in DLBCL patients after treatment with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP) or similar regimens. Prednisone 238-248 tumor protein p53 Homo sapiens 58-62 29397839-1 2018 OBJECTIVE: To study the value of absolute lymphocyte count/absolute monocyte count (ALC/AMC) and its effect on prognosis in patients with primary follicular lymphoma treated with rituximab combined with cyclophosphamide + doxorubicin + vincristine + prednisone (R-CHOP) chemotherapy. Prednisone 250-260 allantoicase Homo sapiens 84-87 28363827-9 2018 In cohort II, this model revealed a comparable AUC in PREDN-negative patients (0.78), but AUC in PREDN-positive patients was significantly lower (0.63), which seemed due to effect modification of the IFN score by prednisone. Prednisone 213-223 interferon alpha 1 Homo sapiens 200-203 28363827-10 2018 CONCLUSIONS: Combination of predictive parameters provided a promising model for the prediction of non-response to rituximab, with possibilities for optimization via definition of the exact interfering effect of prednisone on IFN score. Prednisone 212-222 interferon alpha 1 Homo sapiens 226-229 29511707-8 2018 Levels of miR-21-5p displayed a negative correlation with the prednisone dose within the prednisone-only group (p <= 0.001). Prednisone 62-72 microRNA 215 Homo sapiens 10-18 29511707-8 2018 Levels of miR-21-5p displayed a negative correlation with the prednisone dose within the prednisone-only group (p <= 0.001). Prednisone 89-99 microRNA 215 Homo sapiens 10-18 28243944-9 2018 P-gp levels correlated with the scores of SLEDAI (r = 0.26; p = 0.01), Mexican-SLEDAI (MEX-SLEDAI) (r = 0.32; p = 0.002), SLICC/ACR damage index (r = 0.47; p < 0.001), and with prednisone doses (r = 0.33; p = 0.001). Prednisone 180-190 phosphoglycolate phosphatase Homo sapiens 0-4 29403563-1 2018 The aim of this study was to analyze the prevalence and prognostic value of myeloid differentiation factor 88 (MYD88) L265P in diffuse large B-cell lymphoma (DLBCL) patients treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP). Prednisone 250-260 MYD88 innate immune signal transduction adaptor Homo sapiens 76-109 29403563-1 2018 The aim of this study was to analyze the prevalence and prognostic value of myeloid differentiation factor 88 (MYD88) L265P in diffuse large B-cell lymphoma (DLBCL) patients treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP). Prednisone 250-260 MYD88 innate immune signal transduction adaptor Homo sapiens 111-116 28751233-7 2018 RESULTS: We report a "polyclonal" autoimmune event occurring in the airways of prednisone-dependent asthmatic patients with increased eosinophil activity, recurrent pulmonary infections, or both, as evident by the concomitant presence of sputum anti-EPX and anti-nuclear antibodies of the IgG subtype. Prednisone 79-89 eosinophil peroxidase Homo sapiens 250-253 29266182-1 2018 BACKGROUND: Two androgen receptor (AR)-targeted therapies, enzalutamide and abiraterone acetate plus prednisone (abiraterone), have been approved for the treatment of metastatic castration-resistant prostate cancer (CRPC). Prednisone 101-111 androgen receptor Homo sapiens 16-33 29266182-1 2018 BACKGROUND: Two androgen receptor (AR)-targeted therapies, enzalutamide and abiraterone acetate plus prednisone (abiraterone), have been approved for the treatment of metastatic castration-resistant prostate cancer (CRPC). Prednisone 101-111 androgen receptor Homo sapiens 35-37 29686956-4 2018 Since she was in her second trimester, we decided to treat her with rituximab-cyclophosphamide, doxorubicin, vincristine, prednisone (R-CHOP). Prednisone 122-132 DNA damage inducible transcript 3 Homo sapiens 136-140 29721381-1 2018 Diminished overall survival rate of non-Hodgkin lymphoma (NHL) patients treated with a combination regimen of rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP) has been recently linked to recurrent somatic mutations activating FOXO1. Prednisone 168-178 DNA damage inducible transcript 3 Homo sapiens 182-186 29721381-1 2018 Diminished overall survival rate of non-Hodgkin lymphoma (NHL) patients treated with a combination regimen of rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP) has been recently linked to recurrent somatic mutations activating FOXO1. Prednisone 168-178 forkhead box O1 Homo sapiens 255-260 29086009-4 2018 According to the chemotherapy regimens, patients were classified in four groups: combination of vincristine, cyclophosphamide, doxorubicin, and prednisone (CHOP group) with rituximab (RCHOP group) and combination of vincristine, cyclophosphamide, pegylated liposomal doxorubicin and prednisone (CDOP group) with rituximab (RCDOP group). Prednisone 144-154 DNA damage inducible transcript 3 Homo sapiens 156-160 29038005-0 2018 Prednisone alleviates demyelination through regulation of the NLRP3 inflammasome in a C57BL/6 mouse model of cuprizone-induced demyelination. Prednisone 0-10 NLR family, pyrin domain containing 3 Mus musculus 62-67 30238070-11 2018 The ontology can be used to reason individual components from regimens mentioned in electronic health records (eg, R-CHOP maps to rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone) and also to probabilistically reconstruct regimens from individual drug components. Prednisone 189-199 DNA damage inducible transcript 3 Homo sapiens 117-121 29194765-0 2018 c-Kit Mutation and Localization Status as Response Predictors in Mast Cell Tumors in Dogs Treated with Prednisone and Toceranib or Vinblastine. Prednisone 103-113 KIT proto-oncogene, receptor tyrosine kinase Canis lupus familiaris 0-5 29387400-6 2018 The patient received chemotherapy with six cycles of cyclophosphamide, hydroxydaunomycin, oncovin and prednisone (CHOP regimen) and a complete radiological response was achieved after six cycles of treatment. Prednisone 102-112 DNA damage inducible transcript 3 Homo sapiens 114-118 29529610-5 2018 RESULTS: Prednisone therapy significantly reduced proteinuria and levels of serum IgA, galactose-deficient IgA1, and IgA-IgG immune complexes in IgA nephropathy patients and thus reduced differences in all of the above parameters between IgAN patients and control groups. Prednisone 9-19 immunoglobulin heavy constant alpha 1 Homo sapiens 107-111 29529610-7 2018 CONCLUSION: The prednisone therapy reduces overall aberrancy in IgA1 O-glycosylation in IgA nephropathy patients, but the measurement of IgA1 parameters does not allow us to predict the prednisone therapy outcome in individual patients. Prednisone 16-26 immunoglobulin heavy constant alpha 1 Homo sapiens 64-68 28789937-7 2017 rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone (R-CHOP) was initial treatment in 15 (79%) of patients with aggFL and 21 (72%) of those with FL3A; rituximab was included in initial therapy in 18 (95%) and 24 (83%), respectively. Prednisone 55-65 DNA damage inducible transcript 3 Homo sapiens 69-73 29415941-7 2018 Although the patient received two courses of cyclophosphamide, hydroxydaunorubicin, oncovin, and prednisone (CHOP) and dexamethasone, etoposide, ifosfamide, and carboplatin (DeVIC) therapy, facial nerve and lower limb paralysis manifested. Prednisone 97-107 DNA damage inducible transcript 3 Homo sapiens 109-113 29737107-7 2018 R-CHOP (rituximab,cyclophosphamide,epirubicin,vindesine,prednisone) or CHOP regimen chemotherapy significantly improved the survival of the patients (P=0.000 2). Prednisone 56-66 DNA damage inducible transcript 3 Homo sapiens 2-6 28847710-2 2017 Specifically, the nongerminal center B cell-like (non-GCB) subtype, composed predominantly of the activated B cell-like (ABC) molecular subtype, has been shown to portend poor prognosis because of its more aggressive nature and resistance to standard cyclophosphamide, hydroxydaunorubicin, oncovin, prednisone (CHOP)-like chemotherapy compared with the GCB subtype. Prednisone 299-309 ATP binding cassette subfamily B member 6 (Langereis blood group) Homo sapiens 98-119 28847710-2 2017 Specifically, the nongerminal center B cell-like (non-GCB) subtype, composed predominantly of the activated B cell-like (ABC) molecular subtype, has been shown to portend poor prognosis because of its more aggressive nature and resistance to standard cyclophosphamide, hydroxydaunorubicin, oncovin, prednisone (CHOP)-like chemotherapy compared with the GCB subtype. Prednisone 299-309 ATP binding cassette subfamily B member 6 (Langereis blood group) Homo sapiens 121-124 29390581-8 2017 The patient attained partial remission after undergoing 2 rounds of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP regimen) before autologous stem cell transplantation, however, he quickly relapsed and developed new cutaneous lesions. Prednisone 116-126 DNA damage inducible transcript 3 Homo sapiens 128-132 28906482-2 2017 Currently, VMP (bortezomib, melphalan, prednisone) is one of the standard regimens recommended as the first-line therapy for patients with MM ineligible for high-dose chemotherapy (HDT) with autologous stem-cell transplantation (auto-SCT). Prednisone 39-49 neurensin 1 Homo sapiens 11-14 27937011-12 2017 DISCUSSION AND CONCLUSION: Pirfenidone, prednisone and acetylcysteine can inhibit airsacculitis and pulmonary fibrosis in rat IPF models, which may be related with enhanced caveolin-1, reduced TNF-alpha, TGF-beta1, PDGF. Prednisone 40-50 tumor necrosis factor Rattus norvegicus 193-202 27937011-12 2017 DISCUSSION AND CONCLUSION: Pirfenidone, prednisone and acetylcysteine can inhibit airsacculitis and pulmonary fibrosis in rat IPF models, which may be related with enhanced caveolin-1, reduced TNF-alpha, TGF-beta1, PDGF. Prednisone 40-50 transforming growth factor, beta 1 Rattus norvegicus 204-213 27937011-12 2017 DISCUSSION AND CONCLUSION: Pirfenidone, prednisone and acetylcysteine can inhibit airsacculitis and pulmonary fibrosis in rat IPF models, which may be related with enhanced caveolin-1, reduced TNF-alpha, TGF-beta1, PDGF. Prednisone 40-50 caveolin 1 Rattus norvegicus 173-183 28358937-11 2017 Main Outcomes and Measures: The primary end point was a PSA level of 0.2 ng/mL or lower within 12 months of starting abiraterone acetate plus prednisone. Prednisone 142-152 kallikrein related peptidase 3 Homo sapiens 56-59 28921665-0 2017 Effects of Oral Prednisone Administration on Serum Cystatin C in Dogs. Prednisone 16-26 cystatin C Homo sapiens 51-61 28893901-0 2017 Expression of PD-L1 in Hormone-naive and Treated Prostate Cancer Patients Receiving Neoadjuvant Abiraterone Acetate plus Prednisone and Leuprolide. Prednisone 121-131 CD274 molecule Homo sapiens 14-19 28893901-4 2017 In this study, we evaluated the effect of neoadjuvant androgen deprivation therapy with abiraterone acetate plus prednisone and leuprolide (Neo-AAPL) on PD-L1 expression in prostate cancer.Experimental Design: Radical prostatectomy (RP) tissues were collected from 44 patients with intermediate- to high-risk prostate cancer who underwent RP after Neo-AAPL treatment. Prednisone 113-123 CD274 molecule Homo sapiens 153-158 28884287-8 2017 The risk factors for the most frequent cause of hospitalization, hospitalized infection, were age [odds ratio (OR) 1.03; 95% CI 1.00-1.05], serum albumin level (OR 0.30; 95% CI 0.13-0.69), and corticosteroid use (prednisone > 5 mg/day; OR 3.66; 95% CI 1.81-7.35), but not methotrexate or biological agent use. Prednisone 213-223 albumin Homo sapiens 146-153 28982056-3 2017 In this study, we retrospectively evaluate safety and efficacy of a salvage regimen (CAGLP) consisting of G-CSF, low-dose cytarabine, aclarubicin, l-asparaginase and prednisone. Prednisone 166-176 calmodulin like 6 Homo sapiens 85-90 29296861-2 2017 Despite producing somewhat less-than-satisfactory results, the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) remains the de facto standard in PTCL treatment. Prednisone 126-136 DNA damage inducible transcript 3 Homo sapiens 138-142 29254235-4 2017 After treatment with prednisone alone, levels of STAT5 and FOXP3 mRNA were significantly higher than in untreated control cells (both P < 0.01), while levels of RORC mRNA were significantly lower than in controls (P < 0.05). Prednisone 21-31 signal transducer and activator of transcription 5A Homo sapiens 49-54 29254235-4 2017 After treatment with prednisone alone, levels of STAT5 and FOXP3 mRNA were significantly higher than in untreated control cells (both P < 0.01), while levels of RORC mRNA were significantly lower than in controls (P < 0.05). Prednisone 21-31 forkhead box P3 Homo sapiens 59-64 29254235-4 2017 After treatment with prednisone alone, levels of STAT5 and FOXP3 mRNA were significantly higher than in untreated control cells (both P < 0.01), while levels of RORC mRNA were significantly lower than in controls (P < 0.05). Prednisone 21-31 RAR related orphan receptor C Homo sapiens 164-168 29254235-6 2017 After treatment with prednisone alone, proportions of Th17/CD4+ cells and levels of IL-17A were significantly lower than in control cells, and proportions of Treg/CD4+ cells and levels of IL-10 significantly higher than in controls (all P < 0.01). Prednisone 21-31 interleukin 17A Homo sapiens 84-90 29254235-6 2017 After treatment with prednisone alone, proportions of Th17/CD4+ cells and levels of IL-17A were significantly lower than in control cells, and proportions of Treg/CD4+ cells and levels of IL-10 significantly higher than in controls (all P < 0.01). Prednisone 21-31 interleukin 10 Homo sapiens 188-193 29254235-7 2017 Our results suggest that prednisone may improve pregnancy outcomes by restoring immunological homeostasis through up-regulation of STAT5 and FOXP3, induction of DIC differentiation into Treg cells, inhibition of DIC differentiation into Th17 cells, reduction of IL-17A secretion and induction of IL-10 secretion. Prednisone 25-35 signal transducer and activator of transcription 5A Homo sapiens 131-136 29254235-7 2017 Our results suggest that prednisone may improve pregnancy outcomes by restoring immunological homeostasis through up-regulation of STAT5 and FOXP3, induction of DIC differentiation into Treg cells, inhibition of DIC differentiation into Th17 cells, reduction of IL-17A secretion and induction of IL-10 secretion. Prednisone 25-35 forkhead box P3 Homo sapiens 141-146 29254235-7 2017 Our results suggest that prednisone may improve pregnancy outcomes by restoring immunological homeostasis through up-regulation of STAT5 and FOXP3, induction of DIC differentiation into Treg cells, inhibition of DIC differentiation into Th17 cells, reduction of IL-17A secretion and induction of IL-10 secretion. Prednisone 25-35 interleukin 17A Homo sapiens 262-268 29254235-7 2017 Our results suggest that prednisone may improve pregnancy outcomes by restoring immunological homeostasis through up-regulation of STAT5 and FOXP3, induction of DIC differentiation into Treg cells, inhibition of DIC differentiation into Th17 cells, reduction of IL-17A secretion and induction of IL-10 secretion. Prednisone 25-35 interleukin 10 Homo sapiens 296-301 28392046-7 2017 The use of anti-TNF allowed reducing prednisone dosage at end of follow-up (p < 0.001). Prednisone 37-47 tumor necrosis factor Homo sapiens 16-19 29296854-7 2017 Although there was no significant difference in the exacerbation rate, suppression of the anti-ADAMTS13 antibodies and improvement in ADAMTS13 activity in the first month after stopping PEX were significantly better in the prednisone-treated subjects. Prednisone 223-233 ADAM metallopeptidase with thrombospondin type 1 motif 13 Homo sapiens 95-103 29296854-7 2017 Although there was no significant difference in the exacerbation rate, suppression of the anti-ADAMTS13 antibodies and improvement in ADAMTS13 activity in the first month after stopping PEX were significantly better in the prednisone-treated subjects. Prednisone 223-233 ADAM metallopeptidase with thrombospondin type 1 motif 13 Homo sapiens 134-142 29296854-9 2017 These data demonstrate the superiority of prednisone over CSA as an adjunct to PEX in the suppression of the anti-ADAMTS13 antibodies and improvement in ADAMTS13 activity. Prednisone 42-52 ADAM metallopeptidase with thrombospondin type 1 motif 13 Homo sapiens 114-122 29296854-9 2017 These data demonstrate the superiority of prednisone over CSA as an adjunct to PEX in the suppression of the anti-ADAMTS13 antibodies and improvement in ADAMTS13 activity. Prednisone 42-52 ADAM metallopeptidase with thrombospondin type 1 motif 13 Homo sapiens 153-161 32300400-5 2017 Patients with MLL- and CDKN2A-positive DLBCL may benefit from therapy with a dose-adjusted regimen of rituximab, etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin (DA-R-EPOCH) compared to traditional rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone (R-CHOP). Prednisone 124-134 lysine methyltransferase 2A Homo sapiens 14-17 32300400-5 2017 Patients with MLL- and CDKN2A-positive DLBCL may benefit from therapy with a dose-adjusted regimen of rituximab, etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin (DA-R-EPOCH) compared to traditional rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone (R-CHOP). Prednisone 124-134 cyclin dependent kinase inhibitor 2A Homo sapiens 23-29 32300400-5 2017 Patients with MLL- and CDKN2A-positive DLBCL may benefit from therapy with a dose-adjusted regimen of rituximab, etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin (DA-R-EPOCH) compared to traditional rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone (R-CHOP). Prednisone 275-285 lysine methyltransferase 2A Homo sapiens 14-17 32300400-5 2017 Patients with MLL- and CDKN2A-positive DLBCL may benefit from therapy with a dose-adjusted regimen of rituximab, etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin (DA-R-EPOCH) compared to traditional rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone (R-CHOP). Prednisone 275-285 cyclin dependent kinase inhibitor 2A Homo sapiens 23-29 27813290-7 2017 Subgroup analysis revealed that the associations of prednisone use and presence of autoantibodies were only present in patients with moderate-to-high disease activity (DAS28-CRP-3 >=3.2) in the first trimester. Prednisone 52-62 CCAAT enhancer binding protein delta Homo sapiens 174-179 28791403-10 2017 Among DLBCL cases, the TP53 mutations shortened both OS and PFS of patients treated with R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone) and decreased both OS and PFS of patients with secondary DLBCL disease. Prednisone 155-165 tumor protein p53 Homo sapiens 23-27 28791403-10 2017 Among DLBCL cases, the TP53 mutations shortened both OS and PFS of patients treated with R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone) and decreased both OS and PFS of patients with secondary DLBCL disease. Prednisone 155-165 DNA damage inducible transcript 3 Homo sapiens 91-95 29228594-5 2017 Results showed that 90% of rats injected with prednisone developed ONFH, whereas BSP administration prevented ONFH development in 70% of prednisone-injected rats. Prednisone 137-147 integrin-binding sialoprotein Rattus norvegicus 81-84 28742852-3 2017 Some of the complexes showed the ability to suppress significantly the activation of nuclear factor kappaB (NF-kappaB) both by lipopolysaccharide (LPS) and TNF-alpha (complexes 3-7 at 100 nM level) in the similar manner as the reference drug prednisone (at 1 muM level). Prednisone 242-252 nuclear factor kappa B subunit 1 Homo sapiens 100-106 31966830-11 2017 We deduce that the traditional chemotherapy with cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) is inadequate for the treatment of IVNKTL. Prednisone 96-106 DNA damage inducible transcript 3 Homo sapiens 108-112 32300390-1 2017 Rituximab (R) with cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) is the current standard of care as first-line treatment for diffuse large B-cell lymphoma (DLBCL), the most common lymphoma subtype. Prednisone 66-76 DNA damage inducible transcript 3 Homo sapiens 78-82 28452416-7 2017 Low-CREBBP patients were associated with unfavourable clinical presentations, poor prednisone response and high minimal residual disease (>10-2 ) after induction. Prednisone 83-93 CREB binding protein Homo sapiens 4-10 28522441-2 2017 We hypothesized that rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) could decrease rates of relapse and transformation. Prednisone 84-94 DNA damage inducible transcript 3 Homo sapiens 98-102 28742852-3 2017 Some of the complexes showed the ability to suppress significantly the activation of nuclear factor kappaB (NF-kappaB) both by lipopolysaccharide (LPS) and TNF-alpha (complexes 3-7 at 100 nM level) in the similar manner as the reference drug prednisone (at 1 muM level). Prednisone 242-252 nuclear factor kappa B subunit 1 Homo sapiens 108-117 28742852-3 2017 Some of the complexes showed the ability to suppress significantly the activation of nuclear factor kappaB (NF-kappaB) both by lipopolysaccharide (LPS) and TNF-alpha (complexes 3-7 at 100 nM level) in the similar manner as the reference drug prednisone (at 1 muM level). Prednisone 242-252 tumor necrosis factor Homo sapiens 156-165 28238957-10 2017 Most users of anti-TNF agents had evidence of corticosteroid dependence (more than 2 g prednisone within any 12-month period) before initiation of anti-TNF therapy. Prednisone 87-97 tumor necrosis factor Homo sapiens 19-22 28725161-1 2017 BACKGROUND: Rituximab combined with cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) is used as standard frontline regimen for diffuse large B-cell lymphoma (DLBCL). Prednisone 83-93 DNA damage inducible transcript 3 Homo sapiens 95-99 28515208-10 2017 After a 4-week course of prednisone, serum Ca and PTH normalized, and her anti-CaSR titers declined. Prednisone 25-35 calcium sensing receptor Homo sapiens 79-83 28556506-0 2017 Dissociated Agonist of Glucocorticoid Receptor or Prednisone for Active Rheumatoid Arthritis: Effects on P1NP and Osteocalcin Pharmacodynamics. Prednisone 50-60 bone gamma-carboxyglutamate protein Homo sapiens 114-125 28556506-5 2017 Changes with prednisone 5 and 10 mg were -15% and -18% (P1NP) and -10% and -17% (OC). Prednisone 13-23 bone gamma-carboxyglutamate protein Homo sapiens 81-83 28215945-12 2017 CONCLUSIONS: MMF plus prednisone versus full-dose prednisone did not differ in reducing proteinuria, but patients treated with the former had fewer adverse events in patients with IgAN with active proliferative lesions. Prednisone 22-32 IGAN1 Homo sapiens 180-184 28445949-6 2017 These cells survived longer following treatment with a combination of cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP). Prednisone 117-127 DNA damage inducible transcript 3 Homo sapiens 129-133 28345428-6 2017 These data demonstrate that prednisone can reduce the extent of intramuscular T-cell infiltrates in AAV-treated muscles, which may aid in achieving long-term transgene expression, as may the induction of PDL2 expression on skeletal myofibers to promote PD1-mediated programmed T-cell death. Prednisone 28-38 patr class I histocompatibility antigen, A-126 alpha chain-like Sus scrofa 253-256 28154089-0 2017 Genetic polymorphism at BCL2 as a predictor for rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone efficacy in patients with diffuse large B-cell lymphoma. Prednisone 106-116 BCL2 apoptosis regulator Homo sapiens 24-28 28291124-2 2017 MYC, a transcriptional factor and oncoprotein, is overexpressed in a fraction of DLBCL and indicates poor prognosis and aggressive clinical course when treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP). Prednisone 228-238 MYC proto-oncogene, bHLH transcription factor Homo sapiens 0-3 28035387-13 2017 In conclusion, prednisone, ibuprofen and betamethasone may prevent OA by suppressing the expression of IL-6 and IL-8, subsequently inactivating NF-kappaB and STAT3 pathways, and ultimately, leading to decreased levels of collagen I, MMP-1, and MMP-13. Prednisone 15-25 interleukin 6 Homo sapiens 103-107 28559645-7 2017 TREATMENT AND OUTCOME: The patient had a good initial response to a CHOP scheme (cyclophosphamide, doxorubicin, vincristine and prednisone) with filgrastim. Prednisone 128-138 DNA damage inducible transcript 3 Homo sapiens 68-72 26968188-3 2017 The principal objective of this study was to determine whether the tumors" microenvironment expressions of CD11c and FOXP3 are predictive of clinical outcomes in diffuse large B-cell lymphoma (DLBCL) patients receiving treatment with rituximab, cyclophosphamide, anthracycline, vincristine, and prednisone (R-CHOP) combination chemotherapy. Prednisone 295-305 integrin subunit alpha X Homo sapiens 107-112 28035387-10 2017 Additionally, levels of IL-6 and IL-8 were significantly decreased by prednisone, ibuprofen and betamethasone. Prednisone 70-80 interleukin 6 Homo sapiens 24-28 28413663-6 2017 The patient completed three cycles of combination chemotherapy consisting of cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP regimen) followed by radiation consolidation therapy, and has maintained a complete remission ever since. Prednisone 124-134 DNA damage inducible transcript 3 Homo sapiens 136-140 28115372-2 2017 Anthracycline-containing regimens, namely cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP), nowadays represent the standard first-line treatment; for patients who achieve a satisfactory response, a consolidation by means of autologous stem cell transplantation may offer a greater chance of long-term survival. Prednisone 90-100 DNA damage inducible transcript 3 Homo sapiens 102-106 28035387-10 2017 Additionally, levels of IL-6 and IL-8 were significantly decreased by prednisone, ibuprofen and betamethasone. Prednisone 70-80 C-X-C motif chemokine ligand 8 Homo sapiens 33-37 28035387-13 2017 In conclusion, prednisone, ibuprofen and betamethasone may prevent OA by suppressing the expression of IL-6 and IL-8, subsequently inactivating NF-kappaB and STAT3 pathways, and ultimately, leading to decreased levels of collagen I, MMP-1, and MMP-13. Prednisone 15-25 C-X-C motif chemokine ligand 8 Homo sapiens 112-116 28035387-12 2017 In combination with IL-6 or IL-8, prednisone, ibuprofen and betamethasone significantly reduced the levels of collagen I, MMP-1 and MMP-13, and inactivated NF-kappaB and STAT3 pathways. Prednisone 34-44 interleukin 6 Homo sapiens 20-24 28035387-13 2017 In conclusion, prednisone, ibuprofen and betamethasone may prevent OA by suppressing the expression of IL-6 and IL-8, subsequently inactivating NF-kappaB and STAT3 pathways, and ultimately, leading to decreased levels of collagen I, MMP-1, and MMP-13. Prednisone 15-25 signal transducer and activator of transcription 3 Homo sapiens 158-163 28035387-12 2017 In combination with IL-6 or IL-8, prednisone, ibuprofen and betamethasone significantly reduced the levels of collagen I, MMP-1 and MMP-13, and inactivated NF-kappaB and STAT3 pathways. Prednisone 34-44 matrix metallopeptidase 1 Homo sapiens 122-127 28035387-12 2017 In combination with IL-6 or IL-8, prednisone, ibuprofen and betamethasone significantly reduced the levels of collagen I, MMP-1 and MMP-13, and inactivated NF-kappaB and STAT3 pathways. Prednisone 34-44 matrix metallopeptidase 13 Homo sapiens 132-138 28035387-12 2017 In combination with IL-6 or IL-8, prednisone, ibuprofen and betamethasone significantly reduced the levels of collagen I, MMP-1 and MMP-13, and inactivated NF-kappaB and STAT3 pathways. Prednisone 34-44 signal transducer and activator of transcription 3 Homo sapiens 170-175 28035387-13 2017 In conclusion, prednisone, ibuprofen and betamethasone may prevent OA by suppressing the expression of IL-6 and IL-8, subsequently inactivating NF-kappaB and STAT3 pathways, and ultimately, leading to decreased levels of collagen I, MMP-1, and MMP-13. Prednisone 15-25 matrix metallopeptidase 1 Homo sapiens 233-238 28035387-13 2017 In conclusion, prednisone, ibuprofen and betamethasone may prevent OA by suppressing the expression of IL-6 and IL-8, subsequently inactivating NF-kappaB and STAT3 pathways, and ultimately, leading to decreased levels of collagen I, MMP-1, and MMP-13. Prednisone 15-25 matrix metallopeptidase 13 Homo sapiens 244-250 28573228-7 2017 In the moxibustion and prednisone group, however, TGF-beta1 was decreased and IFN-gamma was increased at both protein and mRNA levels in comparison to the model groups. Prednisone 23-33 transforming growth factor, beta 1 Rattus norvegicus 50-59 28122538-7 2017 A significant positive association between elevated Bmi-1 levels and a poor response to prednisone as well as an increased clinical risk was observed. Prednisone 88-98 BMI1 proto-oncogene, polycomb ring finger Homo sapiens 52-57 28573228-7 2017 In the moxibustion and prednisone group, however, TGF-beta1 was decreased and IFN-gamma was increased at both protein and mRNA levels in comparison to the model groups. Prednisone 23-33 interferon gamma Rattus norvegicus 78-87 27324190-1 2017 BACKGROUND AND OBJECTIVES: Recent analysis revealed strong associations between prostate-specific antigen (PSA) dynamics and overall survival (OS) in metastatic castration-resistant prostate cancer (mCRPC) and supported PSA dynamics as bridging surrogacy endpoints for clinical benefit from treatment with abiraterone acetate plus prednisone. Prednisone 331-341 kallikrein related peptidase 3 Homo sapiens 80-111 29212067-2 2017 Standard treatment is usually a combined immune chemotherapy with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP). Prednisone 125-135 DNA damage inducible transcript 3 Homo sapiens 139-143 27324190-1 2017 BACKGROUND AND OBJECTIVES: Recent analysis revealed strong associations between prostate-specific antigen (PSA) dynamics and overall survival (OS) in metastatic castration-resistant prostate cancer (mCRPC) and supported PSA dynamics as bridging surrogacy endpoints for clinical benefit from treatment with abiraterone acetate plus prednisone. Prednisone 331-341 kallikrein related peptidase 3 Homo sapiens 107-110 28916403-10 2017 Autoantibodies to LPL decreased by 37% while patient was on prednisone, and by 68% as she subsequently transitioned to hydroxychloroquine monotherapy. Prednisone 60-70 lipoprotein lipase Homo sapiens 18-21 28768265-0 2017 Prompt Response to Prednisone Predicts Benign Course in MuSK-MG. BACKGROUND: The difficult course of patients with myasthenia gravis (MG) with anti-muscle-specific tyrosine kinase antibodies (MuSK) has been emphasized. Prednisone 19-29 muscle associated receptor tyrosine kinase Homo sapiens 56-60 28123744-1 2017 The standard of care for first-line therapy in diffuse large B-cell lymphoma (DLBCL) is the rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP) regimen. Prednisone 150-160 DNA damage inducible transcript 3 Homo sapiens 164-168 27737889-2 2016 It is well documented that ABC-DLBCL cases have a significantly poorer survival response than GCB-DLBCLs in both the CHOP (cyclophosphamide, vincristine, doxorubicin, and prednisone) and the rituximab (R)-CHOP eras. Prednisone 171-181 ATP binding cassette subfamily B member 6 (Langereis blood group) Homo sapiens 27-30 27738789-0 2016 Outcomes with two different schedules of bortezomib, melphalan, and prednisone (VMP) for previously untreated multiple myeloma: matched pair analysis using long-term follow-up data from the phase 3 VISTA and PETHEMA/GEM05 trials. Prednisone 68-78 neurensin 1 Homo sapiens 80-83 27930655-12 2016 The exposure to prednisone most clearly influenced the serum levels of Gd-IgA1. Prednisone 16-26 immunoglobulin heavy constant alpha 1 Homo sapiens 74-78 27812954-6 2016 Targeting mTORC1 over-activation with N-acetylcysteine, rapamycin, and rapalogs provides an opportunity to supplant current therapies with severe side effect profiles such as prednisone or cyclophosphamide. Prednisone 175-185 CREB regulated transcription coactivator 1 Mus musculus 10-16 28154512-11 2016 In the additive genetic model results for each IL10 polymorphism, the rs1800871 and rs1800872 polymorphisms represented a marginal association with OS (p = 0.09 and p = 0.06) and PFS (p = 0.05 and p = 0.08) in B-cell lymphoma patients treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP). Prednisone 311-321 interleukin 10 Homo sapiens 47-51 27315156-0 2016 Rituximab plus reduced-dose cyclophosphamide, doxorubicin, vincristine and prednisone (RD R-CHOP) chemotherapy is feasible for very elderly patients (>=80 years) with B-cell lymphoma: analysis of treatment outcome. Prednisone 75-85 DNA damage inducible transcript 3 Homo sapiens 92-96 27955694-7 2016 This analysis revealed lower IFN scores in patients using hydroxychloroquine, prednisone, and/or sulfasalazine, but it did not show significant associations between the other parameters and the IFN score. Prednisone 78-88 interferon alpha 1 Homo sapiens 29-32 27913503-1 2016 Although rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) is the standard treatment for patients with diffuse large B-cell lymphoma (DLBCL), ~30% to 50% of patients are not cured by this treatment, depending on disease stage or prognostic index. Prednisone 72-82 DNA damage inducible transcript 3 Homo sapiens 86-90 26306417-11 2016 Prednisone treatment inhibited both expressions; however it also resulted in up-regulation of the GATA-3/T-bet ratio. Prednisone 0-10 GATA binding protein 3 Rattus norvegicus 98-104 28030899-8 2016 In univariate analysis, the rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) regimen resulted in a better PFS than the cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) regimen (88.9% vs. 50.0%; p = 0.053). Prednisone 87-97 DNA damage inducible transcript 3 Homo sapiens 101-105 28101356-6 2016 After treatment with chemotherapy regimens comprising cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP), followed by high-dose treatment with methotrexate, dexamethasone, ifosfamide, etoposide and L-asparaginasum (SMILE), the patient succumbed to the disease. Prednisone 101-111 DNA damage inducible transcript 3 Homo sapiens 113-117 28030899-8 2016 In univariate analysis, the rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) regimen resulted in a better PFS than the cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) regimen (88.9% vs. 50.0%; p = 0.053). Prednisone 87-97 DNA damage inducible transcript 3 Homo sapiens 209-213 27821150-19 2016 True monotherapy with the first TNF antagonist without prednisone or csDMARDs is infrequent. Prednisone 55-65 tumor necrosis factor Homo sapiens 32-35 27841334-8 2016 Prednisone stimulation or overexpression of 11beta-HSD1 also caused JNK activation in cultured adipocytes. Prednisone 0-10 mitogen-activated protein kinase 8 Mus musculus 68-71 27841334-10 2016 Furthermore, prednisone significantly impaired the insulin signaling pathway, and these effects were reversed by 11beta-HSD1 and JNK inhibition. Prednisone 13-23 hydroxysteroid 11-beta dehydrogenase 1 Mus musculus 113-124 27841334-10 2016 Furthermore, prednisone significantly impaired the insulin signaling pathway, and these effects were reversed by 11beta-HSD1 and JNK inhibition. Prednisone 13-23 mitogen-activated protein kinase 8 Mus musculus 129-132 27324990-7 2016 In addition, Syk inhibitor-induced lesions were prevented by the coadministration of prednisone. Prednisone 85-95 spleen associated tyrosine kinase Rattus norvegicus 13-16 27882163-4 2016 After treating with prednisone for 2 months, his insulin level started decreasing. Prednisone 20-30 insulin Homo sapiens 49-56 27459525-9 2016 RESULTS: Oral administration of the glucocorticoid prednisone to healthy human subjects resulted in a time-dependent increase of FKBP5 mRNA to peak levels of approximately 12-fold compared with unstimulated levels within 4 hours of steroid administration, followed by a reduction to baseline levels within 24 hours. Prednisone 51-61 FKBP prolyl isomerase 5 Homo sapiens 129-134 27459525-10 2016 Furthermore, oral administration of mifepristone or the selective GR antagonist CORT125134 had the desired effect of inhibiting prednisone-mediated activation of GR as seen by a reduction of FKBP5 mRNA levels. Prednisone 128-138 nuclear receptor subfamily 3 group C member 1 Homo sapiens 66-68 27459525-10 2016 Furthermore, oral administration of mifepristone or the selective GR antagonist CORT125134 had the desired effect of inhibiting prednisone-mediated activation of GR as seen by a reduction of FKBP5 mRNA levels. Prednisone 128-138 nuclear receptor subfamily 3 group C member 1 Homo sapiens 162-164 27459525-10 2016 Furthermore, oral administration of mifepristone or the selective GR antagonist CORT125134 had the desired effect of inhibiting prednisone-mediated activation of GR as seen by a reduction of FKBP5 mRNA levels. Prednisone 128-138 FKBP prolyl isomerase 5 Homo sapiens 191-196 27562137-0 2016 The metronomic therapy with prednisone, etoposide, and cyclophosphamide reduces the serum levels of VEGF and circulating endothelial cells and improves response rates and progression-free survival in patients with relapsed or refractory non-Hodgkin"s lymphoma. Prednisone 28-38 vascular endothelial growth factor A Homo sapiens 100-104 27562137-10 2016 CONCLUSION: Metronomic chemotherapy with prednisone, etoposide, and cyclophosphamide resulted in higher ORR and DCR, fewer adverse effects, and longer PFS in patients with relapsed or refractory NHL, with significant reduction in serum CECs and VEGF levels. Prednisone 41-51 vascular endothelial growth factor A Homo sapiens 245-249 26752024-1 2016 This is a proof of concept study that aims to establish feasibility and safety of a new strategy that includes an action plan for early treatment of acute exacerbations of COPD (AECOPD) with doubling dose of a combination of a long-acting beta2 agonist and an inhaled corticosteroid, and to explore its potential for avoiding the requirement of prednisone and its safety. Prednisone 345-355 potassium calcium-activated channel subfamily M regulatory beta subunit 2 Homo sapiens 239-244 27644318-2 2016 The apoptotic signaling mediated by receptor of activated C kinase 1 (Rack1), protein kinase C (PKC) and FEM1 homolog b (FEM1b) was investigated in two T-ALL-derived cell lines (Jurkat and CCRF-CEM) following treatment with chemotherapy drugs vincristine and prednisone. Prednisone 259-269 fem-1 homolog B Homo sapiens 121-126 27571786-7 2016 METHODS: We are conducting a randomized, double-blind, placebo-controlled trial of prophylactic prednisone (40 mg/day for 2 weeks, followed by 20 mg/day for 2 weeks) initiated at the same time as ART in patients at high risk for TB-IRIS (starting ART within 30 days of TB treatment and CD4 count <=100/muL). Prednisone 96-106 CD4 molecule Homo sapiens 286-289 27683148-8 2016 There was a significant reduction in the number of patients on prednisone and csDMARDs during anti-TNF treatment. Prednisone 63-73 tumor necrosis factor Homo sapiens 99-102 27683148-9 2016 CONCLUSION: Remission with first-line anti-TNF treatment is an achievable goal in clinical practice, allowing a reduction in concomitant csDMARD and prednisone treatment. Prednisone 149-159 tumor necrosis factor Homo sapiens 43-46 27621650-2 2016 Although the majority of patients with diffuse large B-cell lymphoma (DLBCL) can be cured with cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP), chemoresistance is a common cause of treatment failure. Prednisone 143-153 DNA damage inducible transcript 3 Homo sapiens 155-159 27424036-8 2016 RESULTS: Daily doses of prednisone up to 60 mg resulted in dose- and time-dependent decreases in plasma osteocalcin, plasma P1NP, serum cortisol, and absolute blood eosinophil counts. Prednisone 24-34 bone gamma-carboxyglutamate protein Homo sapiens 104-115 29931963-9 2016 Compared with bleomycin group, the corresponding mRNA and protein expression of 5-HTR2B and a-SMA in bleomycin+prednisone group had decreased (P<0.05); however, the corresponding mRNA and protein expression of E-cad had increased(P<0.05). Prednisone 111-121 cadherin 1 Rattus norvegicus 213-218 27133302-7 2016 RESULTS: In PF mice, paeoniflorin (50, 100 mg kg(-1) d(-1)) or prednisone (6 mg kg(-1) d(-1)) significantly decreased the expression of FSP-1 and alpha-SMA, and increased the expression of E-cadherin in lung tissues. Prednisone 63-73 atlastin GTPase 1 Mus musculus 136-141 27133302-7 2016 RESULTS: In PF mice, paeoniflorin (50, 100 mg kg(-1) d(-1)) or prednisone (6 mg kg(-1) d(-1)) significantly decreased the expression of FSP-1 and alpha-SMA, and increased the expression of E-cadherin in lung tissues. Prednisone 63-73 actin alpha 2, smooth muscle, aorta Mus musculus 146-155 27133302-7 2016 RESULTS: In PF mice, paeoniflorin (50, 100 mg kg(-1) d(-1)) or prednisone (6 mg kg(-1) d(-1)) significantly decreased the expression of FSP-1 and alpha-SMA, and increased the expression of E-cadherin in lung tissues. Prednisone 63-73 cadherin 1 Mus musculus 189-199 27352191-1 2016 BACKGROUND: Children with relapsed acute lymphoblastic leukemia (ALL) typically receive vincristine-prednisone-L-asparaginase-doxorubicin reinduction chemotherapy similar to contemporary induction regimens. Prednisone 100-110 asparaginase and isoaspartyl peptidase 1 Homo sapiens 111-125 27569951-5 2016 CD4(+) T-cell iATP level in the FK506 group and FK506 + prednisone (Pred) groups was higher than in the FK506 + mycophenolate mofetil (MMF), FK506 + MMF + Pred, and rapamycin (Rapa) groups. Prednisone 56-66 CD4 molecule Homo sapiens 0-3 27569951-5 2016 CD4(+) T-cell iATP level in the FK506 group and FK506 + prednisone (Pred) groups was higher than in the FK506 + mycophenolate mofetil (MMF), FK506 + MMF + Pred, and rapamycin (Rapa) groups. Prednisone 68-72 CD4 molecule Homo sapiens 0-3 27382316-0 2016 Expression of CD40 is a positive prognostic factor of diffuse large B-cell lymphoma treated with R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone). Prednisone 164-174 CD40 molecule Homo sapiens 14-18 27382316-1 2016 OBJECTIVES: The objective of this study was to investigate the expression level of CD40 and its role in the prognosis of patients with diffuse large B-cell lymphoma (DLBCL) who were treated with rituximab-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone). Prednisone 270-280 CD40 molecule Homo sapiens 83-87 26426431-8 2016 Increased infiltration of PD-1(+) cells was associated with prolonged progression-free survival (P = 0.005) and overall survival (P = 0.026) in DLBCL patients treated with rituximab-cyclophosphamide, doxorubicin, vincristine, prednisone (R-CHOP), whereas PD-L1 expression had no prognostic significance. Prednisone 226-236 programmed cell death 1 Homo sapiens 26-30 27007325-8 2016 In cytokine assay, we noticed increasing levels of IL-17 with increasing doses of concanavalin A in control group and in group of dams treated with cyclosporine A, mycophenolate mofetil and prednisone. Prednisone 190-200 interleukin 17A Rattus norvegicus 51-56 27052658-0 2016 A phase II trial of abiraterone acetate plus prednisone in patients with triple-negative androgen receptor positive locally advanced or metastatic breast cancer (UCBG 12-1). Prednisone 45-55 androgen receptor Homo sapiens 89-106 26879374-3 2016 RESULTS: Abiraterone acetate-prednisone treatment significantly decreased prostate-specific antigen progression risk by 49%, with longer median time to prostate-specific antigen progression of 5.55 months versus 2.76 months in the placebo-prednisone group (hazard ratio 0.506, P = 0.0001, primary end-point). Prednisone 29-39 kallikrein related peptidase 3 Homo sapiens 74-99 26879374-3 2016 RESULTS: Abiraterone acetate-prednisone treatment significantly decreased prostate-specific antigen progression risk by 49%, with longer median time to prostate-specific antigen progression of 5.55 months versus 2.76 months in the placebo-prednisone group (hazard ratio 0.506, P = 0.0001, primary end-point). Prednisone 29-39 kallikrein related peptidase 3 Homo sapiens 152-177 26879374-5 2016 The prostate-specific antigen response rate was higher in the abiraterone-prednisone group (49.7%) than in the placebo-prednisone group (14.1%). Prednisone 74-84 kallikrein related peptidase 3 Homo sapiens 4-29 26879374-5 2016 The prostate-specific antigen response rate was higher in the abiraterone-prednisone group (49.7%) than in the placebo-prednisone group (14.1%). Prednisone 119-129 kallikrein related peptidase 3 Homo sapiens 4-29 27099776-11 2016 CONCLUSIONS: Initial combination therapy with methotrexate, sulfasalazine and prednisone, or methotrexate and infliximab, is the most effective treatment strategy for ACPA-negative patients, resulting in earlier functional improvement than when on initial methotrexate monotherapy. Prednisone 78-88 proteinase 3 Homo sapiens 167-171 26985958-10 2016 The WT1 mutation, IVS4+14T>C, which is not predicted to affect splicing, was identified in one patient who achieved complete remission after 8 weeks of oral prednisone treatment, indicating that IVS4+14T>C is not a causative mutation. Prednisone 160-170 WT1 transcription factor Homo sapiens 4-7 26129902-11 2016 The levels of the IFN-gamma and IL-10 in the supernatants of the spleen lymph node cells were 382.33+-6.30, 155.87+-4.46 mug/L in the Yanyankang group and 270.93+-7.76, 265.32+-11.88 mug/L in the prednisone group. Prednisone 196-206 interferon gamma Rattus norvegicus 18-27 26754260-0 2016 A phase 2 multimodality trial of docetaxel/prednisone with sunitinib followed by salvage radiation therapy in men with PSA recurrent prostate cancer after radical prostatectomy. Prednisone 43-53 aminopeptidase puromycin sensitive Homo sapiens 119-122 26370103-11 2016 Otherwise, IL-1beta level was higher in MetS patients than in non-MetS patients (p = 0.012), and this finding was confirmed (p = 0.048) by multivariate analysis with adjustments for age, ethnicity, prednisone use, current and cumulative prednisone doses, and duration of use. Prednisone 198-208 interleukin 1 beta Homo sapiens 11-19 26370103-11 2016 Otherwise, IL-1beta level was higher in MetS patients than in non-MetS patients (p = 0.012), and this finding was confirmed (p = 0.048) by multivariate analysis with adjustments for age, ethnicity, prednisone use, current and cumulative prednisone doses, and duration of use. Prednisone 237-247 interleukin 1 beta Homo sapiens 11-19 26861642-5 2016 miR-34b expression and methylation of its promoter were not associated with most clinical parameters assessed; however, miR-34b levels in prednisone-sensitive ALL were significantly different from those in insensitive ALL. Prednisone 138-148 microRNA 34b Homo sapiens 120-127 26845678-3 2016 Moreover, miR-15a expression was significantly decreased after stimulation, and prednisone treatment could upregulate miR-15a expression in steroid-responsive MG patients. Prednisone 80-90 microRNA 15a Homo sapiens 118-125 26500140-5 2016 In R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone)-treated DLBCL patients (n=150), reduced HLA-DRA (<90% frequency) expression correlated with inferior overall survival (P=0.0003) and progression-free survival (P=0.0012) and with non-GCB subtype stratified by the Hans, Choi or Visco-Young algorithms (all P<0.01). Prednisone 69-79 major histocompatibility complex, class II, DR alpha Homo sapiens 121-128 26823489-3 2016 Here, we hypothesize that including a selective human CAR activator with the CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) regimen can improve the efficacy without exacerbating off-target toxicity of this regimen in non-Hodgkin lymphoma treatment. Prednisone 131-141 nuclear receptor subfamily 1 group I member 3 Homo sapiens 54-57 26875463-11 2016 Excluding the influence of sex, age, WBC count at diagnosis, cerebrospinal fluid state and prednisone response IKZF1 deletion still affected the patients" DFS, EFS and OS ( P<0.05 for all comparisons). Prednisone 91-101 IKAROS family zinc finger 1 Homo sapiens 111-116 27034868-10 2016 The patient was initiated on cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy, demonstrating a striking response. Prednisone 77-87 DNA damage inducible transcript 3 Homo sapiens 89-93 27188649-1 2016 BACKGROUND/AIMS: Rituximab-cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) every 14 days seems to achieve better outcomes than R-CHOP every 21 days in diffuse large B-cell lymphoma (DLBCL) patients. Prednisone 75-85 DNA damage inducible transcript 3 Homo sapiens 89-93 27188649-1 2016 BACKGROUND/AIMS: Rituximab-cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) every 14 days seems to achieve better outcomes than R-CHOP every 21 days in diffuse large B-cell lymphoma (DLBCL) patients. Prednisone 75-85 DNA damage inducible transcript 3 Homo sapiens 149-153 26823507-1 2016 In this issue of Blood, Mateos et al report that bortezomib plus melphalan and prednisone (VMP) and lenalidomide plus low-dose dexamethasone (Rd) administered in a sequential or an alternating scheme were equally active and induced comparable toxicities in elderly myeloma patients. Prednisone 79-89 neurensin 1 Homo sapiens 91-94 24675549-1 2016 This article describes the first reported case of dramatic lymphocytosis flare after initiation of R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone) therapy for an indolent lymphoma. Prednisone 166-176 DNA damage inducible transcript 3 Homo sapiens 101-105 27039799-1 2016 BACKGROUND: A combination of rituximab to cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) is one of the most effective front-line therapies to treat B-cell non-Hodgkin"s lymphoma (NHL). Prednisone 90-100 DNA damage inducible transcript 3 Homo sapiens 104-108 26986862-5 2016 We present a patient with T/myeloid mixed-phenotype acute leukemia secondary to rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone R-CHOP chemotherapy for primary cutaneous diffuse large B-cell lymphoma. Prednisone 139-149 DNA damage inducible transcript 3 Homo sapiens 152-156 27012051-8 2016 RESULTS: Prednisone treatment significantly increased serum cystatin C concentration from 1.24 +/- 0.40 mg/L at baseline to 1.61 +/- 0.80 mg/L at the end of study (p < 0.05). Prednisone 9-19 cystatin C Homo sapiens 60-70 27181540-4 2016 After two years of treatment with bortezomib, melphalan and prednisone (VMP) administered at shorter intervals relative to regular cycles, the patient showed a hematological and organ response. Prednisone 60-70 neurensin 1 Homo sapiens 72-75 26077666-7 2016 Survival of the patients treated with cyclophosphamide-/doxorubicin-/vincristine-/prednisone-based chemotherapy demonstrated that the prognosis of diffuse large B cell patients was unfavorable in the mRNA-positive group compared with the negative group, and that AID expression levels were correlated with the poor prognosis. Prednisone 82-92 activation induced cytidine deaminase Homo sapiens 263-266 26986862-11 2016 We describe a case of therapy-related T/myeloid mixed phenotype acute leukemia following rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone R-CHOP chemotherapy for primary cutaneous diffuse large B-cell lymphoma DLBCL. Prednisone 148-158 DNA damage inducible transcript 3 Homo sapiens 161-165 26341140-2 2015 We have previously shown that low HIP1R protein expression was associated with poorer survival in diffuse large B-cell lymphoma (DLBCL) patients from Denmark treated with R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone). Prednisone 234-244 huntingtin interacting protein 1 related Homo sapiens 34-39 26885255-2 2015 The combined chemotherapy of rituximab, cyclophosphamide, Adriamycin, vincristine, and prednisone (R-CHOP) is considered as the standard therapy for DLBCL; however, nearly half of the patients become refractory to the R-CHOP regimen. Prednisone 87-97 DNA damage inducible transcript 3 Homo sapiens 101-105 26885255-2 2015 The combined chemotherapy of rituximab, cyclophosphamide, Adriamycin, vincristine, and prednisone (R-CHOP) is considered as the standard therapy for DLBCL; however, nearly half of the patients become refractory to the R-CHOP regimen. Prednisone 87-97 DNA damage inducible transcript 3 Homo sapiens 220-224 26497689-15 2015 For patients who received docetaxel plus prednisone as first-line chemotherapy, positive stem cell gene expression suggested a poor PSA-PFS (p = 0.01) and a low PSA response rate (p = 0.008). Prednisone 41-51 aminopeptidase puromycin sensitive Homo sapiens 132-135 26497689-15 2015 For patients who received docetaxel plus prednisone as first-line chemotherapy, positive stem cell gene expression suggested a poor PSA-PFS (p = 0.01) and a low PSA response rate (p = 0.008). Prednisone 41-51 aminopeptidase puromycin sensitive Homo sapiens 161-164 27096481-5 2016 The patient was treated with multiagent cytotoxic chemotherapy, consisting of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP). Prednisone 126-136 DNA damage inducible transcript 3 Homo sapiens 138-142 25953530-7 2015 The patient was in partial response after four cycles of rituximab plus cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP). Prednisone 119-129 DNA damage inducible transcript 3 Homo sapiens 133-137 26884853-8 2015 We concluded that CD30 may be useful as a prognostic marker in rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) treated DLBCLs, indicating favorable outcomes in a Chinese population. Prednisone 122-132 TNF receptor superfamily member 8 Homo sapiens 18-22 26884853-8 2015 We concluded that CD30 may be useful as a prognostic marker in rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) treated DLBCLs, indicating favorable outcomes in a Chinese population. Prednisone 122-132 DNA damage inducible transcript 3 Homo sapiens 136-140 26582328-6 2015 Initial treatment with long-acting somatostatin analogue (octreotide LAR) and prednisone achieved a biochemical response (reduction of chromogranin A level) and a radiological disease control, but patient experienced only a brief improvement of neurological symptoms. Prednisone 78-88 chromogranin A Homo sapiens 135-149 26375845-1 2015 OBJECTIVE: To conduct a phase II trial of the combination of carboplatin, prednisone, and everolimus in metastatic castrate-resistant prostate cancer (mCRPC) as mTOR inhibition can overcome resistance to chemotherapy in prostate cancer. Prednisone 74-84 mechanistic target of rapamycin kinase Homo sapiens 161-165 26092330-14 2015 The median daily (interquartile range) dose of prednisone was also reduced from 10 (0-30)mg at the onset of the anti-TNF-alpha therapy to 0 (0-0)mg at 2 years (p = 0.02). Prednisone 47-57 tumor necrosis factor Homo sapiens 117-126 26456588-9 2015 Prednisone treatment also significantly decreased the elevated percentages of plasma cells and plasma cell precursors, decreased the percentages of activated T cells, and increased the frequency of CD4(+)CD62L(+) cells, demonstrated that decreased anti-nuclear antibodies and improvements in lupus symptoms were associated with decreased plasma cells. Prednisone 0-10 CD4 antigen Mus musculus 198-201 26456588-10 2015 Furthermore, prednisone treatment decreased serum IL-21 and IL-10 levels and reduced the expression of splenic Blimp-1 and Bcl-6 (two key regulatory factors for plasma cell differentiation) in MRL/lpr mice. Prednisone 13-23 interleukin 21 Mus musculus 50-55 26456588-10 2015 Furthermore, prednisone treatment decreased serum IL-21 and IL-10 levels and reduced the expression of splenic Blimp-1 and Bcl-6 (two key regulatory factors for plasma cell differentiation) in MRL/lpr mice. Prednisone 13-23 interleukin 10 Mus musculus 60-65 26456588-10 2015 Furthermore, prednisone treatment decreased serum IL-21 and IL-10 levels and reduced the expression of splenic Blimp-1 and Bcl-6 (two key regulatory factors for plasma cell differentiation) in MRL/lpr mice. Prednisone 13-23 PR domain containing 1, with ZNF domain Mus musculus 111-118 26456588-10 2015 Furthermore, prednisone treatment decreased serum IL-21 and IL-10 levels and reduced the expression of splenic Blimp-1 and Bcl-6 (two key regulatory factors for plasma cell differentiation) in MRL/lpr mice. Prednisone 13-23 B cell leukemia/lymphoma 6 Mus musculus 123-128 26456588-11 2015 CONCLUSION: Prednisone treatment restricts B lymphocyte differentiation into plasma cells in MRL/lpr mice, which may be correlated with the inhibition of IL-21 production and the restoration of the balance between Blimp-1 and Bcl-6. Prednisone 12-22 interleukin 21 Mus musculus 154-159 26456588-11 2015 CONCLUSION: Prednisone treatment restricts B lymphocyte differentiation into plasma cells in MRL/lpr mice, which may be correlated with the inhibition of IL-21 production and the restoration of the balance between Blimp-1 and Bcl-6. Prednisone 12-22 PR domain containing 1, with ZNF domain Mus musculus 214-221 26456588-11 2015 CONCLUSION: Prednisone treatment restricts B lymphocyte differentiation into plasma cells in MRL/lpr mice, which may be correlated with the inhibition of IL-21 production and the restoration of the balance between Blimp-1 and Bcl-6. Prednisone 12-22 B cell leukemia/lymphoma 6 Mus musculus 226-231 26408680-5 2015 CONCLUSION: Patients with primary MF showed aberrant expression of several genes involved in maintaining BM homeostasis and our findings suggest that treatment with lenalidomide plus prednisone up-regulates SOCS3. Prednisone 183-193 suppressor of cytokine signaling 3 Homo sapiens 207-212 26459042-0 2015 Prednisone inhibits the focal adhesion kinase/receptor activator of NF-kappaB ligand/mitogen-activated protein kinase signaling pathway in rats with adriamycin-induced nephropathy. Prednisone 0-10 protein tyrosine kinase 2 Rattus norvegicus 24-45 26459042-1 2015 The aim of the present study was to investigate the mechanisms underlying the effects of prednisone on adriamycin-induced nephritic rat kidney damage via the focal adhesion kinase (FAK)/receptor activator of nuclear factor-kappaB ligand (RANKL)/mitogen-activated protein kinase (MAPK) signaling pathway. Prednisone 89-99 protein tyrosine kinase 2 Rattus norvegicus 158-179 26459042-1 2015 The aim of the present study was to investigate the mechanisms underlying the effects of prednisone on adriamycin-induced nephritic rat kidney damage via the focal adhesion kinase (FAK)/receptor activator of nuclear factor-kappaB ligand (RANKL)/mitogen-activated protein kinase (MAPK) signaling pathway. Prednisone 89-99 protein tyrosine kinase 2 Rattus norvegicus 181-184 26459042-1 2015 The aim of the present study was to investigate the mechanisms underlying the effects of prednisone on adriamycin-induced nephritic rat kidney damage via the focal adhesion kinase (FAK)/receptor activator of nuclear factor-kappaB ligand (RANKL)/mitogen-activated protein kinase (MAPK) signaling pathway. Prednisone 89-99 TNF superfamily member 11 Rattus norvegicus 186-236 26459042-1 2015 The aim of the present study was to investigate the mechanisms underlying the effects of prednisone on adriamycin-induced nephritic rat kidney damage via the focal adhesion kinase (FAK)/receptor activator of nuclear factor-kappaB ligand (RANKL)/mitogen-activated protein kinase (MAPK) signaling pathway. Prednisone 89-99 TNF superfamily member 11 Rattus norvegicus 238-243 26459042-10 2015 In the prednisone group, the protein expression levels of p-ERK decreased, as compared with the normal group. Prednisone 7-17 Eph receptor B1 Rattus norvegicus 60-63 26459042-12 2015 In the prednisone group, the mRNA and protein expression levels of nephrin and the serum expression levels of RANKL increased, the serum expression levels of osteoprotegerin (OPG) were decreased, as compared with the model group. Prednisone 7-17 NPHS1 adhesion molecule, nephrin Rattus norvegicus 67-74 26459042-12 2015 In the prednisone group, the mRNA and protein expression levels of nephrin and the serum expression levels of RANKL increased, the serum expression levels of osteoprotegerin (OPG) were decreased, as compared with the model group. Prednisone 7-17 TNF superfamily member 11 Rattus norvegicus 110-115 26459042-12 2015 In the prednisone group, the mRNA and protein expression levels of nephrin and the serum expression levels of RANKL increased, the serum expression levels of osteoprotegerin (OPG) were decreased, as compared with the model group. Prednisone 7-17 TNF receptor superfamily member 11B Rattus norvegicus 158-173 26459042-12 2015 In the prednisone group, the mRNA and protein expression levels of nephrin and the serum expression levels of RANKL increased, the serum expression levels of osteoprotegerin (OPG) were decreased, as compared with the model group. Prednisone 7-17 TNF receptor superfamily member 11B Rattus norvegicus 175-178 26459042-14 2015 These results suggested that prednisone is able to protect podocytes from apoptosis, and reduce urinary protein levels by inhibiting the FAK/RANKL/MAPK signaling pathway in kidney tissue samples. Prednisone 29-39 protein tyrosine kinase 2 Rattus norvegicus 137-140 26459042-14 2015 These results suggested that prednisone is able to protect podocytes from apoptosis, and reduce urinary protein levels by inhibiting the FAK/RANKL/MAPK signaling pathway in kidney tissue samples. Prednisone 29-39 TNF superfamily member 11 Rattus norvegicus 141-146 26459042-15 2015 Serum prednisone may induce osteoporosis via the OPG/RANK/RANKL signaling pathway. Prednisone 6-16 TNF receptor superfamily member 11B Rattus norvegicus 49-52 26459042-15 2015 Serum prednisone may induce osteoporosis via the OPG/RANK/RANKL signaling pathway. Prednisone 6-16 TNF superfamily member 11 Rattus norvegicus 58-63 24833784-7 2015 Longer TTP was related to age, nulliparity, disease activity (DAS28), and preconception use of non-steroidal anti-inflammatory drugs (NSAIDs) and prednisone. Prednisone 146-156 ZFP36 ring finger protein Homo sapiens 7-10 24833784-8 2015 These variables were independently associated with TTP, with HRs for occurrence of pregnancy of 0.96 (95% CI 0.92 to 1.00) per year of age, 0.52 (0.38 to 0.70) for nulliparity, 0.81 (0.71 to 0.93) per point increase in DAS28, 0.66 (0.46 to 0.94) for NSAIDs and 0.61 (0.45 to 0.83) for prednisone use. Prednisone 285-295 ZFP36 ring finger protein Homo sapiens 51-54 24833784-9 2015 The impact of prednisone use was dose dependent, with significantly longer TTP when daily dose was >7.5 mg. Prednisone 14-24 ZFP36 ring finger protein Homo sapiens 75-78 24833784-11 2015 CONCLUSIONS: TTP in RA is longer if patients are older or nulliparous, have higher disease activity, use NSAIDs or use prednisone >7.5 mg daily. Prednisone 119-129 ZFP36 ring finger protein Homo sapiens 13-16 26220348-6 2015 Targeting 11beta-HSD1, LG13 could inhibit prednisone-induced adverse changes in mice, but had no effects on dexamethasone-induced ones. Prednisone 42-52 hydroxysteroid 11-beta dehydrogenase 1 Mus musculus 10-21 26458444-2 2015 The current standard therapy for DLBCL is R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone) therapy, which allows many patients to achieve disease cure. Prednisone 109-119 DNA damage inducible transcript 3 Homo sapiens 44-48 26248188-11 2015 Diaphragms from P-188 NF or prednisone treated mdx and dko mice showed signs of muscle fiber protection including less centralized nuclei, less variation in fiber size, greater fiber density, and exhibited a decreased amount of collagen deposition. Prednisone 28-38 dystrophin, muscular dystrophy Mus musculus 47-50 26315113-1 2015 Treatment with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) has greatly improved clinical outcomes in patients with diffuse large B-cell lymphoma (DLBCL) compared with CHOP. Prednisone 78-88 DNA damage inducible transcript 3 Homo sapiens 92-96 26315113-1 2015 Treatment with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) has greatly improved clinical outcomes in patients with diffuse large B-cell lymphoma (DLBCL) compared with CHOP. Prednisone 78-88 DNA damage inducible transcript 3 Homo sapiens 206-210 25998512-3 2015 METHODS: Patients who were newly diagnosed with DLBCL and treated with rituximab plus cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP) were analysed. Prednisone 133-143 DNA damage inducible transcript 3 Homo sapiens 147-151 26314844-8 2015 In particular, the treatment with ABCG2 McAb plus PTX-NPs induced the strongest therapeutic response and had an efficacy even better than that of melphalan/prednisone, a conventional regimen for MM patients. Prednisone 156-166 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 34-39 25880119-4 2015 MATERIALS AND METHODS: TRIM21 expression levels were assessed by immunohistochemistry in lymphoma biopsies from three cohorts of patients with DLBCL: 42 patients with rheumatic disease treated with a cyclophosphamide, vincristine, doxorubicin and prednisone (CHOP)-like regimen, 76 CHOP-treated and 196 rituximab-CHOP-treated nonrheumatic patients. Prednisone 247-257 tripartite motif containing 21 Homo sapiens 23-29 26625571-0 2015 Stability of Prednisone in Oral Mix Suspending Vehicle. Prednisone 13-23 Mix paired-like homeobox Homo sapiens 32-35 25869285-7 2015 Anthracycline-based regimens such as cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) remain the standard first-line treatment choice for systemic ALCL, but in many patients with ALK- ALCL, it is ineffective, and thus it is often followed by consolidative autologous stem cell transplantation. Prednisone 85-95 DNA damage inducible transcript 3 Homo sapiens 97-101 25869285-7 2015 Anthracycline-based regimens such as cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) remain the standard first-line treatment choice for systemic ALCL, but in many patients with ALK- ALCL, it is ineffective, and thus it is often followed by consolidative autologous stem cell transplantation. Prednisone 85-95 ALK receptor tyrosine kinase Homo sapiens 196-199 25648098-1 2015 PURPOSE: Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) is the standard chemotherapy in diffuse large B-cell lymphoma (DLBCL) patients. Prednisone 72-82 DNA damage inducible transcript 3 Homo sapiens 86-90 26108069-9 2015 Additionally, levels of B7-H3 decreased remarkably after prednisone treatment. Prednisone 57-67 CD276 molecule Homo sapiens 24-29 25401491-9 2015 The independent factors affecting PTX3 expression included Systemic Lupus Erythematosus Disease Activity Index, prednisone dose and anemia severity. Prednisone 112-122 pentraxin 3 Homo sapiens 34-38 26076798-2 2015 Historically, PTCL was treated like aggressive B-cell lymphomas, and to date cyclophosphamide, prednisone, vincristine, and doxorubicin (CHOP) remains the most commonly used regimen, despite disappointing results. Prednisone 95-105 DNA damage inducible transcript 3 Homo sapiens 137-141 25611207-7 2015 A significant increment in IL-10 and a significant decrement in IL-6 (p<0.05) were also observed with prednisone both at rest and during exercise, without significant change in IL-1beta. Prednisone 105-115 interleukin 10 Homo sapiens 27-32 25675909-1 2015 BACKGROUND: Although the combination of rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) is considered standard therapy for diffuse large B-cell lymphoma (DLBCL), patterns of use and the impact of R-CHOP on survival in patients aged >80 years are less clear. Prednisone 99-109 DNA damage inducible transcript 3 Homo sapiens 113-117 25675909-1 2015 BACKGROUND: Although the combination of rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) is considered standard therapy for diffuse large B-cell lymphoma (DLBCL), patterns of use and the impact of R-CHOP on survival in patients aged >80 years are less clear. Prednisone 99-109 DNA damage inducible transcript 3 Homo sapiens 229-233 25611207-7 2015 A significant increment in IL-10 and a significant decrement in IL-6 (p<0.05) were also observed with prednisone both at rest and during exercise, without significant change in IL-1beta. Prednisone 105-115 interleukin 6 Homo sapiens 64-68 26316483-2 2015 The aim of this study was to examine the FcgammaRIIIA gene polymorphism distribution of DLBCL patients who had been treated with R-CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) chemotherapy. Prednisone 185-195 Fc gamma receptor IIIa Homo sapiens 41-53 25644744-2 2015 Here, we investigated five single nucleotide polymorphisms (SNPs) in both the coding and non-coding regions of the glucocorticoid receptor (GR) gene, and analyzed their association with prednisone responsiveness in vivo in 63 pediatric patients with ALL in China. Prednisone 186-196 nuclear receptor subfamily 3 group C member 1 Homo sapiens 115-138 25644744-2 2015 Here, we investigated five single nucleotide polymorphisms (SNPs) in both the coding and non-coding regions of the glucocorticoid receptor (GR) gene, and analyzed their association with prednisone responsiveness in vivo in 63 pediatric patients with ALL in China. Prednisone 186-196 nuclear receptor subfamily 3 group C member 1 Homo sapiens 140-142 25644744-6 2015 Our results suggested that polymorphisms in the non-coding region of the GR gene were associated with prednisone response in vivo in pediatric ALL in Han Chinese. Prednisone 102-112 nuclear receptor subfamily 3 group C member 1 Homo sapiens 73-75 25675382-3 2015 We report the successful treatment of a patient with type B insulin resistance with rituximab, cyclophosphamide, and prednisone. Prednisone 117-127 insulin Homo sapiens 60-67 26056479-7 2015 The patient underwent cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) regime of chemotherapy and achieved a complete remission after four cycles. Prednisone 70-80 DNA damage inducible transcript 3 Homo sapiens 82-86 24956143-3 2015 In this prospective cohort study of 44 patients aged 70 years or older with NHL receiving rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP), a GA was administered before the start of chemotherapy. Prednisone 148-158 DNA damage inducible transcript 3 Homo sapiens 162-166 25587129-0 2015 Associations of HSD11B1 polymorphisms with tacrolimus concentrations in Chinese renal transplant recipients with prednisone combined therapy. Prednisone 113-123 hydroxysteroid 11-beta dehydrogenase 1 Homo sapiens 16-23 26032070-17 2015 4) The TNF-alpha expression was significantly down-regulated in the novaferon groups (at low-dose, middle-dose or high-dose), the mesalazine group and the prednisone group compared with model group (all P<0.01); but there was no significant difference between the mesalazine group and the prednisone group (P>0.05); the decrease of TNF-alpha expression by novaferon displayed a dose-dependent manner. Prednisone 155-165 tumor necrosis factor Mus musculus 7-16 26032070-17 2015 4) The TNF-alpha expression was significantly down-regulated in the novaferon groups (at low-dose, middle-dose or high-dose), the mesalazine group and the prednisone group compared with model group (all P<0.01); but there was no significant difference between the mesalazine group and the prednisone group (P>0.05); the decrease of TNF-alpha expression by novaferon displayed a dose-dependent manner. Prednisone 292-302 tumor necrosis factor Mus musculus 7-16 26032070-18 2015 Compared with the mesalazine group or the prednisone group, the TNF-alpha expression in novaferon groups at all dosages was dramatically reduced (all P<0.01). Prednisone 42-52 tumor necrosis factor Mus musculus 64-73 25918482-7 2015 RESULTS: Visfatin gene expression levels in peripheral blood were significantly higher in newly diagnosed adult DM cases compared to non-disease controls (P = 0.004) and these levels correlated with baseline clinical parameters such as age (r = 0.34, P = 0.020), male sex (r = -0.35, P = 0.017), prednisone use (r = -0.42, P = 0.006), and DMARD use (r = 0.35, P = 0.025). Prednisone 296-306 nicotinamide phosphoribosyltransferase Homo sapiens 9-17 25812008-9 2015 Patients treated with prednisone had lower eotaxin-3 and eosinophil levels compared to patients not taking glucocorticoids irrespective of disease activity. Prednisone 22-32 C-C motif chemokine ligand 26 Homo sapiens 43-52 26687958-2 2015 Although it has limited efficacy, cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) therapy is widely used for treatment of de-novo peripheral T-cell lymphoma. Prednisone 82-92 DNA damage inducible transcript 3 Homo sapiens 94-98 25635435-1 2015 BACKGROUND: Rituximab in combination with cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly prolonged event-free survival in first-line chemotherapy for patients with diffuse large B-cell lymphoma (DLBCL). Prednisone 90-100 DNA damage inducible transcript 3 Homo sapiens 102-106 25889713-10 2015 CONCLUSIONS: Because of prednisone-related suppression of IFN-score, higher accuracy of rituximab response prediction was achieved in PREDN(-) patients. Prednisone 24-34 interferon alpha 1 Homo sapiens 58-61 25889713-11 2015 These results suggest that the IFN-score-based rituximab response prediction model could be improved upon implementation of prednisone use. Prednisone 124-134 interferon alpha 1 Homo sapiens 31-34 25617430-2 2015 In this population, the most commonly used plasma creatinine (PCr)-based or cystatin C (CystC)-based GFR-predicting formulas may underperform (e.g., corticosteroids and trimethoprim may affect PCr concentration, whereas prednisone and calcineurin inhibitors may affect CystC concentration). Prednisone 220-230 cystatin C Homo sapiens 88-93 25498913-8 2015 We also identified predictive miRNA biomarker signatures in DLBCL, including high expression of miR-155, which is significantly associated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) treatment failure. Prednisone 207-217 microRNA 155 Mus musculus 96-103 25498913-8 2015 We also identified predictive miRNA biomarker signatures in DLBCL, including high expression of miR-155, which is significantly associated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) treatment failure. Prednisone 207-217 DNA-damage inducible transcript 3 Mus musculus 221-225 25418196-3 2015 A total of 197 patients treated with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) were enrolled between October 2005 and July 2011; PET/CT was performed at the time of diagnosis (PET/CT0), after 2 and 4 cycles of chemotherapy (PET/CT2 and PET/CT4, respectively), and at the end of treatment (F-PET/CT). Prednisone 96-106 DNA damage inducible transcript 3 Homo sapiens 110-114 25389028-5 2015 Although the prevalence of MetS is low in pediatric liver transplant recipients, it is associated with CKD and prednisone therapy (p < 0.05). Prednisone 111-121 ETS variant transcription factor 3 Homo sapiens 27-31 25530566-6 2015 Furthermore, low expression of ARS2 was closely correlated to poor treatment response including poor prednisone response and high minimal residual disease (MRD), and the patients with high MRD (>=10(-4)) and low ARS2 were more subject to relapse. Prednisone 101-111 serrate, RNA effector molecule Homo sapiens 31-35 25591142-9 2015 Under treatment with oral prednisone mean eGFR significantly improved from 38 +- 21 ml/min to 57 +- 26 ml/min and proteinuria decreased from 981 +- 304 mg/24 hrs to 176 +- 77 mg/24 hrs at the end of follow-up. Prednisone 26-36 epidermal growth factor receptor Homo sapiens 42-46 25559283-1 2015 BACKGROUND: The role of the multidrug resistance-1 (MDR1 or ABCB1) gene polymorphisms 1236T>C, 2677T>G, and 3435T>C was studied in relation to susceptibility, demographics, and pathological characteristics, as well as their role in the therapeutic response (TR) to prednisone treatment in children with idiopathic nephrotic syndrome (INS). Prednisone 274-284 ATP binding cassette subfamily B member 1 Homo sapiens 28-50 25559283-1 2015 BACKGROUND: The role of the multidrug resistance-1 (MDR1 or ABCB1) gene polymorphisms 1236T>C, 2677T>G, and 3435T>C was studied in relation to susceptibility, demographics, and pathological characteristics, as well as their role in the therapeutic response (TR) to prednisone treatment in children with idiopathic nephrotic syndrome (INS). Prednisone 274-284 ATP binding cassette subfamily B member 1 Homo sapiens 52-56 25559283-1 2015 BACKGROUND: The role of the multidrug resistance-1 (MDR1 or ABCB1) gene polymorphisms 1236T>C, 2677T>G, and 3435T>C was studied in relation to susceptibility, demographics, and pathological characteristics, as well as their role in the therapeutic response (TR) to prednisone treatment in children with idiopathic nephrotic syndrome (INS). Prednisone 274-284 ATP binding cassette subfamily B member 1 Homo sapiens 60-65 25559283-7 2015 CONCLUSIONS: These data suggest that prednisone TR may be influenced by histology, age at the onset of INS, and MDR1 3435T>C polymorphism. Prednisone 37-47 ATP binding cassette subfamily B member 1 Homo sapiens 112-116 25591142-12 2015 Furthermore, prednisone therapy is effective in improving eGFR and in reducing total urinary protein secretion. Prednisone 13-23 epidermal growth factor receptor Homo sapiens 58-62 26000299-5 2015 Both prednisone and celecoxib decreased MMP-1 and PGE-2 production while the nonspecific piroxicam decreased only the latter. Prednisone 5-15 matrix metallopeptidase 1 Homo sapiens 40-45 26137775-13 2015 The most widely used and most effective is the combination Cyclophosphamide, Doxorubicin, Vincristine and Prednisone (CHOP). Prednisone 106-116 DNA damage inducible transcript 3 Homo sapiens 118-122 25878913-3 2015 The patient received cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) with rituximab and had excellent results. Prednisone 69-79 DNA damage inducible transcript 3 Homo sapiens 81-85 26000299-6 2015 Both prednisone and celecoxib decreased gene expression of MMP-1 and increased expression of aggrecan. Prednisone 5-15 matrix metallopeptidase 1 Homo sapiens 59-64 25684797-0 2015 Bortezomib, Melphalan, and Prednisone (VMP) Regimen for Multiple Myeloma. Prednisone 27-37 neurensin 1 Homo sapiens 39-42 26167311-6 2015 The patient received cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) followed by salvage ifosfamide, carboplatin, and etoposide (ICE) but had continuous progression of cutaneous involvement. Prednisone 69-79 DNA damage inducible transcript 3 Homo sapiens 81-85 25493453-11 2015 Importantly, 13 of the 20 (65%) NOTCH1/FBXW7-mutated T-ALL patients showed a good prednisone response (P=0.01) and a better clinical outcome compared with NOTCH1/FBXW7 nonmutated patients (P=0.03). Prednisone 82-92 notch receptor 1 Homo sapiens 32-38 25493453-11 2015 Importantly, 13 of the 20 (65%) NOTCH1/FBXW7-mutated T-ALL patients showed a good prednisone response (P=0.01) and a better clinical outcome compared with NOTCH1/FBXW7 nonmutated patients (P=0.03). Prednisone 82-92 F-box and WD repeat domain containing 7 Homo sapiens 39-44 25227591-5 2015 Circadian use of low-dose, long-term prednisone, by using night-release formulations (ingested at 10 to 11 p.m.) especially in early RA patients, appears characterized by a significantly superior efficacy on decreasing morning stiffness and IL-6 serum levels, compared to conventional daytime immediate-release prednisone. Prednisone 37-47 interleukin 6 Homo sapiens 241-245 25686648-3 2015 The summary hazard ratios of low ALC/AMC ratio for overall survival were 2.00 (p = 0.000) in the population that received R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone) and 1.12 (p = 0.479) in the population that received CHOP. Prednisone 185-195 allantoicase Homo sapiens 33-36 25468432-3 2015 Molecular analyses support the concept that there is a biological continuum between BL and DLBCL that includes variable activity of MYC, an oncoprotein once thought to be only associated with BL, but now recognized as a major predictor of survival among patients with DLBCL treated with R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone). Prednisone 354-364 MYC proto-oncogene, bHLH transcription factor Homo sapiens 132-135 25227901-12 2015 [Lancet 2008;371:205-214] reported CAPRA-1, which documented that modified-release prednisone or prednisolone taken at bedtime led to lower morning stiffness and IL-6 levels compared to usual morning prednisone. Prednisone 83-93 interleukin 6 Homo sapiens 162-166 25314055-13 2014 CONCLUSIONS: Durable PSA responses occur in up to 40% of patients following a "steroid switch" for PSA progression on abiraterone and prednisone. Prednisone 134-144 aminopeptidase puromycin sensitive Homo sapiens 21-24 26334344-1 2015 INTRODUCTION: R-CHOP immunochemotherapy (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone) is a standard first-line treatment for diffuse large B-cell lymphoma (DLBCL). Prednisone 96-106 DNA damage inducible transcript 3 Homo sapiens 16-20 24723488-5 2014 RESULTS: Six courses of cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) or cyclophosphamide, doxorubicin, vincristine, etoposide and prednisone (CHOEP) chemotherapy were recommended for first-line therapy of patients with nodal, intestinal or hepatosplenic T-cell lymphomas (evidence: low; recommendation: do, weak). Prednisone 71-81 DNA damage inducible transcript 3 Homo sapiens 83-87 25323007-2 2014 Although patient outcomes have significantly improved to a greater than 40% cure rate by the combinatorial cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) chemotherapy, which is widely used, resistance to the CHOP regimen continues to pose a problem in managing or curing DLBCL. Prednisone 154-164 DNA damage inducible transcript 3 Homo sapiens 166-170 25319133-0 2014 Prednisone inhibits the IL-1beta-induced expression of COX-2 in HEI-OC1 murine auditory cells through the inhibition of ERK-1/2, JNK-1 and AP-1 activity. Prednisone 0-10 interleukin 1 beta Homo sapiens 24-32 25319133-0 2014 Prednisone inhibits the IL-1beta-induced expression of COX-2 in HEI-OC1 murine auditory cells through the inhibition of ERK-1/2, JNK-1 and AP-1 activity. Prednisone 0-10 mitochondrially encoded cytochrome c oxidase II Homo sapiens 55-60 25319133-0 2014 Prednisone inhibits the IL-1beta-induced expression of COX-2 in HEI-OC1 murine auditory cells through the inhibition of ERK-1/2, JNK-1 and AP-1 activity. Prednisone 0-10 mitogen-activated protein kinase 3 Mus musculus 120-127 25319133-0 2014 Prednisone inhibits the IL-1beta-induced expression of COX-2 in HEI-OC1 murine auditory cells through the inhibition of ERK-1/2, JNK-1 and AP-1 activity. Prednisone 0-10 mitogen-activated protein kinase 8 Mus musculus 129-134 25323007-2 2014 Although patient outcomes have significantly improved to a greater than 40% cure rate by the combinatorial cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) chemotherapy, which is widely used, resistance to the CHOP regimen continues to pose a problem in managing or curing DLBCL. Prednisone 154-164 DNA damage inducible transcript 3 Homo sapiens 226-230 24895078-9 2014 AUC(0- ) GMR (90%CI) [midazolam + prednisone (Day 28, Period 2)/midazolam alone (Day -1, Period 1] was 1.08 (0.93,1.26). Prednisone 34-44 period circadian regulator 2 Homo sapiens 54-62 25361624-2 2014 This review evaluates the basis for the effects of prednisone on mineralocorticoid-related adverse events that arise because of CYP17A1 inhibition with abiraterone. Prednisone 51-61 cytochrome P450 family 17 subfamily A member 1 Homo sapiens 128-135 25344211-2 2014 The aim of this study was to investigate the role of aldehyde dehydrogenase (ALDH) 1A1 in the resistance of diffuse large B cell lymphoma to the chemotherapeutic mixture consisting of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP). Prednisone 232-242 aldehyde dehydrogenase 1 family member A1 Homo sapiens 53-86 25410844-7 2014 CONCLUSIONS: In patients with moderate-to-severe eosinophilic bronchitis, treatment with prednisone caused a significant reduction in sputum eosinophil counts, as well as in the sputum levels of IL-5 and ECP. Prednisone 89-99 interleukin 5 Homo sapiens 195-199 25408580-1 2014 Febrile neutropenia (FN) is the major toxicity of rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) regimen in the treatment of diffuse large B-cell lymphoma (DLBCL). Prednisone 113-123 DNA damage inducible transcript 3 Homo sapiens 127-131 25229255-2 2014 Improvements in overall survival have been observed with the introduction of rituximab in combination with cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP), however, prognostic markers are still needed. Prednisone 155-165 DNA damage inducible transcript 3 Homo sapiens 169-173 25469343-0 2014 Rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) chemotherapy for diffuse large B-cell lymphoma in pregnancy may be associated with preterm birth. Prednisone 59-69 DNA damage inducible transcript 3 Homo sapiens 73-77 25410844-7 2014 CONCLUSIONS: In patients with moderate-to-severe eosinophilic bronchitis, treatment with prednisone caused a significant reduction in sputum eosinophil counts, as well as in the sputum levels of IL-5 and ECP. Prednisone 89-99 ribonuclease A family member 3 Homo sapiens 204-207 25325035-1 2014 BACKGROUND: Although adding rituximab to the chemotherapy regimen of cyclophosphamide, vincristine, doxorubicin, and prednisone (R-CHOP) has improved clinical outcomes of patients with diffuse large B-cell lymphoma (DLBCL), several recent studies have shown that the effect of rituximab is dominantly in the non-germinal center (non-GC) subtype compared to the germinal center (GC) subtype. Prednisone 117-127 DNA damage inducible transcript 3 Homo sapiens 131-135 25313181-11 2014 The base-case ICER was $389K/QALY for abiraterone and $547K/QALY for sipuleucel-T. Prednisone dominates both abiraterone and sipuleucel-T in terms of NMB at willingness-to-pay (WTP) thresholds of $400K or less. Prednisone 83-93 cAMP responsive element modulator Homo sapiens 14-18 25313181-11 2014 The base-case ICER was $389K/QALY for abiraterone and $547K/QALY for sipuleucel-T. Prednisone dominates both abiraterone and sipuleucel-T in terms of NMB at willingness-to-pay (WTP) thresholds of $400K or less. Prednisone 83-93 neuromedin B Homo sapiens 150-153 25203561-13 2014 CONCLUSIONS: The TNF-alpha inhibitor GLM stabilized hearing in 3 of 7 per-protocol subjects with AIED and allowed a complete tapering off of prednisone in those 7 subjects. Prednisone 141-151 tumor necrosis factor Homo sapiens 17-26 24975830-7 2014 Treatment with prednisone or/and immunosuppressive drugs significantly reduced the frequency of CD4(+)CXCR5(+), CD4(+)CXCR5(+)PD-1(+) TFH cells and serum IL-21 level, but increased IL-4 and IL-10 levels in the patients. Prednisone 15-25 CD4 molecule Sus scrofa 96-99 24975830-7 2014 Treatment with prednisone or/and immunosuppressive drugs significantly reduced the frequency of CD4(+)CXCR5(+), CD4(+)CXCR5(+)PD-1(+) TFH cells and serum IL-21 level, but increased IL-4 and IL-10 levels in the patients. Prednisone 15-25 C-X-C motif chemokine receptor 5 Homo sapiens 102-107 24975830-7 2014 Treatment with prednisone or/and immunosuppressive drugs significantly reduced the frequency of CD4(+)CXCR5(+), CD4(+)CXCR5(+)PD-1(+) TFH cells and serum IL-21 level, but increased IL-4 and IL-10 levels in the patients. Prednisone 15-25 CD4 molecule Sus scrofa 112-115 25145685-0 2014 P-glycoprotein inhibition promotes prednisone retention in human sinonasal polyp explants. Prednisone 35-45 ATP binding cassette subfamily B member 1 Homo sapiens 0-14 24975830-7 2014 Treatment with prednisone or/and immunosuppressive drugs significantly reduced the frequency of CD4(+)CXCR5(+), CD4(+)CXCR5(+)PD-1(+) TFH cells and serum IL-21 level, but increased IL-4 and IL-10 levels in the patients. Prednisone 15-25 C-X-C motif chemokine receptor 5 Homo sapiens 118-123 25145685-8 2014 RESULTS: The intracytoplasmic prednisone concentration was significantly greater relative to control following P-gp inhibition with Verapamil (155.28% +- 22.48%, p < 0.05) and Zosuquidar (125.81% +- 12.41%, p < 0.05). Prednisone 30-40 ATP binding cassette subfamily B member 1 Homo sapiens 111-115 25145685-9 2014 Similarly, the amount of prednisone secreted by the explant was significantly reduced at 30 minutes following P-gp inhibition with Zosuquidar (78.64% +- 2.98%, p < 0.05) and 40 minutes following P-gp inhibition with Verapamil (80.56% +- 5.02%, p < 0.05). Prednisone 25-35 ATP binding cassette subfamily B member 1 Homo sapiens 110-114 25145685-9 2014 Similarly, the amount of prednisone secreted by the explant was significantly reduced at 30 minutes following P-gp inhibition with Zosuquidar (78.64% +- 2.98%, p < 0.05) and 40 minutes following P-gp inhibition with Verapamil (80.56% +- 5.02%, p < 0.05). Prednisone 25-35 ATP binding cassette subfamily B member 1 Homo sapiens 198-202 24975830-7 2014 Treatment with prednisone or/and immunosuppressive drugs significantly reduced the frequency of CD4(+)CXCR5(+), CD4(+)CXCR5(+)PD-1(+) TFH cells and serum IL-21 level, but increased IL-4 and IL-10 levels in the patients. Prednisone 15-25 interleukin 21 Sus scrofa 154-159 25145685-10 2014 CONCLUSION: Inhibition of P-gp enhances the intracellular accumulation of prednisone in nasal polyps. Prednisone 74-84 ATP binding cassette subfamily B member 1 Homo sapiens 26-30 24975830-7 2014 Treatment with prednisone or/and immunosuppressive drugs significantly reduced the frequency of CD4(+)CXCR5(+), CD4(+)CXCR5(+)PD-1(+) TFH cells and serum IL-21 level, but increased IL-4 and IL-10 levels in the patients. Prednisone 15-25 interleukin 4 Sus scrofa 181-185 24975830-7 2014 Treatment with prednisone or/and immunosuppressive drugs significantly reduced the frequency of CD4(+)CXCR5(+), CD4(+)CXCR5(+)PD-1(+) TFH cells and serum IL-21 level, but increased IL-4 and IL-10 levels in the patients. Prednisone 15-25 IL10 Sus scrofa 190-195 24304372-0 2014 Polycomb protein EZH2 expression in diffuse large B-cell lymphoma is associated with better prognosis in patients treated with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone. Prednisone 185-195 enhancer of zeste 2 polycomb repressive complex 2 subunit Homo sapiens 17-21 24590536-3 2014 Here, we aimed to assess whether SA can be an independent prognostic marker in patients with newly diagnosed DLBCL treated with rituximab, cyclophosphamide, vincristine, doxorubicin, and prednisone (R-CHOP). Prednisone 187-197 albumin Homo sapiens 33-35 25131489-11 2014 Generally, abiraterone and prednisone resulted in prolonged radiographic progression-free survival and delayed in PSA progression in mCRPC no prior chemotherapy. Prednisone 27-37 kallikrein related peptidase 3 Homo sapiens 114-117 25054764-7 2014 R-CHOP chemotherapy regimen (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone) is the most widely accepted treatment. Prednisone 87-97 DNA damage inducible transcript 3 Homo sapiens 2-6 24931464-2 2014 We report here that low expression of miR-146b-5p and miR-320d is associated with poor prognosis of DLBCL patients treated with the standard cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) regimen and that this is related to the inhibitory effect of these miRs on DLBCL cell proliferation. Prednisone 189-199 DNA damage inducible transcript 3 Homo sapiens 201-205 25002376-1 2014 The aim of the present study was to evaluate the efficacy of cyclosporine A (CsA) combined with medium/low dose prednisone in the treatment of progressive immunoglobulin A nephropathy (IgAN). Prednisone 112-122 IGAN1 Homo sapiens 185-189 25002376-9 2014 Moreover, at the end of the course, a higher remission rate was observed in patients with Lee"s Grade III IgAN after combined treatment with prednisone and CsA (p < 0.05). Prednisone 141-151 IGAN1 Homo sapiens 106-110 25002376-11 2014 CsA at a dose of 2-3 mg/kg/day in combination with medium/low dose prednisone was effective in inducing remission of IgAN, especially for patients with Lee"s Grade III IgAN, and is a safe and effective choice for short-term treatment of patients with progressive IgAN. Prednisone 67-77 IGAN1 Homo sapiens 117-121 25002376-11 2014 CsA at a dose of 2-3 mg/kg/day in combination with medium/low dose prednisone was effective in inducing remission of IgAN, especially for patients with Lee"s Grade III IgAN, and is a safe and effective choice for short-term treatment of patients with progressive IgAN. Prednisone 67-77 IGAN1 Homo sapiens 168-172 25002376-11 2014 CsA at a dose of 2-3 mg/kg/day in combination with medium/low dose prednisone was effective in inducing remission of IgAN, especially for patients with Lee"s Grade III IgAN, and is a safe and effective choice for short-term treatment of patients with progressive IgAN. Prednisone 67-77 IGAN1 Homo sapiens 168-172 25042202-0 2014 Combination of ibrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) for treatment-naive patients with CD20-positive B-cell non-Hodgkin lymphoma: a non-randomised, phase 1b study. Prednisone 89-99 DNA damage inducible transcript 3 Homo sapiens 103-107 25042202-0 2014 Combination of ibrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) for treatment-naive patients with CD20-positive B-cell non-Hodgkin lymphoma: a non-randomised, phase 1b study. Prednisone 89-99 keratin 20 Homo sapiens 143-147 24470378-11 2014 Infection risk was greater for those taking prednisone >7.5 mg/day (HR 1.8, 95% CI 1.3-2.7) and in the highest quartile of C-reactive protein (HR 2.3, 95% CI 1.4-3.8) and erythrocyte sedimentation rate (HR 4.1, 95% CI 2.3-7.2) compared to the lowest quartile. Prednisone 44-54 RAD18 E3 ubiquitin protein ligase Homo sapiens 71-77 24880571-9 2014 Conversely, corticosterone, prednisone, and dexamethasone similarly inhibited cell invasion and expression of related genes, including MMP-9, VEGF, and IL-6, in GR-positive lines. Prednisone 28-38 matrix metallopeptidase 9 Homo sapiens 135-140 24880571-9 2014 Conversely, corticosterone, prednisone, and dexamethasone similarly inhibited cell invasion and expression of related genes, including MMP-9, VEGF, and IL-6, in GR-positive lines. Prednisone 28-38 vascular endothelial growth factor A Homo sapiens 142-146 24880571-9 2014 Conversely, corticosterone, prednisone, and dexamethasone similarly inhibited cell invasion and expression of related genes, including MMP-9, VEGF, and IL-6, in GR-positive lines. Prednisone 28-38 interleukin 6 Homo sapiens 152-156 24880571-9 2014 Conversely, corticosterone, prednisone, and dexamethasone similarly inhibited cell invasion and expression of related genes, including MMP-9, VEGF, and IL-6, in GR-positive lines. Prednisone 28-38 nuclear receptor subfamily 3 group C member 1 Homo sapiens 161-163 25803374-5 2014 RESULTS: The ELISA results showed that E-selectin levels were higher in GD patients with leukopenia than those with normal leukocytes (p < 0.05), but these levels decreased after glucocorticoid (prednisone) treatment (p < 0.05). Prednisone 198-208 selectin E Homo sapiens 39-49 25803374-8 2014 CONCLUSION: E-selectin may have an important function in GD with leukopenia, and glucocorticoids (prednisone) could decrease E-selectin level, which may be a new therapy target for GD with leukopenia. Prednisone 98-108 selectin E Homo sapiens 125-135 25176084-0 2014 [Effects of prednisone on renal FAK and Pyk2 expressions in rats with adriamycin- induced nephritis]. Prednisone 12-22 protein tyrosine kinase 2 Rattus norvegicus 32-35 24180329-4 2014 Subanalysis of patients receiving cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) +- rituximab showed higher predictive power for both PFS (HR 2.75, 95% confidence interval [CI] 1.24-6.11, p = 0.01) and OS (HR 3.33, 95% CI 1.15-9.63, p = 0.02). Prednisone 81-91 DNA damage inducible transcript 3 Homo sapiens 93-97 24924474-1 2014 The objective was to investigate the expression and prognostic value of CD59 expression in patients with diffuse large B-cell lymphoma (DLBCL) who underwent rituximab-cyclophosphamide, adriamycin, vincristine, and prednisone (R-CHOP). Prednisone 214-224 CD59 molecule (CD59 blood group) Homo sapiens 72-76 25176084-0 2014 [Effects of prednisone on renal FAK and Pyk2 expressions in rats with adriamycin- induced nephritis]. Prednisone 12-22 protein tyrosine kinase 2 beta Rattus norvegicus 40-44 25176084-1 2014 OBJECTIVE: To investigate the effects of prednisone on the expressions of FAK and Pyk2 in the kidneys of rats with adriamycin-induced nephritis. Prednisone 41-51 protein tyrosine kinase 2 Rattus norvegicus 74-77 25176084-1 2014 OBJECTIVE: To investigate the effects of prednisone on the expressions of FAK and Pyk2 in the kidneys of rats with adriamycin-induced nephritis. Prednisone 41-51 protein tyrosine kinase 2 beta Rattus norvegicus 82-86 25176084-8 2014 Prednisone treatment promoted nephrin expression in the kidney (P<0.05). Prednisone 0-10 NPHS1 adhesion molecule, nephrin Rattus norvegicus 30-37 25176084-9 2014 Compared with the control group, the model and prednisone treated groups showed significantly lowered nephrin mRNA expression (P<0.01) but increased FAK mRNA expression (P<0.01), but prednisone-treated group had a higher nephrin mRNA expression than the model group (P<0.05). Prednisone 47-57 NPHS1 adhesion molecule, nephrin Rattus norvegicus 102-109 25176084-9 2014 Compared with the control group, the model and prednisone treated groups showed significantly lowered nephrin mRNA expression (P<0.01) but increased FAK mRNA expression (P<0.01), but prednisone-treated group had a higher nephrin mRNA expression than the model group (P<0.05). Prednisone 47-57 protein tyrosine kinase 2 Rattus norvegicus 152-155 25176084-9 2014 Compared with the control group, the model and prednisone treated groups showed significantly lowered nephrin mRNA expression (P<0.01) but increased FAK mRNA expression (P<0.01), but prednisone-treated group had a higher nephrin mRNA expression than the model group (P<0.05). Prednisone 47-57 NPHS1 adhesion molecule, nephrin Rattus norvegicus 227-234 25176084-9 2014 Compared with the control group, the model and prednisone treated groups showed significantly lowered nephrin mRNA expression (P<0.01) but increased FAK mRNA expression (P<0.01), but prednisone-treated group had a higher nephrin mRNA expression than the model group (P<0.05). Prednisone 189-199 NPHS1 adhesion molecule, nephrin Rattus norvegicus 227-234 25176084-13 2014 Prednisone inhibits Pyk2 and FAK activation, decreases proteinuria, and alleviates podocyte lesions to protect the glomerular filtration barrier. Prednisone 0-10 protein tyrosine kinase 2 beta Rattus norvegicus 20-24 25176084-13 2014 Prednisone inhibits Pyk2 and FAK activation, decreases proteinuria, and alleviates podocyte lesions to protect the glomerular filtration barrier. Prednisone 0-10 protein tyrosine kinase 2 Rattus norvegicus 29-32 25129083-6 2014 The incidence of FN in patients receiving the standard rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone(R-CHOP)regimen is approximately 20%. Prednisone 114-124 DNA damage inducible transcript 3 Homo sapiens 127-131 24677208-3 2014 As the VMP regimen (bortezomib plus melphalan and prednisone) has been reported to be highly effective in the treatment of other types of myeloma, we treated a patient with newly diagnosed IgE myeloma using the VMP regimen. Prednisone 50-60 neurensin 1 Homo sapiens 211-214 24719189-1 2014 This study aims to investigate the prognostic significance of the MYC protein expression in diffuse large B cell lymphoma (DLBCL) patients treated with RCHOP (rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone). Prednisone 222-232 MYC proto-oncogene, bHLH transcription factor Homo sapiens 66-69 24961832-6 2014 The first episode of insulin-induced localized involutional lipoatrophy two years previously had been cured by oral prednisone. Prednisone 116-126 insulin Homo sapiens 21-28 25018638-3 2014 Such ALK-positive ALCLs are usually responsive to a multidrug chemotherapy with CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone). Prednisone 130-140 ALK receptor tyrosine kinase Homo sapiens 5-8 24677208-0 2014 Bortezomib plus melphalan and prednisone (VMP regimen) as the initial treatment for IgE multiple myeloma: a case study. Prednisone 30-40 neurensin 1 Homo sapiens 42-45 24677208-3 2014 As the VMP regimen (bortezomib plus melphalan and prednisone) has been reported to be highly effective in the treatment of other types of myeloma, we treated a patient with newly diagnosed IgE myeloma using the VMP regimen. Prednisone 50-60 neurensin 1 Homo sapiens 7-10 24703255-0 2014 The effects of prednisone and steroid-sparing agents on decay accelerating factor (CD55) expression: implications in myasthenia gravis. Prednisone 15-25 CD55 molecule, decay accelerating factor for complement Mus musculus 56-81 24637537-10 2014 CONCLUSIONS: Abiraterone plus prednisone significantly reduced serum androgens, as measured by ultrasensitive assays and was generally associated with PSA response. Prednisone 30-40 aminopeptidase puromycin sensitive Homo sapiens 151-154 24849305-7 2014 The combination of bortezomib, melphalan and prednisone (VMP) was shown to significantly improve overall survival (OS) compared to melphalan and prednisone (MP, 56.4 vs. 43.1 months, p = < 0.01). Prednisone 45-55 neurensin 1 Homo sapiens 57-60 24703255-4 2014 We show that prednisone repressed C>G DAF expression in lymphoblasts and increased their susceptibility to cytotoxicity. Prednisone 13-23 CD55 molecule, decay accelerating factor for complement Mus musculus 38-41 24703255-6 2014 In mouse myotubes expressing wild-type Daf, prednisone also repressed Daf expression. Prednisone 44-54 CD55 molecule, decay accelerating factor for complement Mus musculus 39-42 24703255-6 2014 In mouse myotubes expressing wild-type Daf, prednisone also repressed Daf expression. Prednisone 44-54 CD55 molecule, decay accelerating factor for complement Mus musculus 70-73 24703255-8 2014 Therefore, prednisone negatively influences DAF expression in C>G lymphoblasts and in myotubes expressing wild-type Daf. Prednisone 11-21 CD55 molecule, decay accelerating factor for complement Mus musculus 44-47 24703255-8 2014 Therefore, prednisone negatively influences DAF expression in C>G lymphoblasts and in myotubes expressing wild-type Daf. Prednisone 11-21 CD55 molecule, decay accelerating factor for complement Mus musculus 116-119 24769598-2 2014 was diagnosed with non-Hodgkin lymphoma and underwent treatment with standard rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) chemotherapy. Prednisone 137-147 DNA damage inducible transcript 3 Homo sapiens 151-155 24759590-5 2014 Regulatory approval of abiraterone in 2011, based on a phase III trial showing a significant improvement in overall survival (OS) with abiraterone and prednisone versus prednisone, represented proof of principle that targeting AR is essential for improving outcomes in men with CRPC. Prednisone 151-161 androgen receptor Homo sapiens 227-229 24759590-5 2014 Regulatory approval of abiraterone in 2011, based on a phase III trial showing a significant improvement in overall survival (OS) with abiraterone and prednisone versus prednisone, represented proof of principle that targeting AR is essential for improving outcomes in men with CRPC. Prednisone 169-179 androgen receptor Homo sapiens 227-229 24493716-1 2014 PURPOSE: R-CHOP (rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone) is standard care for aggressive B-cell lymphoma. Prednisone 80-90 DNA damage inducible transcript 3 Homo sapiens 11-15 24774748-8 2014 Time course analyses of CD4+CD25-Foxp3+ T cells were performed in patients with active disease activity before and after treatment with cyclophosphamide and prednisone. Prednisone 157-167 CD4 molecule Homo sapiens 24-27 24273190-0 2014 Bortezomib, melphalan, prednisone (VMP) versus melphalan, prednisone, thalidomide (MPT) in elderly newly diagnosed multiple myeloma patients: A retrospective case-matched study. Prednisone 23-33 neurensin 1 Homo sapiens 35-38 24394473-7 2014 The treatment was generally well tolerated; side effects secondary to mineralocorticoid excess resulting from blockade of CYP17 were largely controlled with prednisone. Prednisone 157-167 cytochrome P450 family 17 subfamily A member 1 Homo sapiens 122-127 24333338-4 2014 Treatment with prednisone significantly reduced the frequency of CD4(+)CXCR5(+) and CD4(+)CXCR5(+)PD-1(+) TFH cells and the levels of serum IL-21, but increased IL-4 and IL-10 in those patients. Prednisone 15-25 CD4 molecule Sus scrofa 65-68 24650765-9 2014 In SLE patients treated with corticosteroids, Mer expression on monocytes correlated with prednisone dose, CD1c+ myeloid dendritic cells in patients treated with prednisone had higher levels of Mer expression than those in patients not receiving prednisone. Prednisone 90-100 MER proto-oncogene, tyrosine kinase Homo sapiens 46-49 24650765-9 2014 In SLE patients treated with corticosteroids, Mer expression on monocytes correlated with prednisone dose, CD1c+ myeloid dendritic cells in patients treated with prednisone had higher levels of Mer expression than those in patients not receiving prednisone. Prednisone 162-172 MER proto-oncogene, tyrosine kinase Homo sapiens 46-49 24650765-9 2014 In SLE patients treated with corticosteroids, Mer expression on monocytes correlated with prednisone dose, CD1c+ myeloid dendritic cells in patients treated with prednisone had higher levels of Mer expression than those in patients not receiving prednisone. Prednisone 162-172 CD1c molecule Homo sapiens 107-111 24650765-9 2014 In SLE patients treated with corticosteroids, Mer expression on monocytes correlated with prednisone dose, CD1c+ myeloid dendritic cells in patients treated with prednisone had higher levels of Mer expression than those in patients not receiving prednisone. Prednisone 162-172 MER proto-oncogene, tyrosine kinase Homo sapiens 194-197 24650765-9 2014 In SLE patients treated with corticosteroids, Mer expression on monocytes correlated with prednisone dose, CD1c+ myeloid dendritic cells in patients treated with prednisone had higher levels of Mer expression than those in patients not receiving prednisone. Prednisone 162-172 MER proto-oncogene, tyrosine kinase Homo sapiens 46-49 24650765-9 2014 In SLE patients treated with corticosteroids, Mer expression on monocytes correlated with prednisone dose, CD1c+ myeloid dendritic cells in patients treated with prednisone had higher levels of Mer expression than those in patients not receiving prednisone. Prednisone 162-172 CD1c molecule Homo sapiens 107-111 24650765-9 2014 In SLE patients treated with corticosteroids, Mer expression on monocytes correlated with prednisone dose, CD1c+ myeloid dendritic cells in patients treated with prednisone had higher levels of Mer expression than those in patients not receiving prednisone. Prednisone 162-172 MER proto-oncogene, tyrosine kinase Homo sapiens 194-197 24333338-4 2014 Treatment with prednisone significantly reduced the frequency of CD4(+)CXCR5(+) and CD4(+)CXCR5(+)PD-1(+) TFH cells and the levels of serum IL-21, but increased IL-4 and IL-10 in those patients. Prednisone 15-25 CD4 molecule Sus scrofa 84-87 24333338-4 2014 Treatment with prednisone significantly reduced the frequency of CD4(+)CXCR5(+) and CD4(+)CXCR5(+)PD-1(+) TFH cells and the levels of serum IL-21, but increased IL-4 and IL-10 in those patients. Prednisone 15-25 interleukin 21 Sus scrofa 140-145 24333338-4 2014 Treatment with prednisone significantly reduced the frequency of CD4(+)CXCR5(+) and CD4(+)CXCR5(+)PD-1(+) TFH cells and the levels of serum IL-21, but increased IL-4 and IL-10 in those patients. Prednisone 15-25 interleukin 4 Sus scrofa 161-165 24333338-4 2014 Treatment with prednisone significantly reduced the frequency of CD4(+)CXCR5(+) and CD4(+)CXCR5(+)PD-1(+) TFH cells and the levels of serum IL-21, but increased IL-4 and IL-10 in those patients. Prednisone 15-25 IL10 Sus scrofa 170-175 24462857-3 2014 We used the human promyelocytic cell line THP-1 to investigate the effects of cortisol, prednisone, prednisolone, budesonide, betamethasone and methylprednisolone on RACK-1 expression and cytokine production. Prednisone 88-98 receptor for activated C kinase 1 Homo sapiens 166-172 24469952-2 2014 Three hundred and eighty four DLBCL patients treated with rituximab, cyclophosphamide, doxorubicin/epirubicin, vincristine and prednisone (R-CHOP-like regimens) or CHOP-like regimens were included. Prednisone 127-137 DNA damage inducible transcript 3 Homo sapiens 141-145 24460726-0 2014 Reduced levels of CCL2 and CXCL10 in systemic lupus erythematosus patients under treatment with prednisone, mycophenolate mofetil, or hydroxychloroquine, except in a high STAT1 subset. Prednisone 96-106 C-C motif chemokine ligand 2 Homo sapiens 18-22 24313261-6 2014 After treatment with prednisone and hydroxychloroquine, the levels of plasma IL-22 in new-onset SLE patients were obviously increased but still lower than healthy controls. Prednisone 21-31 interleukin 22 Homo sapiens 77-82 24342979-8 2014 Prednisone significantly reduced both IFNgamma production and degranulation (50%-66% reduction at maximum therapeutic levels). Prednisone 0-10 interferon gamma Homo sapiens 38-46 24342979-9 2014 Calcineurin inhibitors (CNIs) in combination with prednisone additively suppressed IFNgamma production and degranulation. Prednisone 50-60 interferon gamma Homo sapiens 83-91 24444537-2 2014 The purpose of our study was to investigate the safety and efficacy in terms of prostate-specific antigen (PSA) response of a low-dose oral combination of etoposide and prednisone in patients with CRPC. Prednisone 169-179 kallikrein related peptidase 3 Homo sapiens 80-111 24872902-7 2014 The patient was able to complete six cycles of rituximab combined with cyclophosphamide, adriamycin, vincristine, and prednisone (R-CHOP) chemotherapy and achieved a complete response verified by positron emission tomography-computed tomography (PET-CT). Prednisone 118-128 DNA damage inducible transcript 3 Homo sapiens 132-136 24955264-11 2014 Long-term therapy was initiated with cyclophosphamide and prednisone with normalization of FVIII activity. Prednisone 58-68 coagulation factor VIII Homo sapiens 91-96 25413040-5 2014 RESULTS: mRNA and protein expression of occludin in polyp tissues was significantly upregulated after prednisone administration (p < 0.05). Prednisone 102-112 occludin Homo sapiens 40-48 24225487-5 2014 SUMMARY: Anti-TNF agents are recommended for the treatment of Takayasu"s patients who are unable to taper prednisone despite treatment with a nonbiologic immunosuppressive medication. Prednisone 106-116 tumor necrosis factor Homo sapiens 14-17 23868108-7 2014 CONCLUSIONS: We demonstrate the long-term efficiency and safety of cyclophosphamide pulses combined with PEs and prednisone in anti-CFH Ab-associated aHUS leading to a prolonged decrease in anti-CFH Ab titers and prevention of relapses without the need for maintenance therapy. Prednisone 113-123 complement factor H Homo sapiens 132-135 23868108-7 2014 CONCLUSIONS: We demonstrate the long-term efficiency and safety of cyclophosphamide pulses combined with PEs and prednisone in anti-CFH Ab-associated aHUS leading to a prolonged decrease in anti-CFH Ab titers and prevention of relapses without the need for maintenance therapy. Prednisone 113-123 complement factor H Homo sapiens 195-198 24062391-5 2013 Skeletal involvement was associated with a worse outcome after cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) plus rituximab (HREFS = 1.5, P = .048; HROS = 1.1; P = .828), but not after CHOP without rituximab (HREFS = 0.8, P = .181; HROS = 0.7, P = .083). Prednisone 111-121 DNA damage inducible transcript 3 Homo sapiens 123-127 23968502-6 2013 Treatment with the anti-SLE therapy, particularly with prednisone, leflunomide and methotrexate, significantly improved the imbalance of these types of FoxP3(+) T cells and increased the concentrations of serum IL-10 in the drug-responding patients. Prednisone 55-65 forkhead box P3 Homo sapiens 152-157 23968502-6 2013 Treatment with the anti-SLE therapy, particularly with prednisone, leflunomide and methotrexate, significantly improved the imbalance of these types of FoxP3(+) T cells and increased the concentrations of serum IL-10 in the drug-responding patients. Prednisone 55-65 interleukin 10 Homo sapiens 211-216 24335377-10 2013 She was successfully treated with 8 courses of rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone(R-CHOP) chemotherapy, and maintains a complete remission. Prednisone 110-120 DNA damage inducible transcript 3 Homo sapiens 123-127 24088574-7 2013 Within the high-risk group, 50% of BCL2-938CC patients were classified as high-risk due to poor prednisone response whereas only 33% of patients with AC and AA genotypes were classified as high-risk for the same reason. Prednisone 96-106 BCL2 apoptosis regulator Homo sapiens 35-39 23775435-1 2013 BACKGROUND: High levels of cyclin E (CCNE) are accompanied by shorter survival in cyclophosphamide, hydroxydaunorubicin, oncovin and prednisone (CHOP)-treated diffuse large B-cell lymphomas (DLBCL), independent of the international prognostic index (IPI). Prednisone 133-143 cyclin E1 Homo sapiens 27-35 23775435-1 2013 BACKGROUND: High levels of cyclin E (CCNE) are accompanied by shorter survival in cyclophosphamide, hydroxydaunorubicin, oncovin and prednisone (CHOP)-treated diffuse large B-cell lymphomas (DLBCL), independent of the international prognostic index (IPI). Prednisone 133-143 cyclin E1 Homo sapiens 37-41 23775435-1 2013 BACKGROUND: High levels of cyclin E (CCNE) are accompanied by shorter survival in cyclophosphamide, hydroxydaunorubicin, oncovin and prednisone (CHOP)-treated diffuse large B-cell lymphomas (DLBCL), independent of the international prognostic index (IPI). Prednisone 133-143 DNA damage inducible transcript 3 Homo sapiens 145-149 24177566-7 2013 After treatment with prednisone, the expression of Foxp3 mRNA was elevated in the peripheral blood, and expression of (ROR)gammat mRNA showed a downward trend. Prednisone 21-31 forkhead box P3 Homo sapiens 51-56 24177566-7 2013 After treatment with prednisone, the expression of Foxp3 mRNA was elevated in the peripheral blood, and expression of (ROR)gammat mRNA showed a downward trend. Prednisone 21-31 long intergenic non-protein coding RNA, regulator of reprogramming Homo sapiens 119-122 25073258-5 2013 Our patient showed a high dermal Ki-67 level and concomitant C-MYC/8q24 translocation, which may account for the aggressive clinical course and refractoriness to CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) chemotherapy. Prednisone 216-226 MYC proto-oncogene, bHLH transcription factor Homo sapiens 61-66 24144108-8 2013 After 4 weeks prednisone treatment, the relative mRNA expression of apoE and the serum levels of apoE and related cytokines decreased. Prednisone 14-24 apolipoprotein E Homo sapiens 68-72 24144108-8 2013 After 4 weeks prednisone treatment, the relative mRNA expression of apoE and the serum levels of apoE and related cytokines decreased. Prednisone 14-24 apolipoprotein E Homo sapiens 97-101 24143112-1 2013 Fludarabine-based regimens and CHOP (doxorubicin, cyclophosphamide, vincristine, prednisone)-like regimens with or without rituximab are the most common treatment modalities for indolent lymphoma. Prednisone 81-91 DNA damage inducible transcript 3 Homo sapiens 31-35 23636313-7 2013 Activation of the PI3K/AKT/mTOR pathway was related to poor disease outcome in DLBCL patients treated with cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) but not in those treated with rituximab-CHOP. Prednisone 155-165 DNA damage inducible transcript 3 Homo sapiens 167-171 23948281-0 2013 The expression of histone deacetylase 4 is associated with prednisone poor-response in childhood acute lymphoblastic leukemia. Prednisone 59-69 histone deacetylase 4 Homo sapiens 18-39 24064903-7 2013 Then the patient was treated with activated prothrombin complex concentrates, prednisone and intravenous immunoglobulin, resulting in a complete remission of the bleeding, recovering the FVIII level and negativity for FVIII antibody titers. Prednisone 78-88 coagulation factor VIII Homo sapiens 187-192 23636313-7 2013 Activation of the PI3K/AKT/mTOR pathway was related to poor disease outcome in DLBCL patients treated with cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) but not in those treated with rituximab-CHOP. Prednisone 155-165 AKT serine/threonine kinase 1 Homo sapiens 23-26 23636313-7 2013 Activation of the PI3K/AKT/mTOR pathway was related to poor disease outcome in DLBCL patients treated with cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) but not in those treated with rituximab-CHOP. Prednisone 155-165 mechanistic target of rapamycin kinase Homo sapiens 27-31 23948281-5 2013 Particularly, high HDAC4 expression was associated with high initial leukocyte count, T cell ALL and prednisone poor-response. Prednisone 101-111 histone deacetylase 4 Homo sapiens 19-24 23948281-7 2013 In conclusion, our data point to HDAC4 as drug target in childhood ALL, especially in prednisone poor-responders. Prednisone 86-96 histone deacetylase 4 Homo sapiens 33-38 23804523-14 2013 Enzyme inhibition experiments suggested that exposure to bupropion is not likely to impair 11beta-HSD1-dependent glucocorticoid activation but that pharmacological administration of cortisone or prednisone may inhibit 11beta-HSD1-dependent bupropion metabolism. Prednisone 195-205 hydroxysteroid 11-beta dehydrogenase 1 Mus musculus 218-229 24432683-26 2013 CONCLUSIONS: Prednisone could induce osteoporosis through the OPG/RANKL/RANK pathway. Prednisone 13-23 TNF receptor superfamily member 11B Rattus norvegicus 62-65 24432683-26 2013 CONCLUSIONS: Prednisone could induce osteoporosis through the OPG/RANKL/RANK pathway. Prednisone 13-23 TNF superfamily member 11 Rattus norvegicus 66-71 23832117-6 2013 Patients with chronic inflammation receiving high-dose prednisone therapy displayed substantially increased MFG-E8 mRNA levels in circulating monocytes. Prednisone 55-65 milk fat globule EGF and factor V/VIII domain containing Homo sapiens 108-114 23846963-0 2013 Levels of alpha7 integrin and laminin-alpha2 are increased following prednisone treatment in the mdx mouse and GRMD dog models of Duchenne muscular dystrophy. Prednisone 69-79 laminin, alpha 2 Mus musculus 30-44 23846963-7 2013 The prednisone-mediated increase in alpha7 integrin was associated with increased laminin-alpha2 in prednisone-treated dystrophin-deficient muscle. Prednisone 4-14 laminin, alpha 2 Mus musculus 82-96 22993227-8 2013 Surprisingly, patients with strong IL-17A expression tended to experience less relapses, and required significantly shorter treatment periods (median 25 vs 44 weeks to achieve <10 mg prednisone/day, p=0.0079). Prednisone 186-196 interleukin 17A Homo sapiens 35-41 23804523-5 2013 11beta-HSD1 catalyzes the conversion of inactive glucocorticoids (cortisone, prednisone) to their active forms (cortisol, prednisolone). Prednisone 77-87 hydroxysteroid 11-beta dehydrogenase 1 Mus musculus 0-11 23846963-7 2013 The prednisone-mediated increase in alpha7 integrin was associated with increased laminin-alpha2 in prednisone-treated dystrophin-deficient muscle. Prednisone 4-14 dystrophin, muscular dystrophy Mus musculus 119-129 24010700-5 2013 Dystrophin-specific T cell immunity was evaluated in subjects with DMD who were either receiving the glucocorticoid steroid prednisone (n=24) or deflazacort (n=29), or who were not receiving steroids (n=17), as well as from normal age-matched control subjects (n=21). Prednisone 124-134 dystrophin Homo sapiens 0-10 23846963-7 2013 The prednisone-mediated increase in alpha7 integrin was associated with increased laminin-alpha2 in prednisone-treated dystrophin-deficient muscle. Prednisone 100-110 laminin, alpha 2 Mus musculus 82-96 23846963-7 2013 The prednisone-mediated increase in alpha7 integrin was associated with increased laminin-alpha2 in prednisone-treated dystrophin-deficient muscle. Prednisone 100-110 dystrophin, muscular dystrophy Mus musculus 119-129 23846963-8 2013 Together, our results suggest that prednisone acts in part through increased merosin in the muscle basal lamina and through sarcolemmal stabilization of alpha7beta1 integrin in dystrophin-deficient muscle. Prednisone 35-45 laminin, alpha 2 Mus musculus 77-84 23846963-8 2013 Together, our results suggest that prednisone acts in part through increased merosin in the muscle basal lamina and through sarcolemmal stabilization of alpha7beta1 integrin in dystrophin-deficient muscle. Prednisone 35-45 dystrophin, muscular dystrophy Mus musculus 177-187 24010700-7 2013 The frequency of dystrophin-specific T cells detected by enzyme-linked immunospot assay was lower in subjects treated with deflazacort versus prednisone, despite similar overall corticosteroid exposure, suggesting that the effects of the two corticosteroids may not be identical in patients with DMD. Prednisone 142-152 dystrophin Homo sapiens 17-27 23921690-5 2013 Follow-up after six courses of R-CHOP (rituximab, cyclophosphamide, vindesine, epirubicin and prednisone) regimen revealed complete resolution of symptoms. Prednisone 94-104 DNA damage inducible transcript 3 Homo sapiens 33-37 24103876-8 2013 The expression of miR-203 was significantly related with the gender, immunophenotype, chromosome, fusion gene, BCR-ABL, SIL-TAL1 and prednisone experiment in pediatric ALL and the gender, chromosome, fusion gene, SIL-TAL1 in pediatric acute leukemia (P<0.05). Prednisone 133-143 microRNA 203a Homo sapiens 18-25 23647505-11 2013 A full-dosage regimen of rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) was successfully used in the patient with WAS and B-cell lymphoma; he was still in remission after 3 years. Prednisone 88-98 DNA damage inducible transcript 3 Homo sapiens 102-106 24325066-0 2013 [Effect of fermented cordyceps powder and prednisone on the Notch2/Hes-1 signaling activation in the kidney tubules of rats with acute aristolochic acid nephropathy]. Prednisone 42-52 notch receptor 2 Rattus norvegicus 60-66 23095082-6 2013 CONCLUSIONS: Kidney transplant recipients with long-term CNI and prednisone use may have a low incidence of symptomatic BPH, which may be related to TGF-beta and keratinocyte growth factor expression, testosterone levels and lymphocyte infiltration. Prednisone 65-75 transforming growth factor beta 1 Homo sapiens 149-157 23137070-3 2013 Patients treated with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP) had significantly superior survival rates. Prednisone 80-90 DNA damage inducible transcript 3 Homo sapiens 94-98 24325066-0 2013 [Effect of fermented cordyceps powder and prednisone on the Notch2/Hes-1 signaling activation in the kidney tubules of rats with acute aristolochic acid nephropathy]. Prednisone 42-52 hes family bHLH transcription factor 1 Rattus norvegicus 67-72 24325066-1 2013 OBJECTIVE: To investigate the effect of both fermented Cordyceps powder (CS) and prednisone on the Notch2/hes-1 signaling activation in the kidney tubules of rats with acute aristolochic acid nephropathy (AAAN). Prednisone 81-91 notch receptor 2 Rattus norvegicus 99-105 24325066-1 2013 OBJECTIVE: To investigate the effect of both fermented Cordyceps powder (CS) and prednisone on the Notch2/hes-1 signaling activation in the kidney tubules of rats with acute aristolochic acid nephropathy (AAAN). Prednisone 81-91 hes family bHLH transcription factor 1 Rattus norvegicus 106-111 23657985-5 2013 Among the eight drugs studied, prednisone, desloratadine, and azelastine exhibited the highest binding affinity (K(d) = 1.65, 2.05, and 8.47 muM, respectively) toward DNA photolyase. Prednisone 31-41 latexin Homo sapiens 141-144 23692856-2 2013 Nonetheless, outcomes are suboptimal for patients failing rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP). Prednisone 117-127 DNA damage inducible transcript 3 Homo sapiens 131-135 24649228-2 2013 The reported 5-year overall survival for patients with localized nasal NKTCL treated with cyclophosphamide, hydroxydaunorubicin, oncovin and prednisone (CHOP) is <50%. Prednisone 141-151 DNA damage inducible transcript 3 Homo sapiens 153-157 23866275-8 2013 RESULTS: Compared with the SRNS group, the SSNS group had significantly decreased urinary NGAL/Cr ratios after 3 and 4 weeks of prednisone treatment (P < 0.05). Prednisone 128-138 lipocalin 2 Homo sapiens 90-94 23828551-2 2013 We found that cells from prednisone-resistant T-acute lymphoblastic leukemia (T-ALL) patients showed cytoplasmic localization of FOXO3 in comparison to prednisone-sensitive patients suggesting its inactivation. Prednisone 25-35 forkhead box O3 Homo sapiens 129-134 23828551-2 2013 We found that cells from prednisone-resistant T-acute lymphoblastic leukemia (T-ALL) patients showed cytoplasmic localization of FOXO3 in comparison to prednisone-sensitive patients suggesting its inactivation. Prednisone 152-162 forkhead box O3 Homo sapiens 129-134 23866275-13 2013 These results suggest that dynamic monitoring of urinary NGAL/Cr ratio is useful for early judgment of response to prednisone in patients with INS. Prednisone 115-125 lipocalin 2 Homo sapiens 57-61 23486009-7 2013 Prednisone reduced podocyte apoptosis measured by synaptopodin+/caspase-3+ double staining. Prednisone 0-10 caspase 3 Mus musculus 64-73 23349303-7 2013 Notably, in the subgroup of patients with a prednisone- and minimal residual disease (MRD)-response based medium risk profile, PTEN-mutations without co-existing NOTCH1-mutations represented an MRD-independent highly significant high-risk biomarker. Prednisone 44-54 phosphatase and tensin homolog Homo sapiens 127-131 23543480-7 2013 : RESULTS: NGAL and KIM-1 tended to rise after the procedure, but to a lesser degree in the prednisone group (delta NGAL: hydration = +128%, prednisone = +46%; : p = 0.26; delta KIM-1: hydration = +99%, prednisone = +11%; p = 0.02). Prednisone 93-103 lipocalin 2 Homo sapiens 117-121 23702100-6 2013 After prednisone treatment, the serum levels of PGRN decreased significantly, and the relative expression of PGRN mRNA was decreased by 1.34-fold compared with the untreated controls (P < 0.01). Prednisone 6-16 granulin precursor Homo sapiens 48-52 23702100-6 2013 After prednisone treatment, the serum levels of PGRN decreased significantly, and the relative expression of PGRN mRNA was decreased by 1.34-fold compared with the untreated controls (P < 0.01). Prednisone 6-16 granulin precursor Homo sapiens 109-113 23460611-6 2013 FOXO1 mutation was associated with decreased overall survival in patients treated with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (P = .037), independent of cell of origin (COO) and the revised International Prognostic Index (R-IPI). Prednisone 146-156 forkhead box O1 Homo sapiens 0-5 23532557-3 2013 In addition, progression-free survival, the times to tumour progression and prostate specific antigen (PSA) progression, and tumour and PSA response rates were improved with cabazitaxel plus prednisone. Prednisone 191-201 kallikrein related peptidase 3 Homo sapiens 76-101 23532557-3 2013 In addition, progression-free survival, the times to tumour progression and prostate specific antigen (PSA) progression, and tumour and PSA response rates were improved with cabazitaxel plus prednisone. Prednisone 191-201 kallikrein related peptidase 3 Homo sapiens 103-106 23352254-2 2013 METHODS: We report a case of anti-GBM antibody disease with both anti-GBM antibodies and anti-myeloperoxidase (MPO) specific p-ANCA, who developed thrombotic thrombocytopenic purpura (TTP) on high dose prednisone, plasmapheresis, and cyclophosphamide therapy. Prednisone 202-212 myeloperoxidase Homo sapiens 89-109 23352254-2 2013 METHODS: We report a case of anti-GBM antibody disease with both anti-GBM antibodies and anti-myeloperoxidase (MPO) specific p-ANCA, who developed thrombotic thrombocytopenic purpura (TTP) on high dose prednisone, plasmapheresis, and cyclophosphamide therapy. Prednisone 202-212 myeloperoxidase Homo sapiens 111-114 23532557-3 2013 In addition, progression-free survival, the times to tumour progression and prostate specific antigen (PSA) progression, and tumour and PSA response rates were improved with cabazitaxel plus prednisone. Prednisone 191-201 kallikrein related peptidase 3 Homo sapiens 136-139 23543480-7 2013 : RESULTS: NGAL and KIM-1 tended to rise after the procedure, but to a lesser degree in the prednisone group (delta NGAL: hydration = +128%, prednisone = +46%; : p = 0.26; delta KIM-1: hydration = +99%, prednisone = +11%; p = 0.02). Prednisone 93-103 hepatitis A virus cellular receptor 1 Homo sapiens 180-185 23335369-1 2013 MYC rearrangements occur in 5% to 10% of diffuse large B-cell lymphomas (DLBCL) and confer an increased risk to cyclophosphamide, hydroxydaunorubicin, oncovin, and prednisone (CHOP) and rituximab (R)-CHOP treated patients. Prednisone 164-174 MYC proto-oncogene, bHLH transcription factor Homo sapiens 0-3 23578722-1 2013 BACKGROUND: Immunochemotherapy with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) has become the standard of care for elderly patients with diffuse large B-cell lymphoma. Prednisone 98-108 DNA damage inducible transcript 3 Homo sapiens 112-116 23460351-4 2013 We analyzed 122 newly diagnosed consecutive DLBCL patients treated with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) chemo-immunotherapy. Prednisone 131-141 DNA damage inducible transcript 3 Homo sapiens 145-149 23352640-2 2013 The aim of this retrospective study is to compare characteristics, prognostic factors and outcomes of Asian and Western patients with DLBCL treated with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP). Prednisone 211-221 DNA damage inducible transcript 3 Homo sapiens 225-229 23339126-5 2013 As standard rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) chemotherapy may cure the majority of patients, it must always be the first proposed option. Prednisone 71-81 DNA damage inducible transcript 3 Homo sapiens 85-89 23334362-1 2013 MLL-rearranged infant acute lymphoblastic leukemia (ALL) (<1 year of age) are frequently resistant to glucocorticoids, like prednisone and dexamethasone. Prednisone 127-137 lysine methyltransferase 2A Homo sapiens 0-3 23394581-1 2013 Diffuse large B-cell lymphoma primary of lung (DLBCL-PL) is a rare presentation of extranodal lymphoma, in most cases chemotherapy-based anthracyclines: CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) has been the treatment, with excellent outcome. Prednisone 207-217 DNA damage inducible transcript 3 Homo sapiens 153-157 23228172-8 2013 Abiraterone-prednisone showed superiority over prednisone alone with respect to time to initiation of cytotoxic chemotherapy, opiate use for cancer-related pain, prostate-specific antigen progression, and decline in performance status. Prednisone 12-22 kallikrein related peptidase 3 Homo sapiens 162-187 22972488-1 2013 PURPOSE: Treatment of non-Hodgkin lymphoma (NHL) with cyclophosphamide, vincristine, doxorubicin and prednisone (CHOP) is known to be associated with a significant risk of febrile neutropenia (FN) of up to 50% [Osby et al. Prednisone 101-111 DNA damage inducible transcript 3 Homo sapiens 113-117 22772331-7 2013 Prednisone treatment significantly normalized the intensities of peaks 9069 and 15005 (which correspond to cortexin-1 and interleukin-17A, respectively, according to Swiss Prot database) by increasing the expression of 9069 but reducing expression of 15005. Prednisone 0-10 cortexin 1 Rattus norvegicus 107-117 22772331-7 2013 Prednisone treatment significantly normalized the intensities of peaks 9069 and 15005 (which correspond to cortexin-1 and interleukin-17A, respectively, according to Swiss Prot database) by increasing the expression of 9069 but reducing expression of 15005. Prednisone 0-10 interleukin 17A Rattus norvegicus 122-137 23646469-0 2013 [Effects of qingyang toujie mixture in combination with prednisone tablet on Th1/Th2 cytokines in patients suffering from systemic lupus erythematosus]. Prednisone 56-66 negative elongation factor complex member C/D Homo sapiens 77-80 23646469-1 2013 OBJECTIVE: To research the effects of Qingyang Toujie Mixture (QTM) in combination with prednisone tablet on the balance of Th1 and Th2 (Th1/Th2) of systemic lupus erythematosus (SLE) patients of yin deficiency syndrome (YDS). Prednisone 88-98 negative elongation factor complex member C/D Homo sapiens 124-135 23646469-1 2013 OBJECTIVE: To research the effects of Qingyang Toujie Mixture (QTM) in combination with prednisone tablet on the balance of Th1 and Th2 (Th1/Th2) of systemic lupus erythematosus (SLE) patients of yin deficiency syndrome (YDS). Prednisone 88-98 negative elongation factor complex member C/D Homo sapiens 124-127 23646469-19 2013 CONCLUSION: QTM in combination with prednisone tablet was effective to improve the balance of Th1/Th2 cytokines, and alleviate the toxic and adverse reactions of hormone or immune inhibitors. Prednisone 36-46 negative elongation factor complex member C/D Homo sapiens 94-97 23400962-7 2013 Four patients were treated with cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) alone: One was alive with no evidence of disease, and three were alive with disease. Prednisone 80-90 DNA damage inducible transcript 3 Homo sapiens 92-96 23275230-2 2013 In the present study, we investigated whether miR-21 is involved in regulating the sensitivity of the diffuse large B-cell lymphoma (DLBCL) cell line CRL2631 to the cyclophosphamide, vincristine, Adriamycin, and prednisone (CHOP) chemotherapeutic regimen. Prednisone 212-222 microRNA 21 Homo sapiens 46-52 23166041-2 2013 The CHOP chemotherapy regimen, which includes cyclophosphamide, doxorubicin, vincristine and prednisone, has been used previously to treat other types of lymphomas. Prednisone 105-115 DNA damage inducible transcript 3 Homo sapiens 4-8 23737767-5 2013 In particular, clinically relevant DDIs have been described during the treatment with MTX and NSAIDs, for example, diclofenac, indomethacin, or COX-2 inhibitors, and between MTX and prednisone or immunosuppressant drugs (e.g., leflunomide and cyclosporine). Prednisone 182-192 mitochondrially encoded cytochrome c oxidase II Homo sapiens 144-149 23814970-2 2012 Standard chemotherapy is CHOP regimen (cyclophosphamide, doxorubicin, vincristine and prednisone). Prednisone 86-96 DNA damage inducible transcript 3 Homo sapiens 25-29 23064959-1 2013 PURPOSE: To assess the effect of abiraterone acetate plus prednisone on the pharmacokinetics of dextromethorphan HBr (CYP2D6 substrate) and theophylline (CYP1A2 substrate) in patients with metastatic castration-resistant prostate cancer (mCRPC). Prednisone 58-68 cytochrome P450 family 2 subfamily D member 6 Homo sapiens 118-124 23064959-11 2013 CONCLUSION: Abiraterone acetate plus prednisone increased the exposure of dextromethorphan, suggesting a need for caution when coadministrating with known CYP2D6 substrates. Prednisone 37-47 cytochrome P450 family 2 subfamily D member 6 Homo sapiens 155-161 24371535-6 2013 The most common treatment is chemotherapy with cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) or CHOP-like regimens, but the overall survival rate is poor despite its relative responsiveness to chemotherapy. Prednisone 95-105 DNA damage inducible transcript 3 Homo sapiens 107-111 23984169-8 2013 Complete response of this PTLD was achieved with 6 cycles of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy; however, 4 months off therapy he developed CNS PTLD (monomorphic CD20-, EBV+, lambda-restricted, plasmacytoid PTLD) of the brain and spine. Prednisone 109-119 DNA damage inducible transcript 3 Homo sapiens 121-125 24072968-8 2013 A recently performed large randomized study for elderly patients, however, has shown that R-CHOP (rituximab with cyclophosphamide, doxorubicin, vincristine, and prednisone) chemotherapy followed by maintenance rituximab can result in a long progression-free survival. Prednisone 161-171 DNA damage inducible transcript 3 Homo sapiens 92-96 23996885-4 2013 We describe a patient with follicular lymphoma treated with R-CHOP scheme (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone) who had pulmonary symptoms during chemotherapy which were diagnosed as rituximab-induced interstitial pneumonia. Prednisone 130-140 DNA damage inducible transcript 3 Homo sapiens 62-66 22936125-6 2012 Patients using prednisone with low and normal DHEAS levels reported a similar level of fatigue (p >= 0.39). Prednisone 15-25 sulfotransferase family 2A member 1 Homo sapiens 46-51 22941914-10 2012 In muscle cells exposed to IFNgamma plus IL-1beta, IgG and/or prednisone down-regulated mRNA expression of IL-1beta 2.5-fold. Prednisone 62-72 interferon gamma Homo sapiens 27-35 22941914-10 2012 In muscle cells exposed to IFNgamma plus IL-1beta, IgG and/or prednisone down-regulated mRNA expression of IL-1beta 2.5-fold. Prednisone 62-72 interleukin 1 beta Homo sapiens 41-49 22941914-10 2012 In muscle cells exposed to IFNgamma plus IL-1beta, IgG and/or prednisone down-regulated mRNA expression of IL-1beta 2.5-fold. Prednisone 62-72 interleukin 1 beta Homo sapiens 107-115 23278573-2 2012 EPITOME is the first randomized control trial in patients with ocular myasthenia and aims to evaluate the efficacy and tolerability of prednisone over a period of four months in patients with newly diagnosed ocular myasthenia whose symptoms have failed to remit in response to a trial of cholinesterase inhibitor therapy. Prednisone 135-145 butyrylcholinesterase Homo sapiens 288-302 22752807-11 2012 We found that the mRNA expression levels of the TSHbeta splice variant were higher in the PBLs of HT patients who were not undergoing prednisone therapy (n = 10, P < 0.0001) and in the PBLs of HT patients with a longer duration of illness (>18 months) who were undergoing prednisone therapy (n = 5, P = 0.023) than in those of the control group. Prednisone 134-144 thyroid stimulating hormone subunit beta Homo sapiens 48-55 21883784-2 2012 AIMS: We report the largest study to date assessing FCGR3A-V158F polymorphisms in diffuse large B-cell lymphoma (DLBCL) treated with cyclophosphamide/hydroxydaunorubicin/Oncovin (vincristine)/prednisone/rituximab (CHOP-R). Prednisone 192-202 Fc gamma receptor IIIa Homo sapiens 52-58 22752807-11 2012 We found that the mRNA expression levels of the TSHbeta splice variant were higher in the PBLs of HT patients who were not undergoing prednisone therapy (n = 10, P < 0.0001) and in the PBLs of HT patients with a longer duration of illness (>18 months) who were undergoing prednisone therapy (n = 5, P = 0.023) than in those of the control group. Prednisone 278-288 thyroid stimulating hormone subunit beta Homo sapiens 48-55 22983648-0 2012 Cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) in the treatment of stage IE/IIE extranodal natural killer/T cell lymphoma, nasal type: 13-year follow-up in 135 patients. Prednisone 48-58 DNA damage inducible transcript 3 Homo sapiens 60-64 22955915-1 2012 TP53 mutation is an independent marker of poor prognosis in patients with diffuse large B-cell lymphoma (DLBCL) treated with cyclophosphamide, hydroxydaunorubicin, vincristine, and prednisone (CHOP) therapy. Prednisone 181-191 tumor protein p53 Homo sapiens 0-4 22922069-7 2012 Incubations were then conducted with dexamethasone (50 nM-1 muM), betamethasone (20-400 nM) and prednisone (50 nM-1 muM) versus no drug for 24 h (n = 6). Prednisone 96-106 latexin Homo sapiens 116-119 24900382-2 2012 A representative compound 4ek, obtained through SAR and structure optimization studies, demonstrates excellent in vitro potency against 11beta-HSD-1 and dose-dependent in vivo inhibition of 11beta-HSD-1 in a prednisone/prednisolone transformation biomarker study in mice. Prednisone 208-218 sarcosinemia autosomal recessive Mus musculus 48-51 22962380-1 2012 The authors present the first case report of a patient with lymphoma who developed disseminated cryptococcal osteomyelitis and meningitis while being treated with the PEP-C (prednisone, etoposide, procarbazine and cyclophosphamide) chemotherapy regimen. Prednisone 174-184 peptidase C Homo sapiens 167-172 22851565-0 2012 Concurrent expression of MYC and BCL2 in diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone. Prednisone 147-157 MYC proto-oncogene, bHLH transcription factor Homo sapiens 25-28 22851565-0 2012 Concurrent expression of MYC and BCL2 in diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone. Prednisone 147-157 BCL2 apoptosis regulator Homo sapiens 33-37 22448918-2 2012 For this reason we decided to explore the combination of rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP) given every 14 days with pegfilgrastim (Neulasta) and GM-CSF (Leukine). Prednisone 115-125 DNA damage inducible transcript 3 Homo sapiens 129-133 24900382-2 2012 A representative compound 4ek, obtained through SAR and structure optimization studies, demonstrates excellent in vitro potency against 11beta-HSD-1 and dose-dependent in vivo inhibition of 11beta-HSD-1 in a prednisone/prednisolone transformation biomarker study in mice. Prednisone 208-218 hydroxysteroid 11-beta dehydrogenase 1 Mus musculus 190-202 22213394-2 2012 The aim of this study was to investigate the frequency and prognostic impact of BCL2, BCL6, and MYC rearrangements in cyclophosphamide, doxorubicin, vincristine, and prednisone plus rituximab (R-CHOP)-treated DLBCL cases. Prednisone 166-176 BCL2 apoptosis regulator Homo sapiens 80-84 22213394-2 2012 The aim of this study was to investigate the frequency and prognostic impact of BCL2, BCL6, and MYC rearrangements in cyclophosphamide, doxorubicin, vincristine, and prednisone plus rituximab (R-CHOP)-treated DLBCL cases. Prednisone 166-176 BCL6 transcription repressor Homo sapiens 86-90 22213394-2 2012 The aim of this study was to investigate the frequency and prognostic impact of BCL2, BCL6, and MYC rearrangements in cyclophosphamide, doxorubicin, vincristine, and prednisone plus rituximab (R-CHOP)-treated DLBCL cases. Prednisone 166-176 MYC proto-oncogene, bHLH transcription factor Homo sapiens 96-99 22765024-7 2012 GEE showed a significant reduction in weight-adjusted CyA daily dose in patients carrying the deletion of 6 bp in SXR with a significant group-by-time effect that persisted also when analysis was corrected for age, prednisone dose, and acute rejection episodes. Prednisone 215-225 nuclear receptor subfamily 1 group I member 2 Homo sapiens 114-117 22759738-4 2012 SUMMARY: Rituximab administered as induction or maintenance therapy in combination with cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly prolonged event-free survival. Prednisone 136-146 DNA damage inducible transcript 3 Homo sapiens 148-152 23181121-4 2012 A multicentre retrospective analysis of DLBCL patients who were treated with cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP)-like chemotherapy alone or chemotherapy plus rituximab (R-CHOP-like) was performed. Prednisone 124-134 DNA damage inducible transcript 3 Homo sapiens 136-140 21923839-12 2012 Among any time prednisone users, the adjusted HR was 1.11 (95% CI, 0.87-1.42) for BCC, and 1.05 (95% CI, 0.76-1.45) for SCC. Prednisone 15-25 serpin family B member 3 Homo sapiens 120-123 21923839-13 2012 Among those who used prednisone for 30 or more days, the HR was 1.26 (95% CI, 0.90-1.78) for BCC, and 1.03 (95% CI, 0.66-1.60) for SCC. Prednisone 21-31 serpin family B member 3 Homo sapiens 131-134 22592163-8 2012 Two hours after LPS stimulation, cells influenced by sanguinarine and chelerythrine significantly declined the CCL-2 expression by a factors of 3.5 (p<0.001) and 1.9 (p<0.01); for those treated with prednisone the factor was 5.3 (p<0.001). Prednisone 205-215 C-C motif chemokine ligand 2 Homo sapiens 111-116 22700860-8 2012 In serum, significant decreases in IL-6, IL-10, IL-12 p40, tumor necrosis factor-alpha, IFN-gamma, and IFN-gamma-induced protein-10 concentrations during prednisone, but not placebo, treatment were observed. Prednisone 154-164 tumor necrosis factor Homo sapiens 59-86 22700860-8 2012 In serum, significant decreases in IL-6, IL-10, IL-12 p40, tumor necrosis factor-alpha, IFN-gamma, and IFN-gamma-induced protein-10 concentrations during prednisone, but not placebo, treatment were observed. Prednisone 154-164 interferon gamma Homo sapiens 88-97 22700860-8 2012 In serum, significant decreases in IL-6, IL-10, IL-12 p40, tumor necrosis factor-alpha, IFN-gamma, and IFN-gamma-induced protein-10 concentrations during prednisone, but not placebo, treatment were observed. Prednisone 154-164 interferon gamma Homo sapiens 103-112 22795634-10 2012 Seven of 8 patients improved with discontinuation of therapy (mean time to resolution, 6.9 months) and adjuvant treatment (all 8 received prednisone; another agent was also used in 7); rechallenge with anti-TNF-alpha therapy was not attempted in any patient. Prednisone 138-148 tumor necrosis factor Homo sapiens 207-216 22474249-5 2012 With the use of Cox-marginal structural models, rituximab plus corticosteroids showed the greater therapeutic efficacy compared with corticosteroids alone and alkylating agents plus corticosteroids to achieve complete clinical, renal, and immunologic responses and a prednisone dosage < 10 mg/d at 6 months. Prednisone 267-277 cytochrome c oxidase subunit 8A Homo sapiens 16-19 22447883-9 2012 CONCLUSION: The present study provides the first evidence of increased CD25(-)FOXP3(+) cells in RA patients, which were associated with disease activity and with GC treatment in carriers of the high IL-10 genotype, suggesting that this population plays a role in the clinical response to prednisone in RA. Prednisone 288-298 interleukin 2 receptor subunit alpha Homo sapiens 71-75 22447883-9 2012 CONCLUSION: The present study provides the first evidence of increased CD25(-)FOXP3(+) cells in RA patients, which were associated with disease activity and with GC treatment in carriers of the high IL-10 genotype, suggesting that this population plays a role in the clinical response to prednisone in RA. Prednisone 288-298 forkhead box P3 Homo sapiens 78-83 22447883-9 2012 CONCLUSION: The present study provides the first evidence of increased CD25(-)FOXP3(+) cells in RA patients, which were associated with disease activity and with GC treatment in carriers of the high IL-10 genotype, suggesting that this population plays a role in the clinical response to prednisone in RA. Prednisone 288-298 interleukin 10 Homo sapiens 199-204 22160255-1 2012 The purpose of the study is to evaluate the 10 years follow-up of the efficacy in Chinese patients receiving cyclophosphamide, doxorubicin/epirubicin, vincristine, and prednisone (CHOP) or rituximab plus CHOP (R-CHOP) regimen as the initial treatment for diffuse large B cell lymphoma (DLBCL). Prednisone 168-178 DNA damage inducible transcript 3 Homo sapiens 180-184 22783780-4 2012 Surprisingly, through the expression of the 11beta-hydroxysteroid dehydrogenase type 1 (11beta-HSD1) enzyme, osteoblasts can generate active glucocorticoids (cortisol and/or prednisolone) from their inactive counterparts (cortisone and/or prednisone). Prednisone 239-249 RNA, U1 small nuclear 1 Homo sapiens 44-99 22513146-7 2012 The second CAMERA (Computer Assisted Management in Early Rheumatoid Arthritis) study in early RA has demonstrated that including prednisone from the start in an MTX-based tight control strategy aimed at remission improves disease activity variables, time to remission, functional disability and radiological joint damage compared with the same strategy without prednisone. Prednisone 129-139 metaxin 1 Homo sapiens 161-164 22282267-1 2012 MLL-rearranged acute lymphoblastic leukemia (ALL) in infants is characterized by a poor clinical outcome and resistance to glucocorticoids (for example, prednisone and dexamethasone). Prednisone 153-163 lysine methyltransferase 2A Homo sapiens 0-3 21948810-5 2012 RESULTS: Only 46% of patients received the standard therapy [aggressive chemotherapy with cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP)-like chemotherapy]. Prednisone 137-147 DNA damage inducible transcript 3 Homo sapiens 149-153 22180452-6 2012 Ex vivo, LPS-stimulated TNF-alpha was significantly reduced by all prednisone doses on days 1 and 7. Prednisone 67-77 tumor necrosis factor Homo sapiens 24-33 22035416-1 2012 The prognosis of patients with peripheral T-cell lymphoma (PTCL) treated with cyclophosphamide, adriamycin, vincristine and prednisone (CHOP) is poor, but their laboratory prognostic parameters had not previously been evaluated. Prednisone 124-134 DNA damage inducible transcript 3 Homo sapiens 136-140 22431705-2 2012 The objective of this study was to limit nuclear factor kappaB (NF-kappaB) activation which is up-regulated in these patients, aiming at decreasing proteinuria and prednisone need. Prednisone 164-174 nuclear factor kappa B subunit 1 Homo sapiens 56-62 22431705-2 2012 The objective of this study was to limit nuclear factor kappaB (NF-kappaB) activation which is up-regulated in these patients, aiming at decreasing proteinuria and prednisone need. Prednisone 164-174 nuclear factor kappa B subunit 1 Homo sapiens 64-73 22400913-6 2012 In the follow-up visit, we found a significant decrease in the frequency of patients with active TA (93% vs. 20%, p = 0.002), in the mean daily dose of prednisone (34.2 vs. 13.9 mg, p < 0.001) and in the median values of ESR (29.0 vs. 27.0 mm/h, p = 0.012) and CRP (10.3 vs. 5.3 mg/L, p = 0.012). Prednisone 152-162 C-reactive protein Homo sapiens 264-267 22464980-7 2012 Hydrocortisone and aldosterone had efflux ratios below 1.5, while prednisone showed a P-gp mediated efflux ratio of only 1.8 compared to its active drug, prednisolone, with an efflux ratio of 4.5. Prednisone 66-76 ATP binding cassette subfamily B member 1 Homo sapiens 86-90 22425183-7 2012 ITGAL and ITGB2 were both overexpressed in vincristine resistant cell line whereas they were both downregulated in prednisone resistant subline. Prednisone 115-125 integrin subunit alpha L Homo sapiens 0-5 22425183-7 2012 ITGAL and ITGB2 were both overexpressed in vincristine resistant cell line whereas they were both downregulated in prednisone resistant subline. Prednisone 115-125 integrin subunit beta 2 Homo sapiens 10-15 22425183-8 2012 On the other hand, LAMC1 gene was drastically overexpressed in prednisone resistant subline whereas it was downregulated in its melphalan resistant variant. Prednisone 63-73 laminin subunit gamma 1 Homo sapiens 19-24 22234490-9 2012 After anti-TNF treatment, prednisone reduction was observed in all studies. Prednisone 26-36 tumor necrosis factor Homo sapiens 11-14 22507791-2 2012 Immunochemotherapy, R-CHOP (rituximab, cyclophosphamide, adriamycin, vincristine, and prednisone) is the standard of care. Prednisone 86-96 DNA damage inducible transcript 3 Homo sapiens 22-26 22180452-8 2012 Oral glucose tolerance tests revealed significant increases in glycaemic excursion on days 1 and 7, whereas increases in insulin and C-peptide excursions were more notable on day 7 with all doses of prednisone. Prednisone 199-209 insulin Homo sapiens 121-128 21504484-7 2012 Longitudinal studies in five patients with early dcSSc treated with oral prednisone demonstrated that serum adiponectin levels inversely correlate with the activity of progressive skin sclerosis in dcSSc patients. Prednisone 73-83 adiponectin, C1Q and collagen domain containing Homo sapiens 108-119 22180248-2 2012 The aim of this work was to study the mechanism of neuroprotection conferred by targeting cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) in the acute brain injury following subarachnoid hemorrhage. Prednisone 138-148 DNA-damage inducible transcript 3 Rattus norvegicus 150-154 22037998-8 2012 After the initial bolus of intravenous corticosteroids, therapy transitions to oral prednisone administered at 1 mg/kg per day until the activity of the disease process attenuates, as demonstrated by improvement in systemic symptoms and normalization of both ESR and CRP. Prednisone 84-94 C-reactive protein Homo sapiens 267-270 22969886-1 2012 The addition of rituximab to cyclophosphamide, doxorubicin, vincristine and prednisone [CHOP (i.e., R-CHOP)] is considered to be the standard regimen for treating localized, primary gastric diffuse large B-cell lymphoma (PG-DLBCL). Prednisone 76-86 DNA damage inducible transcript 3 Homo sapiens 88-92 21651460-0 2012 The dynamics of urinary N-acetyl-beta-D-glucosaminidase (NAG), a marker of renal tubular dysfunction, in patients with lupus nephritis undergoing oral prednisone therapy. Prednisone 151-161 O-GlcNAcase Homo sapiens 24-55 21651460-0 2012 The dynamics of urinary N-acetyl-beta-D-glucosaminidase (NAG), a marker of renal tubular dysfunction, in patients with lupus nephritis undergoing oral prednisone therapy. Prednisone 151-161 O-GlcNAcase Homo sapiens 57-60 21651460-14 2012 After 7 days of prednisone, urinary NAG was 23.55 +- 25.25 U/gCr (P = 0.878 compared with baseline, and P = 0.02 compared with controls). Prednisone 16-26 O-GlcNAcase Homo sapiens 36-39 21651460-14 2012 After 7 days of prednisone, urinary NAG was 23.55 +- 25.25 U/gCr (P = 0.878 compared with baseline, and P = 0.02 compared with controls). Prednisone 16-26 nuclear receptor subfamily 3 group C member 1 Homo sapiens 61-64 21651460-16 2012 After 30 days of prednisone, urinary NAG was 11.77 +- 12.18 U/gCr (P = 0.203 compared with baseline, P = 0.022 compared with the value after 7 days of prednisone, and P = 0.01 compared with controls). Prednisone 17-27 O-GlcNAcase Homo sapiens 37-40 21651460-16 2012 After 30 days of prednisone, urinary NAG was 11.77 +- 12.18 U/gCr (P = 0.203 compared with baseline, P = 0.022 compared with the value after 7 days of prednisone, and P = 0.01 compared with controls). Prednisone 17-27 nuclear receptor subfamily 3 group C member 1 Homo sapiens 62-65 21651460-16 2012 After 30 days of prednisone, urinary NAG was 11.77 +- 12.18 U/gCr (P = 0.203 compared with baseline, P = 0.022 compared with the value after 7 days of prednisone, and P = 0.01 compared with controls). Prednisone 151-161 O-GlcNAcase Homo sapiens 37-40 21651460-22 2012 Further studies incorporating a longer follow-up are needed to observe whether the reduction in NAG persists upon continuation of prednisone therapy. Prednisone 130-140 O-GlcNAcase Homo sapiens 96-99 22546724-2 2012 In lymphocytes, two glucocorticoids, prednisone and prednisolone, have been shown to induce ABCB1 activity. Prednisone 37-47 ATP binding cassette subfamily B member 1 Homo sapiens 92-97 22184372-7 2012 Cumulative risk of POF after alkylating chemotherapy was 60% (95% CI, 41% to 79%) and only 3% (95% CI, 1% to 7%) after nonalkylating chemotherapy (doxorubicin, bleomycin, vinblastine, and dacarbazine; epirubicin, bleomycin, vinblastine, and prednisone). Prednisone 241-251 POF1B actin binding protein Homo sapiens 19-22 22218276-8 2012 Consequently, in the MuSK+MG group, prednisone doses were significantly reduced and concomitant immunosuppressants could be withdrawn. Prednisone 36-46 muscle associated receptor tyrosine kinase Homo sapiens 21-25 22260632-4 2012 The patient initially received 6 cycles of chemotherapy with CHOP regimen (cyclophosphamide, vincristine, adriamycin, prednisone), but his symptoms did not disappear. Prednisone 118-128 DNA damage inducible transcript 3 Homo sapiens 61-65 22260632-9 2012 CHOP-R chemotherapy (cyclophosphamide, doxorubicin, vincristine, prednisone and rituximab) was then administered, resulting in partial response of the disease with pancytopenia and suppression of cellular immunity. Prednisone 65-75 DNA damage inducible transcript 3 Homo sapiens 0-4 22372177-7 2012 Recently genetic testing has become available for TGF-beta1 mutation Several therapeutic agents including biphosphonates, NSAIDs, prednisone and losartan have been described as therapeutic options with mixed results, as described in our cases. Prednisone 130-140 transforming growth factor beta 1 Homo sapiens 50-59 21460380-3 2012 The combination chemotherapy with cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) with addition of etoposide (CHOEP) has in other patient groups been shown to be effective. Prednisone 81-91 DNA damage inducible transcript 3 Homo sapiens 93-97 22906294-4 2012 The patient received two cycles of cyclophosphamide + epirubicin + vincristine + prednisone (CHOP) chemo therapy, which was ineffective. Prednisone 81-91 DNA damage inducible transcript 3 Homo sapiens 93-97 21864040-1 2012 In the rituximab era, several large studies have suggested that full-dose rituximab plus cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP) might be the best treatment for patients with diffuse large B-cell lymphoma (DLBCL) aged 60 years and older. Prednisone 136-146 DNA damage inducible transcript 3 Homo sapiens 150-154 22145998-0 2011 Relapsing insulin-induced lipoatrophy, cured by prolonged low-dose oral prednisone: a case report. Prednisone 72-82 insulin Homo sapiens 10-17 22481760-6 2012 Immunochemotherapy consisting of rituximab, cyclophosphamide, vincristine and prednisone (R-COP) induced complete remission of the symptoms and endoscopic lesion. Prednisone 78-88 caspase recruitment domain family member 16 Homo sapiens 92-95 22175899-15 2011 All of these patients were treated with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP), and this was followed by clinical remission (CR). Prednisone 99-109 DNA damage inducible transcript 3 Homo sapiens 113-117 21788064-0 2011 Reduced production of IFN-gamma and LT-alpha is associated with successful prednisone therapy in patients with acquired hemophilia A: a pilot study. Prednisone 75-85 interferon gamma Homo sapiens 22-31 21851218-7 2011 In the current study generation, the addition of high-dose Ara-C to a rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP)-like regimen followed by myeloablative consolidation achieved a significant improvement of progression-free survival. Prednisone 128-138 DNA damage inducible transcript 3 Homo sapiens 142-146 22027711-11 2011 CONCLUSION: Based on the overall safety profile, 200 mg BID was the recommended dose for the combination of BIBF 1120 with the standard dose of 75 mg m(-2) of docetaxel and prednisone that might be further investigated in HRPC patients. Prednisone 173-183 BH3 interacting domain death agonist Homo sapiens 56-59 21635675-2 2011 METHODS: The objective of this study was to quantify the effects of daily 10 or 25 mg prednisone administration for one week on insulin sensitivity by employing a two-step hyperinsulinemic euglycemic glucose clamp (Step 1: insulin infusion = 20 mU/m2/min; Step 2: insulin infusion = 80 mU/m2/min) in healthy, lean males. Prednisone 86-96 insulin Homo sapiens 128-135 21635675-7 2011 The insulin sensitivity index, Si, calculated as the quotient of augmentation of M/I between Step 1 and 2, was reduced by 35.3% (p < 0.01) and 23.5% (p < 0.05) for 25 and 10 mg prednisone, respectively. Prednisone 183-193 insulin Homo sapiens 4-11 21702643-0 2011 Granulocyte-macrophage colony stimulating factor-induced immune priming of cyclophosphamide, doxorubicin, vincristine, and prednisone with rituximab chemoimmunotherapy in previously untreated patients with diffuse large B-cell lymphoma and mantle cell lymphoma. Prednisone 123-133 colony stimulating factor 2 Homo sapiens 0-48 21788064-0 2011 Reduced production of IFN-gamma and LT-alpha is associated with successful prednisone therapy in patients with acquired hemophilia A: a pilot study. Prednisone 75-85 lymphotoxin alpha Homo sapiens 36-44 21788064-8 2011 This study suggests that the secretion level of IFN-gamma and/or LT-alpha could be a predictive marker of prednisone responsiveness. Prednisone 106-116 interferon gamma Homo sapiens 48-57 21788064-8 2011 This study suggests that the secretion level of IFN-gamma and/or LT-alpha could be a predictive marker of prednisone responsiveness. Prednisone 106-116 lymphotoxin alpha Homo sapiens 65-73 22586509-2 2011 The cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) treatment regimen has been the standard of care for more than 20 years. Prednisone 52-62 DNA damage inducible transcript 3 Homo sapiens 64-68 22099782-4 2011 The grafts were saved by treatments with rituximab, cyclophosphamide, hydroxydaunorubicin, and prednisone-based chemotherapy (R-CHOP) after reduction of immunosuppression (IR). Prednisone 95-105 DNA damage inducible transcript 3 Homo sapiens 128-132 22586511-1 2011 Chemotherapy with cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) has long been a standard treatment for lymphoma. Prednisone 66-76 DNA damage inducible transcript 3 Homo sapiens 78-82 22586513-3 2011 To date, the most widely used regimen seems to be rituximab combined with cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP). Prednisone 122-132 DNA damage inducible transcript 3 Homo sapiens 136-140 22117311-5 2011 Both patients were successfully treated with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP). Prednisone 104-114 DNA damage inducible transcript 3 Homo sapiens 118-122 22288215-7 2011 The patient was placed on intravenous steroids and later oral prednisone that resulted in the resolution of the liver failure and disappearance of the encephalopathy along with a downward trend of the liver enzymes, bilirubin and the prothrombin time. Prednisone 62-72 coagulation factor II, thrombin Homo sapiens 234-245 21931035-1 2011 PURPOSE: Rituximab with cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) is one of the most effective front-line therapies to treat indolent B-cell lymphoma. Prednisone 72-82 DNA damage inducible transcript 3 Homo sapiens 86-90 21257672-1 2011 BACKGROUND: Rituximab plus combination chemotherapy with cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) is widely recommended for the treatment of aggressive B-cell lymphomas. Prednisone 105-115 DNA damage inducible transcript 3 Homo sapiens 119-123 21811948-8 2011 Genetic analysis showed the compound heterozygous variants ABCB11 A 444V and 3084A > G. Treatment with ursodesoxycholic acid and intermittent therapy with prednisone reduced pruritus and jaundice with concomitant improvement of blood test. Prednisone 158-168 ATP binding cassette subfamily B member 11 Homo sapiens 59-65 21699635-3 2011 The aim of the present study was to investigate the mechanisms by which prednisone and the related factors, transforming growth factor (TGF)-beta1 and connective tissue growth factor (CTGF), prevent liver fibrosis and the pathogenesis of HSOS. Prednisone 72-82 transforming growth factor, beta 1 Mus musculus 108-146 21699635-3 2011 The aim of the present study was to investigate the mechanisms by which prednisone and the related factors, transforming growth factor (TGF)-beta1 and connective tissue growth factor (CTGF), prevent liver fibrosis and the pathogenesis of HSOS. Prednisone 72-82 cellular communication network factor 2 Mus musculus 151-182 21699635-3 2011 The aim of the present study was to investigate the mechanisms by which prednisone and the related factors, transforming growth factor (TGF)-beta1 and connective tissue growth factor (CTGF), prevent liver fibrosis and the pathogenesis of HSOS. Prednisone 72-82 cellular communication network factor 2 Mus musculus 184-188 21699635-10 2011 Prednisone treatment significantly inhibited expression of TGF-beta1 and CTGF mRNA and protein (P < 0.05), and inhibited expression of TNF-alpha and NF-kappaBp65 mRNA (P < 0.05) in the liver tissue of HSOS mice. Prednisone 0-10 transforming growth factor, beta 1 Mus musculus 59-68 21699635-10 2011 Prednisone treatment significantly inhibited expression of TGF-beta1 and CTGF mRNA and protein (P < 0.05), and inhibited expression of TNF-alpha and NF-kappaBp65 mRNA (P < 0.05) in the liver tissue of HSOS mice. Prednisone 0-10 cellular communication network factor 2 Mus musculus 73-77 21699635-10 2011 Prednisone treatment significantly inhibited expression of TGF-beta1 and CTGF mRNA and protein (P < 0.05), and inhibited expression of TNF-alpha and NF-kappaBp65 mRNA (P < 0.05) in the liver tissue of HSOS mice. Prednisone 0-10 tumor necrosis factor Mus musculus 138-147 21699635-11 2011 CONCLUSION: Prednisone suppresses the development of liver fibrosis in HSOS mice by inhibiting TGF-beta1, CTGF, TNF-alpha and NF-kappaBp65 expression. Prednisone 14-24 transforming growth factor, beta 1 Mus musculus 97-106 21699635-11 2011 CONCLUSION: Prednisone suppresses the development of liver fibrosis in HSOS mice by inhibiting TGF-beta1, CTGF, TNF-alpha and NF-kappaBp65 expression. Prednisone 14-24 cellular communication network factor 2 Mus musculus 108-112 21699635-11 2011 CONCLUSION: Prednisone suppresses the development of liver fibrosis in HSOS mice by inhibiting TGF-beta1, CTGF, TNF-alpha and NF-kappaBp65 expression. Prednisone 14-24 tumor necrosis factor Mus musculus 114-123 21747882-1 2011 BACKGROUND: The addition of rituximab to cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy (R-CHOP) has significantly improved clinical outcomes for patients with diffuse large B-cell lymphoma (DLBCL). Prednisone 89-99 DNA damage inducible transcript 3 Homo sapiens 101-105 21489796-6 2011 A diagnosis of a grade III LYG was made and chemotherapy with cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) was administered. Prednisone 109-119 DNA damage inducible transcript 3 Homo sapiens 121-125 20661652-6 2011 Prednisone treatment in mdx mice resulted in decreased CTSB activity and increased grip strength in forelimbs and hindlimbs. Prednisone 0-10 cathepsin B Mus musculus 55-59 21399901-6 2011 The only factor that influenced a PSR was the degree of SD: the group PSR+ relapsed at prednisone dose of 0.96 +- 0.51 mg/kg vs. 1.29 +- 0.59 mg/kg in group PSR- (p = 0.01). Prednisone 87-97 jumonji domain containing 6, arginine demethylase and lysine hydroxylase Homo sapiens 70-73 21399901-6 2011 The only factor that influenced a PSR was the degree of SD: the group PSR+ relapsed at prednisone dose of 0.96 +- 0.51 mg/kg vs. 1.29 +- 0.59 mg/kg in group PSR- (p = 0.01). Prednisone 87-97 jumonji domain containing 6, arginine demethylase and lysine hydroxylase Homo sapiens 70-73 21747882-1 2011 BACKGROUND: The addition of rituximab to cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy (R-CHOP) has significantly improved clinical outcomes for patients with diffuse large B-cell lymphoma (DLBCL). Prednisone 89-99 DNA damage inducible transcript 3 Homo sapiens 123-127 21640055-5 2011 Cumulative prednisone dose correlated with total cholesterol (r=0.5790, p<0.001) and elevated LDL-C (r=0.4488, p=0.0012). Prednisone 11-21 component of oligomeric golgi complex 2 Homo sapiens 97-102 21531233-2 2011 BACKGROUND: Prednisone at immunosuppressive doses after stenting has shown remarkable efficacy in reducing ischemic recurrences in nondiabetic patients with high post-procedural levels of C-reactive protein; the study aim was to compare the clinical outcome obtained in a control group of patients treated with bare metal stents versus 2 other study groups--bare metal stent plus oral prednisone or drug eluting stents--assuming similar optimal adjunctive medical treatment. Prednisone 12-22 C-reactive protein Homo sapiens 188-206 21640055-7 2011 In multivariate analysis LDL-C correlated with cumulative prednisone dose and negatively with hydroxychloroquine treatment (R2=0.40, p<0.001). Prednisone 58-68 component of oligomeric golgi complex 2 Homo sapiens 25-30 20817712-6 2011 Serum IL-6 and TNF decreased during prednisone therapy in TB-IRIS patients. Prednisone 36-46 interleukin 6 Homo sapiens 6-10 20817712-6 2011 Serum IL-6 and TNF decreased during prednisone therapy in TB-IRIS patients. Prednisone 36-46 tumor necrosis factor Homo sapiens 15-18 20521053-2 2011 CHOP and CVP represent untargeted combination chemotherapy comprised of cyclophosphamide, vincristine and prednisone with or without doxorubicin, commonly used in the treatment of NHL. Prednisone 106-116 DNA damage inducible transcript 3 Homo sapiens 0-4 21498532-1 2011 UNLABELLED: R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone)-like chemotherapy is the standard therapy in aggressive B-cell lymphoma. Prednisone 79-89 DNA damage inducible transcript 3 Homo sapiens 14-18 21323512-1 2011 Development of resistance to the CHOP chemotherapeutic regimen (cyclophosphamide, doxorubicin, vincristine, prednisone) remains a major cause of treatment failure and mortality in approximately 40% of patients with diffuse large B-cell lymphoma (DLBCL). Prednisone 108-118 DNA damage inducible transcript 3 Homo sapiens 33-37 20938662-3 2011 In this study, we performed immunohistochemical analysis for IDO expression using mouse anti-human IDO monoclonal antibody in 119 tissue samples of diffuse large B-cell lymphoma (DLBCL) obtained before treatment with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP). Prednisone 276-286 indoleamine 2,3-dioxygenase 1 Homo sapiens 61-64 21366694-2 2011 This post hoc analysis of the phase III VISTA trial of bortezomib plus melphalan-prednisone (VMP) vs. MP in previously untreated myeloma patients assessed clinical bone disease events and changes in alkaline phosphatase (ALP), a marker for osteoblast activation, and serum Dickkopf-1 (DKK-1), an inhibitor of osteoblast differentiation, during treatment. Prednisone 81-91 neurensin 1 Homo sapiens 93-96 21482186-3 2011 We aimed to investigate the efficacy and safety of a decreased dose of CHOP (doxorubicin, cyclophosphamide, vincristine, and prednisone) chemotherapy with a conventional dose of rituximab in elderly patients with diffuse large B-cell lymphoma. Prednisone 125-135 DNA damage inducible transcript 3 Homo sapiens 71-75 21559001-4 2011 The standard management for PTCL patients is cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) or CHOP-like regimens. Prednisone 93-103 DNA damage inducible transcript 3 Homo sapiens 105-109 22087145-4 2011 The patient was treated with R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone) without surgical resection with a favorable response. Prednisone 95-105 DNA damage inducible transcript 3 Homo sapiens 31-35 20354901-4 2011 The patient was treated with cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) with rituximab, and a dramatic improvement of renal function was noticed after two weeks of treatment. Prednisone 77-87 DNA damage inducible transcript 3 Homo sapiens 89-93 21094842-8 2010 Serum midkine was related to kidney function, NT-proBNP, transferrin, and prednisone dose. Prednisone 74-84 midkine Homo sapiens 6-13 20469972-3 2011 Early in her third remission, with vincristine (weekly x 4 doses) and prednisone (for 2 weeks) her ADAMTS13 increased to 99% in 24 weeks, but decreased to <4% in the next 38 weeks. Prednisone 70-80 ADAM metallopeptidase with thrombospondin type 1 motif 13 Homo sapiens 99-107 21276247-3 2011 In the present study, we examined the effects of prednisone, thalidomide, cyclosporine A, and amitriptyline, drugs used in a variety of clinical conditions, on the production of TNF-alpha, IL-10, and IL-12 by purified epidermal Langerhans cells and peritoneal macrophages in BALB/c mice. Prednisone 49-59 tumor necrosis factor Mus musculus 178-187 21704311-5 2011 The IC(50) of r-RahU (0.6 muM) was distinct from the known inhibitors of NO production: prednisone (50 muM) and L-NMMA (100 muM). Prednisone 88-98 latexin Homo sapiens 103-106 21429398-14 2011 There was significant difference in the expression level of TOP2A between remission and prednisone good responder groups (P < 0.05). Prednisone 88-98 DNA topoisomerase II alpha Homo sapiens 60-65 21084053-3 2010 Herein, we report a 75-year-old female patient with infiltrative CD20 (+) B-cell lymphoma who underwent 4 consecutive courses of chemotherapy with R-CVP (rituximab, cyclophosphamide, vincristine, and prednisone) and after 12 sessions became free from hemodialysis in good general condition. Prednisone 200-210 keratin 20 Homo sapiens 65-69 20952465-10 2010 The antiinflammatory balance observed in high IL-10/low TNF-alpha patients treated with prednisone supports the use of these genetic polymorphisms as predictors of response to corticosteroid therapy. Prednisone 88-98 interleukin 10 Homo sapiens 46-51 20952465-10 2010 The antiinflammatory balance observed in high IL-10/low TNF-alpha patients treated with prednisone supports the use of these genetic polymorphisms as predictors of response to corticosteroid therapy. Prednisone 88-98 tumor necrosis factor Homo sapiens 56-65 20861909-0 2010 NOTCH1 and/or FBXW7 mutations predict for initial good prednisone response but not for improved outcome in pediatric T-cell acute lymphoblastic leukemia patients treated on DCOG or COALL protocols. Prednisone 55-65 notch receptor 1 Homo sapiens 0-6 21050687-8 2010 The classic CHOP protocol (combination of doxorubicin-cyclophosphamide-vincristine-prednisone) does not have satisfactory results and survival remains poor, especially in patients with underlying RCD. Prednisone 83-93 DNA damage inducible transcript 3 Homo sapiens 12-16 21535956-6 2011 Eight miRNAs (miR-18a, miR-532, miR-218, miR-625, miR-193a, miR-638, miR-550 and miR-633) could distinguish prednisone sensitive from insensitive. Prednisone 108-118 microRNA 18a Homo sapiens 14-21 21535956-6 2011 Eight miRNAs (miR-18a, miR-532, miR-218, miR-625, miR-193a, miR-638, miR-550 and miR-633) could distinguish prednisone sensitive from insensitive. Prednisone 108-118 microRNA 532 Homo sapiens 23-30 21535956-6 2011 Eight miRNAs (miR-18a, miR-532, miR-218, miR-625, miR-193a, miR-638, miR-550 and miR-633) could distinguish prednisone sensitive from insensitive. Prednisone 108-118 microRNA 625 Homo sapiens 41-48 21535956-6 2011 Eight miRNAs (miR-18a, miR-532, miR-218, miR-625, miR-193a, miR-638, miR-550 and miR-633) could distinguish prednisone sensitive from insensitive. Prednisone 108-118 microRNA 193a Homo sapiens 50-58 21535956-6 2011 Eight miRNAs (miR-18a, miR-532, miR-218, miR-625, miR-193a, miR-638, miR-550 and miR-633) could distinguish prednisone sensitive from insensitive. Prednisone 108-118 microRNA 638 Homo sapiens 60-67 21535956-6 2011 Eight miRNAs (miR-18a, miR-532, miR-218, miR-625, miR-193a, miR-638, miR-550 and miR-633) could distinguish prednisone sensitive from insensitive. Prednisone 108-118 microRNA 633 Homo sapiens 81-88 21704311-5 2011 The IC(50) of r-RahU (0.6 muM) was distinct from the known inhibitors of NO production: prednisone (50 muM) and L-NMMA (100 muM). Prednisone 88-98 latexin Homo sapiens 103-106 21760772-4 2011 Extensive imaging showed no signs of hepatocellular carcinoma or other cancer, and treatment with Prednisone led to rapid normalization of both liver enzymes and aFP. Prednisone 98-108 alpha fetoprotein Homo sapiens 162-165 21529308-12 2011 Taken at bedtime (approximately 10:00 pm), these tablets give programmed delivery of prednisone around 4 h later, at the optimal time to suppress IL-6. Prednisone 85-95 interleukin 6 Homo sapiens 146-150 21302497-4 2010 RESULTS: Levels of RANTES expression was significantly reduced in the prednisone treated group after treatment. Prednisone 70-80 chemokine (C-C motif) ligand 5 Mus musculus 19-25 21042682-6 2010 Immunosuppressive treatment with a combination of oral prednisone (1 mg/kg daily) and cyclophosphamide (1,5 mg/kg daily) was administered to reduce the FVIII inhibitor. Prednisone 55-65 coagulation factor VIII Homo sapiens 152-157 21042412-8 2010 Second, in patients with poor clinical response to prednisone we observed the up-modulation of LCK activity with respect to patients with good response. Prednisone 51-61 LCK proto-oncogene, Src family tyrosine kinase Homo sapiens 95-98 21042412-9 2010 This tyrosine-kinase can be down-modulated with clinically used inhibitors, thus modulating LCK activity could be considered for further studies as a new additional therapy for prednisone-resistant patients. Prednisone 177-187 LCK proto-oncogene, Src family tyrosine kinase Homo sapiens 92-95 20595929-9 2010 CONCLUSION: The benefit of IL2ra induction with TAC/MPA/prednisone maintenance immunosuppression is less than previously reported due to a low baseline incidence of acute rejection. Prednisone 56-66 interleukin 2 receptor subunit alpha Homo sapiens 27-32 20548096-1 2010 We report the outcome of patients included in the LNH-98.5 study, which compared cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) to rituximab plus CHOP (R-CHOP) therapy in 399 patients with diffuse large B-cell lymphoma (DLBCL) aged 60 to 80 years, with a median follow-up time of 10 years. Prednisone 129-139 DNA damage inducible transcript 3 Homo sapiens 141-145 20548261-3 2010 RESULTS: We first demonstrated that Nox-2 and alpha-smooth muscle actin (SMA) were increased in renal tubules from kidney transplant recipients on calcineurin inhibitors, mycophenolic acid (MPA), and prednisone with IFTANOS, suggestive of EMT (n=6). Prednisone 200-210 cytochrome b-245 beta chain Rattus norvegicus 36-41 20538348-2 2010 Our previous studies had confirmed that the combined treatment of minocycline and prednisone produced beneficial effects partially through preventing the reduction of brain-derived neurotrophic factor and nerve growth factor mRNA expression in the cerebral cortex of experimental autoimmune encephalomyelitis (EAE) mice. Prednisone 82-92 brain derived neurotrophic factor Mus musculus 167-200 20538348-2 2010 Our previous studies had confirmed that the combined treatment of minocycline and prednisone produced beneficial effects partially through preventing the reduction of brain-derived neurotrophic factor and nerve growth factor mRNA expression in the cerebral cortex of experimental autoimmune encephalomyelitis (EAE) mice. Prednisone 82-92 nerve growth factor Mus musculus 205-224 20669178-0 2010 Durable complete remission of primary plasma cell leukemia with the bortezomib plus melphalan and prednisone (VMP) regimen. Prednisone 98-108 neurensin 1 Homo sapiens 110-113 20830228-1 2010 BACKGROUND/AIMS: Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy (R-CHOP) has improved survival in patients with diffuse large B-cell lymphoma (DLBCL) and weakened the prognostic power of the international prognostic index (IPI). Prednisone 80-90 DNA damage inducible transcript 3 Homo sapiens 107-111 20548261-3 2010 RESULTS: We first demonstrated that Nox-2 and alpha-smooth muscle actin (SMA) were increased in renal tubules from kidney transplant recipients on calcineurin inhibitors, mycophenolic acid (MPA), and prednisone with IFTANOS, suggestive of EMT (n=6). Prednisone 200-210 actin gamma 2, smooth muscle Rattus norvegicus 46-71 20548261-3 2010 RESULTS: We first demonstrated that Nox-2 and alpha-smooth muscle actin (SMA) were increased in renal tubules from kidney transplant recipients on calcineurin inhibitors, mycophenolic acid (MPA), and prednisone with IFTANOS, suggestive of EMT (n=6). Prednisone 200-210 actin gamma 2, smooth muscle Rattus norvegicus 73-76 20582956-6 2010 In patients with T-cell ALL, poor prednisone response was associated with increased XIAP expression (median: 2.8 in good vs. 5.8 in poor responders; P = 0.005). Prednisone 34-44 X-linked inhibitor of apoptosis Homo sapiens 84-88 20435884-3 2010 Losses of TP53 and CDKN2A, observed in 8% and 35% of patients, respectively, were significantly associated with a shorter survival after rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) treatment, independently of the International Prognostic Index and of the cell of origin. Prednisone 196-206 tumor protein p53 Homo sapiens 10-14 20435884-3 2010 Losses of TP53 and CDKN2A, observed in 8% and 35% of patients, respectively, were significantly associated with a shorter survival after rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) treatment, independently of the International Prognostic Index and of the cell of origin. Prednisone 196-206 cyclin dependent kinase inhibitor 2A Homo sapiens 19-25 20565230-4 2010 Systemic corticosteroids, such as prednisone, are first-line therapy for the management of patients with symptomatic HES who lack the Fip1-like 1-platelet-derived growth factor receptor-alpha (FIP1L1-PDGFRA) gene fusion mutation. Prednisone 34-44 platelet derived growth factor receptor alpha Homo sapiens 200-206 20650041-1 2010 OBJECTIVE: To evaluate the therapeutic effects and safety of a combination therapy of leflunomide (LEF) and prednisone for the treatment of immunoglobulin A (IgA) nephropathy manifesting with nephrotic syndrome. Prednisone 108-118 CD79a molecule Homo sapiens 140-156 20650041-1 2010 OBJECTIVE: To evaluate the therapeutic effects and safety of a combination therapy of leflunomide (LEF) and prednisone for the treatment of immunoglobulin A (IgA) nephropathy manifesting with nephrotic syndrome. Prednisone 108-118 CD79a molecule Homo sapiens 158-161 20582956-8 2010 XIAP inhibition using the low-molecular-weight SMAC mimetic LBW242 resulted in a significant increase of prednisone-induced apoptosis in vitro. Prednisone 105-115 X-linked inhibitor of apoptosis Homo sapiens 0-4 20582956-8 2010 XIAP inhibition using the low-molecular-weight SMAC mimetic LBW242 resulted in a significant increase of prednisone-induced apoptosis in vitro. Prednisone 105-115 diablo IAP-binding mitochondrial protein Homo sapiens 47-51 20497628-0 2010 Effects of low or medium-dose of prednisone on insulin resistance in patients with systemic lupus erythematosus. Prednisone 33-43 insulin Homo sapiens 47-54 20498406-2 2010 The aim of this study was to determine the frequency of MYC translocations in DLBCL and their prognostic impact in the era of cyclophosphamide, doxorubicin, vincristine, and prednisone plus rituximab (CHOP-R) therapy. Prednisone 174-184 MYC proto-oncogene, bHLH transcription factor Homo sapiens 56-59 20206356-2 2010 The aim of this study was to test the effects of a short-course, high-dose oral prednisone on the release of interleukin-6 (IL-6) and tumour necrosis factor (TNF)-alpha from circulating monocytes and on the neointimal growth that follows bare metal stent (BMS) implantation. Prednisone 80-90 interleukin 6 Homo sapiens 109-122 20206356-2 2010 The aim of this study was to test the effects of a short-course, high-dose oral prednisone on the release of interleukin-6 (IL-6) and tumour necrosis factor (TNF)-alpha from circulating monocytes and on the neointimal growth that follows bare metal stent (BMS) implantation. Prednisone 80-90 interleukin 6 Homo sapiens 124-128 20206356-2 2010 The aim of this study was to test the effects of a short-course, high-dose oral prednisone on the release of interleukin-6 (IL-6) and tumour necrosis factor (TNF)-alpha from circulating monocytes and on the neointimal growth that follows bare metal stent (BMS) implantation. Prednisone 80-90 tumor necrosis factor Homo sapiens 134-168 20206356-7 2010 RESULTS: Plasma concentrations of prednisone correlated inversely with IL-6 and TNF-alpha release (R2=0.45, p=0.04 and R2=0.69, p=0.005, respectively) and NF-kappaB activation from monocytes (R2=0.58, p=0.01). Prednisone 34-44 interleukin 6 Homo sapiens 71-75 20206356-7 2010 RESULTS: Plasma concentrations of prednisone correlated inversely with IL-6 and TNF-alpha release (R2=0.45, p=0.04 and R2=0.69, p=0.005, respectively) and NF-kappaB activation from monocytes (R2=0.58, p=0.01). Prednisone 34-44 tumor necrosis factor Homo sapiens 80-89 20206356-7 2010 RESULTS: Plasma concentrations of prednisone correlated inversely with IL-6 and TNF-alpha release (R2=0.45, p=0.04 and R2=0.69, p=0.005, respectively) and NF-kappaB activation from monocytes (R2=0.58, p=0.01). Prednisone 34-44 nuclear factor kappa B subunit 1 Homo sapiens 155-164 20206356-9 2010 Prednisone patients showed a significantly larger reduction of cytokine release and NF-kappaB activation compared to non-treated patients, at 10 days and 30 days. Prednisone 0-10 nuclear factor kappa B subunit 1 Homo sapiens 84-93 20206356-10 2010 LLL was lower in the prednisone group (0.44+/-0.35 mm versus 0.80+/-0.53 mm, p=0.02) and correlated with reduction of TNF-alpha (R2=0.41, p=0.01). Prednisone 21-31 tumor necrosis factor Homo sapiens 118-127 20206356-11 2010 CONCLUSIONS: High doses of oral prednisone reduce NF-kappaB pathway activation and pro-inflammatory cytokine release in circulating activated monocytes of patients treated with coronary stenting. Prednisone 32-42 nuclear factor kappa B subunit 1 Homo sapiens 50-59 20497628-8 2010 Prednisone dose correlated with the HOMA index and insulin but not with inflammatory parameters (erythrocyte sedimentation rate p=0.075) after adjusting for confounder. Prednisone 0-10 insulin Homo sapiens 51-58 20497628-9 2010 CONCLUSIONS: Daily medium-dose prednisone use (>7.5 mg/d) but not low-dose (< or =7.5 mg/d) use increased insulin levels and IR in SLE, which may contribute to increased CV risk experienced by these patients. Prednisone 31-41 insulin Homo sapiens 112-119 20568377-6 2010 After treatment, forced expiratory volume in 1 second significantly increased and sputum eosinophil percentages and IL-5 and IL-8 concentrations significantly decreased in the prednisone group, whereas no changes were observed in the placebo group. Prednisone 176-186 interleukin 5 Homo sapiens 116-120 20568377-6 2010 After treatment, forced expiratory volume in 1 second significantly increased and sputum eosinophil percentages and IL-5 and IL-8 concentrations significantly decreased in the prednisone group, whereas no changes were observed in the placebo group. Prednisone 176-186 C-X-C motif chemokine ligand 8 Homo sapiens 125-129 20568377-7 2010 The positive effect of prednisone treatment was observed only in patients with baseline sputum eosinophilia, whereas in noneosinophilic patients with severe asthma prednisone induced only a significant decrease of sputum IL-8. Prednisone 164-174 C-X-C motif chemokine ligand 8 Homo sapiens 221-225 20388848-11 2010 CONCLUSION: The findings suggest that STAT5a activity in immunologically active nonmalignant cells acts as molecular predictor for rituximab and cyclophoshamide-doxorubicin-vincristine-prednisone-treated FL patients. Prednisone 185-195 signal transducer and activator of transcription 5A Homo sapiens 38-44 20535794-9 2010 IL-6 was significantly higher in patients still requiring prednisone (mean +/- SD 29 +/- 45 versus 13 +/- 17 pg/ml; P = 0.008), and TNFalpha correlated with cumulated prednisone dose (r = 0.292, P = 0.04). Prednisone 58-68 interleukin 6 Homo sapiens 0-4 20535794-9 2010 IL-6 was significantly higher in patients still requiring prednisone (mean +/- SD 29 +/- 45 versus 13 +/- 17 pg/ml; P = 0.008), and TNFalpha correlated with cumulated prednisone dose (r = 0.292, P = 0.04). Prednisone 167-177 interleukin 6 Homo sapiens 0-4 20535794-9 2010 IL-6 was significantly higher in patients still requiring prednisone (mean +/- SD 29 +/- 45 versus 13 +/- 17 pg/ml; P = 0.008), and TNFalpha correlated with cumulated prednisone dose (r = 0.292, P = 0.04). Prednisone 167-177 tumor necrosis factor Homo sapiens 132-140 20385988-2 2010 The introduction of rituximab has markedly improved outcome, and R-CHOP (rituximab + cyclophosphamide, doxorubicin, vincristine, prednisone) has become the standard treatment for CD20(+) diffuse large B-cell lymphoma. Prednisone 129-139 DNA damage inducible transcript 3 Homo sapiens 67-71 20132303-13 2010 One patient became ZAP-70-negative during treatment with prednisone for autoimmune hemolytic anemia. Prednisone 57-67 zeta chain of T cell receptor associated protein kinase 70 Homo sapiens 19-25 20096776-1 2010 The chemotherapeutic agents used to treat non-Hodgkin lymphoma, cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP), have adverse effects on male reproductive function and progeny outcome. Prednisone 112-122 DNA-damage inducible transcript 3 Rattus norvegicus 124-128 19850640-2 2010 cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) is recognized as the standard chemotherapy regimen and the addition of rituximab to B-cell subtypes has been shown to significantly improve treatment outcomes. Prednisone 47-57 DNA damage inducible transcript 3 Homo sapiens 59-63 20142368-10 2010 Receiver operating curve (ROC) analysis performed to predict a suppressed adrenal function on day 7 after the withdrawal of prednisone showed an area under the curve (AUC) of 0.76 (95% confidence interval (CI) 0.58-0.89) for cortisol after the administration of dexamethasone, which was in the range of the AUC of 0.78 (95% CI 0.6-0.9) for pre-intervention cortisol after the administration of ACTH. Prednisone 124-134 proopiomelanocortin Homo sapiens 394-398 20368561-1 2010 PURPOSE: The purpose of this study was to confirm overall survival (OS) and other clinical benefits with bortezomib, melphalan, and prednisone (VMP) versus melphalan and prednisone (MP) in the phase III VISTA (Velcade as Initial Standard Therapy in Multiple Myeloma) trial after prolonged follow-up, and evaluate the impact of subsequent therapies. Prednisone 132-142 V-set immunoregulatory receptor Homo sapiens 203-208 19941344-2 2010 We report a mother and son with a prednisone-responsive, multifocal, demyelinating, predominantly sensory polyneuropathy that was associated with an isoleucine92valine polymorphism of lipopolysaccharide-induced TNF-alpha factor (LITAF). Prednisone 34-44 lipopolysaccharide induced TNF factor Homo sapiens 184-227 20539272-3 2010 Traditional treatments for MCL rely on conventional chemotherapy agents, including cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP). Prednisone 131-141 DNA damage inducible transcript 3 Homo sapiens 143-147 20552750-3 2010 Traditional treatments for MCLrely on conventional chemotherapy agents, including cyclophosphamide, doxorubicin, vincristine, and prednisone(CHOP). Prednisone 130-140 DNA damage inducible transcript 3 Homo sapiens 141-145 20198460-1 2010 The addition of rituximab to cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) improved the outcome of patients with diffuse large B-cell lymphoma (DLBCL). Prednisone 76-86 DNA damage inducible transcript 3 Homo sapiens 88-92 19941344-2 2010 We report a mother and son with a prednisone-responsive, multifocal, demyelinating, predominantly sensory polyneuropathy that was associated with an isoleucine92valine polymorphism of lipopolysaccharide-induced TNF-alpha factor (LITAF). Prednisone 34-44 lipopolysaccharide induced TNF factor Homo sapiens 229-234 20350662-2 2010 Until then, a combination of cyclophosphamide, vincristine, doxorubicin, and prednisone (CHOP) had been the standard of treatment for aggressive B-cell lymphoma for more than 25 years. Prednisone 77-87 DNA damage inducible transcript 3 Homo sapiens 89-93 20199368-5 2010 The homeostasis model assessment of insulin sensitivity showed intermediate values for patients who underwent a simultaneous pancreas-kidney transplant and correlated with prednisone dosages (in those who underwent kidney transplant alone) and tacrolimus levels (in patients who underwent a simultaneous pancreas-kidney transplant). Prednisone 172-182 insulin Homo sapiens 36-43 19659514-3 2010 We describe a case of a patient with alpha-1-antitrypsin deficiency who underwent single lung transplantation in 2005 and was maintained on tacrolimus, cytoxan and prednisone. Prednisone 164-174 serpin family A member 1 Homo sapiens 37-56 20080912-6 2010 Evaluation of clinical response to treatments indicated that carriage of the high IL-10 genotype was associated with a favorable outcome (p = 0.009), specifically to prednisone therapy (p = 0.0003). Prednisone 166-176 interleukin 10 Homo sapiens 82-87 20214520-1 2010 For more than 25 years, the combination of cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) was considered the "gold standard" for the treatment of aggressive lymphomas, 90% of which are diffuse large B-cell lymphomas (DLBCLs). Prednisone 90-100 DNA damage inducible transcript 3 Homo sapiens 102-106 20080912-8 2010 CONCLUSION: Results show an association between the low IL-10 producer genotype and protection from RA; nevertheless, when other specific genetic and/or environmental factors trigger onset of RA, this genotype may predispose to development of anti-CCP+ RA disease with reduced response to prednisone treatment. Prednisone 289-299 interleukin 10 Homo sapiens 56-61 20195409-0 2010 Severe pulmonary adverse effects in lymphoma patients treated with cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) regimen plus rituximab. Prednisone 115-125 DNA damage inducible transcript 3 Homo sapiens 127-131 20051005-9 2010 CRP concentrations in prednisone-treated dogs were increased because of many dogs having active disease. Prednisone 22-32 C-reactive protein Canis lupus familiaris 0-3 20195409-1 2010 BACKGROUND/AIMS: The aim of our study was to determine the incidence and clinical features of severe pulmonary complications in patients receiving cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) or rituximab plus CHOP (R-CHOP) as the initial treatment for lymphoma. Prednisone 195-205 DNA damage inducible transcript 3 Homo sapiens 207-211 20506637-9 2010 (2) Compared with nephropathy group, the average fluorescence intensity of HSPG dramatically increased in Qufeng group and prednisone group (P < 0.01), similarly, it also increased in D and F groups (P < 0.01). Prednisone 123-133 syndecan 2 Rattus norvegicus 75-79 20048181-4 2010 PATIENTS AND METHODS We studied the immunohistochemical protein expression of HIF-1alpha on tissue microarrays from 153 patients with DLBCL treated in sequential cohorts with cyclophosphamide, doxorubicin, oncovin, and prednisone (CHOP) or rituximab-CHOP (R-CHOP) from 1999 to 2002. Prednisone 219-229 hypoxia inducible factor 1 subunit alpha Homo sapiens 78-88 19965632-0 2010 Association of high-level MCL-1 expression with in vitro and in vivo prednisone resistance in MLL-rearranged infant acute lymphoblastic leukemia. Prednisone 69-79 MCL1 apoptosis regulator, BCL2 family member Homo sapiens 26-31 20367943-11 2010 Similar to [Ca(2+)]i changes, the density of NMDA-R1 also increased mostly in PD7 group after prednisone administration, that was 0.36 +/- 0.03 (control group: 0.21 +/- 0.05) while that was only 0.18 +/- 0.05 in PD60 group (control group: 0.15 +/- 0.02). Prednisone 94-104 glutamate ionotropic receptor NMDA type subunit 1 Rattus norvegicus 45-52 19965632-0 2010 Association of high-level MCL-1 expression with in vitro and in vivo prednisone resistance in MLL-rearranged infant acute lymphoblastic leukemia. Prednisone 69-79 lysine methyltransferase 2A Homo sapiens 94-97 19965632-1 2010 MLL-rearranged acute lymphoblastic leukemia (ALL) represents an unfavorable type of leukemia that often is highly resistant to glucocorticoids such as prednisone and dexamethasone. Prednisone 151-161 lysine methyltransferase 2A Homo sapiens 0-3 19965632-5 2010 In addition, MCL-1 expression appeared to be significantly higher in MLL-rearranged infant patients who showed a poor response to prednisone in vivo compared with prednisone good responders. Prednisone 130-140 MCL1 apoptosis regulator, BCL2 family member Homo sapiens 13-18 19965632-5 2010 In addition, MCL-1 expression appeared to be significantly higher in MLL-rearranged infant patients who showed a poor response to prednisone in vivo compared with prednisone good responders. Prednisone 130-140 lysine methyltransferase 2A Homo sapiens 69-72 19733251-1 2010 The purpose of this study was to evaluate the efficacy and safety of short-course bortezomib, melphalan, prednisone (VMP) in previously untreated multiple myeloma as frontline therapy for transplant-ineligible patients and induction prior to autologous stem cell transplantation (ASCT). Prednisone 105-115 neurensin 1 Homo sapiens 117-120 19857547-10 2010 CONCLUSION: Evaluation of CD44v-RHAMM coexpression may improve the accuracy of DLBCL prognosis and identify a subgroup of patients who will benefit from therapeutic alternatives to cyclophosphamide, doxorubicin, vincristine, and prednisone. Prednisone 229-239 hyaluronan mediated motility receptor Homo sapiens 32-37 19963133-2 2010 This study was performed to evaluate the effect of polymorphisms and haplotypes of the XRCC1 gene on the risk of diffuse large B-cell lymphoma (DLBCL) and treatment outcomes after rituximab plus cyclophosphamide/doxorubicin/vincristine/prednisone (R-CHOP) chemotherapy in a Korean population. Prednisone 236-246 X-ray repair cross complementing 1 Homo sapiens 87-92 21403886-6 2010 This study demonstrated that salivary IFN-gamma, TNF-alpha, and sTNFR-2 can be detectable in ELP patients and decreased significantly after treatment with prednisone, which may reveal the possibility of using these disease-related biomarkers in diagnosis and monitoring. Prednisone 155-165 interferon gamma Homo sapiens 38-47 20064082-4 2010 Furthermore, the levels of CCL20 expression in active IBD patients after treatment with salazosulphapyridine or prednisone were significantly reduced, as compared with before treatment (p < 0.01). Prednisone 112-122 C-C motif chemokine ligand 20 Homo sapiens 27-32 21290342-0 2010 Simultaneous assessment of p53 and MDM2 expression in leukemic cells in response to initial prednisone therapy in children with acute lymphoblastic leukemia. Prednisone 92-102 tumor protein p53 Homo sapiens 27-30 21290342-0 2010 Simultaneous assessment of p53 and MDM2 expression in leukemic cells in response to initial prednisone therapy in children with acute lymphoblastic leukemia. Prednisone 92-102 MDM2 proto-oncogene Homo sapiens 35-39 21290342-2 2010 p53 plays a crucial role in triggering apoptosis of ALL in response to prednisone treatment. Prednisone 71-81 tumor protein p53 Homo sapiens 0-3 21290342-4 2010 This study is aimed to evaluate changes in MDM2 and p53 expression in peripheral blood mononuclear cells collected from children with ALL prior to and after 6 and 12 h of prednisone administration in relation to early treatment response. Prednisone 171-181 MDM2 proto-oncogene Homo sapiens 43-47 21290342-4 2010 This study is aimed to evaluate changes in MDM2 and p53 expression in peripheral blood mononuclear cells collected from children with ALL prior to and after 6 and 12 h of prednisone administration in relation to early treatment response. Prednisone 171-181 tumor protein p53 Homo sapiens 52-55 19642986-1 2009 BACKGROUND: Prednisone, one of the most highly prescribed drugs, has well characterized effects on gene transcription mediated by the glucocorticoid receptor. Prednisone 12-22 nuclear receptor subfamily 3, group C, member 1 Mus musculus 134-157 20431280-10 2010 At the 6-month follow-up, only patients recently treated with anti-TNF-alpha therapy (n = 42) demonstrated a significant improvement in the CFQ score (Delta -7.07 +/- 7.23) compared with the untreated patients (Delta -0.08 +/- 9.35) and patients treated with prednisone with or without methotrexate (Delta 1.67 +/- 9.22; p < 0.0001). Prednisone 259-269 tumor necrosis factor Homo sapiens 67-76 19860620-1 2009 The prognostic significance of O6-methylguanine DNA methyltransferase (MGMT) inactivation was evaluated in patients with diffuse large B-cell lymphoma (DLBCL) who received cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) in addition to rituximab. Prednisone 220-230 O-6-methylguanine-DNA methyltransferase Homo sapiens 71-75 20045917-8 2009 The fluorescence intensity of nephrin and the expression of nephrin mRNA significantly increased in the qufeng group and the prednisone group compared with the model group at the week 7 (P<0.01). Prednisone 125-135 NPHS1 adhesion molecule, nephrin Rattus norvegicus 30-37 20045917-8 2009 The fluorescence intensity of nephrin and the expression of nephrin mRNA significantly increased in the qufeng group and the prednisone group compared with the model group at the week 7 (P<0.01). Prednisone 125-135 NPHS1 adhesion molecule, nephrin Rattus norvegicus 60-67 19696060-9 2009 Prednisone treatment induced remission of clinical symptoms and normalized IL-1beta secretion and P2X(7) and ASC expression. Prednisone 0-10 interleukin 1 beta Homo sapiens 75-83 19696060-9 2009 Prednisone treatment induced remission of clinical symptoms and normalized IL-1beta secretion and P2X(7) and ASC expression. Prednisone 0-10 purinergic receptor P2X 7 Homo sapiens 98-104 19696060-9 2009 Prednisone treatment induced remission of clinical symptoms and normalized IL-1beta secretion and P2X(7) and ASC expression. Prednisone 0-10 PYD and CARD domain containing Homo sapiens 109-112 19703135-2 2009 Following short-term therapy with insulin and cyclosporin A, the dog remained on prednisone therapy but required no further insulin therapy for 12 weeks, at which time the dog became permanently diabetic. Prednisone 81-91 insulin Canis lupus familiaris 34-41 19703135-3 2009 We hypothesise that prednisone and cyclosporin A contributed to insulin resistance in a prediabetic dog with suboptimal endogenous insulin concentration and that the degree of insulin resistance decreased when cyclosporin A therapy was discontinued. Prednisone 20-30 insulin Canis lupus familiaris 64-71 19703135-3 2009 We hypothesise that prednisone and cyclosporin A contributed to insulin resistance in a prediabetic dog with suboptimal endogenous insulin concentration and that the degree of insulin resistance decreased when cyclosporin A therapy was discontinued. Prednisone 20-30 insulin Canis lupus familiaris 131-138 19703135-3 2009 We hypothesise that prednisone and cyclosporin A contributed to insulin resistance in a prediabetic dog with suboptimal endogenous insulin concentration and that the degree of insulin resistance decreased when cyclosporin A therapy was discontinued. Prednisone 20-30 insulin Canis lupus familiaris 131-138 19858394-0 2009 VMP (Bortezomib, Melphalan, and Prednisone) is active and well tolerated in newly diagnosed patients with multiple myeloma with moderately impaired renal function, and results in reversal of renal impairment: cohort analysis of the phase III VISTA study. Prednisone 32-42 neurensin 1 Homo sapiens 0-3 19858394-1 2009 PURPOSE To assess bortezomib plus melphalan and prednisone (VMP) and melphalan and prednisone (MP) in previously untreated patients with multiple myeloma (MM) with renal impairment enrolled on the phase III VISTA study, and to evaluate renal impairment reversibility. Prednisone 48-58 neurensin 1 Homo sapiens 60-63 19738036-0 2009 Short-term prednisone use antagonizes insulin"s anabolic effect on muscle protein and glucose metabolism in young healthy people. Prednisone 11-21 insulin Homo sapiens 38-45 19738036-2 2009 The purpose of this study was to test a hypothesis that prednisone (Pred) counteracts insulin"s anabolic effects on muscle. Prednisone 56-66 insulin Homo sapiens 86-93 20016232-2 2009 Conventional chemotherapy (CHOP: cyclophosphamide, doxorubicin, vincristine, prednisone) seems unsatisfactory, so modifications of CHOP are used to improve the efficacy. Prednisone 77-87 DNA damage inducible transcript 3 Homo sapiens 27-31 20016232-2 2009 Conventional chemotherapy (CHOP: cyclophosphamide, doxorubicin, vincristine, prednisone) seems unsatisfactory, so modifications of CHOP are used to improve the efficacy. Prednisone 77-87 DNA damage inducible transcript 3 Homo sapiens 131-135 19633198-6 2009 Furthermore, anti-CD79b-vcMMAE was significantly more effective than a standard-of-care regimen, R-CHOP (ie, rituximab with a single intravenous injection of 30 mg/kg cyclophosphamide, 2.475 mg/kg doxorubicin, 0.375 mg/kg vincristine, and oral dosing of 0.15 mg/kg prednisone once a day for 5 days), in 3 xenograft models of NHL. Prednisone 265-275 CD79b molecule Homo sapiens 18-23 19636007-3 2009 PATIENTS AND METHODS: We retrospectively analyzed 38 patients with ALK-positive DLBCL treated with cyclophosphamide, doxorubicin, vincristine, prednisone (CHOP) or CHOP-like regimens from different institutions to better define the presenting features, clinical course, and response to treatment. Prednisone 143-153 ALK receptor tyrosine kinase Homo sapiens 67-70 20449933-0 2009 Long-term results of immunosuppressive oral prednisone after coronary angioplasty in non-diabetic patients with elevated C-reactive protein levels. Prednisone 44-54 C-reactive protein Homo sapiens 123-141 19199277-10 2009 Patients receiving high dose prednisone produced higher IL10, but they also were the patients with a more active disease. Prednisone 29-39 interleukin 10 Homo sapiens 56-60 19395464-3 2009 METHODS: Tumor specimens from 23 patients with previously untreated NK/T-cell lymphoma initially treated with cyclophosphamide, vincristine, doxorubicin and prednisone (CHOP) or CHOP-based chemotherapy were examined by immunohistochemistry for three NF-kappaB subunits (p65, p50 and p52), which are involved in either the canonical or alternative pathway. Prednisone 157-167 DNA damage inducible transcript 3 Homo sapiens 169-173 19584951-8 2009 Prednisone and azathioprine treatment decreased total serum IgG, IgE, IFN-gamma and IL-4 levels, and blood CD19+ and CD23+ cells; however serum IL-12, TNFalpha and blood CD4+ T cells increased with treatment. Prednisone 0-10 immunoglobulin heavy constant epsilon Homo sapiens 65-68 19584951-8 2009 Prednisone and azathioprine treatment decreased total serum IgG, IgE, IFN-gamma and IL-4 levels, and blood CD19+ and CD23+ cells; however serum IL-12, TNFalpha and blood CD4+ T cells increased with treatment. Prednisone 0-10 interferon gamma Homo sapiens 70-79 19584951-8 2009 Prednisone and azathioprine treatment decreased total serum IgG, IgE, IFN-gamma and IL-4 levels, and blood CD19+ and CD23+ cells; however serum IL-12, TNFalpha and blood CD4+ T cells increased with treatment. Prednisone 0-10 interleukin 4 Homo sapiens 84-88 19584951-8 2009 Prednisone and azathioprine treatment decreased total serum IgG, IgE, IFN-gamma and IL-4 levels, and blood CD19+ and CD23+ cells; however serum IL-12, TNFalpha and blood CD4+ T cells increased with treatment. Prednisone 0-10 CD19 molecule Homo sapiens 107-111 19584951-8 2009 Prednisone and azathioprine treatment decreased total serum IgG, IgE, IFN-gamma and IL-4 levels, and blood CD19+ and CD23+ cells; however serum IL-12, TNFalpha and blood CD4+ T cells increased with treatment. Prednisone 0-10 Fc epsilon receptor II Homo sapiens 117-121 19422445-3 2009 OBJECTIVES: We have investigated the effect of two corticoids, dexamethasone and prednisone, on the conformational consequences of L-ASP treatment on antithrombin. Prednisone 81-91 asparaginase and isoaspartyl peptidase 1 Homo sapiens 131-136 19422445-6 2009 RESULTS: In all models, L-ASP alone or in combination with prednisone caused the intracellular retention of antithrombin associated with a severe deficiency. Prednisone 59-69 serpin family C member 1 Homo sapiens 108-120 19615321-8 2009 RESULTS: When the rats were administered with prednisone, SKL correspondingly, the contents of NF-kappaB p65, TNF-alpha and NO as well as 24-hour urine protein excretion were lower than those in the untreated group (P<0.01), and the fusion of foot process only recovered partially. Prednisone 46-56 synaptotagmin 1 Rattus norvegicus 105-108 19615321-8 2009 RESULTS: When the rats were administered with prednisone, SKL correspondingly, the contents of NF-kappaB p65, TNF-alpha and NO as well as 24-hour urine protein excretion were lower than those in the untreated group (P<0.01), and the fusion of foot process only recovered partially. Prednisone 46-56 tumor necrosis factor Rattus norvegicus 110-119 19615321-9 2009 Compared with other treated groups, the contents of NF-kappaB p65 and NO as well as 24-hour urine protein excretion were significantly decreased in SKL plus prednisone group (P<0.01, P<0.05), and the fusion of foot process recovered mostly also. Prednisone 157-167 synaptotagmin 1 Rattus norvegicus 62-65 19615321-11 2009 CONCLUSION: Renal injury can be postponed and improved when treated with SKL plus prednisone; it may contribute to the depression of abnormal activation of NF-kappaB, and the inhibition of production of TNF-alpha and NO. Prednisone 82-92 tumor necrosis factor Rattus norvegicus 203-212 19707509-10 2009 Cyclophosphamide, adriamycin, vincristine, and prednisone (CHOP) were administered for a total of 4 cycles. Prednisone 47-57 DNA damage inducible transcript 3 Homo sapiens 59-63 19344957-8 2009 In conclusion, our findings indicated that this combination therapy suppressed disease severity of EAE partially through blocking the downregulation of neurotrophic factor expression, suggesting that the combination of minocycline and prednisone could be a novel treatment in MS. Prednisone 235-245 glial cell line derived neurotrophic factor Mus musculus 152-171 19478700-2 2009 The purpose of this study was to assess time-resolved changes in Bax activation and its intracellular distribution as well as the percentage of apoptotic cells evaluated by PARP cleavage in response to prednisone treatment in childhood ALL. Prednisone 202-212 poly(ADP-ribose) polymerase 1 Homo sapiens 173-177 19478700-7 2009 A significant rise (p<0.05) in cytoplasmic Bax expression was seen in the good responders as early as 6 hours after prednisone administration followed by a significant rise in Bax nuclear expression after 12 hours. Prednisone 119-129 BCL2 associated X, apoptosis regulator Homo sapiens 46-49 19478700-9 2009 CONCLUSIONS: Increased Bax nuclear accumulation (and possibly also aggregation) together with increased PARP cleavage observed within 12 hours after prednisone oral administration were associated with and may predict good outcome in children with newly diagnosed ALL. Prednisone 149-159 poly(ADP-ribose) polymerase 1 Homo sapiens 104-108 19236780-3 2009 FVIII inhibitor in the patient"s serum was at a level >32.0 Bethesda units/ml after acquired hemophilia was diagnosed, the patient was admitted to hospital and given orally prednisone and azathioprine therapy. Prednisone 176-186 coagulation factor VIII Homo sapiens 0-5 19232549-4 2009 The single-arm trial evaluated amsacrine plus cytosine arabinoside, vincristine, and prednisone (a combination abbreviated as OAP) for adult acute leukemia, when standard treatment was adriamycin plus OAP. Prednisone 85-95 OAP Homo sapiens 126-129 19269958-10 2009 There was a significant correlation of adiponectin concentrations with prednisone dose, lipid concentrations and insulin resistance but not with disease activity or homocysteine. Prednisone 71-81 adiponectin, C1Q and collagen domain containing Homo sapiens 39-50 19573409-12 2009 TdT/CD10/CD34/CD19 was expressed more in MLL-AF4 negative group (P = 0.005) and Prednisone Good Response group (P = 0.002). Prednisone 80-90 DNA nucleotidylexotransferase Homo sapiens 0-3 19573409-12 2009 TdT/CD10/CD34/CD19 was expressed more in MLL-AF4 negative group (P = 0.005) and Prednisone Good Response group (P = 0.002). Prednisone 80-90 membrane metalloendopeptidase Homo sapiens 4-8 19573409-12 2009 TdT/CD10/CD34/CD19 was expressed more in MLL-AF4 negative group (P = 0.005) and Prednisone Good Response group (P = 0.002). Prednisone 80-90 CD34 molecule Homo sapiens 9-13 19573409-12 2009 TdT/CD10/CD34/CD19 was expressed more in MLL-AF4 negative group (P = 0.005) and Prednisone Good Response group (P = 0.002). Prednisone 80-90 CD19 molecule Homo sapiens 14-18 19029441-6 2009 The latter had a markedly inferior survival when treated with cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) or rituximab-CHOP (R-CHOP; median survival of 1.2 and 3.0 years vs not reached for the others, P < .001 and P = .001), independent of the International Prognostic Index. Prednisone 110-120 DNA damage inducible transcript 3 Homo sapiens 122-126 19326060-1 2009 We conducted a retrospective analysis to evaluate the impact on clinical outcomes of adding rituximab to cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) treatment for diffuse large B-cell lymphoma (DLBCL) patients in Japan. Prednisone 153-163 DNA damage inducible transcript 3 Homo sapiens 165-169 19061214-0 2009 Kinetics of the in vivo expression of glucocorticoid receptor splice variants during prednisone treatment in childhood acute lymphoblastic leukaemia. Prednisone 85-95 nuclear receptor subfamily 3 group C member 1 Homo sapiens 38-61 19074749-1 2009 BACKGROUND: Soluble interleukin-2 receptor (SIL-2R) is known to be a prognostic parameter in patients with diffuse large B-cell lymphoma (DLBCL) receiving cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) therapy. Prednisone 202-212 DNA damage inducible transcript 3 Homo sapiens 214-218 19404953-6 2009 RESULTS: Based on the mean-mean common or the mean-max CIMT as the dependent variable, univariable analysis showed significant associations of the following variables with increased CIMT: increasing age, longer SLE duration, minority status, higher body mass index (BMI), male sex, increased creatinine clearance, higher lipoprotein(a) level, proteinuria, azathioprine treatment, and prednisone dose. Prednisone 384-394 CIMT Homo sapiens 182-186 19404953-8 2009 A moderate dosage of prednisone (0.15-0.4 mg/kg/day) was associated with decreases in the mean-max CIMT (P=0.024), while high-dose and low-dose prednisone were associated with increases in the mean-mean common CIMT (P=0.021) and the mean-max CIMT (P=0.064), respectively. Prednisone 21-31 CIMT Homo sapiens 99-103 19404953-8 2009 A moderate dosage of prednisone (0.15-0.4 mg/kg/day) was associated with decreases in the mean-max CIMT (P=0.024), while high-dose and low-dose prednisone were associated with increases in the mean-mean common CIMT (P=0.021) and the mean-max CIMT (P=0.064), respectively. Prednisone 21-31 CIMT Homo sapiens 210-214 19404953-8 2009 A moderate dosage of prednisone (0.15-0.4 mg/kg/day) was associated with decreases in the mean-max CIMT (P=0.024), while high-dose and low-dose prednisone were associated with increases in the mean-mean common CIMT (P=0.021) and the mean-max CIMT (P=0.064), respectively. Prednisone 21-31 CIMT Homo sapiens 210-214 19404953-8 2009 A moderate dosage of prednisone (0.15-0.4 mg/kg/day) was associated with decreases in the mean-max CIMT (P=0.024), while high-dose and low-dose prednisone were associated with increases in the mean-mean common CIMT (P=0.021) and the mean-max CIMT (P=0.064), respectively. Prednisone 144-154 CIMT Homo sapiens 210-214 19404953-8 2009 A moderate dosage of prednisone (0.15-0.4 mg/kg/day) was associated with decreases in the mean-max CIMT (P=0.024), while high-dose and low-dose prednisone were associated with increases in the mean-mean common CIMT (P=0.021) and the mean-max CIMT (P=0.064), respectively. Prednisone 144-154 CIMT Homo sapiens 210-214 19404953-12 2009 The relationship between CIMT and prednisone dose may not be linear. Prednisone 34-44 CIMT Homo sapiens 25-29 19404011-8 2009 The treatment with prednisone (1 mg/kg) brought the rapid improvement of muscle weakness and CPK value as well as mouth dryness and cholestatic liver dysfunction like in primary biliary cirrhosis. Prednisone 19-29 phosphatidylinositol-4-phosphate 3-kinase catalytic subunit type 2 alpha Homo sapiens 93-96 19899124-1 2009 The yield of CD34+ cells collected by apheresis for autologous peripheral blood stem cell (PBSC) transplantation was greatly increased when the appropriate timing was determined to begin using G-CSF after COAEP (Cytoxan, Vinblastine, Arabinosylcytosin, Etoposide and Prednisone) mobilization. Prednisone 267-277 CD34 molecule Homo sapiens 13-17 19707399-3 2009 In the near future melphalan-prednisone-lenalidomide (Revlimid((R)), MPR) will also provide a third therapeutic option (MPT, MPV, and MPR), in elderly multiple myeloma, eventually. Prednisone 29-39 progesterone receptor membrane component 1 Homo sapiens 134-137 19293492-7 2009 Treatment with cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) plus etoposide established complete remission. Prednisone 63-73 DNA damage inducible transcript 3 Homo sapiens 75-79 18620786-2 2009 In phase 3 clinical trials, giving rituximab with cyclophosphamide, vincristine, doxorubicin, and prednisone (CHOP) every 3 weeks (R-CHOP-21) has been associated with improved survival, without increased toxicity, in all patient groups studied. Prednisone 98-108 DNA damage inducible transcript 3 Homo sapiens 110-114 19293598-9 2009 The intervention of prednisone and lisinopril evidently reduced proteinuria, effectively attenuated the severe lesions of podocyte foot processes, and restored the reduction in VEGF and nephrin phosphorylation. Prednisone 20-30 vascular endothelial growth factor A Rattus norvegicus 177-181 19293598-9 2009 The intervention of prednisone and lisinopril evidently reduced proteinuria, effectively attenuated the severe lesions of podocyte foot processes, and restored the reduction in VEGF and nephrin phosphorylation. Prednisone 20-30 NPHS1 adhesion molecule, nephrin Rattus norvegicus 186-193 19293598-12 2009 The antiproteinuric effects of lisinopril and prednisone were achieved at least partially by restoring VEGF protein and nephrin phosphorylation. Prednisone 46-56 vascular endothelial growth factor A Rattus norvegicus 103-107 19293598-12 2009 The antiproteinuric effects of lisinopril and prednisone were achieved at least partially by restoring VEGF protein and nephrin phosphorylation. Prednisone 46-56 NPHS1 adhesion molecule, nephrin Rattus norvegicus 120-127 19401759-8 2009 Immediately prior to clinical treatment for acute deterioration of hearing thresholds, their PBMC demonstrated a robust induction of mIL1R2 in PBMC in response to dexamethasone in vitro that correlated with a clinical response to prednisone in vivo (p<0.0001) as measured by hearing restoration. Prednisone 230-240 interleukin 1 receptor, type II Mus musculus 133-139 19292036-4 2009 RESULTS: Relative expression level of TFR2 mRNA in prednisone good responders (median: 0.0848) was significantly higher than that in prednisone poor responders (median: 0.0126) (P = 0.038). Prednisone 51-61 transferrin receptor 2 Homo sapiens 38-42 19292036-4 2009 RESULTS: Relative expression level of TFR2 mRNA in prednisone good responders (median: 0.0848) was significantly higher than that in prednisone poor responders (median: 0.0126) (P = 0.038). Prednisone 133-143 transferrin receptor 2 Homo sapiens 38-42 19149925-3 2009 This study aimed to explore the relationship between the expression of glomerular nephrin and oxidative stress reaction in rats with adriamycin (ADR)-induced nephrosis, and the protection of prednisone and vitamin E against renal injuries. Prednisone 191-201 NPHS1 adhesion molecule, nephrin Rattus norvegicus 82-89 19149925-12 2009 Compared with the untreated nephrosis group, prednisone treatment resulted in an increase in nephrin protein contents 28 days after ADR injection; Vitamin E treatment decreased renal MDA levels and increased renal activities of SOD and T-AOC and nephrin protein contents 28 days after ADR injection. Prednisone 45-55 NPHS1 adhesion molecule, nephrin Rattus norvegicus 93-100 19149925-12 2009 Compared with the untreated nephrosis group, prednisone treatment resulted in an increase in nephrin protein contents 28 days after ADR injection; Vitamin E treatment decreased renal MDA levels and increased renal activities of SOD and T-AOC and nephrin protein contents 28 days after ADR injection. Prednisone 45-55 NPHS1 adhesion molecule, nephrin Rattus norvegicus 246-253 19149925-15 2009 Prednisone or vitamin E treatment ameliorated abnormal expression of nephrin induced by nephrosis. Prednisone 0-10 NPHS1 adhesion molecule, nephrin Rattus norvegicus 69-76 19032367-0 2008 ABCG2 Q141K polymorphism is associated with chemotherapy-induced diarrhea in patients with diffuse large B-cell lymphoma who received frontline rituximab plus cyclophosphamide/doxorubicin/vincristine/prednisone chemotherapy. Prednisone 200-210 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 0-5 19010836-10 2008 Moreover, prednisone-induced apoptosis was attenuated in the presence of EPO in this genetic subgroup. Prednisone 10-20 erythropoietin Homo sapiens 73-76 18768390-9 2008 In an independent cohort of children with ALL, reduced expression of MSH6 was associated with resistance to mercaptopurine and prednisone, thereby providing a plausible mechanism by which this acquired deletion contributes to drug resistance at relapse. Prednisone 127-137 mutS homolog 6 Homo sapiens 69-73 18821672-11 2008 Cadherin 11 staining in vivo was strongly down-regulated by prednisone treatment in RA patients and by TNFalpha blockade in SpA patients. Prednisone 60-70 cadherin 11 Homo sapiens 0-11 18677012-8 2008 CONCLUSIONS: In this group of patients with refractory TAK, anti-TNF therapy was associated with remission in a majority of patients, facilitating dose reduction or discontinuation of prednisone and other immunosuppressive therapy. Prednisone 184-194 tumor necrosis factor Homo sapiens 65-68 18502831-1 2008 Chemotherapy with alemtuzumab and the combination of cyclophosphamide, adriamycin, oncovin, and prednisone (CHOP) has become experimental trial therapy for aggressive T-cell lymphoma. Prednisone 96-106 DNA damage inducible transcript 3 Homo sapiens 108-112 18521602-2 2008 Patients with a poor prednisone response (PPR) have a poor event-free survival as compared to those with a good prednisone response (PGR). Prednisone 21-31 PPR1 Homo sapiens 42-45 18521602-2 2008 Patients with a poor prednisone response (PPR) have a poor event-free survival as compared to those with a good prednisone response (PGR). Prednisone 112-122 progesterone receptor Homo sapiens 133-136 19106649-7 2008 SUMMARY: Dose-intensified approaches, either cyclophosphamide, hydroxydaunorubicin (adriamycin), oncovin (vincristine), and prednisone (CHOP) +/- high-dose Ara-C followed by autologous stem cell transplantation or HyperCVAD with the addition of rituximab remain the current standard approach in younger patients up to 65 years. Prednisone 124-134 DNA damage inducible transcript 3 Homo sapiens 136-140 18701864-12 2008 The patient was treated with 6 cycles of cyclophosphamide, doxorubicin, vincristine, and prednisone(CHOP)chemotherapy followed by the involved field irradiation. Prednisone 89-99 DNA damage inducible transcript 3 Homo sapiens 100-104 18351394-2 2008 She became overtly diabetic while receiving alternate-day prednisone and tacrolimus, requiring insulin injections. Prednisone 58-68 insulin Homo sapiens 95-102 18514101-0 2008 Multidrug resistance-1 in T lymphocytes and natural killer cells of adults with idiopathic thrombocytopenic purpura: effect of prednisone treatment. Prednisone 127-137 ATP binding cassette subfamily B member 1 Homo sapiens 0-22 18537979-6 2008 The addition of the monoclonal anti-CD20 antibody rituximab to standard CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone) chemotherapy improved outcome of adults with DLBCL significantly. Prednisone 122-132 keratin 20 Homo sapiens 36-40 19885233-0 2008 Use of continuous glucose monitoring to estimate insulin requirements in patients with type 1 diabetes mellitus during a short course of prednisone. Prednisone 137-147 insulin Homo sapiens 49-56 19885233-9 2008 CONCLUSIONS: For adults with T1DM, insulin requirements during prednisone induced insulin resistance may need to be increased by 70% or more to normalize blood glucose levels. Prednisone 63-73 insulin Homo sapiens 35-42 19885233-9 2008 CONCLUSIONS: For adults with T1DM, insulin requirements during prednisone induced insulin resistance may need to be increased by 70% or more to normalize blood glucose levels. Prednisone 63-73 insulin Homo sapiens 82-89 18343955-0 2008 Response to prednisone in relation to NR3C1 intron B polymorphisms in childhood nephrotic syndrome. Prednisone 12-22 nuclear receptor subfamily 3 group C member 1 Homo sapiens 38-43 18343955-4 2008 In the SRNS group, we performed a three-marker haplotype analysis of NR3C1 in relation to the response to prednisone, represented as time to proteinuria resolution (TPR) as categorical and ordinal variable. Prednisone 106-116 nuclear receptor subfamily 3 group C member 1 Homo sapiens 69-74 18343955-4 2008 In the SRNS group, we performed a three-marker haplotype analysis of NR3C1 in relation to the response to prednisone, represented as time to proteinuria resolution (TPR) as categorical and ordinal variable. Prednisone 106-116 translocated promoter region, nuclear basket protein Homo sapiens 165-168 18580477-6 2008 Treatment with prednisone resulted in decreased CD86 expression in marrow (P=0.02) and PB (P=0.04) monocytes. Prednisone 15-25 CD86 molecule Homo sapiens 48-52 18702436-7 2008 Treatment included a combination of the chemotherapy regimen of cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) with the monoclonal anti-CD20 antibody rituximab. Prednisone 111-121 DNA damage inducible transcript 3 Homo sapiens 123-127 18760704-1 2008 The concurrent use of rituximab with cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) has established the utility of chemoimmunotherapy for the treatment of aggressive non-Hodgkin"s lymphoma (NHL). Prednisone 85-95 DNA damage inducible transcript 3 Homo sapiens 99-103 18559237-9 2008 Changes of TGF-beta1 level in the prednisone-treated group and the Feixian Formula-treated group were similar to untreated group (P>0.05), and there was no significant difference between the prednisone-treated group and the Feixian Formula-treated group (P>0.05). Prednisone 34-44 transforming growth factor, beta 1 Rattus norvegicus 11-20 18445689-4 2008 However, the standard therapy has evolved into rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP). Prednisone 105-115 DNA damage inducible transcript 3 Homo sapiens 119-123 18294352-4 2008 She was successfully treated with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP) and maintained subsequently on sirolimus and prednisone. Prednisone 92-102 DNA damage inducible transcript 3 Homo sapiens 106-110 18998573-5 2008 CONCLUSION: THPS combination small dose prednisone to treat pulmonary fibrosis of rats is better than classic ways and its efficacy of inhibition TGF-beta1 may be a mechanism. Prednisone 40-50 transforming growth factor, beta 1 Rattus norvegicus 146-155 18271020-0 2008 Prednisone induces immunophenotypic modulation of CD10 and CD34 in nonapoptotic B-cell precursor acute lymphoblastic leukemia cells. Prednisone 0-10 membrane metalloendopeptidase Homo sapiens 50-54 18271020-0 2008 Prednisone induces immunophenotypic modulation of CD10 and CD34 in nonapoptotic B-cell precursor acute lymphoblastic leukemia cells. Prednisone 0-10 CD34 molecule Homo sapiens 59-63 18271020-4 2008 RESULTS: Leukemia samples that sustained the treatment in vitro with prednisone, showed significative reduction of CD10 and CD34 expression compared with control, and it was comparable with that observed in residual leukemic cells of the same patients in BM at day 15 of treatment. Prednisone 69-79 membrane metalloendopeptidase Homo sapiens 115-119 18271020-4 2008 RESULTS: Leukemia samples that sustained the treatment in vitro with prednisone, showed significative reduction of CD10 and CD34 expression compared with control, and it was comparable with that observed in residual leukemic cells of the same patients in BM at day 15 of treatment. Prednisone 69-79 CD34 molecule Homo sapiens 124-128 18409079-1 2008 Several authors have reported interstitial pneumonia (IP) during rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) therapy, while others have encountered Pneumocystis jirovecii pneumonia during rituximab-combined bi-weekly CHOP. Prednisone 128-138 DNA damage inducible transcript 3 Homo sapiens 142-146 18292286-2 2008 One hundred forty-seven patients received a cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP)-like regimen with intensified courses in half of them. Prednisone 92-102 DNA damage inducible transcript 3 Homo sapiens 104-108 18465033-8 2008 Histology confirmed necrotic diffuse large B-cell lymphoma and the cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) chemotherapy regime was subsequently commenced. Prednisone 114-124 DNA damage inducible transcript 3 Homo sapiens 126-130 18420078-5 2008 Following combined chemotherapy with rituximab and mini-CHOP (cyclophosphamide, adriamycin, oncovin and prednisone), complete remission was obtained rapidly, with no relapse at two years. Prednisone 104-114 DNA damage inducible transcript 3 Homo sapiens 56-60 18712992-4 2008 The patient was treated with 6 courses of CHOP chemotherapy (cyclophosphamide, doxorubicin, vincristine, and prednisone). Prednisone 109-119 DNA damage inducible transcript 3 Homo sapiens 42-46 19052456-7 2008 RESULTS: Compared with unaffected mucosa, BCRP expression was significantly reduced in inflamed mucosa of newly diagnosed drug-naive patients with UC (expression reduced to 30%) as well as in patients not responding to treatment (reduced to 25%) with either 5-aminosalicylates (n = 7) or prednisone (n = 4). Prednisone 288-298 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 42-46 18381103-3 2008 The addition of rituximab to cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy (R-CHOP regimen) improves the response rate, progression-free survival (PFS), and overall survival (OS) in diffuse large B-cell lymphoma (DLBCL). Prednisone 77-87 DNA damage inducible transcript 3 Homo sapiens 89-93 18026150-4 2008 The dose of prednisone could be reduced to equal to or lower than 1 mg/kg in the responding patients at the end of MTX therapy. Prednisone 12-22 metaxin 1 Homo sapiens 115-118 18388378-7 2008 The patient received five cycles of a cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) regimen which resulted in the regression in her skin lesions and constitutional symptoms. Prednisone 85-95 DNA damage inducible transcript 3 Homo sapiens 97-101 18300859-1 2008 OBJECTIVE AND METHODS: Prednisone and its active metabolite prednisolone, both substrates for 11beta-hydroxysteroid dehydrogenase type 2 (11beta-HSD2), may represent a pharmacological challenge for the enzyme. Prednisone 23-33 hydroxysteroid 11-beta dehydrogenase 2 Homo sapiens 94-149 18053719-3 2008 We present the case of a MuSK-positive female myasthenic patient with over four years slowly progressive weakness of the neck extensor muscles in the presence of thymus hyperplasia and discuss its uncommon and markedly focal clinical and electrophysiological features, as well as the excellent course under medication with pyridostigmine and prednisone, especially after thymectomy. Prednisone 342-352 muscle associated receptor tyrosine kinase Homo sapiens 25-29 18176967-8 2008 In addition, the high CRP group showed more cumulative days of prednisone use per year (107 +/- 95 vs 58 +/- 48, P < 0.05), as well as a better response to infliximab (93 % vs 33 %, P = 0.06). Prednisone 63-73 C-reactive protein Homo sapiens 22-25 18601606-13 2008 After treatment with Encorton (prednisone), FBP-1 activity and protein concentration in urine dropped to values of the control group. Prednisone 31-41 fructose-bisphosphatase 1 Homo sapiens 44-49 17278123-3 2008 We present a case of advanced stage Burkitt lymphoma in an 8-year-old female with acquired immunodeficiency syndrome (AIDS), who was successfully treated with a 3 month course of modified CHOP-R (cyclophosphamide, daunorubicin, vincristine, prednisone, and rituximab) and HAART therapy. Prednisone 241-251 DNA damage inducible transcript 3 Homo sapiens 188-192 17921190-9 2008 PF-915275 dose-dependently inhibited 11betaHSD1-mediated conversion of prednisone to prednisolone, with a maximum of 87% inhibition at a 3-mg/kg dose. Prednisone 71-81 hydroxysteroid 11-beta dehydrogenase 1 Homo sapiens 37-47 18081361-3 2008 Before the development of monoclonal antibodies, the standard treatment of newly diagnosed DLBCL was based on combination therapy with cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP). Prednisone 182-192 DNA damage inducible transcript 3 Homo sapiens 194-198 18528779-3 2008 Inappropriately high parathyroid (PTH) concentrations were particularly evident after serum calcium was suppressed to slightly above the reference range by the administration of intravenous pamidronate and prednisone. Prednisone 206-216 parathyroid hormone Homo sapiens 34-37 18284716-1 2007 Among the strategies developed to improve results in patients with diffuse large B-cell lymphoma, increasing the dose of CHOP (cyclophosphamide/doxorubicin/vincristine/prednisone) regimen (dose-intense regimen) and decreasing the duration of cycles (dose-dense regimen) or doing both had been proposed before the rituximab era. Prednisone 168-178 DNA damage inducible transcript 3 Homo sapiens 121-125 18026162-13 2007 After the patient was treated with prednisone (60 mg/day), her insulin requirements decreased within 1 week to pre-admission doses. Prednisone 35-45 insulin Homo sapiens 63-70 18026162-16 2007 On a maintenance dose of 10 mg prednisone/day, glucose control improved (HbA(1c) 5.8%) with an average of 60 U of isophane insulin twice daily. Prednisone 31-41 insulin Homo sapiens 123-130 18049109-11 2007 No differences in adiponectin or CRP were found in relation to AGH or atherosclerosis; however, there was a positive correlation between adiponectin levels and prednisone dose (r=0.240; P=0.044). Prednisone 160-170 adiponectin, C1Q and collagen domain containing Homo sapiens 137-148 17925494-3 2007 The CYP3A4 pathway mediates the metabolism of a large number of drug entities, including the corticosteroids prednisone and prednisolone. Prednisone 109-119 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 4-10 18040146-4 2007 The patient was treated with R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone) and achieved complete remission for more than 2 years. Prednisone 95-105 DNA damage inducible transcript 3 Homo sapiens 31-35 18204157-6 2007 The TCD4/CD8 ratio was in favor of CD4 in both BAL and IS samples before prednisone therapy and it significantly decreased after therapy; the ratio was 4.8 vs. 1.8 (P=0.009) in BAL and 3.5 vs. 2.0 (P=0.019) in IS, respectively. Prednisone 73-83 CD8a molecule Homo sapiens 9-12 18204157-6 2007 The TCD4/CD8 ratio was in favor of CD4 in both BAL and IS samples before prednisone therapy and it significantly decreased after therapy; the ratio was 4.8 vs. 1.8 (P=0.009) in BAL and 3.5 vs. 2.0 (P=0.019) in IS, respectively. Prednisone 73-83 CD4 molecule Homo sapiens 5-8 17947475-7 2007 Treatment with high-dose prednisone (>or=30 mg/d) was associated with reduced BAFF levels in patients with active chronic GVHD (P = 0.0005). Prednisone 25-35 TNF superfamily member 13b Homo sapiens 81-85 17968303-10 2007 In this setting, prednisone may lead to a decline of activated mononuclear cells (in the lung and lymph nodes) that are able to produce extrarenal PTH-independent 1,25-OHD. Prednisone 17-27 parathyroid hormone Homo sapiens 147-150 17868260-10 2007 Moreover, prednisone dose significantly correlated with SLEDAI (r = 0.5, P = 0.02) and with the expression levels of CD86 (r = 0.47, P = 0.02). Prednisone 10-20 CD86 molecule Homo sapiens 117-121 17572895-1 2007 The objective of this study is to evaluate the long-term efficacy and safety of rituximab combined with cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) in Chinese patients with newly diagnosed diffuse large B cell lymphoma (DLBCL). Prednisone 152-162 DNA damage inducible transcript 3 Homo sapiens 164-168 17908969-3 2007 EXPERIMENTAL DESIGN: Expression of a macrophage marker, CD68, was determined immunohistochemically from FL samples of 96 patients treated with rituximab and cyclophosphamide-Adriamycin-vincristine-prednisone regimen. Prednisone 197-207 CD68 molecule Homo sapiens 56-60 17922427-7 2007 The prednisone sensitivity test showed that all 12 TEL-AML1 positive patients were good responders, while there were 11 prednisone poor responders among 40 negative patients (27.50%, P < 0.05). Prednisone 4-14 ETS variant transcription factor 6 Homo sapiens 51-54 17922427-7 2007 The prednisone sensitivity test showed that all 12 TEL-AML1 positive patients were good responders, while there were 11 prednisone poor responders among 40 negative patients (27.50%, P < 0.05). Prednisone 4-14 RUNX family transcription factor 1 Homo sapiens 55-59 17922427-10 2007 The load of leukemia cells in TEL-AML1 positive patients is significantly smaller than its counterparts, and the blast cells in TEL-AML1 positive patients are more sensitive to prednisone, indicating childhood ALL with TEL-AML1 fusion gene has a favorable prognosis. Prednisone 177-187 ETS variant transcription factor 6 Homo sapiens 128-131 17922427-10 2007 The load of leukemia cells in TEL-AML1 positive patients is significantly smaller than its counterparts, and the blast cells in TEL-AML1 positive patients are more sensitive to prednisone, indicating childhood ALL with TEL-AML1 fusion gene has a favorable prognosis. Prednisone 177-187 RUNX family transcription factor 1 Homo sapiens 132-136 17922427-10 2007 The load of leukemia cells in TEL-AML1 positive patients is significantly smaller than its counterparts, and the blast cells in TEL-AML1 positive patients are more sensitive to prednisone, indicating childhood ALL with TEL-AML1 fusion gene has a favorable prognosis. Prednisone 177-187 ETS variant transcription factor 6 Homo sapiens 128-131 17922427-10 2007 The load of leukemia cells in TEL-AML1 positive patients is significantly smaller than its counterparts, and the blast cells in TEL-AML1 positive patients are more sensitive to prednisone, indicating childhood ALL with TEL-AML1 fusion gene has a favorable prognosis. Prednisone 177-187 RUNX family transcription factor 1 Homo sapiens 132-136 17823714-6 2007 A significant decrease in CD68+ macrophage density was found in prednisone-treated mice. Prednisone 64-74 CD68 antigen Mus musculus 26-30 17876376-7 2007 Prednisone significantly decreased serum creatinine by 52.21+/-48.68 mumol/L and increased glomerular filtration rate by 33.63+/-15.87 mL/min/1.73 m(2) compared with baseline. Prednisone 0-10 CD59 molecule (CD59 blood group) Homo sapiens 138-143 17591563-3 2007 Cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy has been the standard systemic therapy for this disease with a cure rate of 40% to 50%, although, more recently, the addition of rituximab has been shown in phase III trials to confer a significant survival benefit in both older and younger patients. Prednisone 48-58 DNA damage inducible transcript 3 Homo sapiens 60-64 17683387-2 2007 We report an elderly patient with C-ALCL which recurred after cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) therapy, but was effectively treated with the third-generation etoposide, mitoxantrone, cyclophosphamide, vincristine, prednisolone and bleomycin (VNCOP-B) regimen. Prednisone 109-119 DNA damage inducible transcript 3 Homo sapiens 121-125 17409468-0 2007 Effects of the chemotherapeutic agents for non-Hodgkin lymphoma, cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP), on the male rat reproductive system and progeny outcome. Prednisone 113-123 DNA-damage inducible transcript 3 Rattus norvegicus 125-129 17409468-1 2007 Chemotherapy of non-Hodgkin lymphoma (NHL) with cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) is associated with significant gonadal damage. Prednisone 96-106 DNA-damage inducible transcript 3 Rattus norvegicus 108-112 17825143-11 2007 CONCLUSION: Docetaxel plus prednisone for the treatment of HRPC can delay the progression of the disease, decrease the PSA value, diminish the lymph node, ease the pain, improve the quality of live, and the tolerance is quite good. Prednisone 27-37 kallikrein related peptidase 3 Homo sapiens 119-122 17575218-1 2007 PURPOSE: To evaluate 3"-deoxy-3"-[(18)F]fluorothymidine-positron emission tomography (FLT-PET) for early monitoring response of high-grade non-Hodgkin"s lymphoma to treatment with cyclophosphamide-adriamycin-vincristine-prednisone chemotherapy with or without rituximab immunotherapy (R-CHOP/CHOP). Prednisone 220-230 fms related receptor tyrosine kinase 1 Homo sapiens 86-89 17230494-10 2007 Mucosal Foxp3 mRNA levels and Foxp3+CD3+ cells were significantly reduced in transplant recipients using prednisone/azathioprine/tacrolimus compared with controls but no direct relationship between Foxp3 expression and 1 specific drug was detected. Prednisone 105-115 forkhead box P3 Homo sapiens 8-13 17429839-5 2007 Six RCTs compared rituximab in conjunction with the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) versus CHOP alone for the treatment of B-cell non-Hodgkin lymphoma (NHL). Prednisone 115-125 DNA damage inducible transcript 3 Homo sapiens 127-131 17230494-10 2007 Mucosal Foxp3 mRNA levels and Foxp3+CD3+ cells were significantly reduced in transplant recipients using prednisone/azathioprine/tacrolimus compared with controls but no direct relationship between Foxp3 expression and 1 specific drug was detected. Prednisone 105-115 forkhead box P3 Homo sapiens 30-35 17230494-10 2007 Mucosal Foxp3 mRNA levels and Foxp3+CD3+ cells were significantly reduced in transplant recipients using prednisone/azathioprine/tacrolimus compared with controls but no direct relationship between Foxp3 expression and 1 specific drug was detected. Prednisone 105-115 forkhead box P3 Homo sapiens 30-35 17488991-5 2007 However, response rate is usually lower in elderly patients compared with young patients, even if the patients are treated with the cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) regimen. Prednisone 180-190 DNA damage inducible transcript 3 Homo sapiens 192-196 17218490-1 2007 BACKGROUND: As patients with B-cell lymphomas suffering from an underlying autoimmune condition undergoing therapy with the CD20 antibody rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP) offer the unique possibility of monitoring effects of therapy on various rheumatologic parameters, we have evaluated serologic autoimmune markers and the clinical outcome of patients with autoimmune diseases (ADs) who received lymphoma treatment with R-CHOP during the course of their disease. Prednisone 196-206 keratin 20 Homo sapiens 124-128 17562513-5 2007 We present multidetector CT (MDCT) findings in a case of Hodgkin disease status one month post-chemotherapy (CHOP protocol; cyclophosphamide, doxorubicin, vincristine, prednisone) that presented with acute lower GIS bleeding. Prednisone 168-178 DNA damage inducible transcript 3 Homo sapiens 109-113 17138821-8 2007 Patients with either combined BM/CNS disease at diagnosis or poor response to cyclophosphamide, Oncovin [vincristine], prednisone (COP) reduction therapy had a significantly inferior EFS and S (P < .001). Prednisone 119-129 caspase recruitment domain family member 16 Homo sapiens 131-134 16997373-10 2007 The patient was treated with six cycles of cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP). Prednisone 90-100 DNA damage inducible transcript 3 Homo sapiens 102-106 17341901-2 2007 CASE REPORT: A 62-year old patient was diagnosed with a diffuse large B-cell lymphoma and treated with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone under prophylactic G-CSF substitution. Prednisone 162-172 colony stimulating factor 3 Homo sapiens 192-197 17361405-2 2007 Six cycles of cyclophosphamide, doxorubicin, vincristine, and prednisone-21 (CHOP-21) with rituximab (R-CHOP-21) achieved an event free survival after 3 years of > 90% in patients with a very good prognosis (IPI 0, without bulk). Prednisone 62-72 DNA damage inducible transcript 3 Homo sapiens 77-81 17200165-3 2007 In liver and adipose tissue, 11beta-HSD1 converts endogenous, inactive cortisone to active cortisol but also catalyzes the bioactivation of the synthetic prednisone to prednisolone. Prednisone 154-164 hydroxysteroid 11-beta dehydrogenase 1 Homo sapiens 29-40 17200165-12 2007 Furthermore, a functional consequence of 11beta-HSD1 inhibition was observed, namely decreased prednisone-induced glycerol release into adipose tissue interstitial fluid indicative of inhibition of GC-mediated lipolysis. Prednisone 95-105 hydroxysteroid 11-beta dehydrogenase 1 Homo sapiens 41-52 17413641-2 2007 We report a case of a 62-year-old woman with rheumatoid arthritis treated with etanercept and prednisone, who developed chronic periorbital lymphedema 2 months after Group A beta-hemolytic streptococcus infection of the face. Prednisone 94-104 amyloid beta precursor protein Homo sapiens 172-178 17115196-1 2007 The aim of this study was to assess the serum concentration of high-sensitivity C-reactive protein (hs-CRP) in children with nephrotic syndrome (NS) treated with prednisone and cyclosporine A (CyA). Prednisone 162-172 C-reactive protein Homo sapiens 80-98 17031689-1 2007 Although adding rituximab to standard cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy is an efficacious and well-tolerated regimen in elderly patients with diffuse large B cell lymphoma (DLBCL), it may increase susceptibility to opportunistic infections, and such cases have been reported. Prednisone 86-96 DNA damage inducible transcript 3 Homo sapiens 98-102 17212724-5 2007 In this study, we present four patients with acquired FVIII inhibitor titres >100 BU who were resistant to initial therapy with cyclophosphamide, vincristine and prednisone. Prednisone 165-175 coagulation factor VIII Homo sapiens 54-59 17018705-10 2007 The 3-year progression-free survival in patients who received rituximab plus combination chemotherapy with cyclophosphamide, doxorubicin, vincristine and prednisone (CHOPR) chemotherapy was 88% compared with 52% in those who received CHOP-like chemotherapy without rituximab (P=0.005). Prednisone 154-164 DNA damage inducible transcript 3 Homo sapiens 166-170 17324011-18 2007 This global, multicentre, randomised study, called SPARC (Satraplatin and Prednisone Against Refractory Cancer), is assessing satraplatin plus prednisone versus prednisone alone as second-line therapy in HRPC patients. Prednisone 143-153 secreted protein acidic and cysteine rich Homo sapiens 51-56 17324011-18 2007 This global, multicentre, randomised study, called SPARC (Satraplatin and Prednisone Against Refractory Cancer), is assessing satraplatin plus prednisone versus prednisone alone as second-line therapy in HRPC patients. Prednisone 143-153 secreted protein acidic and cysteine rich Homo sapiens 58-110 17324011-18 2007 This global, multicentre, randomised study, called SPARC (Satraplatin and Prednisone Against Refractory Cancer), is assessing satraplatin plus prednisone versus prednisone alone as second-line therapy in HRPC patients. Prednisone 161-171 secreted protein acidic and cysteine rich Homo sapiens 51-56 17324011-18 2007 This global, multicentre, randomised study, called SPARC (Satraplatin and Prednisone Against Refractory Cancer), is assessing satraplatin plus prednisone versus prednisone alone as second-line therapy in HRPC patients. Prednisone 161-171 secreted protein acidic and cysteine rich Homo sapiens 58-110 18025847-12 2007 CONCLUSIONS: In Chinese patients, docetaxel plus prednisone is better than mitoxantrone plus prednisone in PSA response rate and PSA control, but has a bit more toxicity. Prednisone 49-59 aminopeptidase puromycin sensitive Homo sapiens 107-110 18025847-12 2007 CONCLUSIONS: In Chinese patients, docetaxel plus prednisone is better than mitoxantrone plus prednisone in PSA response rate and PSA control, but has a bit more toxicity. Prednisone 49-59 aminopeptidase puromycin sensitive Homo sapiens 129-132 18025847-12 2007 CONCLUSIONS: In Chinese patients, docetaxel plus prednisone is better than mitoxantrone plus prednisone in PSA response rate and PSA control, but has a bit more toxicity. Prednisone 93-103 aminopeptidase puromycin sensitive Homo sapiens 107-110 16996097-2 2006 The enzyme 11beta-hydroxysteroid dehydrogenase Type-1 (11beta-HSD-1) confers bioactivity upon the inactive GC cortisone (E) and prednisone (P) by converting them to cortisol (F) and prednisolone (L), respectively. Prednisone 128-138 RNA, U1 small nuclear 1 Homo sapiens 11-67 16738866-11 2006 We also found a positive correlation between the P-gp expression and total prednisone dose in the NS children in all examinations: A: (r=0.540, p<0.05); B: (r=0.630, p<0.01); C: (r=0.653, p<0.01). Prednisone 75-85 ATP binding cassette subfamily B member 1 Homo sapiens 49-53 17940628-13 2006 The patient was treated with rituximab, plus cyclophosphamide, Adriamycin, vincristine, and prednisone (CHOP-R), with intrathecal methotrexate prophylaxis. Prednisone 92-102 DNA damage inducible transcript 3 Homo sapiens 104-108 17277854-2 2006 The standard treatment for advanced NHL is 8 cycles of combined chemotherapy, cyclophosphamide, adriamycin, vincristine and prednisone (CHOP). Prednisone 124-134 DNA damage inducible transcript 3 Homo sapiens 136-140 17187697-3 2006 OBJECTIVE: To evaluate the PSA response rate to prednisone in asymptomatic patients with hormone refractory prostate cancer (HRPC). Prednisone 48-58 aminopeptidase puromycin sensitive Homo sapiens 27-30 17187697-10 2006 There was a 22.4% response rate to prednisone as defined by a 50% PSA decline. Prednisone 35-45 aminopeptidase puromycin sensitive Homo sapiens 66-69 17086913-4 2006 Combined therapy with Avonex, prednisone and AZA was associated with a significant increase in the serum level of interleukin (IL)10 (P <0.001). Prednisone 30-40 interleukin 10 Homo sapiens 114-132 16609067-1 2006 The precise mechanism of rituximab plus cyclophosphamide/doxorubicin/vincristine/prednisone (R-CHOP) therapy in diffuse large B-cell lymphoma (DLBCL) is not fully elucidated. Prednisone 81-91 DNA damage inducible transcript 3 Homo sapiens 95-99 16606648-9 2006 CONCLUSIONS: The BDNF Met66 allele was associated with better cognitive functioning in the psychomotor and motor domains, even after controlling for differences in ethnicity, sex, depression status and prednisone treatment. Prednisone 202-212 brain derived neurotrophic factor Homo sapiens 17-21 17027654-4 2006 Second, the discovery of a potential curative combination of drugs, including cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP), for use in advanced disease could eradicate micro-metastatic disease in patients with LD. Prednisone 126-136 DNA damage inducible transcript 3 Homo sapiens 138-142 16788784-5 2006 The standard chemotherapy for aggressive non-Hodgkin"s lymphomas is the CHOP regimen consisting of cyclophosphamide, doxorubicin, vincristine, and prednisone. Prednisone 147-157 DNA damage inducible transcript 3 Homo sapiens 72-76 17121036-0 2006 [Effects of jingui shenqi pill combined prednisone on expression of glucocorticoid receptor and its clinical effect in treating bullous pemphigoid patients]. Prednisone 40-50 nuclear receptor subfamily 3 group C member 1 Homo sapiens 68-91 16985248-1 2006 BACKGROUND: Follicular lymphoma is considered incurable, although cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy can induce sequential remissions. Prednisone 114-124 DNA damage inducible transcript 3 Homo sapiens 126-130 17056460-0 2006 Combined low dose cyclosporine and prednisone down-regulate natural killer cell-like effector functions of CD8brightCD56+ T cells in patients with active Behcet uveitis. Prednisone 35-45 CD8a molecule Homo sapiens 107-110 16943530-2 2006 This conclusion is mainly derived from patients with mixed international prognostic index (IPI) risk profiles treated with CHOP-like therapy (cyclophosphamide, doxorubicin, vincristine, and prednisone). Prednisone 190-200 DNA damage inducible transcript 3 Homo sapiens 123-127 16896003-2 2006 This study was performed to determine the efficacy of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy followed by tositumomab/iodine I-131 tositumomab. Prednisone 102-112 DNA damage inducible transcript 3 Homo sapiens 114-118 16416337-1 2006 The addition of rituximab to cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) has been shown to improve the outcome in all age groups with newly diagnosed diffuse large B-cell lymphoma (DLBCL). Prednisone 77-87 DNA damage inducible transcript 3 Homo sapiens 89-93 16614245-5 2006 The presence of NOTCH1 mutations was significantly correlated with a good prednisone response and favorable minimal residual disease (MRD) kinetics, which was independent from sex, age, white blood cell count, and T-cell immunophenotype at the time of diagnosis. Prednisone 74-84 notch receptor 1 Homo sapiens 16-22 17064544-8 2006 3 weeks after the initial prednisone administration the levels of plasma ICAM-1 and TM began to decrease and were lower than those 1 week after, however, not significantly (both P > 0.05). Prednisone 26-36 ICAM-1 Oryctolagus cuniculus 73-79 16925484-1 2006 For more than 25 years, the combination of cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) was considered the gold standard for the treatment of aggressive lymphomas, 90% of which are diffuse, large B-cell lymphomas (DLBCLs). Prednisone 90-100 DNA damage inducible transcript 3 Homo sapiens 102-106 16644068-6 2006 In our patient, both polymyositis and steroid therapy were predisposing factors of cutaneous leishmaniasis onset; prednisone therapy has been postulated to be associated with immune dysfunction leading to: reduced blood T cells" levels (CD4 et CD8) as well as decreased cytokine synthesis (e.g. interferon gamma). Prednisone 114-124 CD4 molecule Homo sapiens 237-240 16644068-6 2006 In our patient, both polymyositis and steroid therapy were predisposing factors of cutaneous leishmaniasis onset; prednisone therapy has been postulated to be associated with immune dysfunction leading to: reduced blood T cells" levels (CD4 et CD8) as well as decreased cytokine synthesis (e.g. interferon gamma). Prednisone 114-124 CD8a molecule Homo sapiens 244-247 16644068-6 2006 In our patient, both polymyositis and steroid therapy were predisposing factors of cutaneous leishmaniasis onset; prednisone therapy has been postulated to be associated with immune dysfunction leading to: reduced blood T cells" levels (CD4 et CD8) as well as decreased cytokine synthesis (e.g. interferon gamma). Prednisone 114-124 interferon gamma Homo sapiens 295-311 16792147-0 2006 Prednisone/cyclophosphamide treatment in adult-onset autosomal dominant familial focal segmental glomerulosclerosis (FSGS 1). Prednisone 0-10 actinin alpha 4 Homo sapiens 117-123 16702186-1 2006 Rituximab has greatly improved standard cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) chemotherapy, but prospects remain poor in patients with adverse risk factors. Prednisone 87-97 DNA damage inducible transcript 3 Homo sapiens 99-103 16636307-9 2006 With the intervention of lisinopril, prednisone, and ATRA, changes in the expression of nephrin, podocin, and CD2AP were diverse, which was different from that detected in ADR rats. Prednisone 37-47 NPHS1 adhesion molecule, nephrin Rattus norvegicus 88-95 16636307-9 2006 With the intervention of lisinopril, prednisone, and ATRA, changes in the expression of nephrin, podocin, and CD2AP were diverse, which was different from that detected in ADR rats. Prednisone 37-47 NPHS2 stomatin family member, podocin Rattus norvegicus 97-104 16636307-9 2006 With the intervention of lisinopril, prednisone, and ATRA, changes in the expression of nephrin, podocin, and CD2AP were diverse, which was different from that detected in ADR rats. Prednisone 37-47 CD2-associated protein Rattus norvegicus 110-115 16636307-10 2006 After lisinopril and prednisone intervention, podocin exhibited prominent earlier changes compared with those of nephrin and CD2AP, whereas CD2AP showed more prominent changes after ATRA intervention. Prednisone 21-31 NPHS2 stomatin family member, podocin Rattus norvegicus 46-53 16636307-10 2006 After lisinopril and prednisone intervention, podocin exhibited prominent earlier changes compared with those of nephrin and CD2AP, whereas CD2AP showed more prominent changes after ATRA intervention. Prednisone 21-31 NPHS1 adhesion molecule, nephrin Rattus norvegicus 113-120 16636307-10 2006 After lisinopril and prednisone intervention, podocin exhibited prominent earlier changes compared with those of nephrin and CD2AP, whereas CD2AP showed more prominent changes after ATRA intervention. Prednisone 21-31 CD2-associated protein Rattus norvegicus 125-130 16636307-12 2006 In summary, we conclude that the antiproteinuric effects of lisinopril, prednisone, and ATRA were achieved by changes in the expression and distribution of the important podocyte molecules nephrin, podocin, CD2AP, and alpha-actinin-4. Prednisone 72-82 NPHS1 adhesion molecule, nephrin Rattus norvegicus 189-196 16636307-12 2006 In summary, we conclude that the antiproteinuric effects of lisinopril, prednisone, and ATRA were achieved by changes in the expression and distribution of the important podocyte molecules nephrin, podocin, CD2AP, and alpha-actinin-4. Prednisone 72-82 CD2-associated protein Rattus norvegicus 207-212 16636307-12 2006 In summary, we conclude that the antiproteinuric effects of lisinopril, prednisone, and ATRA were achieved by changes in the expression and distribution of the important podocyte molecules nephrin, podocin, CD2AP, and alpha-actinin-4. Prednisone 72-82 actinin alpha 4 Rattus norvegicus 218-233 16541142-10 2006 We conclude that high VCP expression is associated with poor prednisone response in childhood ALL patients. Prednisone 61-71 valosin containing protein Homo sapiens 22-25 17064544-10 2006 The level of VEGF expression in the osteocytes, osteoblasts, and cells of bone matrix and endothelial cells increased first 1 week after and then decreased after the prednisone administration in Group A, and decreased after the prednisone administration in Group B, however, without significant differences between these 2 groups. Prednisone 166-176 vascular endothelial growth factor A Oryctolagus cuniculus 13-17 17064544-10 2006 The level of VEGF expression in the osteocytes, osteoblasts, and cells of bone matrix and endothelial cells increased first 1 week after and then decreased after the prednisone administration in Group A, and decreased after the prednisone administration in Group B, however, without significant differences between these 2 groups. Prednisone 228-238 vascular endothelial growth factor A Oryctolagus cuniculus 13-17 16840195-1 2006 Recently, the cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) regimen plus rituximab (R-CHOP) have been used widely to treat patients with follicular lymphoma. Prednisone 61-71 DNA damage inducible transcript 3 Homo sapiens 73-77 16825140-6 2006 Following prednisone therapy (B), VEGF level was reduced but it was still higher than in the control group. Prednisone 10-20 vascular endothelial growth factor A Homo sapiens 34-38 16753869-3 2006 We used clinical information obtained during pretreatment evaluation to develop a predictive model for severe neutropenia in the first cycle of cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) chemotherapy. Prednisone 191-201 DNA damage inducible transcript 3 Homo sapiens 203-207 16689978-5 2006 Administration of cyclosporine A in addition to prednisone enabled the patient to become transfusion and EPO independent. Prednisone 48-58 erythropoietin Homo sapiens 105-108 16405878-9 2006 In addition, prednisone (but not ibuprofen or cyclosporine) significantly decreased C-reactive protein concentrations and attenuated the increase in endothelial nitric oxide synthase expression caused by atrial tachypacing. Prednisone 13-23 C-reactive protein Canis lupus familiaris 84-102 18651015-5 2006 To allow for the reduction of prednisone, interferon-alpha-2b was added to the patient"s program, but caused aggravation of chest pain and was discontinued. Prednisone 30-40 interferon alpha 2 Homo sapiens 42-61 16553512-10 2006 Consistent with clinical guideline recommendations, safety and efficacy data support the use of low-dose corticosteroid regimens such as prednisone 40 mg orally once/day for 10-14 days in most patients with an acute exacerbation of COPD. Prednisone 137-147 COPD Homo sapiens 232-236 16597193-7 2006 Prednisone administration results in a decrease in ACTH secretion by the anterior pituitary, suppressing synthesis of glucocorticoids, DHEA, and DHEA metabolites. Prednisone 0-10 proopiomelanocortin Homo sapiens 51-55 16502436-2 2006 The German ARL Study Group investigated whether HAART administered concomitantly with cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy compromised the course of immune parameters during and after chemotherapy and exerted a positive effect on remission and survival. Prednisone 134-144 DNA damage inducible transcript 3 Homo sapiens 146-150 16507847-14 2006 In the SS patients, the time to the first exacerbation was longer (by 213 days) especially in those considered to need treatment with a long acting beta2-agonist (by 490 days), the relative risk ratio was lower (by 49%), and the number of exacerbations needing prednisone was reduced (5 versus 15). Prednisone 261-271 potassium calcium-activated channel subfamily M regulatory beta subunit 2 Homo sapiens 148-153 16479196-5 2006 Before starting L-asparaginase treatment all patients had already demonstrated an increased thrombin generation shown by the elevated levels of prothrombin fragment 1+2 and thrombin antithrombin III, presumably due to therapy with prednisone, daunorubicin and vincristine. Prednisone 231-241 asparaginase and isoaspartyl peptidase 1 Homo sapiens 16-30 16479196-5 2006 Before starting L-asparaginase treatment all patients had already demonstrated an increased thrombin generation shown by the elevated levels of prothrombin fragment 1+2 and thrombin antithrombin III, presumably due to therapy with prednisone, daunorubicin and vincristine. Prednisone 231-241 coagulation factor II, thrombin Homo sapiens 92-100 16640819-3 2006 In this regard, we report an 80-year-old patient with follicular grade 3 non-Hodgkin"s lymphoma who developed a fatal interstitial pneumonitis related to treatment with a rituximab/CHOP (cyclophosphamide/doxorubicin/vincristine/prednisone) regimen. Prednisone 228-238 DNA damage inducible transcript 3 Homo sapiens 181-185 16331635-2 2006 Attempts to improve the results achieved with the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) using second-generation or third-generation chemotherapy have failed. Prednisone 113-123 DNA damage inducible transcript 3 Homo sapiens 125-129 16831024-5 2006 The combination of rituximab with cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) was cost effective as first-line therapy for advanced-stage diffuse large B-cell NHL compared with CHOP alone. Prednisone 81-91 DNA damage inducible transcript 3 Homo sapiens 93-97 16831024-5 2006 The combination of rituximab with cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) was cost effective as first-line therapy for advanced-stage diffuse large B-cell NHL compared with CHOP alone. Prednisone 81-91 DNA damage inducible transcript 3 Homo sapiens 198-202 16123223-0 2005 Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Prednisone 109-119 DNA damage inducible transcript 3 Homo sapiens 121-125 16706552-5 2006 The combination of rituximab with cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) was cost effective as first-line therapy for advanced-stage diffuse large B-cell NHL compared with CHOP alone. Prednisone 81-91 DNA damage inducible transcript 3 Homo sapiens 93-97 16706552-5 2006 The combination of rituximab with cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) was cost effective as first-line therapy for advanced-stage diffuse large B-cell NHL compared with CHOP alone. Prednisone 81-91 DNA damage inducible transcript 3 Homo sapiens 198-202 16263818-15 2006 Surprisingly, all APECED-related symptoms including candidiasis and autoantibody levels decreased, presumably due to the reinforced immunosuppression (tacrolimus, mycophenolate mofetil, prednisone). Prednisone 186-196 autoimmune regulator Homo sapiens 18-24 16314190-0 2006 Thyroid hormone and insulin-like growth factor-I in patients with multiple myeloma treated with melphalan and prednisone. Prednisone 110-120 insulin like growth factor 1 Homo sapiens 20-48 16314190-11 2006 CONCLUSIONS: Euthyroid sick syndrome can exist in MM patients, and the therapy with melphalan plus prednisone is accompanied by slightly expressed serum changes of thyroid hormone concentrations and IGF-I levels. Prednisone 99-109 insulin like growth factor 1 Homo sapiens 199-204 16575475-1 2006 Authors conducted a one-year prospective study to determine whether CHOP regimen (cyclophosphamide, doxorubicin, vincristin, and prednisone), used in the treatment of aggressive non-Hodgkin s lymphoma, is associated with the presence of an early impairment of cardiac function. Prednisone 129-139 DNA damage inducible transcript 3 Homo sapiens 68-72 15914552-1 2005 The addition of rituximab to cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy results in significant improvement in clinical outcome for individuals with non-HIV-associated aggressive B-cell lymphoma. Prednisone 77-87 DNA damage inducible transcript 3 Homo sapiens 89-93 16417450-3 2005 Here, we report a patient with fulminant hepatic failure who received an ABO-incompatible liver transplantation who was treated with pre- and posttransplantation double-volume total plasma exchange, splenectomy, and triple immunosuppression (tacrolimus, mycophenolate mofetil, and prednisone) in July 2003. Prednisone 281-291 ABO, alpha 1-3-N-acetylgalactosaminyltransferase and alpha 1-3-galactosyltransferase Homo sapiens 73-76 16217292-10 2005 CONCLUSIONS: Despite major limitations of historical comparison the PSA decrease and decreased symptoms with DPPE-mitoxantrone-prednisone compare favorably to those of mitoxantrone-prednisone and docetaxel-estramustine in the literature. Prednisone 127-137 kallikrein related peptidase 3 Homo sapiens 68-71 16046510-6 2005 Unfortunately, 3 months after cessation of prednisone, a recurrence of PRCA was confirmed by the development of profound anaemia and reappearance of anti-erythropoietin antibodies in the patient"s serum. Prednisone 43-53 erythropoietin Homo sapiens 154-168 16227953-3 2005 AIM: The aim of this paper was to study the distribution of CD8+ subsets, of soluble receptors of CD8 and IL-2 during a steroid treatment with prednisone and deflazacort. Prednisone 143-153 CD8a molecule Homo sapiens 60-63 16227953-3 2005 AIM: The aim of this paper was to study the distribution of CD8+ subsets, of soluble receptors of CD8 and IL-2 during a steroid treatment with prednisone and deflazacort. Prednisone 143-153 CD8a molecule Homo sapiens 98-101 16227953-3 2005 AIM: The aim of this paper was to study the distribution of CD8+ subsets, of soluble receptors of CD8 and IL-2 during a steroid treatment with prednisone and deflazacort. Prednisone 143-153 interleukin 2 Homo sapiens 106-110 16440771-7 2005 The patient received a regimen of cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP). Prednisone 81-91 DNA damage inducible transcript 3 Homo sapiens 93-97 15932900-5 2005 Dose-dense (14-day) CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) with G-CSF support produces better results than 21-day CHOP in patients with previously untreated aggressive lymphoma, without additional toxicity. Prednisone 74-84 colony stimulating factor 3 Homo sapiens 91-96 16226134-1 2005 During pregnancy the placental 11beta-hydroxysteroid dehydrogenase 2 (11beta-HSD2) enzyme inactivates prednisolone by interconversion into prednisone, protecting the fetus from high levels of prednisolone. Prednisone 139-149 hydroxysteroid 11-beta dehydrogenase 2 Homo sapiens 31-68 16226134-1 2005 During pregnancy the placental 11beta-hydroxysteroid dehydrogenase 2 (11beta-HSD2) enzyme inactivates prednisolone by interconversion into prednisone, protecting the fetus from high levels of prednisolone. Prednisone 139-149 hydroxysteroid 11-beta dehydrogenase 2 Homo sapiens 70-81 16335208-5 2005 RESULTS: The content of TGF-beta1mRNA in the pulmonary tissue in the moxibustion group and the prednisone group was significantly lower than the model group (P < 0.01), and there was no significant difference between the moxibustion group and the prednisone group (P > 0. Prednisone 95-105 transforming growth factor, beta 1 Rattus norvegicus 24-33 16335208-5 2005 RESULTS: The content of TGF-beta1mRNA in the pulmonary tissue in the moxibustion group and the prednisone group was significantly lower than the model group (P < 0.01), and there was no significant difference between the moxibustion group and the prednisone group (P > 0. Prednisone 250-260 transforming growth factor, beta 1 Rattus norvegicus 24-33 16335208-7 2005 CONCLUSION: Both moxibustion at Feishu (BL 13) and Gaohuang (BL 43), and prednisone treatment can significantly suppress the expression of TGF-beta1mRNA in the pulmonary tissue in the rat of bleomycin-induced pulmonary fibrosis. Prednisone 73-83 transforming growth factor, beta 1 Rattus norvegicus 139-148 15959811-4 2005 Based on anecdotal reports in literature, prednisone therapy was started in order to increase insulin resistance, reduce glucose utilization, increase hepatic glucose production, and impair insulin secretion. Prednisone 42-52 insulin Homo sapiens 94-101 16093796-4 2005 Phase II trials combining rituximab with either standard cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy or infusional chemotherapy have reported encouraging results, suggesting a similar benefit in HIV-positive individuals. Prednisone 105-115 DNA damage inducible transcript 3 Homo sapiens 117-121 16708557-0 2005 [The influence of IL-6 polymorphism on efficacy of treatment of rheumatoid arthritis patients with methotrexate and prednisone]. Prednisone 116-126 interleukin 6 Homo sapiens 18-22 16708557-5 2005 The aim of the present study was to examine the influence of - 174 interleukin-6 (IL-6) promoter polymorphism on the efficacy of treatment of RA patients with methotrexate and prednisone. Prednisone 176-186 interleukin 6 Homo sapiens 67-80 16708557-5 2005 The aim of the present study was to examine the influence of - 174 interleukin-6 (IL-6) promoter polymorphism on the efficacy of treatment of RA patients with methotrexate and prednisone. Prednisone 176-186 interleukin 6 Homo sapiens 82-86 16006279-1 2005 Treatment of non-Hodgkin"s lymphoma with the CHOP regimen consists of intravenous cyclophosphamide 750 mg/m2 (day 1), intravenous doxorubicin 50 mg/m2 (day 1), intravenous vincristine 1.4 mg/m2 (day 1), and oral prednisone 100 mg (days 1-5). Prednisone 212-222 DNA damage inducible transcript 3 Homo sapiens 45-49 15955905-1 2005 PURPOSE: For more than two decades, cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) has been the standard therapy for diffuse large B-cell lymphoma (DLBCL). Prednisone 84-94 DNA damage inducible transcript 3 Homo sapiens 96-100 15980236-0 2005 Down-regulation of IFN-gamma-producing CD56+ T cells after combined low-dose cyclosporine/prednisone treatment in patients with Behcet"s uveitis. Prednisone 90-100 interferon gamma Homo sapiens 19-28 15980236-0 2005 Down-regulation of IFN-gamma-producing CD56+ T cells after combined low-dose cyclosporine/prednisone treatment in patients with Behcet"s uveitis. Prednisone 90-100 neural cell adhesion molecule 1 Homo sapiens 39-43 15980236-1 2005 PURPOSE: To investigate the effects of combined low-dose cyclosporine and prednisone (Cs/Pd) treatment on circulating CD56+ T cells in patients with Behcet"s uveitis. Prednisone 74-84 neural cell adhesion molecule 1 Homo sapiens 118-122 16200847-0 2005 Expression of glucocorticoid receptors in nephrotic children depending on total prednisone dose. Prednisone 80-90 nuclear receptor subfamily 3 group C member 1 Homo sapiens 14-38 15934892-5 2005 When given with prednisone, docetaxel was also shown to reduce pain and serum prostate specific antigen levels and improve quality of life compared with mitoxantrone/prednisone. Prednisone 16-26 kallikrein related peptidase 3 Homo sapiens 78-103 15791475-3 2005 The patient was treated for diffuse large B-cell non-Hodgkin"s lymphoma with CHOP therapy (doxorubicin, cyclophosphamide, vincristine, and prednisone). Prednisone 139-149 DNA damage inducible transcript 3 Homo sapiens 77-81 16187701-1 2005 The results of the treatment of 14 patients with promyelocytic leukemia (PML) treated with all trans-retinoic acid (ATRA), combined chemotherapy (CT) and prophylactic prednisone are reported; the median age was 30 years (range 7 - 49). Prednisone 167-177 PML nuclear body scaffold Homo sapiens 49-71 16187701-1 2005 The results of the treatment of 14 patients with promyelocytic leukemia (PML) treated with all trans-retinoic acid (ATRA), combined chemotherapy (CT) and prophylactic prednisone are reported; the median age was 30 years (range 7 - 49). Prednisone 167-177 PML nuclear body scaffold Homo sapiens 73-76 15921395-2 2005 In this study we found that HIV-infected patients with diffuse large B-cell lymphoma treated with cyclophosphamide, hydroxydoxorubicin, vincristine and prednisone (CHOP) and HAART showed a similar response rate to chemotherapy, disease-free survival and overall survival as those of HIV-negative patients receiving CHOP. Prednisone 152-162 DNA damage inducible transcript 3 Homo sapiens 315-319 15945343-6 2005 Another phase III trial demonstrated that docetaxel given every 3 weeks plus prednisone significantly improved overall survival, PSA response rate, pain relief response rate, and quality of life compared with mitoxantrone and prednisone. Prednisone 77-87 kallikrein related peptidase 3 Homo sapiens 129-132 15746991-13 2005 RESULTS AND CONCLUSIONS: Prednisone rapidly and significantly decreased serum PINP (p < 0.01), PICP (p < 0.01), and osteocalcin (p < 0.01) and free urinary deoxypyridinoline (p = 0.017). Prednisone 25-35 bone gamma-carboxyglutamate protein Homo sapiens 122-133 15668260-6 2005 After mitoxantrone/prednisone treatment, the prostate-specific antigen (PSA) response rate was 23%, which increased to 63% after completion of sequential mitoxantrone/prednisone and docetaxel/estramustine treatment (12 partial and 7 complete responses). Prednisone 19-29 kallikrein related peptidase 3 Homo sapiens 45-76 15693788-1 2005 OBJECTIVE: To determine the incremental cost-effectiveness ratio (ICER) of cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) vs. CHOP plus rituximab (R-CHOP) in diffuse large B-cell lymphoma (DLBCL) patients in the Netherlands. Prednisone 122-132 DNA damage inducible transcript 3 Homo sapiens 134-138 15727852-4 2005 Quantitatively, an inverse linear relationship (r(2)=0.81, q(2)=0.80) was obtained between DeltaE(bbone) and log1/K(i), showing that DeltaE(bbone) contributes significantly to the experimentally observed affinity for hPEPT1 ligands. Prednisone 91-97 solute carrier family 15 member 1 Homo sapiens 217-223 15666323-1 2005 BACKGROUND: The standard treatment for patients with aggressive non-Hodgkin lymphoma (NHL) is cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP). Prednisone 142-152 DNA damage inducible transcript 3 Homo sapiens 154-158 15975305-5 2005 After treatment with Vit B(6) and XFZY, the level of sIL-2R and TNF-alpha from the patients with LSD decreased significantly (P < 0.01), but there were no difference between the group taking Vit B(6) plus XFZY and the group given prednisone. Prednisone 233-243 vitrin Homo sapiens 21-24 15794864-2 2005 Cyclophosphamide/doxorubicin/vincristine/prednisone/rituximab (CHOP-R) is a stem cellsparing regimen that has been extensively evaluated in patients without WM or non-Hodgkin"s lymphoma. Prednisone 41-51 DNA damage inducible transcript 3 Homo sapiens 63-67 14628151-5 2005 RESULTS: Patients on prednisone had lower BMD than controls (0.94 +/- 0.17 vs 0.96 +/- 0.17 for L2-4 and 0.73 +/- 0.14 vs 0.76 +/- 0.16 for femoral neck), but these differences were not statistically significant (P > 0.05). Prednisone 21-31 immunoglobulin kappa variable 1D-8 Homo sapiens 96-100 15621841-5 2005 The patient responded to chemotherapy with CHOP (doxorubicin, cyclophosphamide, vincristine and prednisone) therapy, with disappearance of the abnormal clone from the bone marrow. Prednisone 96-106 DNA damage inducible transcript 3 Homo sapiens 43-47 16110296-6 2005 We instituted initial therapy, with cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) plus intrathecal chemotherapy without performing a chromosome analysis, because the clinical course was very aggressive. Prednisone 84-94 DNA damage inducible transcript 3 Homo sapiens 96-100 15696567-8 2005 After 4 weeks of prednisone therapy, ESR was elevated in 13.2% patients, CRP in 41.9%, and serum IL-6 in 37.2%. Prednisone 17-27 C-reactive protein Homo sapiens 73-76 15696567-8 2005 After 4 weeks of prednisone therapy, ESR was elevated in 13.2% patients, CRP in 41.9%, and serum IL-6 in 37.2%. Prednisone 17-27 interleukin 6 Homo sapiens 97-101 15780173-4 2005 RESULTS: In the TAX 327 trial, 3-weekly docetaxel plus prednisone proved significantly superior to mitoxantrone plus prednisone (an established reference regimen) in extending survival, reducing levels of prostate specific antigen (PSA), controlling pain and improving quality of life. Prednisone 55-65 kallikrein related peptidase 3 Homo sapiens 205-230 15780173-4 2005 RESULTS: In the TAX 327 trial, 3-weekly docetaxel plus prednisone proved significantly superior to mitoxantrone plus prednisone (an established reference regimen) in extending survival, reducing levels of prostate specific antigen (PSA), controlling pain and improving quality of life. Prednisone 55-65 kallikrein related peptidase 3 Homo sapiens 232-235 15811488-11 2005 RESULTS: Fasting plasma glucose (FPG) level was normalized and the IGF-1 concentration was increased with high-dose prednisone monotherapy (30 mg/d [0.50 mg/kg x d]) or rhGH (2.6 mg/d [0.043 mg/kg x d]). Prednisone 116-126 insulin like growth factor 1 Homo sapiens 67-72 15811488-12 2005 Prednisone monotherapy partially suppressed big IGF-2 secretion, and rhGH monotherapy acted on IGFBP-3 and ALS concentrations. Prednisone 0-10 insulin like growth factor 2 Homo sapiens 48-53 15858449-7 2005 Four courses of adjuvant chemotherapy with cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) were subsequently performed. Prednisone 90-100 DNA damage inducible transcript 3 Homo sapiens 102-106 15995323-5 2005 IFN-alpha has been life-saving for patients with intractable HES that were resistant to prednisone, hydroxyurea, and other agents. Prednisone 88-98 interferon alpha 1 Homo sapiens 0-9 15302722-7 2004 RESULTS: Levels of MPO decreased significantly after treatment with prednisone (p = 0.0004): before treatment median, 2.54 microg/mL (range, 1.49 to 12.58 microg/mL); after treatment median, 1.79 microg/mL (range, 1.32 to 3.57 microg/mL). Prednisone 68-78 myeloperoxidase Homo sapiens 19-22 15496974-6 2005 Thus, we provide evidence that polymorphic IFN-gamma alleles are associated with age at clinical presentation and risk groups such as prednisone response in B-lineage ALL, suggesting distinct effects of IFN-gamma in immunosurveillance and early response to steroid therapy. Prednisone 134-144 interferon gamma Homo sapiens 43-52 15496974-6 2005 Thus, we provide evidence that polymorphic IFN-gamma alleles are associated with age at clinical presentation and risk groups such as prednisone response in B-lineage ALL, suggesting distinct effects of IFN-gamma in immunosurveillance and early response to steroid therapy. Prednisone 134-144 interferon gamma Homo sapiens 203-212 15508904-7 2004 Interestingly, serum TNF-alpha levels were increased in the same patients even after completion of prednisone treatment, indicating ongoing immune activity. Prednisone 99-109 tumor necrosis factor Homo sapiens 21-30 15016643-1 2004 Cyclophosphamide, doxorubicin, vincristine, and prednisone, given every 3 weeks (CHOP-21), is standard chemotherapy for aggressive lymphomas. Prednisone 48-58 DNA damage inducible transcript 3 Homo sapiens 81-85 16266195-5 2005 Compared with mitoxantrone plus prednisone, docetaxel plus prednisone improved prostate specific antigen response rate, pain and health-related quality of life, and docetaxel plus estramustine increased progression-free survival. Prednisone 59-69 kallikrein related peptidase 3 Homo sapiens 79-104 15550586-1 2004 BACKGROUND: We demonstrated that highly active antiretroviral therapy (HAART) increases the toxic effect of cyclophosphamide, vincristine, doxorubicin (DOX) and prednisone (CHOP) in HIV-patients with non-Hodgkin"s lymphoma (NHL). Prednisone 161-171 DNA damage inducible transcript 3 Homo sapiens 173-177 15667418-4 2004 We report three patients with headache attributed to spontaneous low CSF pressure that were successfully treated with oral prednisone. Prednisone 123-133 colony stimulating factor 2 Homo sapiens 69-72 15598322-10 2004 For the IL-10 groups, two of 15 patients with the high producer genotype (13.3%) remained on prednisone, in comparison with 16 of 28 patients with the intermediate producer genotype (57.1%) and 15 of 26 patients with the low producer genotype (57.7%, p = 0.01). Prednisone 93-103 interleukin 10 Homo sapiens 8-13 15500738-2 2004 METHODS: The level of serum anti-C1q antibody of 75 patients with LN was examined by enzyme-linked immunosorbent assay (ELISA) of the 75 patients the incipient cases had never received corticosteroid and immunosuppressant and the recurrent cases had stopped the immunosuppressant treatment for more than 3 months and were treated, if so, with prednisone with the dosage </= 10 mg/d. Prednisone 343-353 complement C1q A chain Homo sapiens 33-36 15472518-0 2004 Identification of budesonide and prednisone as substrates of the intestinal drug efflux pump P-glycoprotein. Prednisone 33-43 ATP binding cassette subfamily B member 1 Homo sapiens 93-107 15472518-4 2004 We tested the hypothesis that budesonide and prednisone are substrates of P-glycoprotein thereby possibly contributing to variable therapeutic effects. Prednisone 45-55 ATP binding cassette subfamily B member 1 Homo sapiens 74-88 15472518-12 2004 In conclusion, budesonide and prednisone were identified as substrates of the intestinal drug efflux pump, P-glycoprotein. Prednisone 30-40 ATP binding cassette subfamily B member 1 Homo sapiens 107-121 14982884-1 2004 The combination of cyclophosphamide, doxorubicin, vincristine, and prednisone, given every 3 weeks (CHOP-21) is standard chemotherapy for aggressive lymphomas. Prednisone 67-77 DNA damage inducible transcript 3 Homo sapiens 100-104 15256984-15 2004 The combined administration of a priming steroid course and IFN appears to be an improvement over prednisone monotherapy and should be considered for every patient with HBV related PAN. Prednisone 98-108 interferon alpha 1 Homo sapiens 60-63 15205203-0 2004 Rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP) for treatment of early-stage gastric diffuse large B-cell lymphoma. Prednisone 58-68 DNA damage inducible transcript 3 Homo sapiens 72-76 15205203-2 2004 Recently, chemotherapy consisting of doxorubicin, cyclophosphamide, vincristine and prednisone (CHOP) has been reported as effective treatment for early-stage gastric DLBCL. Prednisone 84-94 DNA damage inducible transcript 3 Homo sapiens 96-100 15248230-10 2004 RESULTS: The median daily dose of prednisone required to maintain remission prior to anti-TNF therapy was 20 mg. Prednisone 34-44 tumor necrosis factor Homo sapiens 90-93 15350444-5 2004 TGF-beta tended to increase in supernatants from patients under Rapa + CsA + P at 6 months posttransplant and at 1 month after CsA withdrawal without correlation to Rapa blood levels. Prednisone 77-78 transforming growth factor beta 1 Homo sapiens 0-8 15159414-2 2004 We performed a randomized comparative trial of FM with cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) front-line chemotherapy with and without sequential rituximab. Prednisone 103-113 DNA damage inducible transcript 3 Homo sapiens 115-119 15217942-4 2004 EXPERIMENTAL DESIGN: We administered rituximab with CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone) treatment with G-CSF to 15 patients with follicular lymphoma, and we investigated the safety and efficacy of this regimen. Prednisone 102-112 colony stimulating factor 3 Homo sapiens 129-134 15194168-7 2004 As prednisone (PDN) is transported by P-gp, the aim of this study was to evaluate the P-gp function in lymphocytes from myasthenia gravis (MG) patients. Prednisone 3-13 ATP binding cassette subfamily B member 1 Homo sapiens 38-42 15194168-7 2004 As prednisone (PDN) is transported by P-gp, the aim of this study was to evaluate the P-gp function in lymphocytes from myasthenia gravis (MG) patients. Prednisone 3-13 ATP binding cassette subfamily B member 1 Homo sapiens 86-90 15152285-4 2004 An apparent treatment response to a gluten-free diet and prednisone resulted in reduced diarrhea, weight gain and normalization of serum albumin. Prednisone 57-67 albumin Homo sapiens 131-144 15181605-5 2004 In patients with aggressive lymphoma who receive cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy, 40% to 70% of patients attain a complete remission, depending on risk factors such as age and extranodal involvement. Prednisone 97-107 DNA damage inducible transcript 3 Homo sapiens 109-113 15060745-2 2004 The risk is significantly evident in patients with aggressive lymphoma, which is highly responsive to standard chemotherapy with cyclophosphamide, hydroxydaunomycin, vincristine, and prednisone (CHOP) achieving a complete response rate of 60-80% and 5-year survival rate of 30-50% with only 1% of treatment-related mortality. Prednisone 183-193 DNA damage inducible transcript 3 Homo sapiens 195-199 15109455-13 2004 CONCLUSIONS: The results suggest that, in this asthmatic mouse model, prednisone probably inhibits proliferation, differentiation, and migration of CD34+ cells in bone marrow, blocks eosinophilopoiesis in bone marrow, and interferes with eosinophil migration into peripheral blood and subsequent recruitment in the airway. Prednisone 70-80 CD34 antigen Mus musculus 148-152 15110230-2 2004 Broad ranges of structurally unrelated compounds are transported by P-gp, including antineoplastic agents, HIV protease inhibitors, prednisone, gold salts, methotrexate, colchicine as well as several antibiotics. Prednisone 132-142 ATP binding cassette subfamily B member 1 Homo sapiens 68-72 15110639-4 2004 Prednisone was administered with amelioration of the patient"s symptoms, but with persistently increased CPK and myoglobin levels. Prednisone 0-10 phosphatidylinositol-4-phosphate 3-kinase catalytic subunit type 2 alpha Homo sapiens 105-108 15110639-4 2004 Prednisone was administered with amelioration of the patient"s symptoms, but with persistently increased CPK and myoglobin levels. Prednisone 0-10 myoglobin Homo sapiens 113-122 15042528-1 2004 In the past, CHOP chemotherapy (cyclophosphamide, doxorubicin, vincristine, prednisone) was considered the gold standard treatment for aggressive non-Hodgkin"s lymphoma (NHL). Prednisone 76-86 DNA damage inducible transcript 3 Homo sapiens 13-17 14679293-7 2004 A significant correlation was found between the amount of tissue TNFalpha mRNA and the time required to reach a maintenance dose of prednisone <10 mg/day (r = 0.586, P = 0.001). Prednisone 132-142 tumor necrosis factor Homo sapiens 65-73 14635075-2 2003 METHODS: Medical records of 1355 patients with intermediate-grade non-Hodgkin lymphoma receiving cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) or similar chemotherapy were reviewed. Prednisone 145-155 DNA damage inducible transcript 3 Homo sapiens 157-161 28140109-1 2004 In the past, CHOP chemotherapy (cyclophosphamide, doxorubicin, vincristine, prednisone) was considered the gold standard treatment for aggressive non-Hodgkin"s lymphoma (NHL). Prednisone 76-86 DNA damage inducible transcript 3 Homo sapiens 13-17 14752912-4 2004 Current chemotherapy of choice is CHOP [Cyclophosphamide, Hydroxydaunomycin (doxorubicin), Oncovin (vincristine sulfate) and Prednisone]. Prednisone 125-135 DNA damage inducible transcript 3 Homo sapiens 34-38 24936100-14 2004 CONCLUSIONS: In this pilot study of patients with corticosteroid-dependent asthma, 6-week clarithromycin 500 mg BID was clinically effective in allowing a reduction in prednisone dosage, without worsening pulmonary function, QOL, or asthmatic symptoms. Prednisone 168-178 BH3 interacting domain death agonist Homo sapiens 112-115 14979480-1 2004 The present study was performed to examine whether the expression of CD64 Fc gamma receptor type I (FcgammaRI) on both neutrophils and monocytes can be modulated by multiple daily administrations of granulocyte colony-stimulating factor (G-CSF) to patients with non-Hodgkin"s lymphoma in neutropenia caused by CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) chemotherapy. Prednisone 364-374 Fc gamma receptor Ia Homo sapiens 69-110 14979480-1 2004 The present study was performed to examine whether the expression of CD64 Fc gamma receptor type I (FcgammaRI) on both neutrophils and monocytes can be modulated by multiple daily administrations of granulocyte colony-stimulating factor (G-CSF) to patients with non-Hodgkin"s lymphoma in neutropenia caused by CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) chemotherapy. Prednisone 364-374 colony stimulating factor 3 Homo sapiens 199-236 14979480-1 2004 The present study was performed to examine whether the expression of CD64 Fc gamma receptor type I (FcgammaRI) on both neutrophils and monocytes can be modulated by multiple daily administrations of granulocyte colony-stimulating factor (G-CSF) to patients with non-Hodgkin"s lymphoma in neutropenia caused by CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) chemotherapy. Prednisone 364-374 colony stimulating factor 3 Homo sapiens 238-243 12816874-7 2003 Higher levels of MRP3 were found in patients with a poor in vivo response to prednisone, but this could not be confirmed in an independent case-control study (40 patients) for prednisone response. Prednisone 77-87 ATP binding cassette subfamily C member 3 Homo sapiens 17-21 14634722-11 2004 The plasma levels of big ET-1 are dependent on CyA plasma levels 1 year after successful OHTx in patients treated with the immunosuppressive combination of cyclosporine, azathioprine, and prednisone. Prednisone 188-198 endothelin 1 Homo sapiens 25-29 14730612-9 2004 Prednisone dosage explained only 15.6% of the variance in insulin levels. Prednisone 0-10 insulin Homo sapiens 58-65 14766371-0 2004 Inhibition of GM-CSF production in fibroblast-monocyte coculture by prednisone and effects of rhGM-CSF on human lung fibroblasts. Prednisone 68-78 colony stimulating factor 2 Homo sapiens 14-20 14766371-5 2004 Here we show that GM-CSF production from NHLF activated by monocyte contact is inhibited by prednisone, a synthetic glucocorticoid used in the treatment of asthma. Prednisone 92-102 colony stimulating factor 2 Homo sapiens 18-24 14766371-9 2004 Prednisone was used to block NF-kappaB activation and GM-CSF gene expression as well. Prednisone 0-10 colony stimulating factor 2 Homo sapiens 54-60 14581418-5 2003 Eight of 11 patients were treated with a cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP)-like regimen. Prednisone 89-99 DNA damage inducible transcript 3 Homo sapiens 101-105 14738302-7 2003 In children with a history of FSGS, caution is necessary when altering the dosing schedule of prednisone. Prednisone 94-104 actinin alpha 4 Homo sapiens 30-34 14513044-1 2003 For the last decade, cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) has been the best available standard of care for aggressive non-Hodgkin"s lymphoma (NHL), based on equivalent therapeutic results with other multiagent chemotherapy accompanied by lower costs and lesser toxicity. Prednisone 69-79 DNA damage inducible transcript 3 Homo sapiens 81-85 14974365-12 2003 Expression of CD25, CD152 molecule was significantly lower in group A than in group B. Immunosuppression regiment with low CyA dose with daclizumab, MMF, prednisone seems to be efficient and safe in low-risk rejection kidney allograft recipients. Prednisone 154-164 interleukin 2 receptor subunit alpha Homo sapiens 14-18 12895215-0 2003 The mechanisms of prednisone inhibition of inflammation in Crohn"s disease involve changes in intestinal permeability, mucosal TNFalpha production and nuclear factor kappa B expression. Prednisone 18-28 tumor necrosis factor Homo sapiens 127-135 14581895-1 2003 BACKGROUND: Six to eight cycles of CHOP therapy (cyclophosphamide, doxorubicin, vincristine, and prednisone) is standard for intermediate-grade non-Hodgkin"s lymphoma (NHL) but is associated with toxicity that may cause premature termination of therapy. Prednisone 97-107 DNA damage inducible transcript 3 Homo sapiens 35-39 12915593-1 2003 PURPOSE: To investigate whether the relative dose-intensity of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy could be improved by prophylactic administration of granulocyte colony-stimulating factor (G-CSF) in elderly patients with aggressive non-Hodgkin"s lymphoma (NHL). Prednisone 111-121 DNA damage inducible transcript 3 Homo sapiens 123-127 12915593-1 2003 PURPOSE: To investigate whether the relative dose-intensity of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy could be improved by prophylactic administration of granulocyte colony-stimulating factor (G-CSF) in elderly patients with aggressive non-Hodgkin"s lymphoma (NHL). Prednisone 111-121 colony stimulating factor 3 Homo sapiens 194-231 12902896-4 2003 We report a patient with lymphoma refractory to treatment with cyclophosphamide, vincristine, and prednisone, who was successfully treated with rituximab, a CD-20 monoclonal antibody. Prednisone 98-108 keratin 20 Homo sapiens 157-162 12764549-9 2003 Cyclophosphamide, hydroxydaunomycin, vincristine, and prednisone (CHOP)-like chemotherapy with or without local irradiation led to 17% relapses in patients with localized aggressive lymphoma. Prednisone 54-64 DNA damage inducible transcript 3 Homo sapiens 66-70 12869029-0 2003 Combined cyclosporin-A /prednisone therapy of patients with active uveitis suppresses IFN-gamma production and the function of dendritic cells. Prednisone 24-34 interferon gamma Homo sapiens 86-95 12802638-2 2003 The expression of GCR in the lymphocytes (CD3/GCR) and monocytes (CD14/GCR) of peripheral blood of 23 (age 4.9+/-2.7 years) children with steroid-sensitive nephrotic syndrome was assessed before treatment (proteinuria >50 mg/kg per 24 h), after 4-6 weeks of prednisone treatment, without proteinuria, and in remission, without proteinuria and without any treatment. Prednisone 261-271 nuclear receptor subfamily 3 group C member 1 Homo sapiens 18-21 12802638-7 2003 In summary, we report that in children with steroid-sensitive nephrotic syndrome, prednisone treatment causes the temporary decrease of the expression of GCR in lymphocytes. Prednisone 82-92 nuclear receptor subfamily 3 group C member 1 Homo sapiens 154-157 12792130-11 2003 The median time to reach the lowest maintenance dose of prednisone at which the ESR and CRP stayed low and stable was 48.7 months (95% CI: 34.6, 71.4 months), and the median lowest prednisone dose achieved was 7 mg/day (interquartile range of 1-16 mg/day). Prednisone 56-66 C-reactive protein Homo sapiens 88-91 12956443-10 2003 In this study, the t(11;16) was seen in 2 patients with previous lymphomas treated with cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP). Prednisone 136-146 DNA damage inducible transcript 3 Homo sapiens 148-152 12531794-1 2003 This study was designed to test the hypothesis that administration of granulocyte colony-stimulating factor (G-CSF; filgrastim) during induction chemotherapy with CHOP (cyclophosphamide, vincristine, doxorubicin, prednisone) or CNOP (doxorubicin replaced with mitoxantrone) in elderly patients with aggressive non-Hodgkin lymphoma (NHL) improves time to treatment failure (TTF), complete remission (CR) rate, and overall survival (OS). Prednisone 213-223 colony stimulating factor 3 Homo sapiens 70-107 12829664-1 2003 PURPOSE: To test the hypothesis that therapy of intermediate- and high-grade (excluding Burkitt lymphoblastic) lymphoma with cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) could be safely dose-intensified with routine filgrastim support. Prednisone 173-183 DNA damage inducible transcript 3 Homo sapiens 185-189 14653077-5 2003 The CR rate and 5-year survival rate of patients who were treated by the scheme of doxorubicin, cyclophosphamide, vincristine and prednisone (CHOP) were higher than those treated by the scheme of cyclophosphamide, vincristine, prednisone and etoposide (COP + VP16) (P < 0.05). Prednisone 130-140 DNA damage inducible transcript 3 Homo sapiens 142-146 14653077-5 2003 The CR rate and 5-year survival rate of patients who were treated by the scheme of doxorubicin, cyclophosphamide, vincristine and prednisone (CHOP) were higher than those treated by the scheme of cyclophosphamide, vincristine, prednisone and etoposide (COP + VP16) (P < 0.05). Prednisone 130-140 caspase recruitment domain family member 16 Homo sapiens 253-256 14653077-5 2003 The CR rate and 5-year survival rate of patients who were treated by the scheme of doxorubicin, cyclophosphamide, vincristine and prednisone (CHOP) were higher than those treated by the scheme of cyclophosphamide, vincristine, prednisone and etoposide (COP + VP16) (P < 0.05). Prednisone 227-237 DNA damage inducible transcript 3 Homo sapiens 142-146 12531794-1 2003 This study was designed to test the hypothesis that administration of granulocyte colony-stimulating factor (G-CSF; filgrastim) during induction chemotherapy with CHOP (cyclophosphamide, vincristine, doxorubicin, prednisone) or CNOP (doxorubicin replaced with mitoxantrone) in elderly patients with aggressive non-Hodgkin lymphoma (NHL) improves time to treatment failure (TTF), complete remission (CR) rate, and overall survival (OS). Prednisone 213-223 colony stimulating factor 3 Homo sapiens 109-114 12720535-7 2003 At baseline, the mean serum OPG was higher in patients receiving 5-10 mg/day prednisone (82.8+/-4.0 pg/ml, n=16) compared with those receiving <5 mg/day or with no prednisone (69.7+/-4.7 pg/ml, n=23) (P=0.05). Prednisone 77-87 TNF receptor superfamily member 11b Homo sapiens 28-31 12707721-2 2003 During pregnancy chemotherapy with cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) stabilized the disease for 4 months before new manifestations appeared. Prednisone 83-93 DNA damage inducible transcript 3 Homo sapiens 95-99 12720535-7 2003 At baseline, the mean serum OPG was higher in patients receiving 5-10 mg/day prednisone (82.8+/-4.0 pg/ml, n=16) compared with those receiving <5 mg/day or with no prednisone (69.7+/-4.7 pg/ml, n=23) (P=0.05). Prednisone 167-177 TNF receptor superfamily member 11b Homo sapiens 28-31 12792354-10 2003 The prednisone treatment group had a marked increase in the median CD4 cell count in the first 2 weeks, which stabilized at a level similar to that in the nonprednisone treatment group. Prednisone 4-14 CD4 molecule Homo sapiens 67-70 12698082-12 2003 CONCLUSIONS: ABO-incompatible living donor kidney transplants can achieve an acceptable 1-year graft survival rate using an immunosuppressive regimen consisting of Thymoglobulin induction, tacrolimus, mycophenolate mofetil, and prednisone combined with pretransplant plasmapheresis, intravenous immunoglobulin, and splenectomy. Prednisone 228-238 ABO, alpha 1-3-N-acetylgalactosaminyltransferase and alpha 1-3-galactosyltransferase Homo sapiens 13-16 12672196-6 2003 Normal ESR, CRP, and IL-6 levels persisted after the suspension of infliximab and prednisone during the followup period, paralleling the clinical remission. Prednisone 82-92 interleukin 6 Homo sapiens 21-25 12722970-4 2003 RESULTS: The patient"s serum showed elevation of transforming growth factor beta1 and interleukin-5, which improved after treatment with low-dose prednisone. Prednisone 146-156 transforming growth factor beta 1 Homo sapiens 49-81 12722970-4 2003 RESULTS: The patient"s serum showed elevation of transforming growth factor beta1 and interleukin-5, which improved after treatment with low-dose prednisone. Prednisone 146-156 interleukin 5 Homo sapiens 86-99 12747278-0 2003 Glucocorticoid receptor up-regulation in early rheumatoid arthritis treated with low dose prednisone or placebo. Prednisone 90-100 nuclear receptor subfamily 3 group C member 1 Homo sapiens 0-23 12626887-0 2003 A study of the immunology, virology, and safety of prednisone in HIV-1-infected subjects with CD4 cell counts of 200 to 700 mm(-3). Prednisone 51-61 CD4 molecule Homo sapiens 94-97 12626887-4 2003 Prednisone inhibited monocyte TNFalpha production without affecting T-cell responses to antigens or mitogens. Prednisone 0-10 tumor necrosis factor Homo sapiens 30-38 12773967-6 2003 The IL-2R mAbs have been used with a variety of maintenance immunosuppression regimens double therapy with cyclosporine and prednisone, triple therapy with cyclosporine, azathioprine and prednisone and with newer regimens such as cyclosporine or tacrolimus, mycophenolate mofetil (MMF) and prednisone, and most recently with sirolimus, MMF and prednisone. Prednisone 124-134 interleukin 2 receptor subunit alpha Homo sapiens 4-9 12773967-6 2003 The IL-2R mAbs have been used with a variety of maintenance immunosuppression regimens double therapy with cyclosporine and prednisone, triple therapy with cyclosporine, azathioprine and prednisone and with newer regimens such as cyclosporine or tacrolimus, mycophenolate mofetil (MMF) and prednisone, and most recently with sirolimus, MMF and prednisone. Prednisone 187-197 interleukin 2 receptor subunit alpha Homo sapiens 4-9 12773967-6 2003 The IL-2R mAbs have been used with a variety of maintenance immunosuppression regimens double therapy with cyclosporine and prednisone, triple therapy with cyclosporine, azathioprine and prednisone and with newer regimens such as cyclosporine or tacrolimus, mycophenolate mofetil (MMF) and prednisone, and most recently with sirolimus, MMF and prednisone. Prednisone 187-197 interleukin 2 receptor subunit alpha Homo sapiens 4-9 12773967-6 2003 The IL-2R mAbs have been used with a variety of maintenance immunosuppression regimens double therapy with cyclosporine and prednisone, triple therapy with cyclosporine, azathioprine and prednisone and with newer regimens such as cyclosporine or tacrolimus, mycophenolate mofetil (MMF) and prednisone, and most recently with sirolimus, MMF and prednisone. Prednisone 187-197 interleukin 2 receptor subunit alpha Homo sapiens 4-9 12601496-4 2003 Immunosuppression was discontinued and chemotherapy with cyclophosphamide, hydroxydaunomycin, vincristine, and prednisone (CHOP) was started. Prednisone 111-121 DNA damage inducible transcript 3 Homo sapiens 123-127 12760267-6 2003 The lesions of the bladder and left urinary tract were nearly completely regressed after two cycles of systemic cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) chemotherapy with simultaneous restoration of urinary function. Prednisone 159-169 DNA damage inducible transcript 3 Homo sapiens 171-175 12747278-2 2003 The glucocorticoid receptor (GR) number in peripheral mononuclear cells (PBMC) might be helpful to predict which patients will respond to low or medium dose prednisone and therefore do not or will not need higher doses. Prednisone 157-167 nuclear receptor subfamily 3 group C member 1 Homo sapiens 4-27 12747278-2 2003 The glucocorticoid receptor (GR) number in peripheral mononuclear cells (PBMC) might be helpful to predict which patients will respond to low or medium dose prednisone and therefore do not or will not need higher doses. Prednisone 157-167 nuclear receptor subfamily 3 group C member 1 Homo sapiens 29-31 12747278-8 2003 RESULTS: In females the GR number was up-regulated over time in both the prednisone and the placebo group. Prednisone 73-83 nuclear receptor subfamily 3 group C member 1 Homo sapiens 24-26 14988743-10 2003 Impressive results have been seen in combination with CHOP chemotherapy (cyclophosphamide, doxorubicin, vincristine and prednisone) in follicular and high-grade lymphomas. Prednisone 120-130 DNA damage inducible transcript 3 Homo sapiens 54-58 12542495-10 2003 In addition, G-CSF administration to five lymphoma patients after consecutive courses of CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone) chemotherapy, resulted in telomere length preservation or elongation, as opposed to marked attrition in patients who did not receive growth factors. Prednisone 139-149 colony stimulating factor 3 Homo sapiens 13-18 12757659-6 2003 (2) Serum level of IL-13 in asthma attack group was significantly higher than that in asthma remission group (P < 0.01); both were significantly higher than that in normal control group (P < 0.01); in asthma attack group IL-13 level after prednisone treatment was significantly lower than that before treatment (P < 0.01). Prednisone 245-255 interleukin 13 Homo sapiens 19-24 12421593-3 2003 Among the substances tested, the glucocorticoids prednisone, hydrocortisone, dexamethasone and progesterone as well as transforming growth factor-beta (TGF-beta) dose-dependently inhibited LPS-induced nitric oxide synthase (iNOS) and NO synthesis. Prednisone 49-59 nitric oxide synthase 2 Rattus norvegicus 189-222 12421593-3 2003 Among the substances tested, the glucocorticoids prednisone, hydrocortisone, dexamethasone and progesterone as well as transforming growth factor-beta (TGF-beta) dose-dependently inhibited LPS-induced nitric oxide synthase (iNOS) and NO synthesis. Prednisone 49-59 nitric oxide synthase 2 Rattus norvegicus 224-228 12872149-12 2003 CIB was relatively well tolerated although febrile neutropenia or septicaemia occurred in 5% of the cycles and a dose-reduction of cyclophosphamide due to grade IV neutropenia was performed in 11% of the patients.CIB seems to be an effective regimen for remission induction in MM patients aged up to 75 years as an alternative to VAD (vincristine, doxorubicin, dexamethasone) if a regimen with intensity higher than that of oral melphalan/prednisone is warranted. Prednisone 439-449 calcium and integrin binding 1 Homo sapiens 0-3 12469194-0 2003 Determination of the in vivo effects of prednisone on Bcl-2 family protein expression in childhood acute lymphoblastic leukemia. Prednisone 40-50 BCL2 apoptosis regulator Homo sapiens 54-59 12469194-2 2003 In 30 consecutive children with ALL treated with prednisone we determined changes in the expression of Bcl-2, Bax and Bcl-xl proteins in leukemic lymphoblasts and related these to clinical features and rate of prednisone-induced apoptosis. Prednisone 49-59 BCL2 apoptosis regulator Homo sapiens 103-108 12469194-2 2003 In 30 consecutive children with ALL treated with prednisone we determined changes in the expression of Bcl-2, Bax and Bcl-xl proteins in leukemic lymphoblasts and related these to clinical features and rate of prednisone-induced apoptosis. Prednisone 49-59 BCL2 associated X, apoptosis regulator Homo sapiens 110-113 12469194-2 2003 In 30 consecutive children with ALL treated with prednisone we determined changes in the expression of Bcl-2, Bax and Bcl-xl proteins in leukemic lymphoblasts and related these to clinical features and rate of prednisone-induced apoptosis. Prednisone 49-59 BCL2 like 1 Homo sapiens 118-124 12469194-2 2003 In 30 consecutive children with ALL treated with prednisone we determined changes in the expression of Bcl-2, Bax and Bcl-xl proteins in leukemic lymphoblasts and related these to clinical features and rate of prednisone-induced apoptosis. Prednisone 210-220 BCL2 apoptosis regulator Homo sapiens 103-108 12469194-2 2003 In 30 consecutive children with ALL treated with prednisone we determined changes in the expression of Bcl-2, Bax and Bcl-xl proteins in leukemic lymphoblasts and related these to clinical features and rate of prednisone-induced apoptosis. Prednisone 210-220 BCL2 like 1 Homo sapiens 118-124 12469194-5 2003 Prednisone treatment induced a decrease in Bcl-2 and Bcl-xl levels in 17 and 16 of the 28 patients, respectively, while Bax protein increased in 14 of the 21 patients. Prednisone 0-10 BCL2 apoptosis regulator Homo sapiens 43-48 12469194-5 2003 Prednisone treatment induced a decrease in Bcl-2 and Bcl-xl levels in 17 and 16 of the 28 patients, respectively, while Bax protein increased in 14 of the 21 patients. Prednisone 0-10 BCL2 like 1 Homo sapiens 53-59 12466373-10 2002 Reduction by 11beta-HSD1 is diminished by 16alpha-methyl, 16beta-methyl, 2alpha-methyl, and 2-chlor substitution, whereas it is increased by the Delta(1)-dehydro configuration in prednisone, resulting in higher hepatic first pass activation of prednisone compared with cortisone. Prednisone 179-189 hydroxysteroid 11-beta dehydrogenase 1 Homo sapiens 13-24 12475452-8 2002 CONCLUSIONS: In patients with persistently high CRP levels after successful coronary artery stent implantation, oral immunosuppressive therapy with prednisone results in a striking reduction of clinical events and angiographic restenosis rate. Prednisone 148-158 C-reactive protein Homo sapiens 48-51 12466373-10 2002 Reduction by 11beta-HSD1 is diminished by 16alpha-methyl, 16beta-methyl, 2alpha-methyl, and 2-chlor substitution, whereas it is increased by the Delta(1)-dehydro configuration in prednisone, resulting in higher hepatic first pass activation of prednisone compared with cortisone. Prednisone 244-254 hydroxysteroid 11-beta dehydrogenase 1 Homo sapiens 13-24 12467780-4 2002 STUDY DESIGN: Twelve patients with a history of childhood malignancy and chronic hepatitis B were treated with prednisone for 4 weeks (0.6 mg/kg body weight per day orally for 3 weeks followed by 0.3 mg/kg body weight per day for 1 week) followed by IFN-alpha-2a (5 megaunits/m(2) body surface area, three times a week, subcutaneously) at least for 1 year. Prednisone 111-121 interferon alpha 1 Homo sapiens 250-259 12710585-5 2002 The most significant of these strategies is the combination of rituximab and CHOP chemotherapy (cyclophosphamide, doxorubicin, vincristine and prednisone), which is proving a highly effective combination in the treatment of NHL. Prednisone 143-153 DNA damage inducible transcript 3 Homo sapiens 77-81 12441935-8 2002 More patients (27 or 48%) treated with mitoxantrone and prednisone achieved a 50% or greater reduction in prostate specific antigen levels than those who received only prednisone (15 or 24%, p = 0.007). Prednisone 56-66 kallikrein related peptidase 3 Homo sapiens 106-131 12441935-11 2002 CONCLUSIONS: Patients with hormone refractory prostate cancer who are asymptomatic but had progressive disease had a significantly higher response rate when treated with mitoxantrone and prednisone as demonstrated by the 50% or greater decrease in prostate specific antigen compared to treatment with prednisone alone. Prednisone 187-197 kallikrein related peptidase 3 Homo sapiens 248-273 12493413-0 2002 Low-dose prednisone accounts for a transient reduction on CD4+ and CD8+ T cells in renal transplant patients under triple therapy. Prednisone 9-19 CD4 molecule Homo sapiens 58-61 12493413-0 2002 Low-dose prednisone accounts for a transient reduction on CD4+ and CD8+ T cells in renal transplant patients under triple therapy. Prednisone 9-19 CD8a molecule Homo sapiens 67-70 12710590-1 2002 The standard therapy for patients with aggressive lymphoma is cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) chemotherapy, which achieves a complete response in more than 60% of patients but is curative in only about 40-50%. Prednisone 109-119 DNA damage inducible transcript 3 Homo sapiens 121-125 12171158-8 2002 CONCLUSIONS AND CLINICAL RELEVANCE: Synthesis of ALP is increased in the liver, kidneys, and intestinal mucosa of dogs in response to prednisone treatment. Prednisone 134-144 alkaline phosphatase, biomineralization associated Canis lupus familiaris 49-52 12222701-3 2002 If this disease could be diagnosed earlier, therapy with chlorpropamide, doxorubicin, vincristine and prednisone (CHOP) could bring about a remission (2,3,4). Prednisone 102-112 DNA damage inducible transcript 3 Homo sapiens 114-118 12428241-14 2002 Predictors of SRC identified in this study included higher than average skin score, prednisone use at study entry, large joint contractures, and heart enlargement. Prednisone 84-94 SRC proto-oncogene, non-receptor tyrosine kinase Homo sapiens 14-17 12667341-4 2002 Prednisone was taken orally on D1-5 at a dose of 60 mg/m(2). Prednisone 0-10 leiomodin 1 Homo sapiens 31-35 12220475-10 2002 The serum ECP levels decreased to a greater extent in the responder patient group than in the non-responder patients following prednisone treatment. Prednisone 127-137 ribonuclease A family member 3 Homo sapiens 10-13 12436180-5 2002 Treatment with prednisone and/or cyclophosphamide controlled mucocutaneous and nail manifestations in all cases. Prednisone 15-25 CD244 molecule Homo sapiens 79-83 12145682-0 2002 Association of initial response to prednisone treatment in childhood acute lymphoblastic leukaemia and polymorphisms within the tumour necrosis factor and the interleukin-10 genes. Prednisone 35-45 interleukin 10 Homo sapiens 159-173 12176789-1 2002 BACKGROUND: Recent data suggest that chemotherapy with the cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) regimen is a highly effective treatment for localised primary gastric lymphoma of diffuse large B-cell histology (DLBCL). Prednisone 106-116 DNA damage inducible transcript 3 Homo sapiens 118-122 12145682-4 2002 Our data showed a protective effect from prednisone poor response in patients with the IL-10 G/G genotype, whereas no association of the risk of relapse and IL-10 genotype was found. Prednisone 41-51 interleukin 10 Homo sapiens 87-92 12270059-23 2002 In conclusion, 2-CdA applied in monotherapy or in combination with prednisone or cyclophosphamide and mitoxantrone has therapeutic activity in some B-CLL patients in whom these drugs induced earlier complete or partial remission. Prednisone 67-77 cytidine deaminase Homo sapiens 17-20 12102473-2 2002 OBJECTIVE: To evaluate the ability of two different combination therapies with prednisone (PDN), methotrexate (MTX) and cyclosporine (CSA) to modulate both TNFalpha transcription and production in early rheumatoid arthritis (RA). Prednisone 79-89 tumor necrosis factor Homo sapiens 156-164 12194635-6 2002 Prednisone intake was associated with a significant increase in minute ventilation during breathing with no inspiratory loads (Pred = 11.91 +/- 1.28 l/min- x Plac = 9.95 +/- 0.86 l/min). Prednisone 0-10 placenta associated 9 Homo sapiens 158-166 12054173-7 2002 The capacity of 11beta-HSD1 to metabolize the synthetic glucocorticoids prednisone and prednisolone was investigated in human OBs (hOBs) and fetal kidney-293 cells stably transfected with human 11beta-HSD1 cDNA. Prednisone 72-82 hydroxysteroid 11-beta dehydrogenase 1 Homo sapiens 16-27 12044978-12 2002 This work shows that complement insufficiency and weekly prednisone prolong survival and improve strength of the laminin alpha2-deficient mouse. Prednisone 57-67 laminin, alpha 2 Mus musculus 113-127 12102473-2 2002 OBJECTIVE: To evaluate the ability of two different combination therapies with prednisone (PDN), methotrexate (MTX) and cyclosporine (CSA) to modulate both TNFalpha transcription and production in early rheumatoid arthritis (RA). Prednisone 91-94 tumor necrosis factor Homo sapiens 156-164 11921026-0 2002 Acquired factor VIII inhibitor treated with cyclophosphamide, vincristine, and prednisone. Prednisone 79-89 cytochrome c oxidase subunit 8A Homo sapiens 16-20 11870171-1 2002 PURPOSE: To evaluate the efficacy of rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) induction therapy in patients with newly diagnosed mantle-cell lymphoma (MCL). Prednisone 99-109 DNA damage inducible transcript 3 Homo sapiens 111-115 11807147-1 2002 BACKGROUND: The standard treatment for patients with diffuse large-B-cell lymphoma is cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP). Prednisone 134-144 DNA damage inducible transcript 3 Homo sapiens 146-150 11792410-1 2002 Mitoxantrone, etoposide and prednisone (MEP)-based regimens using granulocyte colony-stimulating factor (G-CSF) were designed for relapsed and CHOP-resistant diffuse large B-cell lymphomas in a single institution, and the therapeutic effects and adverse reactions were studied. Prednisone 28-38 colony stimulating factor 3 Homo sapiens 66-103 11792410-1 2002 Mitoxantrone, etoposide and prednisone (MEP)-based regimens using granulocyte colony-stimulating factor (G-CSF) were designed for relapsed and CHOP-resistant diffuse large B-cell lymphomas in a single institution, and the therapeutic effects and adverse reactions were studied. Prednisone 28-38 colony stimulating factor 3 Homo sapiens 105-110 11792410-1 2002 Mitoxantrone, etoposide and prednisone (MEP)-based regimens using granulocyte colony-stimulating factor (G-CSF) were designed for relapsed and CHOP-resistant diffuse large B-cell lymphomas in a single institution, and the therapeutic effects and adverse reactions were studied. Prednisone 28-38 DNA damage inducible transcript 3 Homo sapiens 143-147 12221903-10 2002 In kidney transplant recipients there was a positive correlation between the dose of prednisone and PAI-I activity in plasma (p = 0.01) and an association between BMI value and plasma PAI-I activity (p = 0.008), as well as an association between BMI value and plasma tPA-Ant concentration (p = 0.006). Prednisone 85-95 serpin family E member 1 Homo sapiens 100-103 12221903-13 2002 In patients with chronic graft rejection we found a negative correlation between the dose of prednisone and uPA-Ant plasma level (p = 0.004). Prednisone 93-103 proline rich acidic protein 1 Homo sapiens 108-111 12221903-13 2002 In patients with chronic graft rejection we found a negative correlation between the dose of prednisone and uPA-Ant plasma level (p = 0.004). Prednisone 93-103 solute carrier family 25 member 6 Homo sapiens 112-115 12221903-18 2002 The results of our study suggest a stimulatory effect of CsA on tPA and PAI-I plasma activities as well as on uPA-Ant concentration, while prednisone in turn seems to enhance PAI-I activity in plasma and decrease uPA expression. Prednisone 139-149 serpin family E member 1 Homo sapiens 175-178 12221903-18 2002 The results of our study suggest a stimulatory effect of CsA on tPA and PAI-I plasma activities as well as on uPA-Ant concentration, while prednisone in turn seems to enhance PAI-I activity in plasma and decrease uPA expression. Prednisone 139-149 proline rich acidic protein 1 Homo sapiens 213-216 12479593-3 2002 The gold standard for primary treatment of aggressive NHL is combination chemotherapy with cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP). Prednisone 138-148 DNA damage inducible transcript 3 Homo sapiens 150-154 12479594-9 2002 Beneficial responses to granulocyte colony-stimulating factor (G-CSF; filgrastim) in elderly patients have been found in aggressive non-Hodgkin"s lymphoma with standard cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) therapy and acute myeloid leukaemia (AML) during induction and consolidation chemotherapy. Prednisone 216-226 colony stimulating factor 3 Homo sapiens 24-61 12479594-9 2002 Beneficial responses to granulocyte colony-stimulating factor (G-CSF; filgrastim) in elderly patients have been found in aggressive non-Hodgkin"s lymphoma with standard cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) therapy and acute myeloid leukaemia (AML) during induction and consolidation chemotherapy. Prednisone 216-226 colony stimulating factor 3 Homo sapiens 63-68 11602850-1 2001 BACKGROUND: Sirolimus (Rapamune, rapamycin, RAPA) is a potent immunosuppressive drug that has reduced the rate of acute rejection episodes by more than 40% in phase III trials when added to an immunosuppression regimen of cyclosporine (CsA) and prednisone. Prednisone 245-255 transcriptional regulating factor 1 Homo sapiens 44-48 12884561-8 2002 The highest sputum ECP concentration was determined in exacerbation of asthma 84.5 +/- 78 mcg/L and statistically were reduced after 2-weeks of prednisone treatment 24.4 +/- 12.1 mcg/L (p = 0.05). Prednisone 144-154 ribonuclease A family member 3 Homo sapiens 19-22 12884561-15 2002 In consequence of prednisone treatment the sputum ECP concentration was reduced. Prednisone 18-28 ribonuclease A family member 3 Homo sapiens 50-53 12091638-20 2002 The CHOP regimen is cyclophosphamide, doxorubicine, vincristine and prednisone. Prednisone 68-78 DNA damage inducible transcript 3 Homo sapiens 4-8 11762410-5 2001 High intensity chemotherapy consisting of the anthracycline, doxorubicin along with cyclophosphamide, vincristine and prednisone (CHOP) is offered as standard treatment for intermediate-grade NHL. Prednisone 118-128 DNA damage inducible transcript 3 Homo sapiens 130-134 12102262-3 2001 To obviate these problems, we studied outcome of a protocol of rapid discontinuation of prednisone (RDS) (steroids stopped on POD6). Prednisone 88-98 peripherin 2 Homo sapiens 100-103 11642646-5 2001 Low doses of glucocorticoids (prednisone or prednisolone) accomplish everything NSAIDs or COX-2 inhibitors accomplish but with more antiinflammatory effects, fewer side effects, and much less expense. Prednisone 30-40 mitochondrially encoded cytochrome c oxidase II Homo sapiens 90-95 11642646-6 2001 It is certainly possible (but not precisely tested) that low doses of prednisone (prednisolone) enhance the effects of other DMARDs, including anti-TNF agents. Prednisone 70-80 tumor necrosis factor Homo sapiens 148-151 11578685-10 2001 After MP treatment in corticosteroid-responsive patients (improvement in CAS < or =1) serum concentration of L-selectin and ICAM-1 decreased significantly and gradually increased during subsequent treatment with prednisone. Prednisone 215-225 selectin L Homo sapiens 112-122 11578685-10 2001 After MP treatment in corticosteroid-responsive patients (improvement in CAS < or =1) serum concentration of L-selectin and ICAM-1 decreased significantly and gradually increased during subsequent treatment with prednisone. Prednisone 215-225 intercellular adhesion molecule 1 Homo sapiens 127-133 11878573-3 2001 Prednisone good response was defined as a blast count of less than 1,000/microL and a prednisone poor response (PPR) as a blast count of at least 1,000/microL, both in peripheral smears, after 7 days of oral prednisone (60 mg/m2 per day) and one intrathecal dose of methotrexate. Prednisone 86-96 PPR1 Homo sapiens 112-115 11878581-1 2001 PURPOSE: The authors report the use of a cyclophosphamide, hydroxydaunorubicin, vincristine, and prednisone (CHOP)-based chemotherapy regimen in treating six children with posttransplantation lymphoproliferative disorder (PTLD) that developed after solid organ transplantation. Prednisone 97-107 DNA damage inducible transcript 3 Homo sapiens 109-113 11680327-10 2001 CONCLUSION: Early "high-dose" IS therapy using azathioprine and prednisone in GMG resulted in a significant increase in the number of patients in remission and reduced morbidity at 1 and 2 years. Prednisone 64-74 angiotensin II receptor type 1 Homo sapiens 178-188 11508932-3 2001 A study of rituximab plus cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) chemoimmunotherapy has been carried out in 40 patients with low-grade NHL. Prednisone 73-83 DNA damage inducible transcript 3 Homo sapiens 85-89 11470053-7 2001 Thus, MRI and P-31 MRS are useful in assessing the status of patients with inflammatory myopathies during treatment with prednisone and immunosuppressive drugs. Prednisone 121-131 ATPase H+ transporting V1 subunit E1 Homo sapiens 14-18 11584710-9 2001 Standard treatment of advanced aggressive NHL is polychemotherapy with cyclophosphamide, adriamycin, vincristine and prednisone (CHOP). Prednisone 117-127 DNA damage inducible transcript 3 Homo sapiens 129-133 11466671-1 2001 BACKGROUND: To address the feasibility and outcome of moderate dose intensification with granulocyte-colony stimulating factor (G-CSF) for patients with aggressive non-Hodgkin lymphoma (NHL), the Cancer and Leukemia Group B (CALGB) conducted two studies evaluating dose-escalated cyclophosphamide and etoposide in the cyclophosphamide, doxorubicin, vincristine, prednisone, etoposide (CHOPE) regimen. Prednisone 362-372 colony stimulating factor 3 Homo sapiens 128-133 11447379-6 2001 Prednisone inhibited (median decrease, 66%-97%) the total influx of inflammatory cells, specifically eosinophils, basophils, and some subsets of T lymphocytes (CD4, CD45RA, and CD45RO cells) assessed 19 hours after SAC, but it did not inhibit the influx of neutrophils. Prednisone 0-10 CD4 molecule Homo sapiens 160-163 11447379-8 2001 Prednisone treatment inhibited the appearance of mRNA, protein, or both for T(H)2 cytokines (IL-4 and IL-5), as well as for IL-2 and transforming growth factor alpha, but did not inhibit increases of immunoreactive GM-CSF in bronchoalveolar lavage fluid. Prednisone 0-10 interleukin 4 Homo sapiens 93-97 11447379-8 2001 Prednisone treatment inhibited the appearance of mRNA, protein, or both for T(H)2 cytokines (IL-4 and IL-5), as well as for IL-2 and transforming growth factor alpha, but did not inhibit increases of immunoreactive GM-CSF in bronchoalveolar lavage fluid. Prednisone 0-10 interleukin 5 Homo sapiens 102-106 11447379-8 2001 Prednisone treatment inhibited the appearance of mRNA, protein, or both for T(H)2 cytokines (IL-4 and IL-5), as well as for IL-2 and transforming growth factor alpha, but did not inhibit increases of immunoreactive GM-CSF in bronchoalveolar lavage fluid. Prednisone 0-10 interleukin 2 Homo sapiens 124-128 11447379-8 2001 Prednisone treatment inhibited the appearance of mRNA, protein, or both for T(H)2 cytokines (IL-4 and IL-5), as well as for IL-2 and transforming growth factor alpha, but did not inhibit increases of immunoreactive GM-CSF in bronchoalveolar lavage fluid. Prednisone 0-10 tumor necrosis factor Homo sapiens 133-165 11269797-6 2001 Cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) therapy was given, and the patient became asymptomatic with normal blood tests and was thought to be in remission. Prednisone 48-58 DNA damage inducible transcript 3 Homo sapiens 60-64 11434171-0 2001 [Evaluation of prednisone treatment in children with IgA nephropathy and Schonlein-Henoch nephropathy according to the Waldo protocol with regard to pathomorphologic changes in renal biopsy]. Prednisone 15-25 IGAN1 Homo sapiens 53-68 11434171-11 2001 Long term alternate-day prednisone treatment according the protocol of Waldo allows to decrease haematuria and proteinuria in children with IgAN and HSN 2. Prednisone 24-34 IGAN1 Homo sapiens 140-144 11434171-11 2001 Long term alternate-day prednisone treatment according the protocol of Waldo allows to decrease haematuria and proteinuria in children with IgAN and HSN 2. Prednisone 24-34 WNK lysine deficient protein kinase 1 Homo sapiens 149-154 11304663-10 2001 In children treated with prednisone alone, a marked increase in plasma AT-III (by 76%, P < 0.001) and alpha 2-A (36%, P < 0.019) activity, and a significant decrease of the plasma fibrinogen concentration (6.07 +/- 1.66 vs. 3.17 +/- 1.64 g/L, P < 0.001), and APTT (45.1 +/- 7.6 vs. 33.8 +/- 4.4 s, P < 0.001) were found. Prednisone 25-35 serpin family C member 1 Homo sapiens 71-77 11304663-10 2001 In children treated with prednisone alone, a marked increase in plasma AT-III (by 76%, P < 0.001) and alpha 2-A (36%, P < 0.019) activity, and a significant decrease of the plasma fibrinogen concentration (6.07 +/- 1.66 vs. 3.17 +/- 1.64 g/L, P < 0.001), and APTT (45.1 +/- 7.6 vs. 33.8 +/- 4.4 s, P < 0.001) were found. Prednisone 25-35 serpin family F member 2 Homo sapiens 105-114 11304663-11 2001 Prednisone plus EACA therapy resulted in a significant increase in plasma AT-III activity (by 53%, P < 0.003), whereas plasma fibrinogen concentration and APTT remained unchanged. Prednisone 0-10 serpin family C member 1 Homo sapiens 74-80 11353432-1 2001 The purpose of this study was to assess the impact of prednisone treatment for 8 weeks on the level of transforming growth factor-beta 1 (TGF-beta1), hydroxyproline (HYP) concentrations, and level of the mature, nonreducible collagen cross-link hydroxylysylpyridinoline (HP) in diaphragm muscle from 12-week-old mdx mice. Prednisone 54-64 transforming growth factor, beta 1 Mus musculus 103-136 11353432-3 2001 Prednisone treatment significantly reduced the level of TGF-beta1 and HYP in diaphragm from mdx mice to values similar to control mice, but resulted in a higher level of the HP cross-link compared with untreated mdx mice. Prednisone 0-10 transforming growth factor, beta 1 Mus musculus 56-65 11353432-4 2001 These findings indicate that short-term treatment of mdx mice with prednisone can attenuate the fibrotic response in diaphragm muscle, possibly by mediating the level of TGF-beta. Prednisone 67-77 transforming growth factor, beta 1 Mus musculus 170-178 11426529-1 2001 UNLABELLED: Recent data from GELF (Groupe d"Etude des Lymphomes Folliculaires) have shown that the addition of interferon alfa-2b (IFN) to a doxorubicin-containing regimen (CHVP: cyclophosphamide, doxorubicin, teniposide and prednisone) prolongs both progression-free survival and overall survival in high-tumor-burden follicular non-Hodgkin"s lymphoma. Prednisone 225-235 interferon alpha 1 Homo sapiens 131-134 11230885-1 2001 BACKGROUND: A limited number cycles of cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) chemotherapy followed by involved field radiotherapy is the treatment of choice for Ann Arbor stage I intermediate or high grade non-Hodgkin"s lymphomas (NHL). Prednisone 86-96 DNA damage inducible transcript 3 Homo sapiens 98-102 11145094-1 2000 Four major double-blind randomized trials in kidney transplant patients have shown that the interleukin-2 receptor (IL-2R alpha) antagonists declizumab or basiliximab, when added to an immunosuppressive regimen consisting of cyclosporin and prednisone, reduce the incidence of acute rejections after kidney transplantation by 30-40%, during the first 6 months. Prednisone 241-251 interleukin 2 receptor subunit alpha Homo sapiens 116-127 11771778-7 2001 Daily prednisone doses higher than 5 mg were administered to 43% of the patients with elevated PRL, compared with 25% of patients with normal prolactin concentrations. Prednisone 6-16 prolactin Homo sapiens 95-98 11786679-10 2001 Studies in children on chronic prednisone doses with cystic fibrosis, chronic renal failure or juvenile rheumatoid arthritis have all shown beneficial effects on linear growth after prolonged GH therapy. Prednisone 31-41 growth hormone 1 Homo sapiens 192-194 11156256-0 2000 The addition of bryostatin 1 to cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy improves response in a CHOP-resistant human diffuse large cell lymphoma xenograft model. Prednisone 80-90 DNA damage inducible transcript 3 Homo sapiens 92-96 11156148-2 2000 Preoperative therapeutic interventions including prednisone and immunoglobulin were successful in elevating the platelet count to 93,000/ mm2. Prednisone 49-59 PNMA family member 2 Homo sapiens 138-141 11115481-3 2000 Thus, the purpose of this case report is to describe the effects of prolonged treatment with clarithromycin, 500 mg bid, in reducing prednisone requirements in three elderly patients with prednisone-dependent asthma. Prednisone 133-143 BH3 interacting domain death agonist Homo sapiens 116-119 11115481-3 2000 Thus, the purpose of this case report is to describe the effects of prolonged treatment with clarithromycin, 500 mg bid, in reducing prednisone requirements in three elderly patients with prednisone-dependent asthma. Prednisone 188-198 BH3 interacting domain death agonist Homo sapiens 116-119 11186134-5 2000 In univariate analysis, homozygous deletion of GSTT1 (null genotype) conferred a 6.7-fold reduction in risk of prednisone poor-response compared to individuals who were either heterozygous or homozygous for GSTT1 [odds ratio (OR) = 0.15, P = 0.071; multivariate odds ratio = 0.18, P = 0.117]. Prednisone 111-121 glutathione S-transferase theta 1 Homo sapiens 47-52 11101177-7 2000 Patients with acute IA on prednisone as well as IA patients in remission had a significantly higher percentage of CD 19+ CD23+ cells than normals. Prednisone 26-36 CD19 molecule Homo sapiens 114-119 11101177-7 2000 Patients with acute IA on prednisone as well as IA patients in remission had a significantly higher percentage of CD 19+ CD23+ cells than normals. Prednisone 26-36 Fc epsilon receptor II Homo sapiens 121-125 11146160-11 2000 When small daily doses of oral prednisone were then administered to the patient with conventional doses of subcutaneous G-CSF, the patient responded with increased neutrophil numbers and with a complete reversal of the infectious problems. Prednisone 31-41 colony stimulating factor 3 Homo sapiens 120-125 11048998-4 2000 IL-2 receptor antibodies have been shown to decrease rejection rates when added to a regimen of cyclosporine (CsA), azathioprine and prednisone. Prednisone 133-143 interleukin 2 receptor subunit beta Homo sapiens 0-13 11092996-6 2000 In the multiple regression test, a linear coincidence was observed between apo A1, apo B and prednisone cumulative dosage after the 1st month, TG and cyclosporine in the 6th month and LDL and cyclosporine in the 12th month after transplantation. Prednisone 93-103 apolipoprotein B Homo sapiens 83-88 10950051-9 2000 Alkaline phosphatase (mean: -23.4%; p = 0.03) and IgG (mean: -16.2%; p = 0.04) decreased in the prednisone group, whereas bilirubin, gamma-glutamyl transferase, aspartate aminotransferase, and alanine aminotransferase did not change significantly. Prednisone 96-106 glutamic--pyruvic transaminase Homo sapiens 193-217 10955857-13 2000 We recommend treating patients with aggressive NHL of the breast with cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy, followed by involved field radiation and treating those patients with indolent lymphoma with involved field radiation alone. Prednisone 118-128 DNA damage inducible transcript 3 Homo sapiens 130-134 10891465-6 2000 Furthermore, the extent of apoptosis inhibition by IL-7 in vitro quantitatively correlated with early cytoreduction as determined by the prednisone peripheral blood response on day 8 and cytoreduction in the marrow on day 15 (n = 87; P <.05). Prednisone 137-147 interleukin 7 Homo sapiens 51-55 10914843-8 2000 Among the 824 patients, those taking prednisone were more likely to have had previous DMARD, and at study entry had higher radiographic scores for joint erosion and joint space narrowing and slightly higher swollen joint counts, C-reactive protein values, and rheumatoid factor titers than those not taking prednisone. Prednisone 37-47 C-reactive protein Homo sapiens 229-247 10886146-1 2000 BACKGROUND: Erythrodermic cutaneous T-cell lymphomas (CTCL) including Sezary syndrome have been successfully treated with daily administration of chlorambucil and prednisone (Winkelmann regimen). Prednisone 163-173 TSPY like 2 Homo sapiens 54-58 10930993-5 2000 Good responders to initial prednisone therapy ("prednisone response") revealed significantly higher Bcl-2 expression levels [5.4 +/- 3.4 relative fluorescence intensity (RFI), n = 68] than poor responders (3.7 +/- 2.6 RFI, n = 42; P = 0.002). Prednisone 27-37 BCL2 apoptosis regulator Homo sapiens 100-105 10930993-5 2000 Good responders to initial prednisone therapy ("prednisone response") revealed significantly higher Bcl-2 expression levels [5.4 +/- 3.4 relative fluorescence intensity (RFI), n = 68] than poor responders (3.7 +/- 2.6 RFI, n = 42; P = 0.002). Prednisone 48-58 BCL2 apoptosis regulator Homo sapiens 100-105 11039311-10 2000 These are encouraging results from initial treatment of FSGS with CsA and small doses prednisone. Prednisone 86-96 actinin alpha 4 Homo sapiens 56-60 10942057-1 2000 BACKGROUND: Standard therapy for lymphoma consists of a cyclophosphamide (C), doxorubicin, vincristine (V), and prednisone (P) (CHOP) combination regimen. Prednisone 112-122 DNA damage inducible transcript 3 Homo sapiens 128-132 11002558-6 2000 After forty days of prednisone therapy in the dose mentioned above patient"s immunological status has evolution favorably: T CD4:TCD8 ratio decreased, percentage of B CD19+ and B CD19+5+ lymphocytes decreased, percentage of Natural Killer cells CD3(-)16/56+ decreased, the expression of CD25 and HLA-DR antigens on T CD4+ lymphocytes decreased. Prednisone 20-30 CD19 molecule Homo sapiens 167-171 11002558-6 2000 After forty days of prednisone therapy in the dose mentioned above patient"s immunological status has evolution favorably: T CD4:TCD8 ratio decreased, percentage of B CD19+ and B CD19+5+ lymphocytes decreased, percentage of Natural Killer cells CD3(-)16/56+ decreased, the expression of CD25 and HLA-DR antigens on T CD4+ lymphocytes decreased. Prednisone 20-30 CD19 molecule Homo sapiens 179-183 11002558-6 2000 After forty days of prednisone therapy in the dose mentioned above patient"s immunological status has evolution favorably: T CD4:TCD8 ratio decreased, percentage of B CD19+ and B CD19+5+ lymphocytes decreased, percentage of Natural Killer cells CD3(-)16/56+ decreased, the expression of CD25 and HLA-DR antigens on T CD4+ lymphocytes decreased. Prednisone 20-30 interleukin 2 receptor subunit alpha Homo sapiens 287-291 12515139-3 2000 The results showed the infiltration of cells was inhibited in the "Chinese herbs combined with prednisone" group, the infiltration of cells, TGF-beta expression and interstitial fibrosis were all inhibited in the cyclophosphamide and prednisone" group. Prednisone 95-105 transforming growth factor beta 1 Homo sapiens 141-149 10793033-5 2000 Therapy with oral prednisone and cyclophosphamide led to resolution of pulmonary hemorrhage and negativity of MPO-ANCA. Prednisone 18-28 myeloperoxidase Homo sapiens 110-113 10706056-2 2000 METHODS: Intracellular interleukin- (IL) 2 was measured in phorbol myristic acid-ionomycin-stimulated peripheral lymphocytes by flow cytometry, after isolation from 14 renal transplant recipients receiving CSA+prednisone, and double-blind rapamycin (rapamycin:placebo=4:1). Prednisone 210-220 interleukin 2 Homo sapiens 23-42 10784002-5 2000 (2) To evaluate the effect of ursodeoxycholic acid and prednisone alone and in combination on serum levels of interferon-gamma and soluble inter-cellular adhesion molecule-1. Prednisone 55-65 interferon gamma Homo sapiens 110-173 11723544-7 2000 In conclusion, post-conception IVIg treatment significantly improves reproductive outcome in women with elevated CD56+ NK cells with pregnancy who received preconception lymphocyte immunization, anticoagulation and prednisone treatment. Prednisone 215-225 neural cell adhesion molecule 1 Homo sapiens 113-117 10779036-1 2000 A girl with Diamond-Blackfan anemia diagnosed in infancy started cyclosporine A (CSA) therapy at 9 years and 8 months of age after experiencing unacceptable side effects while receiving prednisone. Prednisone 186-196 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 81-84 10884502-0 2000 The prednisone dosage in the CHOP chemotherapy regimen for non-Hodgkin"s lymphomas (NHL): is there a standard? Prednisone 4-14 DNA damage inducible transcript 3 Homo sapiens 29-33 10871150-1 2000 We have previously demonstrated a decrease in the incidence of acute graft-versus-host disease (GVHD) with the addition of methotrexate (MTX) to cyclosporine (CSP) and prednisone (PSE) chemotherapy in patients with leukemia. Prednisone 180-183 metaxin 1 Homo sapiens 137-140 10765644-4 2000 In 31 asthmatic patients (75.6%), after prednisone treatment, increased of PAI-1 activity together with platelet adhesion and aggregation were observed. Prednisone 40-50 serpin family E member 1 Homo sapiens 75-80 10765644-6 2000 These results suggest that in asthmatic patients after prednisone treatment raises PAI-1 activity, probability because of releasing of the increased amount of PAI-1 from activated platelet. Prednisone 55-65 serpin family E member 1 Homo sapiens 83-88 10765644-6 2000 These results suggest that in asthmatic patients after prednisone treatment raises PAI-1 activity, probability because of releasing of the increased amount of PAI-1 from activated platelet. Prednisone 55-65 serpin family E member 1 Homo sapiens 159-164 10701740-0 2000 Recovery of sperm production following radiation therapy for Hodgkin"s disease after induction chemotherapy with mitoxantrone, vincristine, vinblastine, and prednisone (NOVP). Prednisone 157-167 plexin A1 Homo sapiens 169-173 10618000-6 2000 Oral prednisone has also been advocated, especially in the treatment of children with IgA nephropathy. Prednisone 5-15 CD79a molecule Homo sapiens 86-89 11334052-3 2000 The aims of this study were to determine if the glucocorticosteroid, prednisone, affected the rate of dentine deposition and odontoblast expression of GHr in the rat molar. Prednisone 69-79 growth hormone receptor Rattus norvegicus 151-154 11334052-10 2000 However, odontoblasts and pulp cells were GHr immunoreactive in mature molars from animals treated with prednisone. Prednisone 104-114 growth hormone receptor Rattus norvegicus 42-45 10563431-4 1999 Conventional systemic lymphoma drug combinations such as cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) are ineffective. Prednisone 104-114 DNA damage inducible transcript 3 Homo sapiens 116-120 10523002-7 1999 After prednisone administration, reduction in TRAb was greater in patients with normal IgE than that in patients with IgE elevation. Prednisone 6-16 immunoglobulin heavy constant epsilon Homo sapiens 87-90 10523002-7 1999 After prednisone administration, reduction in TRAb was greater in patients with normal IgE than that in patients with IgE elevation. Prednisone 6-16 immunoglobulin heavy constant epsilon Homo sapiens 118-121 10360582-15 1999 Patients receiving prednisone tended to have greater biochemical signs of cholestasis, higher serum cholesterol and glucose levels, and more frequent insulin requirement than those treated without corticosteroids. Prednisone 19-29 insulin Homo sapiens 150-157 10612091-1 1999 Myelin basic protein CD 2 lymphocyte stimulation index calculated as the proportion of percentage of myelin basic protein stimulated CD 2 lymphocytes to unstimulated CD 2 lymphocytes was evaluated in a group of 23 multiple sclerosis patients in the course of prednisone or methylprednisolone treatment. Prednisone 259-269 myelin basic protein Homo sapiens 0-20 10389134-3 1999 This effect was associated with a greater decrease from baseline in CD3+ lymphocyte number at 4 h after prednisone ingestion (596 +/- 175 vs. 516 +/- 140, p = 0.05), a larger percentage decrease of circulating CD3+ lymphocytes at 8 h (43 +/- 19% vs. 53 +/- 19%, p = 0.04), and a decrease in the number of CD3+ CD8+ T cells at 4 h post-prednisone ingestion (279 +/- 81 vs. 236 +/- 51, p = 0.04). Prednisone 104-114 CD8a molecule Homo sapiens 310-313 10337858-0 1999 Preservation of growth hormone secretion in response to growth hormone-releasing peptide-2 during prednisone therapy. Prednisone 98-108 growth hormone 1 Homo sapiens 16-30 10337858-0 1999 Preservation of growth hormone secretion in response to growth hormone-releasing peptide-2 during prednisone therapy. Prednisone 98-108 growth hormone 1 Homo sapiens 56-70 10337858-9 1999 During prednisone therapy, the peak GH level in response to arginine and to GHRP-2 was 20.1 +/- 8.3 and 71.3 +/- 18.4 microg/L, respectively. Prednisone 7-17 growth hormone 1 Homo sapiens 36-38 10337858-11 1999 The time to the peak GH level during prednisone therapy occurred sooner for both arginine and GHRP-2. Prednisone 37-47 growth hormone 1 Homo sapiens 21-23 10375088-8 1999 The management of diffuse large B-cell lymphoma is combined-modality therapy with radiation and cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy. Prednisone 144-154 DNA damage inducible transcript 3 Homo sapiens 156-160 10438319-0 1999 Effects of short courses of different doses of prednisone and dexamethasone on serum third component of complement (C3) levels in dogs. Prednisone 47-57 complement C3 Canis lupus familiaris 104-118 9934814-5 1998 The patients reporting symptoms were less likely to be insulin resistant with longer time post-PTX, lower body mass index (BMI), and on lower doses of prednisone. Prednisone 151-161 insulin Homo sapiens 55-62 10071353-2 1999 This report describes the application of an immunosuppressive protocol (CNp) using MMF, me-CsA, and prednisone as primary immunosuppression for pediatric liver transplant recipients at the University of California at San Francisco. Prednisone 100-110 2',3'-cyclic nucleotide 3' phosphodiesterase Homo sapiens 72-75 10090131-0 1999 IGF-I levels rise and GH responses to GHRH decrease during long-term prednisone treatment in man. Prednisone 69-79 insulin like growth factor 1 Homo sapiens 0-5 10090131-0 1999 IGF-I levels rise and GH responses to GHRH decrease during long-term prednisone treatment in man. Prednisone 69-79 growth hormone releasing hormone Homo sapiens 38-42 10090131-13 1999 In summary, we observed a marked decrease in the GH response to GHRH after one week and one month of prednisone administration associated with an increase in circulating IGF-I and albumin values. Prednisone 101-111 growth hormone releasing hormone Homo sapiens 64-68 10090131-13 1999 In summary, we observed a marked decrease in the GH response to GHRH after one week and one month of prednisone administration associated with an increase in circulating IGF-I and albumin values. Prednisone 101-111 insulin like growth factor 1 Homo sapiens 170-175 10037207-4 1999 Patients received a three-day course of prednisone (50 mg BID) or placebo perioperatively. Prednisone 40-50 BH3 interacting domain death agonist Homo sapiens 58-61 9918329-9 1999 Prednisone and azathioprine-treated dogs had significant (P < 0.05) decreases in serum IgG levels and Thy-1+ and CD8+ lymphocyte subpopulations, with an increase in the CD4:CD8. Prednisone 0-10 Thy-1 cell surface antigen Canis lupus familiaris 105-110 9918329-9 1999 Prednisone and azathioprine-treated dogs had significant (P < 0.05) decreases in serum IgG levels and Thy-1+ and CD8+ lymphocyte subpopulations, with an increase in the CD4:CD8. Prednisone 0-10 T-cell surface glycoprotein CD4 Canis lupus familiaris 172-175 10836317-9 1999 Treatment with prednisone suppressed median sputum eosinophilia (from 16.3 to 0%, p<0.001), decreased sputum ECP (from 7,480 to 700 microg x L(-1), p = 0.01), but did not improve neutrophil numbers, fibrinogen or IL-5. Prednisone 15-25 ribonuclease A family member 3 Homo sapiens 112-115 10836317-9 1999 Treatment with prednisone suppressed median sputum eosinophilia (from 16.3 to 0%, p<0.001), decreased sputum ECP (from 7,480 to 700 microg x L(-1), p = 0.01), but did not improve neutrophil numbers, fibrinogen or IL-5. Prednisone 15-25 fibrinogen beta chain Homo sapiens 202-212 10836317-9 1999 Treatment with prednisone suppressed median sputum eosinophilia (from 16.3 to 0%, p<0.001), decreased sputum ECP (from 7,480 to 700 microg x L(-1), p = 0.01), but did not improve neutrophil numbers, fibrinogen or IL-5. Prednisone 15-25 interleukin 5 Homo sapiens 216-220 9817701-8 1998 In these patients, prednisone also produced a significant decline in the median sputum eosinophil percentage, from 9.7% to 0.5% (p = 0.002), eosinophil cationic protein (ECP), from 6, 000 microgram/L to 1,140 microgram/L (p < 0.001), and fibrinogen, from 25. Prednisone 19-29 ribonuclease A family member 3 Homo sapiens 141-168 9850025-9 1998 When compared with a historic control group who received a CY, DOX, VCR, and prednisone (CHOP)-like regimen, untreated patients in the study had a 3-year EFS rate of 72% versus 28% (P = .0001) and a better OS rate (92% v 56%; P = .05). Prednisone 77-87 DNA damage inducible transcript 3 Homo sapiens 89-93 9870261-3 1998 Relative potencies for glucocorticoid receptor binding were 1, 1.7, and 2.4 for prednisone (P) (IC50 = 287 nM), FP16CM, and FP16CMAc, respectively. Prednisone 80-90 nuclear receptor subfamily 3, group C, member 1 Mus musculus 23-46 9817701-8 1998 In these patients, prednisone also produced a significant decline in the median sputum eosinophil percentage, from 9.7% to 0.5% (p = 0.002), eosinophil cationic protein (ECP), from 6, 000 microgram/L to 1,140 microgram/L (p < 0.001), and fibrinogen, from 25. Prednisone 19-29 ribonuclease A family member 3 Homo sapiens 170-173 9817701-8 1998 In these patients, prednisone also produced a significant decline in the median sputum eosinophil percentage, from 9.7% to 0.5% (p = 0.002), eosinophil cationic protein (ECP), from 6, 000 microgram/L to 1,140 microgram/L (p < 0.001), and fibrinogen, from 25. Prednisone 19-29 fibrinogen beta chain Homo sapiens 241-251 9697790-0 1998 Effect of prednisone on prostate-specific antigen in patients with hormone-refractory prostate cancer. Prednisone 10-20 kallikrein related peptidase 3 Homo sapiens 24-49 9727645-6 1998 Both prednisone and a prostaglandin analog were effective in downregulating TNF and interleukin-8 production. Prednisone 5-15 tumor necrosis factor Homo sapiens 76-79 9727645-6 1998 Both prednisone and a prostaglandin analog were effective in downregulating TNF and interleukin-8 production. Prednisone 5-15 C-X-C motif chemokine ligand 8 Homo sapiens 84-97 9829612-9 1998 Two patients treated with prednisone or octreotide had insulin levels similar to those of normal TPN children. Prednisone 26-36 insulin Homo sapiens 55-62 9763034-5 1998 She experienced complete remission after dose-intensified therapy with cyclophosphamide, hydroxydaunomycin, vincristine [Oncovin], and prednisone (CHOP), but the disease relapsed in the central nervous system 6 months later. Prednisone 135-145 DNA damage inducible transcript 3 Homo sapiens 147-151 9704736-1 1998 PURPOSE: In a randomized trial conducted by the National Cancer Institute of Canada Clinical Trials Group (NCIC CTG), interferon alpha-2b (IFN) maintenance therapy (2 mU/m2 subcutaneously three times per week) after successful induction with melphalan and prednisone was found to prolong time to progression in patients with multiple myeloma. Prednisone 256-266 interferon alpha 2 Homo sapiens 118-137 9697790-1 1998 OBJECTIVES: To evaluate the effects of prednisone on prostate-specific antigen (PSA) in a cohort of patients with "hormone-refractory" prostate cancer. Prednisone 39-49 kallikrein related peptidase 3 Homo sapiens 53-84 9697790-4 1998 RESULTS: The mean and median PSA decline after initiating prednisone was 33% (95% confidence interval [CI] 20% to 46%) and 24% (range 0% to 99%), respectively. Prednisone 58-68 kallikrein related peptidase 3 Homo sapiens 29-32 9697790-11 1998 CONCLUSIONS: Prednisone (10 mg orally two times a day) can decrease PSA by more than 50% in approximately one third of patients with hormone-refractory progressive prostate cancer. Prednisone 13-23 kallikrein related peptidase 3 Homo sapiens 68-71 9657567-7 1998 IL-2 production was decreased after treatment with prednisone. Prednisone 51-61 interleukin 2 Homo sapiens 0-4 9667250-1 1998 PURPOSE: Standard cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy repeated at 3-week intervals is difficult to deliver in elderly patients with non-Hodgkin"s lymphoma (NHL). Prednisone 66-76 DNA damage inducible transcript 3 Homo sapiens 78-82 9667258-2 1998 METHODS: We determined plasma levels of c-erbB-2 in 79 stages II and III breast cancer patients who received cyclophosphamide, methotrexate, and flourouracil (CMF)/cyclophosphamide, methotrexate, fluorouracil, vincristine, and prednisone (CMFVP) chemotherapy. Prednisone 227-237 erb-b2 receptor tyrosine kinase 2 Homo sapiens 40-48 9793313-1 1998 Our objective in this study was to determine effects, if any, of different doses of of prednisone and the inhalant steroid budesonide on the indices for bone formation (osteocalcin, PICP levels) and bone resorption (piridinoline, deoxypiridinoline, and hydroxyproline) in healthy volunteers (n = 78). Prednisone 87-97 bone gamma-carboxyglutamate protein Homo sapiens 169-180 9752311-1 1998 The CHOP regimen (cyclophosphamide vincristine, adriamycin, prednisone) is considered since twenty years as the standard treatment of disseminated aggressive non-Hodgkin"s lymphomas and cures approximately 30% of patients. Prednisone 60-70 DNA damage inducible transcript 3 Homo sapiens 4-8 9784718-3 1998 The presence of PSC correlated with diurnal dose of prednisone as well as with duration of its administration but no correlation was found between PSC and inhalation corticosteroids. Prednisone 52-62 PSC Homo sapiens 16-19 9563957-12 1998 The mean baseline maintenance dose of prednisone was greater by 2 mg daily in patients who received IFN-alpha with tacrolimus compared with control patients who did not receive IFN-alpha with tacrolimus (IFN-alpha 5. Prednisone 38-48 interferon alpha 1 Homo sapiens 100-109 9563957-12 1998 The mean baseline maintenance dose of prednisone was greater by 2 mg daily in patients who received IFN-alpha with tacrolimus compared with control patients who did not receive IFN-alpha with tacrolimus (IFN-alpha 5. Prednisone 38-48 interferon alpha 5 Homo sapiens 204-215 9563957-14 1998 Similarly, the mean maintenance dose of prednisone was greater by 2.5 mg daily in patients who received IFN-alpha compared with controls who received CyA-based immunosuppression (IFN-alpha 9.8 +/- 3.1 mg daily v controls 7.3 +/- 3.3 mg daily; P = .01). Prednisone 40-50 interferon alpha 1 Homo sapiens 104-113 9563957-14 1998 Similarly, the mean maintenance dose of prednisone was greater by 2.5 mg daily in patients who received IFN-alpha compared with controls who received CyA-based immunosuppression (IFN-alpha 9.8 +/- 3.1 mg daily v controls 7.3 +/- 3.3 mg daily; P = .01). Prednisone 40-50 interferon alpha 1 Homo sapiens 179-188 10327418-3 1998 Interferon-gamma (IFN-gamma) and the anti-inflammatory steroid agents dexamethasone and prednisone were powerful stimulators of C1q production, alone or in combination. Prednisone 88-98 complement C1q A chain Homo sapiens 128-131 9658614-11 1998 Results from few randomized controlled trials of interferon therapy with prednisone priming in Chinese and Caucasian children were comparable to results obtained without prednisone. Prednisone 73-83 interferon alpha 1 Homo sapiens 49-59 9446640-9 1998 Measurement of HGF may identify a group of patients with poor response to melphalan-prednisone treatment and short survival. Prednisone 84-94 hepatocyte growth factor Homo sapiens 15-18 9614845-0 1998 Comparison of pentoxifylline, thalidomide and prednisone in the treatment of ENL. Prednisone 46-56 MLLT1 super elongation complex subunit Homo sapiens 77-80 9519935-7 1998 We describe a patient with non-Hodgkin"s lymphoma treated with conventional cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy and high-dose steroids who developed a rapidly progressive fatal leukoencephalopathy. Prednisone 124-134 DNA damage inducible transcript 3 Homo sapiens 136-140 9796853-7 1998 She was transplanted with autologous mobilized CD34+ SC and progenitor cells after conditioning with cyclosphosphamide, anti-T lymphocyte globulin and prednisone. Prednisone 151-161 CD34 molecule Homo sapiens 47-51 9613991-1 1998 A patient with a stage IV high-grade non-Hodgkin"s lymphoma who developed a fatal hemophagocytic syndrome is presented: When the patient had achieved complete remission and receiving fludarabine and chlorambucil/prednisone, she developed miliary tuberculosis, the CD4+ T-cell count then being 50/microL; the hemophagocytic syndrome ensuing at this point was fatal. Prednisone 212-222 CD4 molecule Homo sapiens 264-267 9443402-6 1998 BCL-X expression in malignant plasma cells strongly correlated with decreased response rates in patient groups treated with either melphalan and prednisone or vincristine, Adriamycin, and dexamethasone. Prednisone 145-155 BCL2 like 1 Homo sapiens 0-5 9876475-4 1998 During remission induction, treatment with high-dose steroid (prednisone or dexamethasone) resulted in further reduction in plasma osteocalcin and elevated parathyroid hormone levels. Prednisone 62-72 bone gamma-carboxyglutamate protein Homo sapiens 131-142 9467587-9 1998 Insulin antibody levels decreased and [123I]insulin biodistribution improved after treatment with plasmapheresis and prednisone. Prednisone 117-127 insulin Homo sapiens 0-7 9467587-9 1998 Insulin antibody levels decreased and [123I]insulin biodistribution improved after treatment with plasmapheresis and prednisone. Prednisone 117-127 insulin Homo sapiens 44-51 9616280-9 1997 In the subgroup of 45 patients receiving 2-CdA with prednisone, CR was obtained in 15 (33%) and PR in 20 (44%) patients giving an overall response rate of 78%. Prednisone 52-62 cytidine deaminase Homo sapiens 43-46 9857661-4 1998 In asthmatic group after 14 days of prednisone administration in a dose of 20 mg/d statistically significant (p < 0.05) shortening of APTT, and a significant increase of adhesion, aggregation and PAI-1 activity were found. Prednisone 36-46 serpin family E member 1 Homo sapiens 199-204 9857661-5 1998 These results suggest that in asthmatic patients after prednisone treatment platelet activity appeared in a form of intensification of adhesion and of aggregation degree, also the activity of PAI-1 probably of the platelet origin increased. Prednisone 55-65 serpin family E member 1 Homo sapiens 192-197 9389719-0 1997 Cyclophosphamide, doxorubicin, vincristine, prednisone dose intensification with granulocyte colony-stimulating factor markedly depletes stem cell reserve for autologous bone marrow transplantation. Prednisone 44-54 colony stimulating factor 3 Homo sapiens 81-118 9616280-13 1997 In the subgroup receiving 2-CdA with prednisone, an earlier response to 2-CdA was observed. Prednisone 37-47 cytidine deaminase Homo sapiens 28-31 9616280-13 1997 In the subgroup receiving 2-CdA with prednisone, an earlier response to 2-CdA was observed. Prednisone 37-47 cytidine deaminase Homo sapiens 74-77 9466281-2 1997 Triple therapy (pentoxifylline, ciprofloxacin and prednisone) with known anti-TNF activity was tested in 37 patients undergoing a hematopoietic progenitor transplant (HPT). Prednisone 50-60 tumor necrosis factor Homo sapiens 78-81 9616280-12 1997 However, we observed a relationship between the response and the number of courses of 2-CdA given in patients receiving and those not receiving prednisone. Prednisone 144-154 cytidine deaminase Homo sapiens 88-91 9415637-7 1997 Further analysis of the relationship of plasma PRL and therapy showed that patients with SLE selected by the attending physician for prednisone therapy in doses > or = 10 mg/day were more frequently hyperprolactinemic. Prednisone 133-143 prolactin Homo sapiens 47-50 9491847-0 1997 Results of treatment with cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) for non-Hodgkin"s aggressive lymphoma analyzed according to the International Prognostic Index. Prednisone 73-83 DNA damage inducible transcript 3 Homo sapiens 85-89 9291288-4 1997 METHODS: Histamine release from basophils to anti-IgE and anti-IgE + IL3 was evaluated following five days of prednisone given 20 mg twice daily in eight subjects with mild disease and 2 h following their daily prednisone ingestion in eight subjects with severe disease, as well as after in vitro DEX was added to the cells. Prednisone 110-120 interleukin 3 Homo sapiens 69-72 9371526-2 1997 Serum insulin and plasma glucose levels in 18 newly diagnosed cases and 11 previously treated cases with prednisone were significantly higher than those in the controls. Prednisone 105-115 insulin Homo sapiens 6-13 9277417-3 1997 Increased hepatic ALP activity was induced in four dogs by daily injections of 4 mg.kg-1.day-1 of prednisone for 10 days. Prednisone 98-108 alkaline phosphatase, biomineralization associated Canis lupus familiaris 18-21 9277417-8 1997 Histochemical staining of endogenous ALP activity showed increased ALP activity over sinusoidal surfaces of prednisone-treated dogs. Prednisone 108-118 alkaline phosphatase, biomineralization associated Canis lupus familiaris 37-40 9277417-9 1997 There was also an increased serum-to-tissue ratio of ALP activity in the prednisone-treated dogs, suggestive of increased release of ALP into blood. Prednisone 73-83 alkaline phosphatase, biomineralization associated Canis lupus familiaris 53-56 9277417-9 1997 There was also an increased serum-to-tissue ratio of ALP activity in the prednisone-treated dogs, suggestive of increased release of ALP into blood. Prednisone 73-83 alkaline phosphatase, biomineralization associated Canis lupus familiaris 133-136 9415539-1 1997 In a double-blind prospective randomized trial, we assessed the efficacy and safety of modified total lymphoid irradiation (TLI) plus low dose prednisone (TLI-LDP) as compared to sham TLI plus identical prednisone therapy (sham TLI-LDP) in 46 patients with progressive forms of multiple sclerosis (MS). Prednisone 143-153 carboxypeptidase Q Homo sapiens 159-162 9293306-1 1997 11 beta-hydroxysteroid dehydrogenase (11 beta HSD) has both dehydrogenase (11 beta DH) and reductase (11 beta R) activities, which catalyse the interconversion of cortisol and cortisone, and prednisolone and prednisone. Prednisone 208-218 carbohydrate sulfotransferase 3 Homo sapiens 46-49 9259593-10 1997 Fasting insulin and C-peptide levels were increased up to 6 mo after transplantation, indicating insulin resistance partially induced by prednisone. Prednisone 137-147 insulin Homo sapiens 8-15 9229189-5 1997 The allergic symptoms disappeared only after treatment with short acting human insulin (up to 100 U/day) associated to prednisone-40 mg/day and cetirizine dihydrochloride for 4 months. Prednisone 119-129 insulin Homo sapiens 79-86 9298501-2 1997 Several drugs and other compounds, e.g. phenobarbital, gemfibrozil, fenofibrate, prednisone, estrogen and alcohol, induce apolipoprotein A-I synthesis. Prednisone 81-91 apolipoprotein A1 Homo sapiens 122-140 9196142-4 1997 All except two patients were treated after first or subsequent relapses after receiving cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy to achieve a good partial (six of 13) or complete (seven of 13) response before stem-cell mobilization with cyclophosphamide 3 g/m2 and filgrastim 300 microg once daily. Prednisone 136-146 DNA damage inducible transcript 3 Homo sapiens 148-152 10173030-3 1997 One such treatment that is considered to have a low potential for inducing fever and neutropenia is the CHOP regimen (cyclophosphamide, doxorubicin, vincristine and prednisone) for non-Hodgkin"s lymphoma. Prednisone 165-175 DNA damage inducible transcript 3 Homo sapiens 104-108 9115450-3 1997 Cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy is well tolerated in patients who have a good performance status and who have aggressive histology lymphoma, but briefer 8-week regimens appear to offer similar benefits more quickly. Prednisone 48-58 DNA damage inducible transcript 3 Homo sapiens 60-64 9229189-6 1997 However, after stopping prednisone the urticaria reappeared and it was relieved with insulin desensitization. Prednisone 24-34 insulin Homo sapiens 85-92 8670597-8 1996 Notwithstanding the rise in absolute numbers of CD8 cell subsets induced by prednisone, the persistently low percentages of CD8+ cells in a group of PMR patients indicate an abnormality connected with the disease. Prednisone 76-86 CD8a molecule Homo sapiens 48-51 8892739-5 1996 The patient attained complete remission with cyclophosphamide, adriamycin, vincristine, and prednisone (CHOP) chemotherapy and remained disease-free for 13 years. Prednisone 92-102 DNA damage inducible transcript 3 Homo sapiens 104-108 8880119-4 1996 Daily treatment with azathioprine and prednisone induced resolution of the intrathoracic abnormalities but was associated with a progressive decrease of circulating IgG and IgA levels and natural killer (NK) lymphocytes that was not related to treatment. Prednisone 38-48 CD79a molecule Homo sapiens 173-176 8768854-9 1996 Exacerbation of thyrotoxicosis with markedly increased IL-6 was controlled by prednisone in 3 of 4 cases. Prednisone 78-88 interleukin 6 Homo sapiens 55-59 9140398-6 1997 In our study we observed eight male HD patients who were treated with NOVP (Novanthrone, Oncovin, Vinblastine, Prednisone) chemotherapy. Prednisone 111-121 plexin A1 Homo sapiens 70-74 9178026-6 1997 Basal levels of SI and FPIR were found to be independent predictors of change in insulin sensitivity and together explained 83% of the change in insulin sensitivity produced by short term treatment with prednisone. Prednisone 203-213 insulin Homo sapiens 81-88 9178026-6 1997 Basal levels of SI and FPIR were found to be independent predictors of change in insulin sensitivity and together explained 83% of the change in insulin sensitivity produced by short term treatment with prednisone. Prednisone 203-213 insulin Homo sapiens 145-152 9024520-0 1997 Successful management with interferon alpha-2a after prednisone therapy failure in an infant with a giant cavernous hemangioma. Prednisone 53-63 interferon alpha 2 Homo sapiens 27-46 9001335-0 1997 Prednisone increases PGH-synthase 2 in atopic humans in vivo. Prednisone 0-10 prostaglandin-endoperoxide synthase 2 Homo sapiens 21-35 9001335-4 1997 In AS, PGHS-2 mRNA and protein significantly increased after prednisone administration, whereas in CS PGHS-2 message and protein remained undetectable or, if present at baseline, was decreased after prednisone. Prednisone 61-71 prostaglandin-endoperoxide synthase 2 Homo sapiens 7-13 9812552-2 1997 The results revealed that after oral prednisone therapy, the serum IL-5, ECP levels and the numbers of peripheral blood eosinophils decreased, whereas the lung function significantly improved. Prednisone 37-47 interleukin 5 Homo sapiens 67-71 9812552-2 1997 The results revealed that after oral prednisone therapy, the serum IL-5, ECP levels and the numbers of peripheral blood eosinophils decreased, whereas the lung function significantly improved. Prednisone 37-47 ribonuclease A family member 3 Homo sapiens 73-76 8957747-0 1996 The effect of long-term prednisone treatment on growth hormone and insulin-like growth factor-1. Prednisone 24-34 growth hormone 1 Homo sapiens 48-62 8957747-0 1996 The effect of long-term prednisone treatment on growth hormone and insulin-like growth factor-1. Prednisone 24-34 insulin like growth factor 1 Homo sapiens 67-95 8957747-5 1996 Whereas no changes were seen in controls, prednisone induced a rapid increase in serum IGF-1 levels, which was sustained during the entire treatment period: 18.2 +/- 5.2 at baseline vs 24.1 +/- 6.7 nmol/l after 12 weeks of treatment (p < 0.001). Prednisone 42-52 insulin like growth factor 1 Homo sapiens 87-92 8957747-7 1996 Basal GH levels were frequently undetectable, but during treatment GH values were lower in the prednisone group (median of detectable values 4.0 mU/L [range 2.0-26.0]) than in controls (11.8 [2.8-44.0]; p < 0.01). Prednisone 95-105 growth hormone 1 Homo sapiens 67-69 8957747-8 1996 In conclusion, long-term prednisone treatment is associated with suppressed GH levels and with an increase in total IGF-1 levels. Prednisone 25-35 growth hormone 1 Homo sapiens 76-78 8957747-8 1996 In conclusion, long-term prednisone treatment is associated with suppressed GH levels and with an increase in total IGF-1 levels. Prednisone 25-35 insulin like growth factor 1 Homo sapiens 116-121 8957747-9 1996 This suggests that prednisone can disrupt the GH/IGF 1 axis. Prednisone 19-29 growth hormone 1 Homo sapiens 46-48 8957747-9 1996 This suggests that prednisone can disrupt the GH/IGF 1 axis. Prednisone 19-29 insulin like growth factor 1 Homo sapiens 49-54 8823326-11 1996 Comparisons with our prior vincristine/prednisone-based induction regimen (the L-20 protocol) suggest that patients treated on the current study were more likely to achieve a CR and that they achieved this remission earlier than patients treated with a traditional four-drug (vincristine, prednisone, doxorubicin, and cyclophosphamide) induction regimen. Prednisone 39-49 immunoglobulin kappa variable 3D-11 Homo sapiens 79-83 8619627-11 1996 Two other glucocorticoid receptor (GR) agonists, cortisol and prednisone, also produced a strong potentiation of CYP1A induction, but other mammalian CYP3A inducers that are not GR agonists, such as the anti-glucocorticoid PCN, the anti-mineralocorticoid spironolactone, or the macrolide antibiotics RIF and troleandomycin, did not potentiate the CYP1A induction in PLHC-1 cells. Prednisone 62-72 nuclear receptor subfamily 3 group C member 1 Homo sapiens 10-33 8667652-13 1996 We analyzed the response to the prednisone pretreatment and found a higher incidence of poor responders among the BCR/ABL-positive children. Prednisone 32-42 BCR activator of RhoGEF and GTPase Homo sapiens 114-117 8667652-13 1996 We analyzed the response to the prednisone pretreatment and found a higher incidence of poor responders among the BCR/ABL-positive children. Prednisone 32-42 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 118-121 8823683-15 1996 Some drugs (prednisone and cyclosporine) inhibit the release of GZB and PF. Prednisone 12-22 granzyme B Homo sapiens 64-67 8619627-11 1996 Two other glucocorticoid receptor (GR) agonists, cortisol and prednisone, also produced a strong potentiation of CYP1A induction, but other mammalian CYP3A inducers that are not GR agonists, such as the anti-glucocorticoid PCN, the anti-mineralocorticoid spironolactone, or the macrolide antibiotics RIF and troleandomycin, did not potentiate the CYP1A induction in PLHC-1 cells. Prednisone 62-72 nuclear receptor subfamily 3 group C member 1 Homo sapiens 35-37 8767532-8 1996 Discontinuation of IFN, often associated with prednisone treatment, caused prompt hematological recovery in all cases; anti-erythrocyte antibodies persisted in the first group of patients and disappeared in the second. Prednisone 46-56 interferon alpha 1 Homo sapiens 19-22 8733437-6 1996 The prednisone dose was decreased as soon as clinical symptoms disappeared and erythrocyte sedimentation rate, C reactive protein level, or both, had normalised. Prednisone 4-14 C-reactive protein Homo sapiens 111-129 8741082-6 1996 The expression of dystrophin in a placebo group and in a group that received 5 mg prednisone/kg body weight per day with and without performing exercise was studied with Western blotting. Prednisone 82-92 dystrophin Rattus norvegicus 18-28 8641640-1 1996 BACKGROUND: Alterations in hemostasis have frequently been observed in patients with leukemia, and thrombotic events are well documented in patients receiving L-asparaginase (ASP) as a single agent or in combination with vincristine, prednisone (sometimes complemented by an anthracycline). Prednisone 234-244 asparaginase and isoaspartyl peptidase 1 Homo sapiens 159-173 8731685-6 1996 Treatment with prednisone and cyclophosphamide was started with a good clinical response, stabilization of renal insufficiency and disappearance of P-ANCA (MPO). Prednisone 15-25 myeloperoxidase Homo sapiens 156-159 8778197-5 1996 Eight of these 12 patients received a 4-month course of prednisone (0.5 mg/kg per day), which increased alanine aminotransferase (mean +/- SE) (174 +/- 31 vs 252 +/- 18 U/l, p < 0.05) and bilirubin levels (0.96 +/- 0.17 vs 1.42 +/- 0.18 mg/dl, p = 0.09), without changing liver histology (Knodell index, 13.6 +/- 0.4 vs 13.1 +/- 0.3). Prednisone 56-66 glutamic--pyruvic transaminase Homo sapiens 104-128 8641640-1 1996 BACKGROUND: Alterations in hemostasis have frequently been observed in patients with leukemia, and thrombotic events are well documented in patients receiving L-asparaginase (ASP) as a single agent or in combination with vincristine, prednisone (sometimes complemented by an anthracycline). Prednisone 234-244 asparaginase and isoaspartyl peptidase 1 Homo sapiens 175-178 8549855-1 1996 Hyperinsulinemia and peripheral insulin resistance caused by systemic insulin delivery and prednisone therapy are recognized consequences of pancreas transplantation. Prednisone 91-101 insulin Homo sapiens 5-12 8973769-6 1996 Short-term (6 weeks) treatment of 15 anti-ANT antibody-positive IDC patients with prednisone was of beneficial effect. Prednisone 82-92 solute carrier family 25 member 6 Homo sapiens 42-45 8848188-4 1995 Prednisone treatment during the first month on the drug prevented the interferon-gamma-secreting cell surge. Prednisone 0-10 interferon gamma Homo sapiens 70-86 11854810-22 1995 The data demonstrate that oral prednisone is effective in reducing proteinuria and improving the biological markers of disease activity (i.e., ESR, CRP, C3, C4, and anti-dsDNA) following short-term treatment of active lupus nephritis. Prednisone 31-41 C-reactive protein Homo sapiens 148-151 8652232-5 1995 In high-grade lymphomas combination chemotherapy with cyclophosphamide, hydroxydaunorubin, vincristine and prednisone (CHOP) represents the treatment of first choice, and may be restricted to 3-4 cycles in patients with limited stages of the disease when followed by involved field radiotherapy. Prednisone 107-117 DNA damage inducible transcript 3 Homo sapiens 119-123 8616952-0 1996 Effects of cyclosporine, azathioprine and prednisone on Kimura"s disease and focal segmental glomerulosclerosis in renal transplant patients. Prednisone 42-52 actinin alpha 4 Homo sapiens 77-111 7477994-1 1995 We evaluated the effectiveness of low-dose, short-term oral prednisone in ameliorating the pain and other symptoms of carpal tunnel syndrome (CTS) in a randomized, double-blind, placebo-controlled study of patients with mild to moderate CTS. Prednisone 60-70 transthyretin Homo sapiens 142-145 7554474-5 1995 Treatment of 5 acute JPS dogs with prednisone resulted in a rapid clinical improvement accompanied by a decrease of IL-6 activity. Prednisone 35-45 interleukin 6 Canis lupus familiaris 116-120 7554474-6 1995 Withdrawal of prednisone treatment caused reappearance of clinical symptoms and high serum IL-6 activity within a few days. Prednisone 14-24 interleukin 6 Canis lupus familiaris 91-95 7538247-4 1995 PSA returned to normal during lymphoma-specific chemotherapy with a cyclophosphamide, mechlorethamine, vincristine, procarbazine, prednisone regimen. Prednisone 130-140 kallikrein related peptidase 3 Homo sapiens 0-3 7563172-0 1995 Accumulation of p53 protein as a possible predictor of response to adjuvant combination chemotherapy with cyclophosphamide, methotrexate, fluorouracil, and prednisone for breast cancer. Prednisone 156-166 tumor protein p53 Homo sapiens 16-19 7677440-12 1995 Patients in whom the percentage of CD8 cells at six months was lower than one SD of the mean of normal controls (26%) had a significantly longer duration of corticosteroid treatment, a greater cumulative dose of prednisone and more relapses or recurrences compared with patients in whom the percentage was in the normal range. Prednisone 212-222 CD8a molecule Homo sapiens 35-38 7677440-14 1995 CONCLUSIONS: A reduced percentage of CD8 cells after six months of treatment may be a useful outcome parameter which would identify a group of PMR/GCA patients likely to experience more severe disease, defined as longer duration of corticosteroid treatment, higher cumulative dose of prednisone, and relapse or recurrence of disease. Prednisone 284-294 CD8a molecule Homo sapiens 37-40 7586978-6 1995 A rapid decrease of serum osteocalcin during prednisone intake was found (p<0.01). Prednisone 45-55 bone gamma-carboxyglutamate protein Homo sapiens 26-37 7586978-9 1995 It is concluded that 10 mg prednisone/day decreases bone formation, as shown by its effect on osteocalcin, while no influence is seen on bone resorption. Prednisone 27-37 bone gamma-carboxyglutamate protein Homo sapiens 94-105 7562773-7 1995 The 4 patients with abnormal AFP-MOM, using the 2.3 cutoff, were taking more prednisone (27.25 +/- 18.54 mg vs 10.85 +/- 12.29 mg, p = 0.02), were more likely to have delivered preterm (31.50 +/- 36.31 weeks, p = 0.02), and were more likely to have a high anticardiolipin (aCL) antibody during the pregnancy (p = 0.03). Prednisone 77-87 alpha fetoprotein Homo sapiens 29-32 7562773-9 1995 An abnormal maternal serum AFP level is associated with higher prednisone dose, preterm delivery and aCL. Prednisone 63-73 alpha fetoprotein Homo sapiens 27-30 7674236-6 1995 As prednisone was reduced more placebo patients experienced an exacerbation of PMR symptoms, elevation of erythrocyte sedimentation rate and increased serum C-reactive protein. Prednisone 3-13 C-reactive protein Homo sapiens 157-175 7662588-7 1995 All-trans-retinoic acid, the progesterone analog R-5020, and prednisone were found to induce heterologous up-regulation of the VDR. Prednisone 61-71 vitamin D receptor Homo sapiens 127-130 7898521-5 1995 METHODS: To investigate whether patients with slow responses, defined as only a partial response after three courses of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP), would benefit from early transplantation, we conducted a prospective, randomized trial. Prednisone 168-178 DNA damage inducible transcript 3 Homo sapiens 180-184 7813278-1 1995 A 53-year-old granulocytopenic woman with malignant lymphoma treated with cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy, including doxorubicin (Adriamycin) and autologues bone marrow transplantation, presented in the clinical state of "refractory septic shock" caused by Escherichia coli. Prednisone 122-132 DNA damage inducible transcript 3 Homo sapiens 134-138 7533772-0 1995 Recombinant human insulin-like growth factor-I enhances whole body protein anabolism and significantly diminishes the protein catabolic effects of prednisone in humans without a diabetogenic effect. Prednisone 147-157 insulin like growth factor 1 Homo sapiens 18-46 7530507-4 1995 We have analyzed the prognostic significance of serum immunoreactive IL-6, as measured by a sensitive immunosorbent assay, in 210 patients with newly diagnosed MM subsequently treated with intermittent melphalan and prednisone. Prednisone 216-226 interleukin 6 Homo sapiens 69-73 7481481-10 1995 With intermediate doses of prednisone (20-45 mg), we observed the largest improvement in IL-2 production and in IL-1 production upon LPS stimulation. Prednisone 27-37 interleukin 2 Homo sapiens 89-93 7807013-8 1995 After a 1-wk course of prednisone, IL-2 expression was not altered in either group. Prednisone 23-33 interleukin 2 Homo sapiens 35-39 7481481-10 1995 With intermediate doses of prednisone (20-45 mg), we observed the largest improvement in IL-2 production and in IL-1 production upon LPS stimulation. Prednisone 27-37 interleukin 1 alpha Homo sapiens 112-116 7481481-11 1995 Higher doses of prednisone reduced also the spontaneous production of IL-1 and resulted in an increase in the expression of CD25+ cells. Prednisone 16-26 interleukin 1 alpha Homo sapiens 70-74 7963155-5 1994 In addition, eosinophil cationic protein levels in induced sputum fell more in the prednisone-treated group than in the placebo-treated group (from 324 +/- 131 ng/ml to 144 +/- 84 ng/ml vs 173 +/- 50 ng/ml to 188 +/- 47 ng/ml; p = 0.002). Prednisone 83-93 ribonuclease A family member 3 Homo sapiens 13-40 7973537-0 1994 [The effect of long-term cyclosporin and prednisone therapy on insulin secretory reserve]. Prednisone 41-51 insulin Homo sapiens 63-70 7973537-1 1994 Insulin secretory reserve assessed by the method of glucose potentiation of arginine induced insulin secretion is decreased in non-diabetic transplant recipients using triple immunosuppressive therapy with prednisone, cyclosporine, and azathioprine. Prednisone 206-216 insulin Homo sapiens 0-7 7936304-1 1994 The activity of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) in the treatment of primary central nervous system lymphoma (PCNSL) prior to radiotherapy was studied in six patients. Prednisone 64-74 DNA damage inducible transcript 3 Homo sapiens 76-80 7804464-5 1994 Initial studies have shown a beneficial effect of GH in reversing the catabolic actions of oral prednisone, and GH treatment has led to an increase in muscle mass and protein synthesis in pilot studies of myotonic dystrophy. Prednisone 96-106 growth hormone 1 Homo sapiens 50-52 8048420-6 1994 Groups DIF and CRES received intensive treatment with high-dose prednisone and cytotoxic drugs. Prednisone 64-74 tumor necrosis factor Homo sapiens 7-10 8042652-4 1994 A kidney biopsy was consistent with Wegener"s granulomatosis, and treatment with prednisone and cyclophosphamide was associated with normalization of serum calcium levels, improved renal function, a marked decrease in serum 1,25(OH)2D levels, and increased serum intact parathyroid hormone levels. Prednisone 81-91 parathyroid hormone Homo sapiens 270-289 7978647-9 1994 Serum total ALP activity was significantly (P < 0.05) high at day 3 in prednisone-treated dogs. Prednisone 74-84 alkaline phosphatase, biomineralization associated Canis lupus familiaris 12-15 8048420-6 1994 Groups DIF and CRES received intensive treatment with high-dose prednisone and cytotoxic drugs. Prednisone 64-74 cystatin 8 Homo sapiens 15-19 8064074-5 1994 All of the patients had a rise in serum IgE levels after the course of prednisone (p = 0.005). Prednisone 71-81 immunoglobulin heavy constant epsilon Homo sapiens 40-43 8064074-7 1994 Peripheral blood mononuclear cells from patients treated with prednisone produced increased levels of IgE in vitro when exogenous IL-4 was added to their cultures. Prednisone 62-72 immunoglobulin heavy constant epsilon Homo sapiens 102-105 8064074-7 1994 Peripheral blood mononuclear cells from patients treated with prednisone produced increased levels of IgE in vitro when exogenous IL-4 was added to their cultures. Prednisone 62-72 interleukin 4 Homo sapiens 130-134 8064074-8 1994 Peripheral blood mononuclear cells obtained from patients before and after administration of prednisone revealed a significant decrease in interferon-gamma synthesis (p = 0.005), but not in interleukin-4 (p = 0.6), after the course of prednisone. Prednisone 93-103 interferon gamma Homo sapiens 139-155 8064074-8 1994 Peripheral blood mononuclear cells obtained from patients before and after administration of prednisone revealed a significant decrease in interferon-gamma synthesis (p = 0.005), but not in interleukin-4 (p = 0.6), after the course of prednisone. Prednisone 93-103 interleukin 4 Homo sapiens 190-203 8064074-8 1994 Peripheral blood mononuclear cells obtained from patients before and after administration of prednisone revealed a significant decrease in interferon-gamma synthesis (p = 0.005), but not in interleukin-4 (p = 0.6), after the course of prednisone. Prednisone 235-245 interferon gamma Homo sapiens 139-155 8064074-11 1994 These data suggest that the observed rise in IgE production associated with prednisone treatment is not clinically deleterious but reflects the immunomodulatory effects of corticosteroids on T lymphocytes. Prednisone 76-86 immunoglobulin heavy constant epsilon Homo sapiens 45-48 8026943-5 1994 ME (0.49 +/- 0.10 pmol/mL) and NMECP (35.1 +/- 2.4 pmol/mg protein) levels after prednisone treatment were significantly higher (P < 0.05) than in basal conditions (0.29 +/- 0.08 pmol/mL and 27.14 +/- 2.4 pmol/mg protein), while no differences were found in catecholamine levels. Prednisone 81-91 proopiomelanocortin Homo sapiens 0-2 8040785-0 1994 Prednisone dose limitation of growth hormone treatment of steroid-induced growth failure. Prednisone 0-10 growth hormone 1 Homo sapiens 30-44 8040785-1 1994 Seven children with prednisone-induced growth failure were treated with recombinant growth hormone to improve linear growth. Prednisone 20-30 growth hormone 1 Homo sapiens 84-98 8040785-3 1994 The response to recombinant growth hormone was found to be related to the prednisone dose. Prednisone 74-84 growth hormone 1 Homo sapiens 28-42 8190529-10 1994 Immunosuppressive treatment with cyclosporin therapy in combination with a minimal dose of alternate-day prednisone would then result in optimal post-transplant growth, particularly if the GFR remains above 50 mL/min/1.73 m2). Prednisone 105-115 CD59 molecule (CD59 blood group) Homo sapiens 213-218 7703552-3 1994 The treatment consisted of a chemotherapy with cyclophosphamide, adriamycine, vincristine and prednisone (CHOP regimen). Prednisone 94-104 DNA damage inducible transcript 3 Homo sapiens 106-110 8188101-7 1994 The tuberculin test 1 month following prednisone therapy was positive, suggesting that previously the skin reaction to tuberculin had been altered by the prednisone. Prednisone 38-48 serine protease 21 Homo sapiens 15-21 8188101-7 1994 The tuberculin test 1 month following prednisone therapy was positive, suggesting that previously the skin reaction to tuberculin had been altered by the prednisone. Prednisone 154-164 serine protease 21 Homo sapiens 15-21 8186172-1 1994 BACKGROUND: Due to the possibility of a synergistic effect between Interferon (IFN-alpha) and 5-fluorouracil (5-FU), a phase II trial was conducted in metastatic renal cell carcinoma (MRCC) combining recombinant IFN-alpha, 5-FU and prednisone. Prednisone 232-242 interferon alpha 1 Homo sapiens 79-88 8186172-2 1994 Prednisone has been shown to decrease IFN-alpha-related toxicity without reducing the response rate. Prednisone 0-10 interferon alpha 1 Homo sapiens 38-47 8164373-5 1994 If the administration of prednisone increases the level of HBV, the withdrawal of prednisone elevates GPT and reduces HBV. Prednisone 82-92 glutamic--pyruvic transaminase Homo sapiens 102-105 8259104-9 1994 Children who were treated with prednisone had significantly higher mean levels of PA, RBP, and AGP than those who were not receiving prednisone. Prednisone 31-41 retinol binding protein 4 Homo sapiens 86-89 7565328-3 1994 Concentrate of VIII coagulation factor was used in treatment, as well as plasmaphaeresis, high doses of immunoglobulins and immunosuppressive drugs: prednisone and azathioprime. Prednisone 149-159 cytochrome c oxidase subunit 8A Homo sapiens 15-19 8106631-12 1994 Treatment of 2 such patients with prednisone was associated with a dramatic reduction and prompt normalization of IL-6 and thyroid hormone values. Prednisone 34-44 interleukin 6 Homo sapiens 114-118 7506802-2 1993 Twelve courses tetrahydropyranyl adriamycin, cyclophosphamide, vincristine and prednisone (THP-COP) combination chemotherapy led him to complete remission. Prednisone 79-89 caspase recruitment domain family member 16 Homo sapiens 95-98 8310505-9 1994 Prednisone-treated dogs given insulin became hyperglycemic at 10, 14, 18, and 19 months post ITx. Prednisone 0-10 insulin Canis lupus familiaris 30-37 8285167-9 1993 After systemic chemotherapy of cyclophosphamide, adriamycin, vincristine, prednisone (CHOP) regimen, renal function improved and the tumor of stomach reduced, but his respiratory condition rapidly worsened, and he died about 1 month after chemotherapy. Prednisone 74-84 DNA damage inducible transcript 3 Homo sapiens 86-90 21607339-2 1994 The prednisone and PTX were administered in an attempt to ameliorate toxicity related to GM-CSF. Prednisone 4-14 colony stimulating factor 2 Homo sapiens 89-95 7515507-10 1994 Prednisone administration was also associated with significant decreases in plasma levels of adrenocorticotropic hormone (ACTH), cortisol, and 3-methoxy,4-hydroxyphenyl glycol (MHPG) and in cerebrospinal fluid (CSF) levels of ACTH, beta-endorphin (BE), beta-lipotropin (BLPH), somatostatin-like immunoreactivity (SLI), and norepinephrine (NE). Prednisone 0-10 proopiomelanocortin Homo sapiens 93-120 7515507-10 1994 Prednisone administration was also associated with significant decreases in plasma levels of adrenocorticotropic hormone (ACTH), cortisol, and 3-methoxy,4-hydroxyphenyl glycol (MHPG) and in cerebrospinal fluid (CSF) levels of ACTH, beta-endorphin (BE), beta-lipotropin (BLPH), somatostatin-like immunoreactivity (SLI), and norepinephrine (NE). Prednisone 0-10 proopiomelanocortin Homo sapiens 232-246 7515507-10 1994 Prednisone administration was also associated with significant decreases in plasma levels of adrenocorticotropic hormone (ACTH), cortisol, and 3-methoxy,4-hydroxyphenyl glycol (MHPG) and in cerebrospinal fluid (CSF) levels of ACTH, beta-endorphin (BE), beta-lipotropin (BLPH), somatostatin-like immunoreactivity (SLI), and norepinephrine (NE). Prednisone 0-10 SHC adaptor protein 2 Homo sapiens 277-311 7515507-10 1994 Prednisone administration was also associated with significant decreases in plasma levels of adrenocorticotropic hormone (ACTH), cortisol, and 3-methoxy,4-hydroxyphenyl glycol (MHPG) and in cerebrospinal fluid (CSF) levels of ACTH, beta-endorphin (BE), beta-lipotropin (BLPH), somatostatin-like immunoreactivity (SLI), and norepinephrine (NE). Prednisone 0-10 SHC adaptor protein 2 Homo sapiens 313-316 8038494-13 1993 In a previous randomized trial, the French Co-operative Group on CLL showed a beneficial role for low-dose adriamycin given with cyclophosphamide, vincristine and prednisone (mini-CHOP) in patients with stage C disease. Prednisone 163-173 DNA damage inducible transcript 3 Homo sapiens 180-184 8414819-9 1993 Among patients who had a suboptimal response to initial beta 2-agonist therapy and who therefore would have been hospitalized had treatment been restricted to 2 hours, 9 (45%) of 20 in the prednisone group ultimately required hospitalization when duration of care was extended 2 additional hours compared with 15 (83%) of 18 in the placebo group (P < .05). Prednisone 189-199 potassium calcium-activated channel subfamily M regulatory beta subunit 2 Homo sapiens 56-62 8246373-0 1993 Prednisone inhibits the efficacy of recombinant human growth hormone in pediatric renal transplant recipients. Prednisone 0-10 growth hormone 1 Homo sapiens 54-68 7685225-5 1993 CRP serum concentration is also reduced by the corticosteroids such as prednisone, but addition of pulse therapy with i.v. Prednisone 71-81 C-reactive protein Homo sapiens 0-3 8411796-11 1993 When cyclosporine A is used in combination with prednisone, the immunologic cycle that causes rejection is interrupted twice by virtue of the fact that prednisone prevents the production of IL-1 by macrophages and cyclosporine A with the production of lymphokines, especially IL-2 (T-cell growth factor). Prednisone 48-58 interleukin 1 alpha Homo sapiens 190-194 8411796-11 1993 When cyclosporine A is used in combination with prednisone, the immunologic cycle that causes rejection is interrupted twice by virtue of the fact that prednisone prevents the production of IL-1 by macrophages and cyclosporine A with the production of lymphokines, especially IL-2 (T-cell growth factor). Prednisone 48-58 interleukin 2 Homo sapiens 276-280 8411796-11 1993 When cyclosporine A is used in combination with prednisone, the immunologic cycle that causes rejection is interrupted twice by virtue of the fact that prednisone prevents the production of IL-1 by macrophages and cyclosporine A with the production of lymphokines, especially IL-2 (T-cell growth factor). Prednisone 152-162 interleukin 1 alpha Homo sapiens 190-194 8411796-11 1993 When cyclosporine A is used in combination with prednisone, the immunologic cycle that causes rejection is interrupted twice by virtue of the fact that prednisone prevents the production of IL-1 by macrophages and cyclosporine A with the production of lymphokines, especially IL-2 (T-cell growth factor). Prednisone 152-162 interleukin 2 Homo sapiens 276-280 8212624-0 1993 [Treatment of resistant forms of multiple myeloma using a combination of mitoxantrone, vincristine and prednisone (the NOP regimen)]. Prednisone 103-113 prepronociceptin Homo sapiens 119-122 8212624-1 1993 In the submitted study the authors summarize experience with the treatment of resistant forms of multiple myeloma by a combination of Mitoxantrone, Vincristine and Prednisone (NOP regime). Prednisone 164-174 prepronociceptin Homo sapiens 176-179 8344127-6 1993 Insulin antibodies (IA) were significantly lower in the prednisone group at second and third month (P < 0.05). Prednisone 56-66 insulin Homo sapiens 0-7 7680764-1 1993 BACKGROUND: CHOP is a first-generation, combination-chemotherapy regimen consisting of cyclophosphamide, doxorubicin, vincristine, and prednisone that has cured approximately 30 percent of patients with advanced stages of intermediate-grade or high-grade non-Hodgkin"s lymphoma in national cooperative-group trials. Prednisone 135-145 DNA damage inducible transcript 3 Homo sapiens 12-16 8344127-7 1993 No patient experienced complete remission but in 10 prednisone and 4 control patients the insulin requirements were below 0.3 IU/kg (P < 0.05). Prednisone 52-62 insulin Homo sapiens 90-97 8344127-9 1993 The profile of the insulin requirements during the follow-up was different in the two groups and at 9 months the prednisone group needed less insulin than the control (P < 0.05). Prednisone 113-123 insulin Homo sapiens 19-26 8344127-9 1993 The profile of the insulin requirements during the follow-up was different in the two groups and at 9 months the prednisone group needed less insulin than the control (P < 0.05). Prednisone 113-123 insulin Homo sapiens 142-149 8480477-1 1993 A single dose of 2.5 mg prednisone leads to a significant transient decrease in serum osteocalcin, which is only demonstrated by frequent serum sampling. Prednisone 24-34 bone gamma-carboxyglutamate protein Homo sapiens 86-97 8472623-5 1993 Introduction of combined immunosuppressive therapy (prednisone plus azathioprine) together with plasmapheresis resulted in rapid lowering of daily insulin requirement and reduction in anti-insulin antibodies. Prednisone 52-62 insulin Homo sapiens 147-154 8427457-0 1993 Effects of oral administration of anti-inflammatory doses of prednisone on thyroid hormone response to thyrotropin-releasing hormone and thyrotropin in clinically normal dogs. Prednisone 61-71 TRH Canis lupus familiaris 103-132 8472623-5 1993 Introduction of combined immunosuppressive therapy (prednisone plus azathioprine) together with plasmapheresis resulted in rapid lowering of daily insulin requirement and reduction in anti-insulin antibodies. Prednisone 52-62 insulin Homo sapiens 189-196 8472623-6 1993 Immunosuppressive therapy was continued with 10 mg of prednisone and a year later the patients insulin daily requirement was 0.66 U/kg BW while his antibodies were 18%. Prednisone 54-64 insulin Homo sapiens 95-102 8300055-4 1993 We have recently demonstrated that high-dose rhGH together with prednisone prevents the protein-catabolic effects observed with treatment with prednisone alone, while inducing insulin resistance and increased secretion of proinsulin. Prednisone 64-74 insulin Homo sapiens 176-183 8300055-4 1993 We have recently demonstrated that high-dose rhGH together with prednisone prevents the protein-catabolic effects observed with treatment with prednisone alone, while inducing insulin resistance and increased secretion of proinsulin. Prednisone 64-74 insulin Homo sapiens 222-232 8232843-8 1993 Further, prednisone-induced increases in theta activity were significantly correlated with prednisone-induced decreases in CSF levels of somatostatin-like immunoreactivity, and prednisone-induced decreases in peak alpha activity were significantly correlated with decreases in CSF levels of norepinephrine and with relative increases (or lesser decreases) in CSF levels of beta-endorphin and beta-lipotropic hormone. Prednisone 9-19 colony stimulating factor 2 Homo sapiens 123-126 8247189-2 1993 Compared to retrobulbar radiotherapy, prednisone treatment was associated with an increase in: (a) plasma creatinine concentration (from 68 +/- 4 to 76 +/- 4 mumol/l), (b) glomerular filtration rate (GFR, from 93 +/- 4 to 102 +/- 5 ml/min/1.73 m2), and (c) urinary creatinine excretion rate (from 510 +/- 40 to 570 +/- 40 mumol/h). Prednisone 38-48 Rap guanine nucleotide exchange factor 5 Homo sapiens 200-203 8247189-3 1993 We conclude that GFR rises during 2 weeks of high-dose prednisone administration, a rise that is not reflected by a decrease in plasma creatine concentration. Prednisone 55-65 Rap guanine nucleotide exchange factor 5 Homo sapiens 17-20 8232843-8 1993 Further, prednisone-induced increases in theta activity were significantly correlated with prednisone-induced decreases in CSF levels of somatostatin-like immunoreactivity, and prednisone-induced decreases in peak alpha activity were significantly correlated with decreases in CSF levels of norepinephrine and with relative increases (or lesser decreases) in CSF levels of beta-endorphin and beta-lipotropic hormone. Prednisone 91-101 colony stimulating factor 2 Homo sapiens 277-280 8232843-8 1993 Further, prednisone-induced increases in theta activity were significantly correlated with prednisone-induced decreases in CSF levels of somatostatin-like immunoreactivity, and prednisone-induced decreases in peak alpha activity were significantly correlated with decreases in CSF levels of norepinephrine and with relative increases (or lesser decreases) in CSF levels of beta-endorphin and beta-lipotropic hormone. Prednisone 9-19 colony stimulating factor 2 Homo sapiens 277-280 8232843-8 1993 Further, prednisone-induced increases in theta activity were significantly correlated with prednisone-induced decreases in CSF levels of somatostatin-like immunoreactivity, and prednisone-induced decreases in peak alpha activity were significantly correlated with decreases in CSF levels of norepinephrine and with relative increases (or lesser decreases) in CSF levels of beta-endorphin and beta-lipotropic hormone. Prednisone 91-101 colony stimulating factor 2 Homo sapiens 277-280 8232843-8 1993 Further, prednisone-induced increases in theta activity were significantly correlated with prednisone-induced decreases in CSF levels of somatostatin-like immunoreactivity, and prednisone-induced decreases in peak alpha activity were significantly correlated with decreases in CSF levels of norepinephrine and with relative increases (or lesser decreases) in CSF levels of beta-endorphin and beta-lipotropic hormone. Prednisone 9-19 colony stimulating factor 2 Homo sapiens 277-280 8232843-8 1993 Further, prednisone-induced increases in theta activity were significantly correlated with prednisone-induced decreases in CSF levels of somatostatin-like immunoreactivity, and prednisone-induced decreases in peak alpha activity were significantly correlated with decreases in CSF levels of norepinephrine and with relative increases (or lesser decreases) in CSF levels of beta-endorphin and beta-lipotropic hormone. Prednisone 91-101 proopiomelanocortin Homo sapiens 373-387 8232843-8 1993 Further, prednisone-induced increases in theta activity were significantly correlated with prednisone-induced decreases in CSF levels of somatostatin-like immunoreactivity, and prednisone-induced decreases in peak alpha activity were significantly correlated with decreases in CSF levels of norepinephrine and with relative increases (or lesser decreases) in CSF levels of beta-endorphin and beta-lipotropic hormone. Prednisone 91-101 colony stimulating factor 2 Homo sapiens 123-126 8232843-8 1993 Further, prednisone-induced increases in theta activity were significantly correlated with prednisone-induced decreases in CSF levels of somatostatin-like immunoreactivity, and prednisone-induced decreases in peak alpha activity were significantly correlated with decreases in CSF levels of norepinephrine and with relative increases (or lesser decreases) in CSF levels of beta-endorphin and beta-lipotropic hormone. Prednisone 91-101 colony stimulating factor 2 Homo sapiens 277-280 8232843-8 1993 Further, prednisone-induced increases in theta activity were significantly correlated with prednisone-induced decreases in CSF levels of somatostatin-like immunoreactivity, and prednisone-induced decreases in peak alpha activity were significantly correlated with decreases in CSF levels of norepinephrine and with relative increases (or lesser decreases) in CSF levels of beta-endorphin and beta-lipotropic hormone. Prednisone 91-101 colony stimulating factor 2 Homo sapiens 277-280 8232843-8 1993 Further, prednisone-induced increases in theta activity were significantly correlated with prednisone-induced decreases in CSF levels of somatostatin-like immunoreactivity, and prednisone-induced decreases in peak alpha activity were significantly correlated with decreases in CSF levels of norepinephrine and with relative increases (or lesser decreases) in CSF levels of beta-endorphin and beta-lipotropic hormone. Prednisone 91-101 proopiomelanocortin Homo sapiens 373-387 8232843-8 1993 Further, prednisone-induced increases in theta activity were significantly correlated with prednisone-induced decreases in CSF levels of somatostatin-like immunoreactivity, and prednisone-induced decreases in peak alpha activity were significantly correlated with decreases in CSF levels of norepinephrine and with relative increases (or lesser decreases) in CSF levels of beta-endorphin and beta-lipotropic hormone. Prednisone 9-19 proopiomelanocortin Homo sapiens 373-387 8232843-8 1993 Further, prednisone-induced increases in theta activity were significantly correlated with prednisone-induced decreases in CSF levels of somatostatin-like immunoreactivity, and prednisone-induced decreases in peak alpha activity were significantly correlated with decreases in CSF levels of norepinephrine and with relative increases (or lesser decreases) in CSF levels of beta-endorphin and beta-lipotropic hormone. Prednisone 91-101 colony stimulating factor 2 Homo sapiens 123-126 1337108-0 1992 Pituitary-adrenal axis responsiveness to ovine corticotropin releasing hormone in patients with rheumatoid arthritis treated with low dose prednisone. Prednisone 139-149 corticotropin releasing hormone Homo sapiens 47-78 1401932-11 1992 Administration of a single 50-mg dose of prednisone at 3 p.m. resulted in diminished IL-1 beta protein concentration in the BAL fluid (28.3 +/- 5.7 pg/ml; p < 0.01 compared to baseline) and completely abrogated IL-1 beta mRNA expression. Prednisone 41-51 interleukin 1 beta Homo sapiens 85-94 1401932-11 1992 Administration of a single 50-mg dose of prednisone at 3 p.m. resulted in diminished IL-1 beta protein concentration in the BAL fluid (28.3 +/- 5.7 pg/ml; p < 0.01 compared to baseline) and completely abrogated IL-1 beta mRNA expression. Prednisone 41-51 interleukin 1 beta Homo sapiens 214-223 1294736-7 1992 Osteocalcin values were also lower (3.0 +/- 1.4 vs 3.9 +/- 1.6 ng/ml; p < 0.05) in prednisone treated patients with respect to deflazacort treated group. Prednisone 86-96 bone gamma-carboxyglutamate protein Homo sapiens 0-11 1294736-9 1992 In conclusion, our postmenopausal patients with RA treated with low dose prednisone had reduced levels of sex hormones and osteocalcin and reduced vertebral bone mass. Prednisone 73-83 bone gamma-carboxyglutamate protein Homo sapiens 123-134 1644247-9 1992 We conclude that, despite prednisone-induced insulin resistance, normal glucose tolerance is achieved by hyperinsulinaemia and normalisation of glucose-dependent glucose disposal following pancreas-kidney transplantation in Type 1 diabetic patients. Prednisone 26-36 insulin Homo sapiens 45-52 1355660-5 1992 Increased mdr1/P-glycoprotein mRNA levels were also found in relapsed state acute myelogenous leukaemias (AML), and in chronic lymphocytic leukaemias (CLL) treated with chlorambucil and/or prednisone for several years. Prednisone 189-199 ATP binding cassette subfamily B member 1 Homo sapiens 10-14 1355660-5 1992 Increased mdr1/P-glycoprotein mRNA levels were also found in relapsed state acute myelogenous leukaemias (AML), and in chronic lymphocytic leukaemias (CLL) treated with chlorambucil and/or prednisone for several years. Prednisone 189-199 ATP binding cassette subfamily B member 1 Homo sapiens 15-29 1354425-9 1992 A dramatic reduction in CD4 counts occurred in patients after fludarabine and prednisone treatment and coincided with the development of listeriosis. Prednisone 78-88 CD4 molecule Homo sapiens 24-27 1525916-3 1992 The danger of PSC develops after one year"s administration of 0.3 mg/kg/day Prednisone or its equivalent. Prednisone 76-86 PSC Homo sapiens 14-17 1607914-2 1992 PATIENTS AND METHODS: Twenty-one patients received six monthly courses of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) and maintenance chemotherapy for 12 months. Prednisone 122-132 DNA damage inducible transcript 3 Homo sapiens 134-138 1639529-9 1992 In conclusion, transplant recipients treated with long-term cyclosporine and prednisone exhibited significant elevation of plasma vWF, D-dimer and protein C concentrations. Prednisone 77-87 von Willebrand factor Homo sapiens 130-133 1505897-6 1992 In patients, but not in healthy subjects, prednisone suppressed eicosanoid production stimulated by FGA and reduced LTB4 and HETE outcome in MNCs treated by ionophor. Prednisone 42-52 fibrinogen alpha chain Homo sapiens 100-103 1326243-4 1992 Baseline plasma ACTH and cortisol and post-ACTH plasma cortisol concentrations were significantly (P less than 0.05) reduced in treated vs control dogs after 14 days of oral prednisone administration. Prednisone 174-184 proopiomelanocortin Canis lupus familiaris 16-20 1326243-4 1992 Baseline plasma ACTH and cortisol and post-ACTH plasma cortisol concentrations were significantly (P less than 0.05) reduced in treated vs control dogs after 14 days of oral prednisone administration. Prednisone 174-184 proopiomelanocortin Canis lupus familiaris 43-47 1547878-0 1992 Bolus therapy with mitoxantrone and vincristine in combination with high-dose prednisone (NOP-bolus) in resistant multiple myeloma. Prednisone 78-88 prepronociceptin Homo sapiens 90-93 1533370-3 1992 Complete remission was achieved by combined cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) chemotherapy and radiotherapy of the heart and mediastinum. Prednisone 91-101 DNA damage inducible transcript 3 Homo sapiens 103-107 1292981-5 1992 The administration of high doses of GH together with prednisone prevents the protein catabolic effects of prednisone alone. Prednisone 106-116 growth hormone 1 Homo sapiens 36-38 1411082-4 1992 CD19+ cells increased significantly in number from baseline in healthy subjects and prednisone-treated controls (P less than 0.05), while remaining unchanged in SLE patients. Prednisone 84-94 CD19 molecule Homo sapiens 0-4 1960362-12 1991 RESULTS: Treatment caused reduction in BGP levels within 24 hours of first dose of prednisone, with levels dropping an average of 78% during the 5 days of treatment (P = 0.004). Prednisone 83-93 bone gamma-carboxyglutamate protein Homo sapiens 39-42 1719250-0 1991 Re: Prostate specific antigen for assessing response to ketoconazole and prednisone in patients with hormone refractory metastatic prostate cancer. Prednisone 73-83 kallikrein related peptidase 3 Homo sapiens 4-29 1897023-11 1991 The indirect evidence of insulin resistance observed in patients treated with CsA plus prednisone is ascribable to corticosteroid treatment. Prednisone 87-97 insulin Homo sapiens 25-32 2068950-0 1991 Acute effect of 1,25-dihydroxyvitamin D3, prednisone, and 1,25-dihydroxyvitamin D3 plus prednisone on serum osteocalcin in normal individuals. Prednisone 88-98 bone gamma-carboxyglutamate protein Homo sapiens 108-119 2031502-2 1991 5-Fluorouracil, and prednisone (CFP) in patients with advanced breast cancer. Prednisone 20-30 complement factor properdin Homo sapiens 32-35 2019924-4 1991 The integrated insulin concentration correlated directly with the prednisone dose on day 1 of an alternate-day regimen (R2 = 0.355) and with age (partial R2 = 0.163). Prednisone 66-76 insulin Homo sapiens 15-22 1896399-5 1991 These elevated erythropoietin levels in azathioprine treated patients seem to be due also to factors other than higher prednisone dosage. Prednisone 119-129 erythropoietin Homo sapiens 15-29 2029988-1 1991 HLA class I antigen expression on peripheral blood mononuclear cells was evaluated by flow cytometry in 21 HBeAg-positive patients with chronic hepatitis B. Measurements were made before, during or after treatment with recombinant interferon-alpha-2b, either given alone or after a 6 wk course of prednisone. Prednisone 297-307 MHC class I polypeptide-related sequence A Homo sapiens 0-19 2016618-8 1991 These results are comparable to those reported with cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) therapy by other investigators. Prednisone 100-110 DNA damage inducible transcript 3 Homo sapiens 112-116 1781820-0 1991 Dystrophin expression and somatic reversion in prednisone-treated and untreated Duchenne dystrophy. Prednisone 47-57 dystrophin Homo sapiens 0-10 1781820-3 1991 We addressed the possibility that clinical improvement was related to prednisone-induced alterations in skeletal muscle dystrophin. Prednisone 70-80 dystrophin Homo sapiens 120-130 2068950-3 1991 The diurnal rhythm in serum OC can be changed by administration of single doses of either 1,25-(OH)2D3 or prednisone. Prednisone 106-116 bone gamma-carboxyglutamate protein Homo sapiens 28-30 2068950-4 1991 However, the two steroids have opposing effects: 1,25-(OH)2D3 increases and prednisone decreases serum OC. Prednisone 76-86 bone gamma-carboxyglutamate protein Homo sapiens 103-105 2068950-5 1991 The aim of the present study was to examine whether 1,25-(OH)2D3 can oppose the acute suppressive effect of prednisone on serum OC in normal subjects. Prednisone 108-118 bone gamma-carboxyglutamate protein Homo sapiens 128-130 2068950-6 1991 We compared the effect of a combined dose of 2 micrograms 1,25-(OH)2D3 and 10 mg prednisone on the diurnal rhythm of serum OC with the effect of 2 micrograms 1,25-(OH)2D3 + placebo in a crossover study. Prednisone 81-91 bone gamma-carboxyglutamate protein Homo sapiens 123-125 2068950-11 1991 Prednisone inhibited and reversed the nocturnal rise in serum OC levels (p less than 0.01). Prednisone 0-10 bone gamma-carboxyglutamate protein Homo sapiens 62-64 2068950-12 1991 The course of serum OC after administration of 1,25-(OH)2D3 + prednisone almost paralleled the course after placebo. Prednisone 62-72 bone gamma-carboxyglutamate protein Homo sapiens 20-22 2068950-13 1991 We conclude that 1,25-(OH)2D3 and prednisone have opposing effects on serum OC. Prednisone 34-44 bone gamma-carboxyglutamate protein Homo sapiens 76-78 1674430-10 1991 High numbers (greater than 10) of CD8+ T cells, even in absence of myocytolysis, should be treated more assertively, including the use of high doses of prednisone, because all our cases with high numbers showed a worse histologic picture at the subsequent biopsy. Prednisone 152-162 CD8a molecule Homo sapiens 34-37 1851508-3 1991 Monocytes from leprosy patients receiving prednisone therapy responded to lower concentrations of IFN-gamma in vitro with enhanced superoxide anion release when challenged with M. leprae or M. bovis BCG than did monocytes from healthy subjects and other leprosy patients. Prednisone 42-52 interferon gamma Homo sapiens 98-107 1851508-4 1991 Although the number of patients was small and the population heterogeneous, the data suggested that prednisone could alter IFN-gamma efficacy and led to the examination of the effect of glucocorticosteroids on IFN-gamma activation of monocytes. Prednisone 100-110 interferon gamma Homo sapiens 123-132 2222533-1 1990 Serum bone Gla-protein (BGP) measurements in 50 rheumatic disease patients receiving long-term prednisone therapy revealed an inverse relationship (r = -0.71, P less than 0.001) between serum BGP levels and prednisone dosage. Prednisone 95-105 CEA cell adhesion molecule 1 Homo sapiens 6-22 2015969-1 1991 Human growth hormone (hGH) and prednisone cause insulin resistance and glucose intolerance. Prednisone 31-41 insulin Homo sapiens 48-55 2015969-6 1991 Plasma insulin concentrations were elevated during therapy with prednisone alone and rhGH alone (667 +/- 72 and 564 +/- 65 pmol/ml, respectively, P less than 0.001) compared with placebo (226 +/- 44 pmol/ml) but lower than with the combined rhGH and prednisone treatment (1249 +/- 54 pmol/ml, P less than 0.01). Prednisone 64-74 insulin Homo sapiens 7-14 2015969-6 1991 Plasma insulin concentrations were elevated during therapy with prednisone alone and rhGH alone (667 +/- 72 and 564 +/- 65 pmol/ml, respectively, P less than 0.001) compared with placebo (226 +/- 44 pmol/ml) but lower than with the combined rhGH and prednisone treatment (1249 +/- 54 pmol/ml, P less than 0.01). Prednisone 250-260 insulin Homo sapiens 7-14 27463358-3 1991 Six years later, an increased serum M-protein became evident (IgG$LD, 3 gr/dl) associated with 35% plasma cells in the bone marrow, which necessitated melphalan/prednisone therapy. Prednisone 161-171 myomesin 2 Homo sapiens 36-45 2128095-6 1990 The two patients subjected to long-term therapy with a combination of prednisone (initially 2-3 mg/kg BW) and azathioprine (2-3 mg/kg BW) responded positively; the F VIII: C concentration increased. Prednisone 70-80 coagulation factor VIII Homo sapiens 164-170 2128095-10 1990 In conclusion, long-term therapy of an acquired F VIII: C inhibitor with a combination of prednisone and azathioprine may lead to complete disappearance of the inhibitor, normalization of the coagulation tests, and complete remission of the bleeding tendency. Prednisone 90-100 coagulation factor VIII Homo sapiens 48-54 1977371-4 1990 Prednisone administration was associated with decreases in cerebrospinal fluid levels of corticotropin, norepinephrine, beta-endorphin, beta-lipotropin, and somatostatinlike immunoreactivity. Prednisone 0-10 proopiomelanocortin Homo sapiens 120-134 1998599-0 1991 Refractory myelomatosis treated with mitoxantrone in combination with vincristine and prednisone (NOP-regimen): a phase II study. Prednisone 86-96 prepronociceptin Homo sapiens 98-101 1820114-6 1991 Prednisone can be withdrawn from almost all patients with no rejection by 1 year with significant improvement in blood pressure, daily insulin requirement in diabetics, total blood cholesterol, and low density lipoproteins (LDL). Prednisone 0-10 insulin Homo sapiens 135-142 1851318-1 1991 The present investigation evaluates the circadian rhythm of renin-angiotensin-aldosterone system (RAAS) in subjects with kidney (KTS) or heart (HTS) transplantation undergoing conventional therapy with prednisone and cyclosporine. Prednisone 202-212 renin Homo sapiens 60-65 1987687-1 1991 Serum interleukin 6 (IL-6) levels were utilized as an immunologic marker of activation of T cells and macrophages in renal allograft recipients treated with a cyclosporine and prednisone immunosuppressive regimen. Prednisone 176-186 interleukin 6 Homo sapiens 21-25 1700145-0 1990 Prostate specific antigen for assessing response to ketoconazole and prednisone in patients with hormone refractory metastatic prostate cancer. Prednisone 69-79 kallikrein related peptidase 3 Homo sapiens 0-25 1700145-1 1990 Serial prostate specific antigen levels were assessed in 15 patients with hormone refractory metastatic prostate cancer treated with ketoconazole and prednisone. Prednisone 150-160 kallikrein related peptidase 3 Homo sapiens 7-32 2222533-1 1990 Serum bone Gla-protein (BGP) measurements in 50 rheumatic disease patients receiving long-term prednisone therapy revealed an inverse relationship (r = -0.71, P less than 0.001) between serum BGP levels and prednisone dosage. Prednisone 95-105 CEA cell adhesion molecule 1 Homo sapiens 24-27 2222533-1 1990 Serum bone Gla-protein (BGP) measurements in 50 rheumatic disease patients receiving long-term prednisone therapy revealed an inverse relationship (r = -0.71, P less than 0.001) between serum BGP levels and prednisone dosage. Prednisone 95-105 CEA cell adhesion molecule 1 Homo sapiens 192-195 2222533-1 1990 Serum bone Gla-protein (BGP) measurements in 50 rheumatic disease patients receiving long-term prednisone therapy revealed an inverse relationship (r = -0.71, P less than 0.001) between serum BGP levels and prednisone dosage. Prednisone 207-217 CEA cell adhesion molecule 1 Homo sapiens 6-22 2222533-1 1990 Serum bone Gla-protein (BGP) measurements in 50 rheumatic disease patients receiving long-term prednisone therapy revealed an inverse relationship (r = -0.71, P less than 0.001) between serum BGP levels and prednisone dosage. Prednisone 207-217 CEA cell adhesion molecule 1 Homo sapiens 24-27 2222533-1 1990 Serum bone Gla-protein (BGP) measurements in 50 rheumatic disease patients receiving long-term prednisone therapy revealed an inverse relationship (r = -0.71, P less than 0.001) between serum BGP levels and prednisone dosage. Prednisone 207-217 CEA cell adhesion molecule 1 Homo sapiens 192-195 2222533-2 1990 Multiple regression analysis demonstrated significant relationships (R2 = 0.72, P less than 0.001) between serum BGP1/2 and prednisone dosage, dosage2, serum creatinine, age, and an age-creatinine interaction. Prednisone 124-134 CEA cell adhesion molecule 1 Homo sapiens 113-119 2252527-6 1990 A lower insulin requirement was observed in the prednisone group than in other patients at 12 months (0.33 +/- 0.11 vs 0.57 +/- 0.06 U/kg/day, P less than 0.05), 18 months (0.34 +/- 0.11 vs 0.64 +/- 0.06, P less than 0.05) and 24 months (0.38 +/- 0.10 vs 0.63 +/- 0.05, P less than 0.05). Prednisone 48-58 insulin Homo sapiens 8-15 2252527-7 1990 Endogenous insulin release, evaluated as urinary C-peptide, was higher in the prednisone group than in other patients at 3, 6, 9, 12, 18 and 24 months (P less than 0.05). Prednisone 78-88 insulin Homo sapiens 11-18 2252527-9 1990 Our study indicates that prednisone administration, at low doses and for a long period of time, effectively restored endogenous insulin release in IDDM patients. Prednisone 25-35 insulin Homo sapiens 128-135 1971857-6 1990 Antirejection therapy with prednisone pulses and/or antithymocyte globuline resulted in a significant decrease of T lymphocytes (CD3+) with a selective reduction of T helper/inducer cells (CD4+). Prednisone 27-37 CD4 molecule Homo sapiens 189-192 2151903-1 1990 UNLABELLED: The present article aimed to study the intactness of the physiological mechanism of ANP secretion in 64 kidney transplant patients treated with cyclosporine A + prednisone (CyA group--35 patients) or azathioprine + prednisone + promethasine respectively (Aza group or--29 patients). Prednisone 173-183 natriuretic peptide A Homo sapiens 96-99 2253832-7 1990 The insulin-stimulated peripheral glucose uptake was reduced in the prednisone-treated group, but normal in cyclosporin-treated subjects. Prednisone 68-78 insulin Homo sapiens 4-11 2337859-5 1990 Reduction of the interferon dose or discontinuation of IFN treatment was necessary in only two of 23 patients receiving IFN plus prednisone. Prednisone 129-139 interferon alpha 1 Homo sapiens 55-58 2337859-7 1990 The subjective tolerability of a high dose of IFN is significantly increased if oral prednisone (10-20 mg) is given concomitantly in patients with metastatic renal cell carcinoma without reducing the response rate. Prednisone 85-95 interferon alpha 1 Homo sapiens 46-49 2395496-1 1990 The basal and calcium-stimulated calcitonin response was measured in 10 patients with giant cell arteritis before and 1, 3 and 6 wk after the start of daily treatment with 60 mg of prednisone. Prednisone 181-191 calcitonin related polypeptide alpha Homo sapiens 33-43 2395496-2 1990 The study shows that plasma calcitonin level in response to a calcium injection is increased after 1 wk treatment with prednisone. Prednisone 119-129 calcitonin related polypeptide alpha Homo sapiens 28-38 2255787-6 1990 Prednisone therapy improved the patient"s pulmonary function testing while constitutional symptoms, splenomegaly and elevated angiotensin-converting enzyme levels completely resolved. Prednisone 0-10 angiotensin I converting enzyme Homo sapiens 126-155 2195062-0 1990 Human growth hormone prevents the protein catabolic side effects of prednisone in humans. Prednisone 68-78 growth hormone 1 Homo sapiens 6-20 1974669-2 1990 We observed that the steroidal anti-inflammatory agent prednisone, but not the nonsteroidal anti-inflammatory agent indomethacin, inhibits the late (but not the early) asthmatic reactions induced by TDI. Prednisone 55-65 TLX1 neighbor Homo sapiens 199-202 2088967-5 1990 CsA, azathioprine and prednisone all appear to have the potential for adverse effects variously on islet engraftment, insulin secretion, and/or peripheral insulin activity. Prednisone 22-32 insulin Homo sapiens 118-125 2088967-5 1990 CsA, azathioprine and prednisone all appear to have the potential for adverse effects variously on islet engraftment, insulin secretion, and/or peripheral insulin activity. Prednisone 22-32 insulin Homo sapiens 155-162 2160758-0 1990 [Effect of 1 week"s administration of prednisone on gastric acid secretion and liberation of gastrin in healthy humans]. Prednisone 38-48 gastrin Homo sapiens 93-100 2160758-1 1990 In a double-blind, randomized study we examined the effects of an oral administration of prednisone (60 mg/day for 6 days) or placebo on gastric acid output basally (BAO), in response to peptone meals 1%, 2%, 4% and 8%, 500 ml each) and to pentagastrin 6 micrograms/kg s.c. to determine maximal acid output, MAO) and on plasma gastrin levels in 14 healthy volunteers. Prednisone 89-99 gastrin Homo sapiens 245-252 1974669-3 1990 Prednisone also inhibits the increase of bronchial responsiveness and the increase of neutrophils, eosinophils, and albumin in bronchoalveolar lavage fluid that are associated with late asthmatic reactions induced by exposure to TDI. Prednisone 0-10 TLX1 neighbor Homo sapiens 229-232 33233444-2 2020 CHOP, consisting of cyclophosphamide (CPA), doxorubicin, vincristine, and prednisone, is a first-generation chemotherapy extensively used to treat NHL. Prednisone 74-84 DNA-damage inducible transcript 3 Mus musculus 0-4 33944646-5 2021 The main focus of this study was on newly diagnosed patients receiving cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) versus other chemotherapy. Prednisone 119-129 DNA damage inducible transcript 3 Homo sapiens 131-135 30011421-10 2018 CONCLUSION: In our cohort of CTD-ILD, two courses of pulse dose methylprednisolone therapy followed by prednisone and oral tacrolimus appeared to be well tolerated, and to have multidimensional efficacy. Prednisone 103-113 CTD Homo sapiens 29-32 25750184-10 2015 After prednisone treatment, serum HSPA5 levels significantly decreased compared to baseline in steroid responders, but no marked decrease was observed in steroid non-responders. Prednisone 6-16 heat shock protein family A (Hsp70) member 5 Homo sapiens 34-39 29600943-11 2018 Daily prednisone dose had an inverse association with lower serum IL-4, IL6, IL-17A, IL-17E, IL-22 and IL-23. Prednisone 6-16 interleukin 4 Homo sapiens 66-70 29600943-11 2018 Daily prednisone dose had an inverse association with lower serum IL-4, IL6, IL-17A, IL-17E, IL-22 and IL-23. Prednisone 6-16 interleukin 6 Homo sapiens 72-75 29600943-11 2018 Daily prednisone dose had an inverse association with lower serum IL-4, IL6, IL-17A, IL-17E, IL-22 and IL-23. Prednisone 6-16 interleukin 17A Homo sapiens 77-83 29600943-11 2018 Daily prednisone dose had an inverse association with lower serum IL-4, IL6, IL-17A, IL-17E, IL-22 and IL-23. Prednisone 6-16 interleukin 25 Homo sapiens 85-91 29600943-11 2018 Daily prednisone dose had an inverse association with lower serum IL-4, IL6, IL-17A, IL-17E, IL-22 and IL-23. Prednisone 6-16 interleukin 22 Homo sapiens 93-98 29600943-11 2018 Daily prednisone dose had an inverse association with lower serum IL-4, IL6, IL-17A, IL-17E, IL-22 and IL-23. Prednisone 6-16 interleukin 23 subunit alpha Homo sapiens 103-108 25593303-11 2015 CONCLUSIONS: Both ERG-rearranged and wild-type cancers had a significant improvement in rPFS with abiraterone acetate and prednisone in the COU-AA-302 trial. Prednisone 122-132 ETS transcription factor ERG Homo sapiens 18-21 34904799-1 2022 BACKGROUND: Diffuse large B-cell lymphoma (DLBCL) is typically treated with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP). Prednisone 135-145 DNA damage inducible transcript 3 Homo sapiens 149-153 34851173-3 2022 Results: Fifty-five clinical studies were included, mostly investigating cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) or "CHOP-like" regimens, with combination regimens showing similar effectiveness to CHOP alone. Prednisone 120-130 DNA damage inducible transcript 3 Homo sapiens 132-136 24210085-10 2013 Abiraterone-prednisone showed superiority over prednisone alone with respect to time to initiation of cytotoxic chemotherapy, opiate use for cancer-related pain, prostate-specific antigen progression, and decline in performance status. Prednisone 12-22 kallikrein related peptidase 3 Homo sapiens 162-187 34936546-8 2021 RESULTS: In the multivariable regression analysis that included prednisone intake, a significant relation of ApoC3 to C-peptide was found (beta coef. Prednisone 64-74 apolipoprotein C3 Homo sapiens 109-114 34864064-0 2022 Prednisone stimulates white adipocyte browning via beta3-AR/p38 MAPK/ERK signaling pathway. Prednisone 0-10 adenosine A3 receptor Mus musculus 51-59 34864064-0 2022 Prednisone stimulates white adipocyte browning via beta3-AR/p38 MAPK/ERK signaling pathway. Prednisone 0-10 mitogen-activated protein kinase 14 Mus musculus 60-68 34864064-0 2022 Prednisone stimulates white adipocyte browning via beta3-AR/p38 MAPK/ERK signaling pathway. Prednisone 0-10 mitogen-activated protein kinase 1 Mus musculus 69-72 34864064-4 2022 KEY FINDINGS: Exposure to prednisone stimulated browning in 3 T3-L1 white adipocytes by increasing the expressions of core fat browning marker proteins (UCP1, PGC-1alpha and PRDM16) as well as beige-specific genes (Cd137, Cidea, Cited1, and Tbx1) via ATF2 and CREB activation mediated by p38 MAPK and ERK signaling, respectively. Prednisone 26-36 uncoupling protein 1 (mitochondrial, proton carrier) Mus musculus 153-157 34864064-4 2022 KEY FINDINGS: Exposure to prednisone stimulated browning in 3 T3-L1 white adipocytes by increasing the expressions of core fat browning marker proteins (UCP1, PGC-1alpha and PRDM16) as well as beige-specific genes (Cd137, Cidea, Cited1, and Tbx1) via ATF2 and CREB activation mediated by p38 MAPK and ERK signaling, respectively. Prednisone 26-36 peroxisome proliferative activated receptor, gamma, coactivator 1 alpha Mus musculus 159-169 34864064-4 2022 KEY FINDINGS: Exposure to prednisone stimulated browning in 3 T3-L1 white adipocytes by increasing the expressions of core fat browning marker proteins (UCP1, PGC-1alpha and PRDM16) as well as beige-specific genes (Cd137, Cidea, Cited1, and Tbx1) via ATF2 and CREB activation mediated by p38 MAPK and ERK signaling, respectively. Prednisone 26-36 PR domain containing 16 Mus musculus 174-180 34864064-4 2022 KEY FINDINGS: Exposure to prednisone stimulated browning in 3 T3-L1 white adipocytes by increasing the expressions of core fat browning marker proteins (UCP1, PGC-1alpha and PRDM16) as well as beige-specific genes (Cd137, Cidea, Cited1, and Tbx1) via ATF2 and CREB activation mediated by p38 MAPK and ERK signaling, respectively. Prednisone 26-36 tumor necrosis factor receptor superfamily, member 9 Mus musculus 215-220 34864064-4 2022 KEY FINDINGS: Exposure to prednisone stimulated browning in 3 T3-L1 white adipocytes by increasing the expressions of core fat browning marker proteins (UCP1, PGC-1alpha and PRDM16) as well as beige-specific genes (Cd137, Cidea, Cited1, and Tbx1) via ATF2 and CREB activation mediated by p38 MAPK and ERK signaling, respectively. Prednisone 26-36 cell death-inducing DNA fragmentation factor, alpha subunit-like effector A Mus musculus 222-227 34864064-4 2022 KEY FINDINGS: Exposure to prednisone stimulated browning in 3 T3-L1 white adipocytes by increasing the expressions of core fat browning marker proteins (UCP1, PGC-1alpha and PRDM16) as well as beige-specific genes (Cd137, Cidea, Cited1, and Tbx1) via ATF2 and CREB activation mediated by p38 MAPK and ERK signaling, respectively. Prednisone 26-36 Cbp/p300-interacting transactivator with Glu/Asp-rich carboxy-terminal domain 1 Mus musculus 229-235 34864064-4 2022 KEY FINDINGS: Exposure to prednisone stimulated browning in 3 T3-L1 white adipocytes by increasing the expressions of core fat browning marker proteins (UCP1, PGC-1alpha and PRDM16) as well as beige-specific genes (Cd137, Cidea, Cited1, and Tbx1) via ATF2 and CREB activation mediated by p38 MAPK and ERK signaling, respectively. Prednisone 26-36 T-box 1 Mus musculus 241-245 34864064-4 2022 KEY FINDINGS: Exposure to prednisone stimulated browning in 3 T3-L1 white adipocytes by increasing the expressions of core fat browning marker proteins (UCP1, PGC-1alpha and PRDM16) as well as beige-specific genes (Cd137, Cidea, Cited1, and Tbx1) via ATF2 and CREB activation mediated by p38 MAPK and ERK signaling, respectively. Prednisone 26-36 activating transcription factor 2 Mus musculus 251-255 34864064-4 2022 KEY FINDINGS: Exposure to prednisone stimulated browning in 3 T3-L1 white adipocytes by increasing the expressions of core fat browning marker proteins (UCP1, PGC-1alpha and PRDM16) as well as beige-specific genes (Cd137, Cidea, Cited1, and Tbx1) via ATF2 and CREB activation mediated by p38 MAPK and ERK signaling, respectively. Prednisone 26-36 cAMP responsive element binding protein 1 Mus musculus 260-264 34864064-4 2022 KEY FINDINGS: Exposure to prednisone stimulated browning in 3 T3-L1 white adipocytes by increasing the expressions of core fat browning marker proteins (UCP1, PGC-1alpha and PRDM16) as well as beige-specific genes (Cd137, Cidea, Cited1, and Tbx1) via ATF2 and CREB activation mediated by p38 MAPK and ERK signaling, respectively. Prednisone 26-36 mitogen-activated protein kinase 14 Mus musculus 288-296 34864064-4 2022 KEY FINDINGS: Exposure to prednisone stimulated browning in 3 T3-L1 white adipocytes by increasing the expressions of core fat browning marker proteins (UCP1, PGC-1alpha and PRDM16) as well as beige-specific genes (Cd137, Cidea, Cited1, and Tbx1) via ATF2 and CREB activation mediated by p38 MAPK and ERK signaling, respectively. Prednisone 26-36 mitogen-activated protein kinase 1 Mus musculus 301-304 34864064-6 2022 In addition, prednisone treatment resulted in reduced expression levels of adipogenic transcription factors while elevating SIRT1, as well as attenuation of lipogenesis and lipid droplets formation. Prednisone 13-23 sirtuin 1 Mus musculus 124-129 34864064-7 2022 Furthermore, molecular docking and mechanistic studies demonstrated the recruitment of beige fat by prednisone via the beta3-AR/p38 MAPK/ERK signaling pathway. Prednisone 100-110 adenosine A3 receptor Mus musculus 119-127 34864064-7 2022 Furthermore, molecular docking and mechanistic studies demonstrated the recruitment of beige fat by prednisone via the beta3-AR/p38 MAPK/ERK signaling pathway. Prednisone 100-110 mitogen-activated protein kinase 14 Mus musculus 128-136 34864064-7 2022 Furthermore, molecular docking and mechanistic studies demonstrated the recruitment of beige fat by prednisone via the beta3-AR/p38 MAPK/ERK signaling pathway. Prednisone 100-110 mitogen-activated protein kinase 1 Mus musculus 137-140 34843406-2 2022 Cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) therapy is widely used as first-line treatment of PTCL; however, it has limited efficacy. Prednisone 48-58 DNA damage inducible transcript 3 Homo sapiens 60-64 34304246-3 2022 The glucocorticoid drug prednisone is established as a major player in the treatment of leukemia and the in vivo response to prednisone monotreatment is currently the best indicator of risk for MLL-r iALL. Prednisone 24-34 lysine methyltransferase 2A Homo sapiens 194-197 34304246-3 2022 The glucocorticoid drug prednisone is established as a major player in the treatment of leukemia and the in vivo response to prednisone monotreatment is currently the best indicator of risk for MLL-r iALL. Prednisone 125-135 lysine methyltransferase 2A Homo sapiens 194-197 34990523-2 2021 We investigated the predictive factors affecting CIN and FN incidence in patients with DLBCL receiving rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) chemotherapy with pegfilgrastim and conducted experiments to find reason for the occurrence of CIN even when pegfilgrastim was used. Prednisone 162-172 DNA damage inducible transcript 3 Homo sapiens 176-180 34921960-2 2022 The ECHELON-2 study demonstrated that brentuximab vedotin plus cyclophosphamide, doxorubicin, and prednisone (A+CHP) exhibited statistically superior progression-free survival (PFS) per independent central review and improvements in overall survival vs cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) for the frontline treatment of patients with systemic anaplastic large cell lymphoma or other CD30-positive PTCL. Prednisone 98-108 ras homolog family member V Homo sapiens 112-115 34921960-2 2022 The ECHELON-2 study demonstrated that brentuximab vedotin plus cyclophosphamide, doxorubicin, and prednisone (A+CHP) exhibited statistically superior progression-free survival (PFS) per independent central review and improvements in overall survival vs cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) for the frontline treatment of patients with systemic anaplastic large cell lymphoma or other CD30-positive PTCL. Prednisone 98-108 TNF receptor superfamily member 8 Homo sapiens 413-417 34174365-3 2021 In this case series, we report longer-term remission and relapse rates, anti-phospholipase A2 receptor (PLA2R) antibody levels, B cell levels, and serious adverse events in patients with PMN who received rituximab combined with an initial short course of low-dose oral cyclophosphamide and a course of rapidly tapered prednisone (RCP). Prednisone 318-328 CGRP receptor component Homo sapiens 330-333 34940065-0 2021 Durable Response to Brentuximab Vedotin Plus Cyclophosphamide, Doxorubicin, and Prednisone (BV-CHP) in a Patient with CD30-Positive PTCL Arising as a Post-Transplant Lymphoproliferative Disorder (PTLD). Prednisone 80-90 TNF receptor superfamily member 8 Homo sapiens 118-122 34956185-10 2021 Agrin-MG patients demonstrated slight improvement following treatment with either acetylcholinesterase inhibitor or prednisone; however, the combination of the two drugs could effectively relieve MG symptoms. Prednisone 116-126 agrin Homo sapiens 0-5 34565287-0 2021 Silencing aurora-kinase-A (AURKA) reinforced the sensitivity of diffuse large B-cell lymphoma cells to cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) via suppressing beta-Catenin and RAS-extracellular signal-regulated protein kinase (ERK1/2) pathway. Prednisone 151-161 aurora kinase A Homo sapiens 10-25 34424816-12 2021 Levels of CXCL12 and its receptor CXCR4 (C-X-C motif chemokine receptor 4) were increased in X-linked muscular dystrophy (mdx) mice (DMD models) but became significantly reduced after prednisone treatment. Prednisone 184-194 chemokine (C-X-C motif) ligand 12 Mus musculus 10-16 34424816-12 2021 Levels of CXCL12 and its receptor CXCR4 (C-X-C motif chemokine receptor 4) were increased in X-linked muscular dystrophy (mdx) mice (DMD models) but became significantly reduced after prednisone treatment. Prednisone 184-194 chemokine (C-X-C motif) receptor 4 Mus musculus 34-39 34424816-12 2021 Levels of CXCL12 and its receptor CXCR4 (C-X-C motif chemokine receptor 4) were increased in X-linked muscular dystrophy (mdx) mice (DMD models) but became significantly reduced after prednisone treatment. Prednisone 184-194 chemokine (C-X-C motif) receptor 4 Mus musculus 41-73 34565287-0 2021 Silencing aurora-kinase-A (AURKA) reinforced the sensitivity of diffuse large B-cell lymphoma cells to cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) via suppressing beta-Catenin and RAS-extracellular signal-regulated protein kinase (ERK1/2) pathway. Prednisone 151-161 aurora kinase A Homo sapiens 27-32 34565287-0 2021 Silencing aurora-kinase-A (AURKA) reinforced the sensitivity of diffuse large B-cell lymphoma cells to cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) via suppressing beta-Catenin and RAS-extracellular signal-regulated protein kinase (ERK1/2) pathway. Prednisone 151-161 DNA damage inducible transcript 3 Homo sapiens 163-167 34565287-1 2021 The therapeutic effects of standard cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) therapy for prevalent lymphoma diffuse large B-cell lymphoma (DLBC, DLBCL) still require improvement. Prednisone 83-93 DNA damage inducible transcript 3 Homo sapiens 95-99 34166800-3 2021 METHODS: This retrospective study included 77 patients with CS treated with prednisone monotherapy (n=32) or a combination with mycophenolate mofetil (MMF) (n=45) between 2003 and 2018. Prednisone 76-86 citrate synthase Homo sapiens 60-62 34166800-10 2021 CONCLUSIONS: MMF in combination with prednisone for treatment of CS may minimize corticosteroid exposure and reduce cardiac inflammation without significant adverse effects. Prednisone 37-47 citrate synthase Homo sapiens 65-67 34792864-11 2022 CXCL13 and MMP-3 were increased during treatment with prednisone, independent of disease activity. Prednisone 54-64 C-X-C motif chemokine ligand 13 Homo sapiens 0-6 34676685-3 2021 METHODS: A total of 267 patients diagnosed with diffuse large B-cell lymphoma who were treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) immunochemotherapy were retrospectively reviewed. Prednisone 163-173 DNA damage inducible transcript 3 Homo sapiens 177-181 34853306-5 2021 Prednisone is significantly more effective in suppressing EGFR inhibition-induced inflammatory signals. Prednisone 0-10 epidermal growth factor receptor Mus musculus 58-62 34853306-6 2021 Remarkably, prednisone induces a shutdown of bypass RTK signaling and inhibits key resistance signals such as STAT3, YAP and TNF-NF-kappaB. Prednisone 12-22 signal transducer and activator of transcription 3 Mus musculus 110-115 34853306-6 2021 Remarkably, prednisone induces a shutdown of bypass RTK signaling and inhibits key resistance signals such as STAT3, YAP and TNF-NF-kappaB. Prednisone 12-22 yes-associated protein 1 Mus musculus 117-120 34792864-11 2022 CXCL13 and MMP-3 were increased during treatment with prednisone, independent of disease activity. Prednisone 54-64 matrix metallopeptidase 3 Homo sapiens 11-16 34764434-3 2022 We aimed to evaluate the prognostic value of BCL2 expression determined by immunohistochemistry (IHC), incorporating both the staining intensity and proportion, in patients with de novo DLBCL who received rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) as first-line treatment. Prednisone 264-274 BCL2 apoptosis regulator Homo sapiens 45-49 34764434-3 2022 We aimed to evaluate the prognostic value of BCL2 expression determined by immunohistochemistry (IHC), incorporating both the staining intensity and proportion, in patients with de novo DLBCL who received rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) as first-line treatment. Prednisone 264-274 DNA damage inducible transcript 3 Homo sapiens 278-282 34732441-6 2021 Moreover, high risk, defined as co-expression of BTK and either or both BCL2/MYC, independently predicted shorter progression-free survival in patients treated with rituximab plus cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP) (all R-CHOP-treated patients: hazard ratio=2.565, p=0.044; R-CHOP-treated non-GCB subgroup: HR=3.833, p=0.019). Prednisone 227-237 Bruton tyrosine kinase Homo sapiens 49-52 34732168-11 2021 A more significant reduction of MuSK-ab titers was observed in patients receiving TAC or RTX plus Pred than those receiving AZA plus Pred. Prednisone 98-102 muscle associated receptor tyrosine kinase Homo sapiens 32-36 34732168-11 2021 A more significant reduction of MuSK-ab titers was observed in patients receiving TAC or RTX plus Pred than those receiving AZA plus Pred. Prednisone 133-137 muscle associated receptor tyrosine kinase Homo sapiens 32-36 34834246-6 2021 Low-dose MR prednisone seems to be able to improve the course of RA, reduce morning stiffness and morning serum levels of IL-6, and induce significant clinical benefits. Prednisone 12-22 interleukin 6 Homo sapiens 122-126 34872317-3 2021 METHODS: By retrospectively searching the hospital"s computer-database, we reviewed the records of DLBCL patients who underwent the first-line rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP)/R-CHOP-like immunochemotherapy at our institution from January 2012 to June 2019. Prednisone 206-216 DNA damage inducible transcript 3 Homo sapiens 220-224 34536949-2 2021 We hypothesised that finite-duration abiraterone acetate plus prednisone (Abi +P) added to ADT will further reduce the duration of treatment exposure by prolonging time to prostate-specific antigen (PSA) recurrence without impacting eugonad state recovery. Prednisone 62-72 kallikrein related peptidase 3 Homo sapiens 172-197 34536949-2 2021 We hypothesised that finite-duration abiraterone acetate plus prednisone (Abi +P) added to ADT will further reduce the duration of treatment exposure by prolonging time to prostate-specific antigen (PSA) recurrence without impacting eugonad state recovery. Prednisone 62-72 kallikrein related peptidase 3 Homo sapiens 199-202 34732441-6 2021 Moreover, high risk, defined as co-expression of BTK and either or both BCL2/MYC, independently predicted shorter progression-free survival in patients treated with rituximab plus cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP) (all R-CHOP-treated patients: hazard ratio=2.565, p=0.044; R-CHOP-treated non-GCB subgroup: HR=3.833, p=0.019). Prednisone 227-237 BCL2 apoptosis regulator Homo sapiens 72-76 34732441-6 2021 Moreover, high risk, defined as co-expression of BTK and either or both BCL2/MYC, independently predicted shorter progression-free survival in patients treated with rituximab plus cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP) (all R-CHOP-treated patients: hazard ratio=2.565, p=0.044; R-CHOP-treated non-GCB subgroup: HR=3.833, p=0.019). Prednisone 227-237 MYC proto-oncogene, bHLH transcription factor Homo sapiens 77-80 34732441-6 2021 Moreover, high risk, defined as co-expression of BTK and either or both BCL2/MYC, independently predicted shorter progression-free survival in patients treated with rituximab plus cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP) (all R-CHOP-treated patients: hazard ratio=2.565, p=0.044; R-CHOP-treated non-GCB subgroup: HR=3.833, p=0.019). Prednisone 227-237 DNA damage inducible transcript 3 Homo sapiens 241-245 34732441-6 2021 Moreover, high risk, defined as co-expression of BTK and either or both BCL2/MYC, independently predicted shorter progression-free survival in patients treated with rituximab plus cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP) (all R-CHOP-treated patients: hazard ratio=2.565, p=0.044; R-CHOP-treated non-GCB subgroup: HR=3.833, p=0.019). Prednisone 227-237 DNA damage inducible transcript 3 Homo sapiens 254-258 34075009-2 2021 MATERIAL AND METHODS: Forty-five patients who received first-line rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP) chemotherapy for DLBCL were included in the study. Prednisone 124-134 DNA damage inducible transcript 3 Homo sapiens 138-142 34668281-4 2021 Although anthracycline-based regimens such as cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) remain the standard first-line treatment for most aggressive PTCLs, there are important variations including incorporation of novel agents, use of radiotherapy and judicious consideration of stem cell transplantation. Prednisone 94-104 DNA damage inducible transcript 3 Homo sapiens 106-110 34815635-2 2021 This phase 1b study evaluated the safety, pharmacokinetics, and preliminary efficacy of chidamide in combination with cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) for treatment-naive PTCL patients. Prednisone 165-175 DNA damage inducible transcript 3 Homo sapiens 177-181 34668817-1 2022 Patients with diffuse large B-cell lymphoma (DLBCL) treated with the R-CHOP regime receive a high cumulative dose of prednisone. Prednisone 117-127 DNA damage inducible transcript 3 Homo sapiens 71-75 34521450-0 2021 Gut microbiota mediated the therapeutic efficacies and the side effects of prednisone in the treatment of MRL/lpr mice. Prednisone 75-85 Fas (TNF receptor superfamily member 6) Mus musculus 110-113 34638128-1 2022 Diffuse large B-cell lymphoma (DLBCL) is the most common B-cell malignancy with varying prognosis after the gold standard rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP). Prednisone 181-191 DNA damage inducible transcript 3 Homo sapiens 195-199 34581697-8 2022 The median (interquartile range) relative percent improvement in CK level was 96% (85%-98%) and in MMT was 29% (14%-36%) at 6 months.There was a significant reduction in the mean (SD) dose of prednisone at 6 months and had minimal adverse effects. Prednisone 192-202 cytidine/uridine monophosphate kinase 1 Homo sapiens 65-67 34521450-4 2021 Then, this study used fecal microbiota transplantation (FMT) to transfer the gut microbiota of prednisone-treated MRL/lpr mice into the blank MRL/lpr mice to reveal whether the gut microbiota regulated by prednisone had similar therapeutic efficiency and side effects as prednisone. Prednisone 95-105 Fas (TNF receptor superfamily member 6) Mus musculus 118-121 34521450-5 2021 RESULTS: The effects of prednisone on gut microbiota were dose-dependent in the treatment of MRL/lpr mice. Prednisone 24-34 Fas (TNF receptor superfamily member 6) Mus musculus 97-100 34521450-6 2021 After transplantation into MRL/lpr mice, prednisone-regulated gut microbiota could alleviate lupus, which might be due to decreasing Ruminococcus and Alistipes and retaining the abundance of Lactobacillus. Prednisone 41-51 Fas (TNF receptor superfamily member 6) Mus musculus 31-34 34552485-0 2021 Salvianolate Ameliorates Osteopenia and Improves Bone Quality in Prednisone-Treated Rheumatoid Arthritis Rats by Regulating RANKL/RANK/OPG Signaling. Prednisone 65-75 TNF superfamily member 11 Rattus norvegicus 124-129 34552485-0 2021 Salvianolate Ameliorates Osteopenia and Improves Bone Quality in Prednisone-Treated Rheumatoid Arthritis Rats by Regulating RANKL/RANK/OPG Signaling. Prednisone 65-75 TNF receptor superfamily member 11B Rattus norvegicus 135-138 34552485-16 2021 The results suggested that salvianolate treatment ameliorated osteopenia and improved bone quality in prednisone-treated RA rats, and the potential mechanism may be related to the regulation of the RANKL/RANK/OPG signaling pathway, TRAIL-TRAF6-NFkappaB signal axis, and downregulation of inflammatory cytokines. Prednisone 102-112 TNF superfamily member 11 Rattus norvegicus 198-203 34552485-16 2021 The results suggested that salvianolate treatment ameliorated osteopenia and improved bone quality in prednisone-treated RA rats, and the potential mechanism may be related to the regulation of the RANKL/RANK/OPG signaling pathway, TRAIL-TRAF6-NFkappaB signal axis, and downregulation of inflammatory cytokines. Prednisone 102-112 TNF receptor superfamily member 11B Rattus norvegicus 209-212 34552485-16 2021 The results suggested that salvianolate treatment ameliorated osteopenia and improved bone quality in prednisone-treated RA rats, and the potential mechanism may be related to the regulation of the RANKL/RANK/OPG signaling pathway, TRAIL-TRAF6-NFkappaB signal axis, and downregulation of inflammatory cytokines. Prednisone 102-112 TNF superfamily member 10 Rattus norvegicus 232-237 34552485-16 2021 The results suggested that salvianolate treatment ameliorated osteopenia and improved bone quality in prednisone-treated RA rats, and the potential mechanism may be related to the regulation of the RANKL/RANK/OPG signaling pathway, TRAIL-TRAF6-NFkappaB signal axis, and downregulation of inflammatory cytokines. Prednisone 102-112 TNF receptor associated factor 6 Rattus norvegicus 238-243 34485198-4 2021 Moreover, low-dose prednisone therapy can improve patients" exercise ability and prolong survival and may be a promising new avenue for ISPD therapy. Prednisone 19-29 CDP-L-ribitol pyrophosphorylase A Homo sapiens 136-140 34252986-4 2021 Presently we identified that pyruvate dehydrogenase kinase 4 (PDK4) is markedly elevated in DLBCL cells derived from both the patients and cell lines with R-CHOP (rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone regimen) resistant. Prednisone 226-236 pyruvate dehydrogenase kinase 4 Homo sapiens 29-60 34252986-4 2021 Presently we identified that pyruvate dehydrogenase kinase 4 (PDK4) is markedly elevated in DLBCL cells derived from both the patients and cell lines with R-CHOP (rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone regimen) resistant. Prednisone 226-236 pyruvate dehydrogenase kinase 4 Homo sapiens 62-66 34265889-2 2021 Chemotherapy with cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) +- rituximab has an intermediate FN risk. Prednisone 66-76 DNA damage inducible transcript 3 Homo sapiens 78-82 34428285-2 2022 Promising early-phase results were reported with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) plus subcutaneous azacitidine, a hypomethylating agent. Prednisone 108-118 DNA damage inducible transcript 3 Homo sapiens 122-126 34586105-2 2021 The current first-line regimen for the treatment of DLBCL is R-CHOP, which is the combination of rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone. Prednisone 155-165 DNA damage inducible transcript 3 Homo sapiens 63-67 34363461-5 2022 Age >= 30 years (OR = 2.09 (1.09; 3.99)) was associated with complete response, whereas vascular signs (0.26 (0.1; 0.65)), baseline prednisone >= 20 mg/day (0.51 (0.28; 0.93)) were negatively associated with the complete response to TNF-alpha antagonists or tocilizumab. Prednisone 132-142 tumor necrosis factor Homo sapiens 233-242 34602937-8 2021 We also found that the HSD11B1 gene which was differentially expressed in GM was used as drug target of prednisone, which is a common treatment for GM. Prednisone 104-114 hydroxysteroid 11-beta dehydrogenase 1 Homo sapiens 23-30 34488372-11 2021 CONCLUSIONS: Treatment with a combination of letrozole and prednisone may lower the rate of severe OHSS in women with prolonged gonadotropin-releasing hormone agonist protocol during assisted fertility treatment. Prednisone 59-69 gonadotropin releasing hormone 1 Homo sapiens 128-158 35397952-18 2022 PATIENT SUMMARY: We evaluated the efficacy and safety of the anti-PD-1 antibody pembrolizumab combined with the chemotherapy drug docetaxel and the steroid prednisone for patients with metastatic prostate cancer resistant to androgen deprivation therapy , and who never received chemotherapy. Prednisone 156-166 spermatogenesis associated 2 Homo sapiens 66-70 34193062-8 2021 Treatment with oral prednisone resulted in a decrease of eosinophil, serum IgE, improvement of cardiac function, and regression of the subcutaneous mass. Prednisone 20-30 immunoglobulin heavy constant epsilon Homo sapiens 75-78 32414850-1 2021 We conducted a phase I/II multicenter trial using 6 cycles of brentuximab vedotin (BV) in combination with rituximab, cyclophosphamide, doxorubicin, and prednisone (R-CHP) for treatment of patients with CD30-positive (+) B-cell lymphomas. Prednisone 153-163 TNF receptor superfamily member 8 Homo sapiens 203-207 34125606-1 2021 OBJECTIVE: To evaluate survival times for dogs with previously untreated, peripheral nodal, intermediate- or large-cell lymphoma treated with prednisone alone. Prednisone 142-152 nodal growth differentiation factor Canis lupus familiaris 85-90 34125606-12 2021 CONCLUSIONS AND CLINICAL RELEVANCE: Results suggested that survival times were short for dogs with previously untreated, peripheral nodal, intermediate- or large-cell lymphoma treated with prednisone alone. Prednisone 189-199 nodal growth differentiation factor Canis lupus familiaris 132-137 34327076-7 2021 She was treated with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) along with intrathecal methotrexate (IT MTX)/cytarabine after CNS involvement was diagnosed. Prednisone 80-90 DNA damage inducible transcript 3 Homo sapiens 94-98 34124276-1 2021 The majority of diffuse large B-cell lymphoma (DLBCL) patients develop relapsed or refractory disease after standard ruxolitinib, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) chemotherapy, which is partly related to a dysregulated tumor immune microenvironment. Prednisone 178-188 DNA damage inducible transcript 3 Homo sapiens 192-196 35278220-7 2022 The numbers of mononuclear cells also increase in 28 days (p=0.025) and TNF-alpha increases in the prednisone group on the 7th day (p = 0.041). Prednisone 99-109 tumor necrosis factor Rattus norvegicus 72-81 35514318-2 2022 Accumulation of CD138+ T cells in the spleen of MRL/lpr mice was significantly reduced by prednisone. Prednisone 90-100 syndecan 1 Mus musculus 16-21 35135708-8 2022 HPS complicated by EBV and CMV coinfection was finally diagnosed, and immediate administration of ganciclovir and prednisone was considered to have prevented a lethal clinical outcome. Prednisone 114-124 HPS1 biogenesis of lysosomal organelles complex 3 subunit 1 Homo sapiens 0-3 35514318-3 2022 Reduced expression of CD138 in DN T cells induced by prednisone treatment alleviated the accumulation of DN T cells in MRL/lpr mice. Prednisone 53-63 syndecan 1 Mus musculus 22-27 35514318-2 2022 Accumulation of CD138+ T cells in the spleen of MRL/lpr mice was significantly reduced by prednisone. Prednisone 90-100 Fas (TNF receptor superfamily member 6) Mus musculus 52-55 35514318-3 2022 Reduced expression of CD138 in DN T cells induced by prednisone treatment alleviated the accumulation of DN T cells in MRL/lpr mice. Prednisone 53-63 Fas (TNF receptor superfamily member 6) Mus musculus 123-126 35514318-4 2022 The frequency of CD138+ cells in CD4+ T cells of prednisone-treated MRL/lpr mice was also significantly reduced, which subsequently contributed to reduced production of anti-dsDNA antibody in the prednisone-treated MRL/lpr mice. Prednisone 49-59 syndecan 1 Mus musculus 17-22 35514318-4 2022 The frequency of CD138+ cells in CD4+ T cells of prednisone-treated MRL/lpr mice was also significantly reduced, which subsequently contributed to reduced production of anti-dsDNA antibody in the prednisone-treated MRL/lpr mice. Prednisone 49-59 CD4 antigen Mus musculus 33-36 35514318-4 2022 The frequency of CD138+ cells in CD4+ T cells of prednisone-treated MRL/lpr mice was also significantly reduced, which subsequently contributed to reduced production of anti-dsDNA antibody in the prednisone-treated MRL/lpr mice. Prednisone 49-59 Fas (TNF receptor superfamily member 6) Mus musculus 72-75 35363257-0 2022 Intermittent prednisone treatment in mice promotes exercise tolerance in obesity through adiponectin. Prednisone 13-23 adiponectin, C1Q and collagen domain containing Mus musculus 89-100 35514318-4 2022 The frequency of CD138+ cells in CD4+ T cells of prednisone-treated MRL/lpr mice was also significantly reduced, which subsequently contributed to reduced production of anti-dsDNA antibody in the prednisone-treated MRL/lpr mice. Prednisone 49-59 Fas (TNF receptor superfamily member 6) Mus musculus 219-222 35514318-4 2022 The frequency of CD138+ cells in CD4+ T cells of prednisone-treated MRL/lpr mice was also significantly reduced, which subsequently contributed to reduced production of anti-dsDNA antibody in the prednisone-treated MRL/lpr mice. Prednisone 196-206 syndecan 1 Mus musculus 17-22 35514318-4 2022 The frequency of CD138+ cells in CD4+ T cells of prednisone-treated MRL/lpr mice was also significantly reduced, which subsequently contributed to reduced production of anti-dsDNA antibody in the prednisone-treated MRL/lpr mice. Prednisone 196-206 CD4 antigen Mus musculus 33-36 35514318-4 2022 The frequency of CD138+ cells in CD4+ T cells of prednisone-treated MRL/lpr mice was also significantly reduced, which subsequently contributed to reduced production of anti-dsDNA antibody in the prednisone-treated MRL/lpr mice. Prednisone 196-206 Fas (TNF receptor superfamily member 6) Mus musculus 219-222 35363257-6 2022 Here we report that in mice with diet-induced obesity, intermittent once-weekly prednisone increased total and high-molecular weight adiponectin levels and improved exercise tolerance and energy expenditure. Prednisone 80-90 adiponectin, C1Q and collagen domain containing Mus musculus 133-144 35020444-14 2022 Of clinical trial patients, concomitant abiraterone/prednisone recipients (n=109 of 180, 60.6%) were more likely to report dAE (OR=3.1 (95% CI 1.53-6.17); p=0.002). Prednisone 52-62 Anion exchanger 2 Drosophila melanogaster 123-126 35383559-10 2022 The use of prednisone, disease-modifying anti-rheumatic drugs and anti-tumour necrosis factor therapies was associated with lower values of ApoC3. Prednisone 11-21 apolipoprotein C3 Homo sapiens 140-145 34605672-0 2022 PLCL vascular external sheath carrying prednisone for improving patency rate of the vein graft. Prednisone 39-49 phospholipase C-like 1 Mus musculus 0-4 35494533-2 2022 We report a 45-year-old man with non-small-cell lung cancer who developed hypophysitis 11 months after initiation of treatment with an anti-PD-L1/CTLA-4 bispecific antibody (KN046) that blocks both programmed death ligand-1 (PD-L1) and cytotoxic T-lymphocyte antigen-4 (CTLA-4), followed by regular oral replacement doses of prednisone and levothyroxine tablets. Prednisone 325-335 CD274 molecule Homo sapiens 140-145 35494533-2 2022 We report a 45-year-old man with non-small-cell lung cancer who developed hypophysitis 11 months after initiation of treatment with an anti-PD-L1/CTLA-4 bispecific antibody (KN046) that blocks both programmed death ligand-1 (PD-L1) and cytotoxic T-lymphocyte antigen-4 (CTLA-4), followed by regular oral replacement doses of prednisone and levothyroxine tablets. Prednisone 325-335 cytotoxic T-lymphocyte associated protein 4 Homo sapiens 146-152 34605672-5 2022 The prednisone loaded in the PLCL sheath was slowly released during the degradation process of PLCL. Prednisone 4-14 phospholipase C-like 1 Mus musculus 29-33 34605672-5 2022 The prednisone loaded in the PLCL sheath was slowly released during the degradation process of PLCL. Prednisone 4-14 phospholipase C-like 1 Mus musculus 95-99 35468783-1 2022 BACKGROUND: Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) has been used to treat patients with diffuse large B-cell lymphoma (DLBCL) under National Health Insurance (NHI) scheme in Indonesia. Prednisone 75-85 DNA damage inducible transcript 3 Homo sapiens 89-93 35347442-12 2022 According to the MD simulation results, prednisone appears to have a higher affinity for TNF-alpha than progesterone, and consequently, the prednisone complex stability is higher. Prednisone 40-50 tumor necrosis factor Homo sapiens 89-98 35573753-3 2022 We report a case of a 67-year-old woman with a story of non-Hodgkin lymphoma treated with R-CHOP (rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone), who got a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection while being totally depleted of B cells. Prednisone 161-171 DNA damage inducible transcript 3 Homo sapiens 92-96 35347442-12 2022 According to the MD simulation results, prednisone appears to have a higher affinity for TNF-alpha than progesterone, and consequently, the prednisone complex stability is higher. Prednisone 140-150 tumor necrosis factor Homo sapiens 89-98 35347442-13 2022 For the first time, this study examined the possible role of prednisone and progesterone in inhibiting TNF-alpha using in silico methods. Prednisone 61-71 tumor necrosis factor Homo sapiens 103-112 35325041-8 2022 Higher adiponectin levels were associated with older age, male sex, white race, lower body mass index (BMI), autoantibody seropositivity, radiographic damage, longer disease duration, prednisone use, and osteoporosis. Prednisone 184-194 adiponectin, C1Q and collagen domain containing Homo sapiens 7-18 35392483-3 2022 With the advent of new therapeutic options, it becomes necessary to predict responses to the standard treatment based on rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP). Prednisone 180-190 DNA damage inducible transcript 3 Homo sapiens 194-198 35392613-5 2022 Results: The model was as follows: Y = 0.0322 x (age) - 0.0696 x (gender) + 0.5492 x (underlying disease) + 0.0963 x (the cumulative dose of prednisone during pre-engraftment phase) - 0.0771 x (CD34+ cell counts in graft) - 1.2926. Prednisone 141-151 CD34 molecule Homo sapiens 194-198 35317846-2 2022 The standard treatment for canine lymphoma is "CHOP" multiagent chemotherapy protocol consisting of Cyclophosphamide, Doxorubicin (Hydroxydaunorubicin), Vincristine (Oncovin ), and Prednisone. Prednisone 181-191 DNA damage inducible transcript 3 Homo sapiens 47-51 35349421-9 2022 However, the use of prednisone and the presence of musculoskeletal manifestations were significantly related to higher alpha-Klotho serum levels. Prednisone 20-30 klotho Homo sapiens 125-131 35244050-4 2022 PATIENT CONCERNS: A 48-year-old Chinese male patient with MALT lymphoma and API2/MALT received 2 courses of standard-dose rituximab, cyclophosphamide, vincristine, prednisone regimen chemotherapy combined with Helicobacter pylori eradication therapy. Prednisone 164-174 baculoviral IAP repeat containing 3 Homo sapiens 76-80 35451406-1 2022 ABSTRACT: Maintaining relative dose intensity (RDI) of rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) improves the prognosis of patients with diffuse large B-cell lymphoma (DLBCL). Prednisone 114-124 DNA damage inducible transcript 3 Homo sapiens 128-132 35317326-7 2022 In comparison to non-stimulated healthy donor neutrophils, prednisone GC neutrophils exhibited enhanced phagocytosis and G-CSF GC neutrophils showed decreased chemotaxis but increased IL-8 production. Prednisone 59-69 colony stimulating factor 3 Homo sapiens 121-126 35179955-6 2022 The light-phase prednisone pulse promoted BMAL1-dependent glucocorticoid receptor recruitment on noncanonical targets, including Nampt and Ppargc1a (peroxisome proliferator-activated receptor-gamma coactivator 1alpha (PGC1alpha)). Prednisone 16-26 nicotinamide phosphoribosyltransferase Mus musculus 129-134 35148603-1 2022 The aim of this study was to evaluate the efficacy and safety of prednisone monotherapy for phospholipase A2 receptor (PLA2R)-associated idiopathic membranous nephropathy (IMN). Prednisone 65-75 phospholipase A2 receptor 1 Homo sapiens 92-117 35148603-1 2022 The aim of this study was to evaluate the efficacy and safety of prednisone monotherapy for phospholipase A2 receptor (PLA2R)-associated idiopathic membranous nephropathy (IMN). Prednisone 65-75 phospholipase A2 receptor 1 Homo sapiens 119-124 35486884-5 2022 RESULTS: Most patients with NHL received 1L chemoimmunotherapy, most commonly cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) with/without rituximab. Prednisone 126-136 DNA damage inducible transcript 3 Homo sapiens 138-142 35184644-5 2022 When assessing which treatments have the greatest impact on AMH levels, we found that the BEACOPP regimen, and the agents vincristine, etoposide, procarbazine, prednisone and the haematopoietic stem cell transplantation were mainly responsible. Prednisone 160-170 anti-Mullerian hormone Homo sapiens 60-63 35179955-6 2022 The light-phase prednisone pulse promoted BMAL1-dependent glucocorticoid receptor recruitment on noncanonical targets, including Nampt and Ppargc1a (peroxisome proliferator-activated receptor-gamma coactivator 1alpha (PGC1alpha)). Prednisone 16-26 peroxisome proliferative activated receptor, gamma, coactivator 1 alpha Mus musculus 139-147 35179955-6 2022 The light-phase prednisone pulse promoted BMAL1-dependent glucocorticoid receptor recruitment on noncanonical targets, including Nampt and Ppargc1a (peroxisome proliferator-activated receptor-gamma coactivator 1alpha (PGC1alpha)). Prednisone 16-26 peroxisome proliferative activated receptor, gamma, coactivator 1 alpha Mus musculus 149-216 35179955-6 2022 The light-phase prednisone pulse promoted BMAL1-dependent glucocorticoid receptor recruitment on noncanonical targets, including Nampt and Ppargc1a (peroxisome proliferator-activated receptor-gamma coactivator 1alpha (PGC1alpha)). Prednisone 16-26 peroxisome proliferative activated receptor, gamma, coactivator 1 alpha Mus musculus 218-227 35179955-7 2022 In mice with muscle-restricted inducible PGC1alpha ablation, bioenergetic stimulation by light-phase prednisone required PGC1alpha. Prednisone 101-111 peroxisome proliferative activated receptor, gamma, coactivator 1 alpha Mus musculus 41-50 35179955-7 2022 In mice with muscle-restricted inducible PGC1alpha ablation, bioenergetic stimulation by light-phase prednisone required PGC1alpha. Prednisone 101-111 peroxisome proliferative activated receptor, gamma, coactivator 1 alpha Mus musculus 121-130 35096395-6 2022 She received six cycles R-CHOP chemotherapy (rituximab, cyclophosphamide, epirubicin, vincristine, and prednisone) with complete resolution of the mass. Prednisone 103-113 DNA damage inducible transcript 3 Homo sapiens 26-30 35350808-3 2022 Herein, we present a patient with metastatic castration-resistant prostate cancer, with progression to soft tissues, bone, and regional lymph nodes, who was treated with abiraterone plus prednisone, with excellent prostate-specific antigen response. Prednisone 187-197 kallikrein related peptidase 3 Homo sapiens 214-239 35158997-5 2022 There is no definitive guideline for the treatment of PEL, although CHOP-like regimens (cyclophosphamide, doxorubicin, vincristine, and prednisone) are frequently prescribed and, given the rarity of this disease, therapeutic focus is being redirected to personalized and targeted approaches in the experimental realm. Prednisone 136-146 DNA damage inducible transcript 3 Homo sapiens 68-72 35166148-4 2022 Prednisone altered expression of hypothalamic neuropeptides melanin-concentrating hormone and histidine decarboxylase within the lateral and posterior hypothalamus, respectively. Prednisone 0-10 histidine decarboxylase Mus musculus 94-117 35141236-10 2021 In addition, we identified that the association of polymorphisms in TLR1/rs4833095, TLR2/rs3804099, and TLR6/rs5783810 with the dose variation of prednisone also were time-dependent. Prednisone 146-156 toll like receptor 1 Homo sapiens 68-72 35141236-10 2021 In addition, we identified that the association of polymorphisms in TLR1/rs4833095, TLR2/rs3804099, and TLR6/rs5783810 with the dose variation of prednisone also were time-dependent. Prednisone 146-156 toll like receptor 2 Homo sapiens 84-88 35141236-10 2021 In addition, we identified that the association of polymorphisms in TLR1/rs4833095, TLR2/rs3804099, and TLR6/rs5783810 with the dose variation of prednisone also were time-dependent. Prednisone 146-156 toll like receptor 6 Homo sapiens 104-108 2531180-7 1989 In the 3 groups the beta-endorphin decrease corresponded to the period of prednisone therapy; the increase was concomitant with the suspension of oral glucocorticoids. Prednisone 74-84 proopiomelanocortin Homo sapiens 20-34 35089671-3 2022 Rituximab (Rituxan), cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) is the current standard of care and cures more than 60% of patients. Prednisone 69-79 DNA damage inducible transcript 3 Homo sapiens 83-87 35023680-6 2022 Then, the relationships between SMC4 expression and clinical features, such as gender, age, white blood cell (WBC) count, French-American-British (FAB) classification, immunophenotype, fusion gene, prednisone response, and minimal residual disease (MRD) were determined. Prednisone 198-208 structural maintenance of chromosomes 4 Homo sapiens 32-36 35043219-5 2022 Importantly, the levels of salivary IL-6, IL-10, IFN-gamma, and TNF-alpha in RAS patients were significantly decreased following prednisone treatment (all P < 0.001). Prednisone 129-139 interleukin 6 Homo sapiens 36-40 35043219-5 2022 Importantly, the levels of salivary IL-6, IL-10, IFN-gamma, and TNF-alpha in RAS patients were significantly decreased following prednisone treatment (all P < 0.001). Prednisone 129-139 interleukin 10 Homo sapiens 42-47 35043219-5 2022 Importantly, the levels of salivary IL-6, IL-10, IFN-gamma, and TNF-alpha in RAS patients were significantly decreased following prednisone treatment (all P < 0.001). Prednisone 129-139 interferon gamma Homo sapiens 49-58 35043219-5 2022 Importantly, the levels of salivary IL-6, IL-10, IFN-gamma, and TNF-alpha in RAS patients were significantly decreased following prednisone treatment (all P < 0.001). Prednisone 129-139 tumor necrosis factor Homo sapiens 64-73 2596599-3 1989 In the postabsorptive state prednisone therapy increased (P less than 0.05) plasma concentrations of leucine, alpha-ketoisocaproate, glucose, insulin, and C-peptide, as well as leucine carbon flux and oxidation calculated by means of isotope dilution techniques and [1-13C]leucine. Prednisone 28-38 insulin Homo sapiens 110-164 2571541-0 1989 Contribution of insulin resistance to catabolic effect of prednisone on leucine metabolism in humans. Prednisone 58-68 insulin Homo sapiens 16-23 2651768-10 1989 The most likely candidates are the immunosuppressive drugs, such as cyclosporine and prednisone, which decrease MHC antigen expression. Prednisone 85-95 major histocompatibility complex, class I, C Homo sapiens 112-115 2778240-7 1989 Oral prednisone pretreatment significantly reduced the mean of each subject"s peak late-phase concentration of both MBP (30.7 +/- 5.8 ng/ml versus 13.3 +/- 4.3 ng/ml; p = 0.005) and EDN (885 +/- 659 ng/ml versus 71 +/- 41 ng/ml; p less than 0.05). Prednisone 5-15 myelin basic protein Homo sapiens 116-119 2778240-7 1989 Oral prednisone pretreatment significantly reduced the mean of each subject"s peak late-phase concentration of both MBP (30.7 +/- 5.8 ng/ml versus 13.3 +/- 4.3 ng/ml; p = 0.005) and EDN (885 +/- 659 ng/ml versus 71 +/- 41 ng/ml; p less than 0.05). Prednisone 5-15 ribonuclease A family member 2 Homo sapiens 182-185 2787959-0 1989 Marrow hypoplasia associated with a monoclonal CD8 large granular lymphocyte proliferation: reversal with cyclophosphamide and prednisone. Prednisone 127-137 CD8a molecule Homo sapiens 47-50 2474211-6 1989 In the pilot study, GAB (1.0-1.5 mg/kg/day) was given in 12-hr infusions, in association with prednisone (Pred) 1 mg/kg/day and azathioprine (Aza) 2 mg/kg/day, as prophylactic treatment of rejection in 12 kidney-transplanted patients during the first 2 weeks postgrafting. Prednisone 94-104 alpha-1-B glycoprotein Homo sapiens 20-23 2709088-2 1989 The rationale for this treatment was that some patients might still have hormone-sensitive disease that was stimulated by weak androgens of adrenal origin, and that these androgens could be suppressed by prednisone through its negative feedback on secretion of adrenocorticotrophic hormone (ACTH). Prednisone 204-214 proopiomelanocortin Homo sapiens 291-295 2466548-12 1989 Thirteen of 22 patients received cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) or CHOP/bleomycin as first chemotherapeutic regimen. Prednisone 81-91 DNA damage inducible transcript 3 Homo sapiens 93-97 2496614-8 1989 Following prednisone therapy, clinical and hemostatic findings were improved, and the multimeric patterns of vWF were normalized. Prednisone 10-20 von Willebrand factor Homo sapiens 109-112 2543690-7 1989 In keeping with her clinical picture, basal (24-h samples drawn every 60 min) and ovine CRH-stimulated plasma adrenal androgen (dehydroepiandrosterone sulfate and delta 4-androstenedione) concentrations and 24-h urinary 17-ketosteroid excretion were low on both the day on and the day off prednisone. Prednisone 289-299 corticotropin releasing hormone Homo sapiens 88-91 2702102-9 1989 We suggest that treatment with prednisone and azathioprine may be beneficial in children with severe IgAN and that a controlled clinical trial is warranted. Prednisone 31-41 IGAN1 Homo sapiens 101-105 2655543-5 1989 Fasting plasma glucose levels were not modified by deflazacort, whereas fasting plasma glucose levels together with insulin and C-peptide values were progressively and significantly increased by prednisone and betamethasone. Prednisone 195-205 insulin Homo sapiens 116-123 2485126-8 1989 The moderate dose prednisone therapy and Mega-dose Solu-Medrol therapy on CSF IgG anti-MBP antibody specific activity were less effective than the Mega-dose prednisone medication. Prednisone 18-28 myelin basic protein Homo sapiens 87-90 2912065-14 1989 The data strongly support the need for a prospective control trial of prednisone therapy in IgAN. Prednisone 70-80 IGAN1 Homo sapiens 92-96 2645703-8 1989 In patients receiving more than 5 mg of prednisone daily, growth hormone levels were lower than normal (less than 10 ng/ml). Prednisone 40-50 growth hormone 1 Homo sapiens 58-72 2645703-10 1989 In 4 pubescent children with growth retardation and need for maintenance prednisone, accelerated growth occurred following growth hormone administration for 3-6 months. Prednisone 73-83 growth hormone 1 Homo sapiens 123-137 2645703-11 1989 Based on these data we suggest that (1) discontinuation of even very small doses of prednisone may be essential for normalizing growth hormone response to L-dopa and (2) further studies are needed to exploit the growth stimulation effect of recombinant growth hormone in transplanted children. Prednisone 84-94 growth hormone 1 Homo sapiens 128-142 2645703-11 1989 Based on these data we suggest that (1) discontinuation of even very small doses of prednisone may be essential for normalizing growth hormone response to L-dopa and (2) further studies are needed to exploit the growth stimulation effect of recombinant growth hormone in transplanted children. Prednisone 84-94 growth hormone 1 Homo sapiens 253-267 2745931-8 1989 The rapid effect of prednisone suggests an impairement of proteolysis of thyroglobulin possibly due to a lysosomal action. Prednisone 20-30 thyroglobulin Homo sapiens 73-86 2744065-0 1989 Plasma cholinesterase activity in patients during therapy with dexamethasone or prednisone. Prednisone 80-90 butyrylcholinesterase Homo sapiens 7-21 2744065-2 1989 dexamethasone and oral prednisone on plasma cholinesterase (ChE) activity in 13 male and 10 female patients during long-term treatment with dexamethasone or prednisone. Prednisone 23-33 butyrylcholinesterase Homo sapiens 44-58 2744065-2 1989 dexamethasone and oral prednisone on plasma cholinesterase (ChE) activity in 13 male and 10 female patients during long-term treatment with dexamethasone or prednisone. Prednisone 23-33 butyrylcholinesterase Homo sapiens 60-63 2744065-6 1989 Our results suggest that the decrease in ChE activity in patients treated with dexamethasone or prednisone depends on the initial dose of the drug as well as on the duration of treatment. Prednisone 96-106 butyrylcholinesterase Homo sapiens 41-44 2642487-5 1989 After the patient had received immunosuppressive therapy with prednisone and cyclophosphamide for 3 months, her insulin resistance remitted, and she developed hypoglycemia. Prednisone 62-72 insulin Homo sapiens 112-119 3263379-0 1988 The effect of single oral doses of prednisone on the circadian rhythm of serum osteocalcin in normal subjects. Prednisone 35-45 bone gamma-carboxyglutamate protein Homo sapiens 79-90 2672532-4 1989 Patients who received cyclosporine A as immunosuppressive treatment excreted little or no EGF during the first month, while patients who received prednisone and azathioprine excreted EGF as early as four days after the transplantation. Prednisone 146-156 epidermal growth factor Homo sapiens 183-186 3142918-0 1988 Inhibition by prednisone of growth hormone (GH) response to GH-releasing hormone in normal men. Prednisone 14-24 growth hormone 1 Homo sapiens 28-42 3142918-0 1988 Inhibition by prednisone of growth hormone (GH) response to GH-releasing hormone in normal men. Prednisone 14-24 growth hormone 1 Homo sapiens 44-46 3142918-0 1988 Inhibition by prednisone of growth hormone (GH) response to GH-releasing hormone in normal men. Prednisone 14-24 growth hormone 1 Homo sapiens 60-62 3142918-5 1988 Prednisone significantly inhibited the mean maximal increase in serum GH after GHRH treatment [20.7 +/- 4.5 (+/- SE) vs. 6.3 +/- 2.4 micrograms/L; P less than 0.01] as well as the GH value obtained by summing and averaging the individual means of the 15, 30, 45, 60, 75, and 90 min serum GH concentrations (11.1 +/- 1.2 vs. 4.3 +/- 0.9 micrograms/L; P less than 0.05). Prednisone 0-10 growth hormone 1 Homo sapiens 70-72 3142918-5 1988 Prednisone significantly inhibited the mean maximal increase in serum GH after GHRH treatment [20.7 +/- 4.5 (+/- SE) vs. 6.3 +/- 2.4 micrograms/L; P less than 0.01] as well as the GH value obtained by summing and averaging the individual means of the 15, 30, 45, 60, 75, and 90 min serum GH concentrations (11.1 +/- 1.2 vs. 4.3 +/- 0.9 micrograms/L; P less than 0.05). Prednisone 0-10 growth hormone releasing hormone Homo sapiens 79-83 3142918-5 1988 Prednisone significantly inhibited the mean maximal increase in serum GH after GHRH treatment [20.7 +/- 4.5 (+/- SE) vs. 6.3 +/- 2.4 micrograms/L; P less than 0.01] as well as the GH value obtained by summing and averaging the individual means of the 15, 30, 45, 60, 75, and 90 min serum GH concentrations (11.1 +/- 1.2 vs. 4.3 +/- 0.9 micrograms/L; P less than 0.05). Prednisone 0-10 growth hormone 1 Homo sapiens 79-81 3142918-5 1988 Prednisone significantly inhibited the mean maximal increase in serum GH after GHRH treatment [20.7 +/- 4.5 (+/- SE) vs. 6.3 +/- 2.4 micrograms/L; P less than 0.01] as well as the GH value obtained by summing and averaging the individual means of the 15, 30, 45, 60, 75, and 90 min serum GH concentrations (11.1 +/- 1.2 vs. 4.3 +/- 0.9 micrograms/L; P less than 0.05). Prednisone 0-10 growth hormone 1 Homo sapiens 79-81 3069247-6 1988 Seventeen of 36 patients treated with Cyclosporine A and prednisone had at least 1 acute rejection; only 8 of these patients experienced a significant rise in the CRP (mean increase 27 micrograms/ml) and in only 5 of these did the increase occur prior to or on the day of rejection diagnosis. Prednisone 57-67 C-reactive protein Homo sapiens 163-166 3263379-2 1988 In a double blind placebo-controlled study, we measured the effects of 2.5 and 10 mg prednisone, orally, on the circadian variation of serum OC in 15 normal subjects (8 women and 7 men), aged 22-46 yr. All subjects were studied twice at an interval of 1 week. Prednisone 85-95 bone gamma-carboxyglutamate protein Homo sapiens 141-143 3263379-5 1988 After placebo administration serum OC increased from 2230 h to a peak value around 0230 h, followed by a gradual decline to a nadir around 1500 h. Both doses of prednisone inhibited and even reversed the nocturnal rise in serum OC levels; the inhibition occurred within 3-4 h. There was no significant difference in the time from prednisone ingestion to maximal decrease (7.2 h vs. 9.8 h) or in the maximal decrease (52% vs. 54%). Prednisone 161-171 bone gamma-carboxyglutamate protein Homo sapiens 35-37 3263379-5 1988 After placebo administration serum OC increased from 2230 h to a peak value around 0230 h, followed by a gradual decline to a nadir around 1500 h. Both doses of prednisone inhibited and even reversed the nocturnal rise in serum OC levels; the inhibition occurred within 3-4 h. There was no significant difference in the time from prednisone ingestion to maximal decrease (7.2 h vs. 9.8 h) or in the maximal decrease (52% vs. 54%). Prednisone 161-171 bone gamma-carboxyglutamate protein Homo sapiens 228-230 3263379-5 1988 After placebo administration serum OC increased from 2230 h to a peak value around 0230 h, followed by a gradual decline to a nadir around 1500 h. Both doses of prednisone inhibited and even reversed the nocturnal rise in serum OC levels; the inhibition occurred within 3-4 h. There was no significant difference in the time from prednisone ingestion to maximal decrease (7.2 h vs. 9.8 h) or in the maximal decrease (52% vs. 54%). Prednisone 330-340 bone gamma-carboxyglutamate protein Homo sapiens 35-37 3263379-7 1988 We conclude that serum OC is sensitive to small doses of prednisone, and that serial serum OC measurements may be a sensitive marker of the effect of exogenous glucocorticoids on osteoblastic activity in vivo. Prednisone 57-67 bone gamma-carboxyglutamate protein Homo sapiens 23-25 3185288-2 1988 After 14 days of prednisone, there was a significant increase in levels (mg/dL) of very low density lipoprotein-triglyceride (VLDL-TG) (51 +/- 9 v 92 +/- 11, P less than .01), very low density lipoprotein-cholesterol (VLDL-C) (19 +/- 2 v 28 +/- 3, P less than .01), high density lipoprotein-cholesterol (HDL-C) (39 +/- 1 v 50 +/- 4, P less than .05), apolipoprotein (apo) AI (124 +/- 7 v 147 +/- 8, P less than .01), and apo E (3.1 +/- 0.4 v 4.1 +/- 0.4, P less than .01). Prednisone 17-27 apolipoprotein A1 Homo sapiens 351-397 3185288-3 1988 In addition, the activity of lipoprotein lipase but not hepatic lipase in postheparin plasma also was higher after prednisone treatment. Prednisone 115-125 lipoprotein lipase Homo sapiens 29-47 3265902-6 1988 Fifteen patients treated with prednisone (5-25 mg once daily, mean 12.33 mg/day) showed a more marked decrease in serum OC than 13 patients treated with equivalent doses of deflazacort (p less than 0.005). Prednisone 30-40 bone gamma-carboxyglutamate protein Homo sapiens 120-122 3063418-6 1988 In 15 prednisone(Pr)-treated INS patients, beta 2m levels were normalized. Prednisone 6-16 beta-2-microglobulin Homo sapiens 43-50 2465387-2 1988 In the multiple sclerosis patients, CSF levels were determined just before and once in the period 3 to 10 weeks after the start of an immunosuppressive treatment with cyclophosphamide and prednisone. Prednisone 188-198 colony stimulating factor 2 Homo sapiens 36-39 2465387-7 1988 If CSF MBP is an indicator of the (activity of) myelin breakdown in the brain, it can be concluded that an intensive immunosuppressive treatment in combination with prednisone has, at least, a short-term, beneficial effect on the amount of demyelinisation and possibly on the disease activity. Prednisone 165-175 colony stimulating factor 2 Homo sapiens 3-6 2465387-7 1988 If CSF MBP is an indicator of the (activity of) myelin breakdown in the brain, it can be concluded that an intensive immunosuppressive treatment in combination with prednisone has, at least, a short-term, beneficial effect on the amount of demyelinisation and possibly on the disease activity. Prednisone 165-175 myelin basic protein Homo sapiens 7-10 3177368-2 1988 The M-protein and bone pain disappeared within 6 weeks after therapy with melphalan and prednisone was started. Prednisone 88-98 myomesin 2 Homo sapiens 4-13 3265902-7 1988 Prednisone therapy at doses higher than 10 mg/day resulted in a severe suppression of OC values in most cases. Prednisone 0-10 bone gamma-carboxyglutamate protein Homo sapiens 86-88 3060443-2 1988 We have investigated the relationship between RDI of the combination of cyclophosphamide, adriamycin, vincristine and prednisone (CHOP) and the results of therapy in a group of 78 newly diagnosed patients with diffuse histiocytic and diffuse mixed non-Hodgkin"s lymphoma. Prednisone 118-128 DNA damage inducible transcript 3 Homo sapiens 130-134 2828820-8 1988 However, despite increased serum levels of 1,25-dihydroxyvitamin D3, the prednisone-treated group revealed a 75% reduction in s-BGP. Prednisone 73-83 bone gamma-carboxyglutamate protein Homo sapiens 128-131 3410932-4 1988 The prednisone-treated group had higher mean plasma levels of triglyceride [2.06 +/- 1.3 (+/- SD) vs. 1.15 +/- 0.35 and 0.95 +/- 0.46 mmol/L; P less than 0.01], low density lipoprotein cholesterol [3.41 +/- 1.4 (+/- SD) vs. 2.79 +/- 0.67 and 2.84 +/- 0.70 mmol/L; P less than 0.01], and apoB [1.16 +/- 0.35 (+/- SD) vs. 0.82 +/- 0.13 and 0.76 +/- 0.22 g/L] than the other 2 groups. Prednisone 4-14 apolipoprotein B Homo sapiens 287-291 3410932-5 1988 Forty-three percent of the prednisone-treated group had apoB levels of 1.20 g/L or more compared to 7% of normal subjects and none of the untreated SLE group (P less than 0.05). Prednisone 27-37 apolipoprotein B Homo sapiens 56-60 3410932-6 1988 However, of the 12 prednisone-treated patients with elevated plasma apoB levels 5 had normal plasma lipid levels. Prednisone 19-29 apolipoprotein B Homo sapiens 68-72 3134387-13 1988 In summary, prednisone induces changes in serum HDL which are characterized by redistribution of particles within HDL density toward less dense particles and a quantitative rise of lipids in the HDL2 fraction. Prednisone 12-22 junctophilin 3 Homo sapiens 195-199 3367382-1 1988 The average relative dose intensity (DI) of conventional oral melphalan and prednisone therapy received by 93 newly diagnosed multiple myeloma patients was correlated with survival and with percent reduction in M-protein. Prednisone 76-86 myomesin 2 Homo sapiens 211-220 3264991-4 1988 When prednisone was discontinued, serum osteocalcin returned promptly to pretreatment levels. Prednisone 5-15 bone gamma-carboxyglutamate protein Homo sapiens 40-51 3264991-6 1988 Serum osteocalcin was not different from baseline after 5 mg of prednisone in five subjects, but after treatment of five subjects each with 10, 15, or 20 mg of prednisone, osteocalcin levels were 83%, 78%, and 74% of baseline, respectively (p less than 0.05). Prednisone 160-170 bone gamma-carboxyglutamate protein Homo sapiens 172-183 3070501-0 1988 [Serum gastrin level in patients treated with cyclosporin A or azathioprine with prednisone after kidney transplantation]. Prednisone 81-91 gastrin Homo sapiens 7-14 3263890-2 1988 In the prednisone group a 75% decrease (P less than 0.001) was found in serum BGP compared to a 6% decrease (P less than 0.05) in serum alkaline phosphatase. Prednisone 7-17 bone gamma-carboxyglutamate protein Homo sapiens 78-81 3397975-3 1988 We measured serum concentrations of insulin-like growth factor I and II in a group of children with systemic JA at different times, and during treatment with only nonsteroidal antiinflammatory therapy or while receiving prednisone. Prednisone 220-230 insulin like growth factor 1 Homo sapiens 36-71 3257806-10 1988 In contrast, serum BGP was significantly decreased by prednisone, with or without exercise (-35%, P less than .001). Prednisone 54-64 bone gamma-carboxyglutamate protein Homo sapiens 19-22 3123558-9 1988 Prednisone and 6-azathioprine reduced the level of IgG anti-Ro/SS-A autoantibody in sera of treated SCLE patients by 50%. Prednisone 0-10 tripartite motif containing 21 Homo sapiens 63-67 3203011-0 1988 Treatment of diffuse histiocytic and diffuse mixed non-Hodgkin lymphomas with cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP). Prednisone 125-135 DNA damage inducible transcript 3 Homo sapiens 137-141 3278431-13 1988 Since most patients started on CsA-prednisone are ultimately switched to triple drug therapy, the latter is now the preferred initial treatment modality. Prednisone 35-45 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 31-34 3272851-9 1988 At transplantation, CSA and prednisone patients were younger, i.e., 10.7 years (range 0.5-18) compared to 13.3 years (range 4-18) and (p less than 0.03) in azathioprine and prednisone patients. Prednisone 173-183 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 20-23 3111251-0 1987 Involvement of von Willebrand factor in thrombosis following asparaginase-prednisone-vincristine therapy for leukemia. Prednisone 74-84 von Willebrand factor Homo sapiens 15-36 2889125-4 1987 Moreover, the magnitude of these reductions was inversely related to the magnitude of prednisone-induced reductions in plasma ACTH levels, suggesting a functional interaction between circulating corticosteroids, central somatostatin and pituitary ACTH release. Prednisone 86-96 proopiomelanocortin Homo sapiens 126-130 2889125-4 1987 Moreover, the magnitude of these reductions was inversely related to the magnitude of prednisone-induced reductions in plasma ACTH levels, suggesting a functional interaction between circulating corticosteroids, central somatostatin and pituitary ACTH release. Prednisone 86-96 proopiomelanocortin Homo sapiens 247-251 3581030-0 1987 Cyclophosphamide, vincristine, adriamycin, and prednisone (CHOP) with and without intermediate dose methotrexate for the treatment of non-Hodgkin"s lymphomas of diffuse histology. Prednisone 47-57 DNA damage inducible transcript 3 Homo sapiens 59-63 3116843-7 1987 We speculate that therapy with CyA and prednisone inhibited the production of interleukins-1 and -2 from monocytes and T-cells, respectively, and was responsible for the reduction of the T gamma cell fraction and B-cell leukemic mass in this patient. Prednisone 39-49 interleukin 1 alpha Homo sapiens 78-99 3476201-8 1987 Mitoxantrone, vincristine, and prednisone are an active combination for the treatment of relapsed or refractory ALL and of terminal deoxynucleotidyl transferase positive BCML. Prednisone 31-41 DNA nucleotidylexotransferase Homo sapiens 123-160 3111251-1 1987 To determine if factor VIII-von Willebrand factor (vWF) complex is involved in the thrombosis associated with asparaginase-prednisone-vincristine induction therapy for acute lymphoblastic leukemia, plasma vWF was analyzed by sodium dodecyl sulfate-agarose gel electrophoresis and crossed immunoelectrophoresis. Prednisone 123-133 von Willebrand factor Homo sapiens 51-54 3827456-7 1987 Also, insulin requirement was significantly lower after deflazacort than after prednisone (29.3 +/- 11.6 vs 47.3 +/- 2.0 U/d). Prednisone 79-89 insulin Homo sapiens 6-13 3731065-1 1986 While studying the effects of chemotherapy on glucocorticoid receptor (GR) binding levels in hematological malignancies, we observed a sizable increase in nuclear GR binding of [3H]dexamethasone in peripheral leukocytes from a chronic basophilic leukemia patient following treatment with hydroxyurea plus prednisone, but not after prednisone alone. Prednisone 305-315 nuclear receptor subfamily 3 group C member 1 Homo sapiens 163-165 3556993-2 1987 In 6 of the 8 (75%) patients, an abrupt fall in serum alanine aminotransferase levels after the initiation of prednisone was noted, and in 4 patients, there was an increase in serum alanine aminotransferase values after prednisone was discontinued. Prednisone 110-120 glutamic--pyruvic transaminase Homo sapiens 54-78 2435050-0 1987 Prednisone-induced increases in serum alpha-2-globulin and haptoglobin concentrations in dogs. Prednisone 0-10 haptoglobin Canis lupus familiaris 59-70 2431991-0 1986 A pilot study on the effects of prednisone withdrawal on serum hepatitis B virus DNA and HBeAg in chronic active hepatitis B. Prednisone 32-42 capsid protein;pre-capsid protein Hepatitis B virus 89-94 3675562-1 1987 Changes in plasma cholinesterase (ChE) activity after administration of glucocorticoids (prednisone, methyl-prednisolone and dexamethasone) were studied in male and female rats. Prednisone 89-99 butyrylcholinesterase Rattus norvegicus 18-32 3675562-1 1987 Changes in plasma cholinesterase (ChE) activity after administration of glucocorticoids (prednisone, methyl-prednisolone and dexamethasone) were studied in male and female rats. Prednisone 89-99 butyrylcholinesterase Rattus norvegicus 34-37 3760404-7 1986 Prednisone caused a significant reduction in plasma levels of Charcot-Leyden crystal protein but not of eosinophil granule major basic protein. Prednisone 0-10 Charcot-Leyden crystal galectin Homo sapiens 62-92 3751969-2 1986 A 30-year-old woman with Stage IIIA diffuse non-Hodgkins lymphoma was treated with doxorubicin, cyclophosphamide, vincristine, and prednisone (CHOP) every 3 weeks. Prednisone 131-141 DNA damage inducible transcript 3 Homo sapiens 143-147 3731065-1 1986 While studying the effects of chemotherapy on glucocorticoid receptor (GR) binding levels in hematological malignancies, we observed a sizable increase in nuclear GR binding of [3H]dexamethasone in peripheral leukocytes from a chronic basophilic leukemia patient following treatment with hydroxyurea plus prednisone, but not after prednisone alone. Prednisone 331-341 nuclear receptor subfamily 3 group C member 1 Homo sapiens 163-165 3080220-2 1986 The authors report the case of a patient with malignant thymoma unresponsive to combination chemotherapy (cyclophosphamide, doxorubicin, vincristine, and prednisone [CHOP] and cisplatin/VP-16) who subsequently achieved clinical response to continuous daily prednisone. Prednisone 154-164 DNA damage inducible transcript 3 Homo sapiens 166-170 3723497-8 1986 High strength and low myoglobin were related to high prednisone dose. Prednisone 53-63 myoglobin Homo sapiens 22-31 3520795-3 1986 Prothrombin index and ascites showed significant interaction with the treatment in such a manner that high prothrombin index and absence of ascites were associated with a beneficial effect of prednisone, whereas low prothrombin index and presence of ascites were associated with a harmful effect of prednisone treatment. Prednisone 192-202 coagulation factor II, thrombin Homo sapiens 0-11 3520795-3 1986 Prothrombin index and ascites showed significant interaction with the treatment in such a manner that high prothrombin index and absence of ascites were associated with a beneficial effect of prednisone, whereas low prothrombin index and presence of ascites were associated with a harmful effect of prednisone treatment. Prednisone 192-202 coagulation factor II, thrombin Homo sapiens 107-118 3520795-3 1986 Prothrombin index and ascites showed significant interaction with the treatment in such a manner that high prothrombin index and absence of ascites were associated with a beneficial effect of prednisone, whereas low prothrombin index and presence of ascites were associated with a harmful effect of prednisone treatment. Prednisone 299-309 coagulation factor II, thrombin Homo sapiens 0-11 3907033-3 1985 Sixty-four CD recipients received cyclosporine (CsA) with prednisone. Prednisone 58-68 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 48-51 4031007-8 1985 Six hours after prednisone, somatomedin activity (rat cartilage bioassay) decreased by 46% (P less than 0.01), yet somatomedin-C did not change. Prednisone 16-26 insulin-like growth factor 1 Rattus norvegicus 28-39 4031007-11 1985 In contrast, somatomedin inhibitory activity at Kav 0.25-0.38 doubled (111 +/- 8% inhibition of somatomedin action vs. 54 +/- 11%; P less than 0.005) after prednisone therapy. Prednisone 156-166 insulin-like growth factor 1 Rattus norvegicus 13-24 6396563-2 1984 Chemotherapy with cyclophosphamide, vincristine and prednisone (COP) yielded partial response, but the addition of adriamycin (CHOP) a complete remission. Prednisone 52-62 caspase recruitment domain family member 16 Homo sapiens 64-67 3875694-0 1985 Altered von Willebrand factor molecule in children with thrombosis following asparaginase-prednisone-vincristine therapy for leukemia. Prednisone 90-100 von Willebrand factor Homo sapiens 8-29 3859585-0 1985 Etoposide (VP-16) with prednisone and vincristine for the treatment of refractory acute lymphoblastic leukemia. Prednisone 23-33 host cell factor C1 Homo sapiens 11-16 3859585-6 1985 That seven patients judged to be clinically resistant to VM-26 had complete responses to prednisone-vincristine-VP-16 indicates that prior treatment with one podophyllotoxin derivative does not preclude responses to the other. Prednisone 89-99 host cell factor C1 Homo sapiens 112-117 3984715-2 1985 The decrease or disappearance of IFN-alpha production was observed in some children with chronic or repeated respiratory diseases and in the majority of children who had been treated with prednisone. Prednisone 188-198 interferon alpha 1 Homo sapiens 33-42 2995446-4 1985 After withdrawal of terbutaline beta 2-adrenoceptor, density and responsiveness gradually increased, reaching predrug levels after 4 d. Prednisone (1 X 100 mg orally) accelerated beta 2-adrenoceptor recovery; only 8-10 h after administration of the steroid beta 2-adrenoceptor density and cAMP responses to (-)-isoprenaline had reached values not significantly different from pretreatment levels. Prednisone 136-146 potassium calcium-activated channel subfamily M regulatory beta subunit 2 Homo sapiens 32-38 2995446-4 1985 After withdrawal of terbutaline beta 2-adrenoceptor, density and responsiveness gradually increased, reaching predrug levels after 4 d. Prednisone (1 X 100 mg orally) accelerated beta 2-adrenoceptor recovery; only 8-10 h after administration of the steroid beta 2-adrenoceptor density and cAMP responses to (-)-isoprenaline had reached values not significantly different from pretreatment levels. Prednisone 136-146 adrenoceptor beta 2 Homo sapiens 179-198 4050327-6 1985 In patients receiving prednisone (Pd) the GR values were significantly lower than in MG patients without Pd therapy, independent of Pd dose or time of administration. Prednisone 22-32 nuclear receptor subfamily 3 group C member 1 Homo sapiens 42-44 3991222-4 1985 After treatment with Salazosulfapyridine, Prednisone and elemental diet during six week a significant drop in fecal lysozyme level was observed (p less than 0.01). Prednisone 42-52 lysozyme Homo sapiens 116-124 6090111-9 1984 In infants receiving prednisone and then prednisone plus ACTH, serum cortisol was suppressed to about one-quarter of baseline levels with the initiation of prednisone, and remained suppressed during ACTH administration. Prednisone 21-31 proopiomelanocortin Homo sapiens 199-203 6237151-17 1984 After steroid doses corresponding to 1 mg/kg of prednisolone, a transient inhibition of 80% of IL 2 production was observed with all three glucocorticoids given, whereas the maximal inhibition of the IL 2 production was 60, 30, and 22% after a low dose (0.1 mg/kg) of prednisolone phosphate, prednisone, or prednisolone phthalate, respectively. Prednisone 292-302 interleukin 2 Mus musculus 95-99 6090111-9 1984 In infants receiving prednisone and then prednisone plus ACTH, serum cortisol was suppressed to about one-quarter of baseline levels with the initiation of prednisone, and remained suppressed during ACTH administration. Prednisone 41-51 proopiomelanocortin Homo sapiens 199-203 6149280-0 1984 Representation and quantitation of the binding interaction between prednisone, prednisolone and corticosteroid binding globulin. Prednisone 67-77 corticosteroid-binding globulin Oryctolagus cuniculus 96-127 6500508-0 1984 Detection of anti-HBc IgM following prednisone treatment in patients with chronic active hepatitis B virus infection. Prednisone 36-46 keratin 88, pseudogene Homo sapiens 18-21 6500508-1 1984 The effect of a short course of prednisone therapy on serum IgM type antibody to the hepatitis B core antigen (anti-HBc IgM) was studied in 14 male patients with chronic active type B hepatitis. Prednisone 32-42 keratin 88, pseudogene Homo sapiens 116-119 6500508-2 1984 Eleven patients (78.5%) became positive for serum anti-HBc IgM either during or shortly after prednisone withdrawal. Prednisone 94-104 keratin 88, pseudogene Homo sapiens 55-58 6500508-4 1984 Six patients with histologic evidence of cirrhosis developed anti-HBc IgM which lasted six or more months after prednisone therapy and had a rapid onset of hepatic decompensation manifested by encephalopathy with ascites and/or variceal bleeding. Prednisone 112-122 keratin 88, pseudogene Homo sapiens 66-69 6149280-1 1984 The interaction between prednisone and prednisolone (0-500 ng ml-1) for binding sites on corticosteroid binding globulin (CBG) in rabbit plasma has been investigated. Prednisone 24-34 corticosteroid-binding globulin Oryctolagus cuniculus 89-120 6149280-1 1984 The interaction between prednisone and prednisolone (0-500 ng ml-1) for binding sites on corticosteroid binding globulin (CBG) in rabbit plasma has been investigated. Prednisone 24-34 corticosteroid-binding globulin Oryctolagus cuniculus 122-125 6385264-7 1984 Combinations of mitoxantrone with vincristine sulfate and prednisone resulted in complete remission in four of nine acute lymphoblastic leukemia patients and one of four patients with Tdt-positive chronic myeloid leukemia in blast crisis. Prednisone 58-68 DNA nucleotidylexotransferase Homo sapiens 184-187 6492791-4 1984 In competition under pharmacologic conditions, prednisolone inhibits prednisone binding to transcortin producing linear binding averaging 55%. Prednisone 69-79 serpin family A member 6 Homo sapiens 91-102 6694777-2 1984 In a multivariate life table analysis that controlled for all these factors simultaneously, the risk of developing terminal renal failure was significantly independently associated only with sex, serum albumin concentration, and prednisone treatment, being higher in men, lower in those treated with prednisone, and inversely related to serum albumin. Prednisone 300-310 albumin Homo sapiens 196-209 6327750-5 1984 A fourth such patient, however, treated with pharmacologic doses of prednisone, had a low normal ACTH response. Prednisone 68-78 proopiomelanocortin Homo sapiens 97-101 6690237-4 1984 Treatment of ABPA with prednisone led to resolution of an upper lobe infiltrate and a dramatic reduction in the total serum IgE level. Prednisone 23-33 immunoglobulin heavy constant epsilon Homo sapiens 124-127 6611602-5 1984 Corticosteroid treatment (40 mg prednisone daily) increased the inhibitory capacity of sputum alpha 1 antitrypsin in 10 patients (2p less than 0.05) from a median value of 0.13 micrograms PPE inhibited per microgram alpha 1AT (range 0.06-0.36) before treatment to 0.22 micrograms PPE inhibited per microgram alpha 1AT (range 0.09-0.65) after treatment. Prednisone 32-42 serpin family A member 1 Homo sapiens 94-113 6611602-5 1984 Corticosteroid treatment (40 mg prednisone daily) increased the inhibitory capacity of sputum alpha 1 antitrypsin in 10 patients (2p less than 0.05) from a median value of 0.13 micrograms PPE inhibited per microgram alpha 1AT (range 0.06-0.36) before treatment to 0.22 micrograms PPE inhibited per microgram alpha 1AT (range 0.09-0.65) after treatment. Prednisone 32-42 serpin family A member 1 Homo sapiens 216-225 6611602-5 1984 Corticosteroid treatment (40 mg prednisone daily) increased the inhibitory capacity of sputum alpha 1 antitrypsin in 10 patients (2p less than 0.05) from a median value of 0.13 micrograms PPE inhibited per microgram alpha 1AT (range 0.06-0.36) before treatment to 0.22 micrograms PPE inhibited per microgram alpha 1AT (range 0.09-0.65) after treatment. Prednisone 32-42 serpin family A member 1 Homo sapiens 308-317 6432287-2 1984 Significant elevations in blood immunoreactive parathyroid hormone, alkaline phosphatase and urinary calcium, phosphate, hydroxyproline and nephrogenous cyclic AMP were observed during prednisone therapy in addition to an increase in the exchangeable calcium pool as estimated by 47Ca-kinetic analyses. Prednisone 185-195 parathyroid hormone Homo sapiens 47-66 6432287-5 1984 The data are consistent with the fact that the skeletal effects of prednisone therapy are mediated, at least in part, by increased parathyroid hormone activity, and that deflazacort is less potent in this regard. Prednisone 67-77 parathyroid hormone Homo sapiens 131-150 6540703-2 1984 The influence of anti-inflammatory steroids (hydrocortisone, prednisone, dexamathasone) upon elastin content in liver was investigated in healthy and CCl4 intoxicated rats. Prednisone 61-71 elastin Rattus norvegicus 93-100 6735556-1 1984 A patient with pemphigus vulgaris had lesions on the lip that proved to be refractory to intralesional corticosteroid therapy and to treatment with azathioprine and later to daily administration of 250 mg of prednisone. Prednisone 208-218 SMG1 nonsense mediated mRNA decay associated PI3K related kinase Homo sapiens 53-56 6735556-4 1984 Eighteen months after the operation, the patient is receiving a single alternate-daily dose of 20 mg prednisone, and both the lip and oral lesions are in remission. Prednisone 101-111 SMG1 nonsense mediated mRNA decay associated PI3K related kinase Homo sapiens 126-129 6202383-0 1984 Prednisone treatment alters the serum amylase and lipase activities in normal dogs without causing pancreatitis. Prednisone 0-10 pancreatic lipase related protein 1 Canis lupus familiaris 50-56 6202383-3 1984 Treatment for two weeks with oral prednisone at 1.2 mg/kg body weight or at 4 mg/kg body weight daily decreased the serum amylase activities, but increased the serum lipase activities. Prednisone 34-44 pancreatic lipase related protein 1 Canis lupus familiaris 166-172 6354903-1 1983 In a controlled clinical trial in 488 patients with chronic liver disease treated with prednisone or placebo, survival data were analyzed using Cox"s proportional hazards model. Prednisone 87-97 cytochrome c oxidase subunit 8A Homo sapiens 144-147 6314462-0 1983 Use of a low dose synthetic ACTH challenge test in normal and prednisone-treated dogs. Prednisone 62-72 proopiomelanocortin Canis lupus familiaris 28-32 6355186-0 1983 An in vivo and in vitro study of the mechanism of prednisone-induced insulin resistance in healthy subjects. Prednisone 50-60 insulin Homo sapiens 69-76 6355186-1 1983 Prednisone-induced insulin resistance may depend on either reduced sensitivity (receptor defect) or reduced response to insulin (postreceptor defect). Prednisone 0-10 insulin Homo sapiens 19-26 6355186-1 1983 Prednisone-induced insulin resistance may depend on either reduced sensitivity (receptor defect) or reduced response to insulin (postreceptor defect). Prednisone 0-10 insulin Homo sapiens 120-127 6355186-2 1983 To clarify the mechanism of prednisone-induced insulin resistance, a [3H]glucose infusion (1 microCi/min) was performed for 120 min before and during a euglycemic clamp repeated at approximately 100, approximately 1,000, and approximately 10,000 microU/ml steady state plasma insulin concentration in 10 healthy, normal weight subjects, aged 35 +/- 7 yr. Each test was repeated after 7-d administration of placebo or prednisone (15 plus 15 mg/d per subject), in a randomized sequence with an interval of 1 mo between the two tests. Prednisone 28-38 insulin Homo sapiens 47-54 6355186-4 1983 The insulin sensitivity index (glucose metabolic clearance rate in ml/kg per min) was significantly lower (P less than 0.001) after prednisone at all three steady state plasma insulin levels: 2.8 +/- 0.3 vs. 7.4 +/- 1.1 at approximately 100 microU/ml; 6.0 +/- 0.5 vs. 12.2 +/- 1.1 at approximately 1,000 microU/ml; 7.4 +/- 0.6 vs. 14.4 +/- 0.5 at approximately 10,000 microU/ml. Prednisone 132-142 insulin Homo sapiens 176-183 6355186-6 1983 Suppression of glucose production at steady state plasma insulin level of approximately 100 microU/ml was less after prednisone (1.01 +/- 0.35 vs. 0.14 +/- 0.13, NS), and total at approximately 1,000 and approximately 10,000 microU/ml after both prednisone and placebo. Prednisone 117-127 insulin Homo sapiens 57-64 6355186-7 1983 The metabolic kinetic parameters of insulin after prednisone were not significantly different from those after placebo. Prednisone 50-60 insulin Homo sapiens 36-43 6355186-10 1983 These results suggest that (a) administration of an anti-inflammatory dose of prednisone for 7 d induces insulin resistance in man; (b) this is more dependent on depressed peripheral glucose utilization than on increased endogenous production; (c) total insulin binding on isolated adipocytes is not significantly affected; (d) insulin resistance is primarily the outcome of postreceptor defect (impaired glucose transport). Prednisone 78-88 insulin Homo sapiens 105-112 6355186-10 1983 These results suggest that (a) administration of an anti-inflammatory dose of prednisone for 7 d induces insulin resistance in man; (b) this is more dependent on depressed peripheral glucose utilization than on increased endogenous production; (c) total insulin binding on isolated adipocytes is not significantly affected; (d) insulin resistance is primarily the outcome of postreceptor defect (impaired glucose transport). Prednisone 78-88 insulin Homo sapiens 254-261 6355186-10 1983 These results suggest that (a) administration of an anti-inflammatory dose of prednisone for 7 d induces insulin resistance in man; (b) this is more dependent on depressed peripheral glucose utilization than on increased endogenous production; (c) total insulin binding on isolated adipocytes is not significantly affected; (d) insulin resistance is primarily the outcome of postreceptor defect (impaired glucose transport). Prednisone 78-88 insulin Homo sapiens 254-261 6314462-5 1983 Plasma cortisol levels were significantly reduced after ACTH injection in dogs previously given prednisone demonstrating that a single intramuscular prednisone dose causes detectable adrenocortical suppression one week after administration. Prednisone 96-106 proopiomelanocortin Canis lupus familiaris 56-60 6314462-5 1983 Plasma cortisol levels were significantly reduced after ACTH injection in dogs previously given prednisone demonstrating that a single intramuscular prednisone dose causes detectable adrenocortical suppression one week after administration. Prednisone 149-159 proopiomelanocortin Canis lupus familiaris 56-60 6347997-1 1983 The combination of cyclophosphamide, adriamycin, vincristine, and prednisone (CHOP) alternating with total body irradiation (TBI) has been shown earlier to be effective therapy in patients with malignant lymphoma who have received prior chemotherapy and/or radiation therapy. Prednisone 66-76 DNA damage inducible transcript 3 Homo sapiens 78-82 6191963-5 1983 In contrast, chronic prednisone therapy lead to a decrease in both basal and PTH-stimulated release of cAMP from bone (3.1 +/- 0.4 and 6.9 +/- 1.6 pmol/min for basal, and 13.1 +/- 1.7 and 26.8 +/- 3.0 pmol/min for stimulated values, respectively). Prednisone 21-31 parathyroid hormone Canis lupus familiaris 77-80 6191963-9 1983 Thus, these studies demonstrate that 1) acute administration of MP enhances the response of bone to PTH, an effect that is not apparent in the presence of the phosphodiesterase inhibitor IBMX; and 2) chronic prednisone therapy decreased basal and PTH-stimulated cAMP release, an effect that correlated with histological evidence of decreased bone turnover. Prednisone 208-218 parathyroid hormone Canis lupus familiaris 100-103 6191963-9 1983 Thus, these studies demonstrate that 1) acute administration of MP enhances the response of bone to PTH, an effect that is not apparent in the presence of the phosphodiesterase inhibitor IBMX; and 2) chronic prednisone therapy decreased basal and PTH-stimulated cAMP release, an effect that correlated with histological evidence of decreased bone turnover. Prednisone 208-218 parathyroid hormone Bos taurus 247-250 6347997-4 1983 CHOP was given in the following manner: cyclophosphamide 400 mg/M2 IV day 1, adriamycin 40 mg/M2 IV day 1, vincristine 2 mg IV day 1, and Prednisone 100 mg po daily X 5. Prednisone 138-148 DNA damage inducible transcript 3 Homo sapiens 0-4 6574797-6 1983 It is postulated that absence of TdT may predict poor therapeutic efficacy of vincristine and prednisone in acute lymphoblastic leukemia in childhood. Prednisone 94-104 DNA nucleotidylexotransferase Homo sapiens 33-36 6583321-1 1983 Two successive protocols (L-10 and L-10M) employing multidrug induction therapy with vincristine, prednisone, and doxorubicin (Adriamycin) plus an intensive consolidation phase and maintenance program have led to a significant improvement in the prognosis of adult acute lymphoblastic leukemia (ALL). Prednisone 98-108 immunoglobulin kappa variable 3-7 (non-functional) Homo sapiens 26-30 6749880-0 1982 Hypercortisolism and insulin resistance: comparative effects of prednisone, hydrocortisone, and dexamethasone on insulin binding of human erythrocytes. Prednisone 64-74 insulin Homo sapiens 113-120 6341389-1 1983 We measured [125I]insulin binding to circulating monocytes or erythrocytes from 16 patients with chronic glucocorticoid excess, 9 chronically treated with prednisone and 7 with adrenocortical hyperfunction. Prednisone 155-165 insulin Homo sapiens 18-25 6575218-5 1983 Thus the determination of GR and TdT might help selection of patients likely to respond to prednisone and vincristine in ALL and CML/BT. Prednisone 91-101 nuclear receptor subfamily 3 group C member 1 Homo sapiens 26-28 6575218-5 1983 Thus the determination of GR and TdT might help selection of patients likely to respond to prednisone and vincristine in ALL and CML/BT. Prednisone 91-101 DNA nucleotidylexotransferase Homo sapiens 33-36 6310274-7 1983 When measuring enzyme activities after 2-4 days of prednisone monotherapy, only mean ADA and HGPRT activities decreased in non-B, non-T ALL. Prednisone 51-61 adenosine deaminase Homo sapiens 85-88 6310274-7 1983 When measuring enzyme activities after 2-4 days of prednisone monotherapy, only mean ADA and HGPRT activities decreased in non-B, non-T ALL. Prednisone 51-61 hypoxanthine phosphoribosyltransferase 1 Homo sapiens 93-98 6749880-8 1982 Prednisone ingestion caused significant insulin resistance with an insignificant decrease in insulin binding. Prednisone 0-10 insulin Homo sapiens 40-47 6688200-0 1983 Cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) in patients with advanced Hodgkin"s disease: a Southwest Oncology Group Phase II Study. Prednisone 48-58 DNA damage inducible transcript 3 Homo sapiens 60-64 6187790-11 1983 Prednisone almost totally suppressed the LCRs induced by both KK and 48/80. Prednisone 0-10 kallikrein related peptidase 4 Homo sapiens 62-64 6336620-3 1983 Normal subjects were studied to determine the effects of diet and oral prednisone on urinary C-peptide excretion. Prednisone 71-81 insulin Homo sapiens 93-102 6336620-5 1983 When insulin production is increased after oral prednisone, there is also a positive correlation with body mass index and percent ideal body weight. Prednisone 49-59 insulin Homo sapiens 5-12 6336620-6 1983 Prednisone increases plasma glucose, immunoreactive insulin, and serum and urinary C-peptide levels beginning 8-12 h after oral administration. Prednisone 0-10 insulin Homo sapiens 52-59 6336620-6 1983 Prednisone increases plasma glucose, immunoreactive insulin, and serum and urinary C-peptide levels beginning 8-12 h after oral administration. Prednisone 0-10 insulin Homo sapiens 83-92 6749880-6 1982 We conclude that although hydrocortisone, dexamethasone, and prednisone all cause deterioration of glucose tolerance and decreased insulin sensitivity, only hydrocortisone and dexamethasone exhibit significant decreases in insulin binding to erythrocytes. Prednisone 61-71 insulin Homo sapiens 131-138 7044535-1 1982 A prospective randomized trial in patients with previously untreated multiple myeloma was performed comparing carmustine (BCNU), cyclophosphamide, and prednisone (BCP) to melphalan (Alkeran) and prednisone (AP). Prednisone 151-161 opsin 1, short wave sensitive Homo sapiens 163-166 6286371-0 1982 Response of the adrenal to adrenocorticotropic hormone (ACTH) in hyperandrogenic women treated chronically with low doses of prednisone. Prednisone 125-135 proopiomelanocortin Homo sapiens 27-54 6286371-0 1982 Response of the adrenal to adrenocorticotropic hormone (ACTH) in hyperandrogenic women treated chronically with low doses of prednisone. Prednisone 125-135 proopiomelanocortin Homo sapiens 56-60 6179448-1 1982 A new multiple-drug protocol consisting of cyclophosphamide, vincristine, prednisone, bleomycin, doxorubicin, and procarbazine, known as COP-BLAM, was administered to 48 patients with stage III or IV diffuse histiocytic lymphoma. Prednisone 74-84 caspase recruitment domain family member 16 Homo sapiens 137-140 6950800-5 1982 Combination chemotherapy with cyclophosphamide, Doxorubicin, vincristine, and prednisone (CHOP) has produced impressive clinical responses in patients with PL. Prednisone 78-88 DNA damage inducible transcript 3 Homo sapiens 90-94 7074523-2 1982 Patients were stratified and randomized to one of the four programs: (1) fluorouracil, cytoxan and prednisone (CFP): (2) fluorouracil, cytoxan and Adriamycin (CAF); (3) cytoxan and Adriamycin (CA); or (4) alternating combinations of CFP-CA. Prednisone 99-109 complement factor properdin Homo sapiens 111-114 6951099-2 1982 A raised level in terminal deoxynucleotidyl transferase (TdT) also seems to suggest clinical responsiveness to prednisone and vincristine therapy. Prednisone 111-121 DNA nucleotidylexotransferase Homo sapiens 18-55 7053252-0 1982 Combination chemotherapy with cyclophosphamide, vincristine, and prednisone (CVP) in TNM-classified stage IV mycosis fungoides. Prednisone 65-75 teneurin transmembrane protein 1 Homo sapiens 85-88 6951099-2 1982 A raised level in terminal deoxynucleotidyl transferase (TdT) also seems to suggest clinical responsiveness to prednisone and vincristine therapy. Prednisone 111-121 DNA nucleotidylexotransferase Homo sapiens 57-60 7337762-1 1981 The Authors have evaluated the serum cholinesterase activity in patients subjected to 2 different schemes of polychemotherapy: COP (CTX, VCR, Prednisone) and C-MOPP (CTX, VCR, PCZ, Prednisone). Prednisone 142-152 butyrylcholinesterase Homo sapiens 37-51 7337762-1 1981 The Authors have evaluated the serum cholinesterase activity in patients subjected to 2 different schemes of polychemotherapy: COP (CTX, VCR, Prednisone) and C-MOPP (CTX, VCR, PCZ, Prednisone). Prednisone 181-191 butyrylcholinesterase Homo sapiens 37-51 7028251-7 1981 These results suggest that blast cell TdT activity may identify leukemic patients who are likely to respond to vincristine and prednisone irrespective of their conventional classification. Prednisone 127-137 DNA nucleotidylexotransferase Homo sapiens 38-41 6946663-2 1981 High TdT activity was correlated with other features of blastic crisis of lymphoid character and with good response to vincristine and prednisone. Prednisone 135-145 DNA nucleotidylexotransferase Homo sapiens 5-8 6955937-4 1981 Therapy with vincristine and prednisone caused the elimination of the TdT-positive cell population. Prednisone 29-39 DNA nucleotidylexotransferase Homo sapiens 70-73 6793616-7 1981 Prednisone also decreased the TSH response to TRH but had no effect on serum thyroid hormone concentrations. Prednisone 0-10 thyrotropin releasing hormone Homo sapiens 46-49 7310640-4 1981 The mean oral dose plasma clearances of prednisone ranged from 572 ml/min/1.73 m 2 for the 5 mg dose to 2271 ml/min/1.73 m 2 for the 50 mg dose. Prednisone 40-50 CD59 molecule (CD59 blood group) Homo sapiens 70-75 6268392-8 1981 The competition of cortisol for the binding of thyroid hormones in cytosol protein fraction B in connection with some serum TBG changes in patients after prednisone administration is discussed. Prednisone 154-164 serpin family A member 7 Homo sapiens 124-127 7014590-5 1981 When prednisone (40 mg/day) was given to normal subjects for 3 days, a moderate state of insulin resistance was induced characterized by a modest increase in blood glucose and a more pronounced increase in plasma insulin concentration. Prednisone 5-15 insulin Homo sapiens 89-96 7014590-5 1981 When prednisone (40 mg/day) was given to normal subjects for 3 days, a moderate state of insulin resistance was induced characterized by a modest increase in blood glucose and a more pronounced increase in plasma insulin concentration. Prednisone 5-15 insulin Homo sapiens 213-220 7002662-0 1980 Decreased insulin binding of human erythrocytes after dexamethasone or prednisone ingestion. Prednisone 71-81 insulin Homo sapiens 10-17 7233568-0 1980 Combination chemotherapy with cyclophosphamide, adriamycin, vincristine and prednisone (CHOP) for non-Hodgkin"s lymphomas with unfavorable histology: preliminary results. Prednisone 76-86 DNA damage inducible transcript 3 Homo sapiens 88-92 7205057-1 1981 Prednisone and prednisolone bind in plasma to albumin and transcortin. Prednisone 0-10 serpin family A member 6 Homo sapiens 58-69 6938125-6 1981 TdT assay of enlarged lymph nodes in acute-phase chronic granulocytic leukemia might be used to identify the patients responsive to vincristine and prednisone despite the granulocytic histologic features of their lymph nodes. Prednisone 148-158 DNA nucleotidylexotransferase Homo sapiens 0-3 7049376-3 1981 Prolongation of remission duration was accomplished more effectively and at lower toxic cost by administration of asparaginase after the vincristine and prednisone treatment had been completed. Prednisone 153-163 asparaginase Homo sapiens 114-126 6947940-3 1981 High levels of TdT activity are associated with a clinical response to remission inducing therapy with vincristine and prednisone in a high proportion of patients (50%-90%), irrespective of clinical and morphologic diagnosis. Prednisone 119-129 DNA nucleotidylexotransferase Homo sapiens 15-18 7002662-1 1980 We have investigated changes in insulin binding in erythrocytes in response to overnight ingestion of 1 mg dexamethasone or 10 mg of prednisone in two groups of eight lean, healthy subjects. Prednisone 133-143 insulin Homo sapiens 32-39 6997328-1 1980 Results of a recent study suggested that depending upon the glucocorticoid or the model used, opposite changes occur in insulin binding; in fact, the increase in insulin receptor number on monocytes after prednisone ingestion in man appears to contrast with previous reports in animals in which a decrease was shown after dexamethasone. Prednisone 205-215 insulin Homo sapiens 120-127 6997328-1 1980 Results of a recent study suggested that depending upon the glucocorticoid or the model used, opposite changes occur in insulin binding; in fact, the increase in insulin receptor number on monocytes after prednisone ingestion in man appears to contrast with previous reports in animals in which a decrease was shown after dexamethasone. Prednisone 205-215 insulin receptor Homo sapiens 162-178 7397660-7 1980 The program that we have come to regard as our standard program in controlled clinical trials (CFP) employs cyclophosphamide, 5-fluorouracil, and prednisone. Prednisone 146-156 complement factor properdin Homo sapiens 95-98 7406249-2 1980 The group receiving prednisone demonstrated significant increases in the PEFR and decreased need for beta-2 agonist nebulization or injections the first 12 hours of the study period and these improvements were maintained over the 72 hours. Prednisone 20-30 potassium calcium-activated channel subfamily M regulatory beta subunit 2 Homo sapiens 101-107 6933170-5 1980 This unusual case of extensive leukemia cutis supports the evidence that patients in blast crisis with TdT positive cells are responsive to vincristine and prednisone. Prednisone 156-166 DNA nucleotidylexotransferase Homo sapiens 103-106 7002662-3 1980 Prednisone ingestion reduced insulin binding from 9.9 to 7.9% (P < 0.01), but the increase in basal insulin from 16.9 to 20.6 microU/ml was not significantly different. Prednisone 0-10 insulin Homo sapiens 29-36 7002662-4 1980 The decrease in insulin binding with both dexamethasone and prednisone was associated with decreased affinity of erythrocyte for insulin at low occupancy and the increase in the dose of unlabeled insulin resulted in 50% inhibition of specific binding without changes in the number of receptors. Prednisone 60-70 insulin Homo sapiens 16-23 7002662-4 1980 The decrease in insulin binding with both dexamethasone and prednisone was associated with decreased affinity of erythrocyte for insulin at low occupancy and the increase in the dose of unlabeled insulin resulted in 50% inhibition of specific binding without changes in the number of receptors. Prednisone 60-70 insulin Homo sapiens 129-136 7002662-4 1980 The decrease in insulin binding with both dexamethasone and prednisone was associated with decreased affinity of erythrocyte for insulin at low occupancy and the increase in the dose of unlabeled insulin resulted in 50% inhibition of specific binding without changes in the number of receptors. Prednisone 60-70 insulin Homo sapiens 129-136 7002662-6 1980 These data suggest that acute alteration of insulin receptor function could occur in erythrocytes by small amounts of dexamethasone or prednisone through a mechanism consistent with a decrease in receptor affinity rather than a decrease in the number of receptors. Prednisone 135-145 insulin receptor Homo sapiens 44-60 7000347-0 1980 Advanced diffuse histiocytic lymphoma treated with cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) without maintenance therapy. Prednisone 99-109 DNA damage inducible transcript 3 Homo sapiens 111-115 7416812-3 1980 SAA levels correlate with disease activity, increasing during acute exacerbations, decreasing during remission and in patients having prednisone therapy. Prednisone 134-144 serum amyloid A1 cluster Homo sapiens 0-3 222143-4 1979 Five days after concluding the prednisone therapy, peak cortisol response to hypoglycemia had returned to near pretreatment levels although peak cortisol response in the adrenal gland to synthetic ACTH (22.3 +/- 1.1 microgram/dl) remained reduced (p less than 0.05). Prednisone 31-41 proopiomelanocortin Homo sapiens 197-201 464387-3 1979 The exacerbations were closely correlated with sharp increases in total serum IgE, which subsequently decreased after resumption of prednisone therapy. Prednisone 132-142 immunoglobulin heavy constant epsilon Homo sapiens 78-81 435002-5 1979 Prednisone cured the diarrhea and was associated with a decrease in plasma VIP levels. Prednisone 0-10 vasoactive intestinal peptide Homo sapiens 75-78 373474-2 1979 In those patients receiving 100 mg or more of prednisone per day and 5 per cent dextrose solution, the hourly infusion rate was determined from tthe following equation: insulin (U) = plasma glucose value divided by 100. Prednisone 46-56 insulin Homo sapiens 169-176 6940442-0 1980 Terminal deoxynucleotidyl transferase in the blastic phase of chronic myelogenous leukemia: an indicator of response to vincristine and prednisone therapy. Prednisone 136-146 DNA nucleotidylexotransferase Homo sapiens 0-37 6940442-2 1980 The TdT levels were correlated with the response to vincristine and prednisone therapy. Prednisone 68-78 DNA nucleotidylexotransferase Homo sapiens 4-7 6940442-5 1980 This study confirms that TdT levels in the majority of patients predict effectiveness of vincristine and prednisone therapy in blastic phase of CML. Prednisone 105-115 DNA nucleotidylexotransferase Homo sapiens 25-28 291471-2 1979 TdT was elevated at the time of diagnosis of blastic transformation, and the patient easily obtained remission after therapy with hydroxyurea, 6-mercaptopurine and prednisone. Prednisone 164-174 DNA nucleotidylexotransferase Homo sapiens 0-3 496450-4 1979 The relationship between CRP and ESR was, however, altered by treatment with gold, penicillamine, or high doses of prednisone. Prednisone 115-125 C-reactive protein Homo sapiens 25-28 38827-1 1979 The activities of orotate phosphoribosyl transferase (OPRT) and orotidine monophosphate decarboxylase (ODC) were significantly elevated (P less than 0.001) in erythrocytes (RBC) from five patients with prednisone-responsive congenital hypoplastic anaemia (CHA). Prednisone 202-212 uridine monophosphate synthetase Homo sapiens 18-52 38827-1 1979 The activities of orotate phosphoribosyl transferase (OPRT) and orotidine monophosphate decarboxylase (ODC) were significantly elevated (P less than 0.001) in erythrocytes (RBC) from five patients with prednisone-responsive congenital hypoplastic anaemia (CHA). Prednisone 202-212 uridine monophosphate synthetase Homo sapiens 54-58 38827-1 1979 The activities of orotate phosphoribosyl transferase (OPRT) and orotidine monophosphate decarboxylase (ODC) were significantly elevated (P less than 0.001) in erythrocytes (RBC) from five patients with prednisone-responsive congenital hypoplastic anaemia (CHA). Prednisone 202-212 ornithine decarboxylase 1 Homo sapiens 64-101 38827-1 1979 The activities of orotate phosphoribosyl transferase (OPRT) and orotidine monophosphate decarboxylase (ODC) were significantly elevated (P less than 0.001) in erythrocytes (RBC) from five patients with prednisone-responsive congenital hypoplastic anaemia (CHA). Prednisone 202-212 ornithine decarboxylase 1 Homo sapiens 103-106 38827-5 1979 In one patient prior to prednisone therapy, the OPRT and ODT activities were elevated 10-fold and remained elevated 3-fold after 16 months of therapy. Prednisone 24-34 uridine monophosphate synthetase Homo sapiens 48-52 109055-0 1979 Effects of gold, dapsone, and prednisone on serum C-reactive protein and haptoglobin and the erythrocyte sedimentation rate in rheumatoid arthritis. Prednisone 30-40 C-reactive protein Homo sapiens 50-68 109055-0 1979 Effects of gold, dapsone, and prednisone on serum C-reactive protein and haptoglobin and the erythrocyte sedimentation rate in rheumatoid arthritis. Prednisone 30-40 haptoglobin Homo sapiens 73-84 109055-5 1979 During treatment with prednisone serum CRP and ESR fell abruptly by 28 days and thereafter altered little. Prednisone 22-32 C-reactive protein Homo sapiens 39-42 295575-2 1979 During therapy with L-asparaginase, prednisone and vincristine, hypocomplementemia developed in all patients, and disappeared within 2 weeks after the discontinuation of L-asparaginase. Prednisone 36-46 asparaginase and isoaspartyl peptidase 1 Homo sapiens 170-184 423017-8 1979 After prednisone was started the total serum IgE sharply declined to a plateau and remained at this level until a flare of allergic aspergillosis occurred. Prednisone 6-16 immunoglobulin heavy constant epsilon Homo sapiens 45-48 308800-5 1978 Plasma and urinary aldosterone levels were still suppressed after 12 months treatment with prednisone despite normalization of the previously suppressed renin levels. Prednisone 91-101 renin Homo sapiens 153-158 507741-1 1979 A case of localized lymphomatous polyposis of the rectum successfully treated with a combination of cyclophosphamide, vincristine and prednisone (COP regimen) is reported and the literature is briefly reviewed. Prednisone 134-144 caspase recruitment domain family member 16 Homo sapiens 146-149 287856-0 1979 L-asparaginase used with cytosine arabinoside in treatment of childhood acute lymphocytic leukemia refractory to vincristine and prednisone. Prednisone 129-139 asparaginase and isoaspartyl peptidase 1 Homo sapiens 0-14 670610-0 1978 Relationships between prednisone therapy, disease activity, and the total serum IgE level in allergic bronchopulmonary aspergillosis. Prednisone 22-32 immunoglobulin heavy constant epsilon Homo sapiens 80-83 205179-5 1978 Elevated levels of VIP returned to normal after prednisone therapy was started. Prednisone 48-58 vasoactive intestinal peptide Homo sapiens 19-22 273142-0 1978 Terminal transferase as a predictor of initial responsiveness to vincristine and prednisone in blastic chronic myelogenous leukemia: a co-operative study. Prednisone 81-91 DNA nucleotidylexotransferase Homo sapiens 0-20 194311-1 1977 Dexamethasone and prednisone in physiologic range increased angiotensin converting enzyme 7- to 16-fold in comparison to control in 3 days at maximal stimulation (4 nM steroid) in rabbit alveolar macrophages in culture. Prednisone 18-28 angiotensin-converting enzyme Oryctolagus cuniculus 60-89 114570-2 1978 Orally administered prednisone, in a dose of 20 mg each day for nine days, resulted in a significant decrease in mean serum TSH levels (p less than 0.01) without significant changes in levels of serum T4, T3, and thyroxine binding globulin (TBG). Prednisone 20-30 serpin family A member 7 Homo sapiens 241-244 310882-2 1978 Free RNP tended to appear when anti-RNP antibody titers fell or when prednisone was initiated or increased. Prednisone 69-79 RNA binding region (RNP1, RRM) containing 3 Homo sapiens 5-8 325982-14 1977 5) Corticosteroid (Prednisone, Decortin) after orchidectomy decreased T and SHBG below the levels found after orchidectomy alone. Prednisone 19-29 sex hormone binding globulin Homo sapiens 76-80 325982-14 1977 5) Corticosteroid (Prednisone, Decortin) after orchidectomy decreased T and SHBG below the levels found after orchidectomy alone. Prednisone 31-39 sex hormone binding globulin Homo sapiens 76-80 645726-5 1978 (2) Treatment with alternate day prednisone (0.5 mg/kg given on alternate days) caused clinical and roentgenologic improvement as well as marked decreases in total serum IgE but does not necessarily prevent recurrence of the disease. Prednisone 33-43 immunoglobulin heavy constant epsilon Homo sapiens 170-173 925820-2 1977 Initially elevated total serum IgE levels fell during prednisone therapy and rose prior to and during an exacerbation. Prednisone 54-64 immunoglobulin heavy constant epsilon Homo sapiens 31-34 898234-4 1977 It was shown that the CPB method has considerably greater precision than the RIA method and could be employed in bioavailability and pharmacokinetic studies of both prednisolone and prednisone. Prednisone 182-192 carboxypeptidase B1 Homo sapiens 22-25 148961-2 1977 In order to elucidate the mechanism of fibrinogen kinetic abnormalities different drugs, including heparin, prednisone, ticlopidin, aspirin and indomethacin were administered in 68 patients and their effects evaluated by change in the 311I fibrinogen disappearance rate. Prednisone 108-118 fibrinogen beta chain Homo sapiens 39-49 781416-9 1976 A cytotoxic immunoglobulin inhibitor of the marrow erythroid cells or erythropoietin has been described and these patients may respond to prednisone and/or to cytotoxic immunosuppressive drugs such as cyclophosphamide and 6-mercaptopurine. Prednisone 138-148 erythropoietin Homo sapiens 70-84 4135071-4 1974 Intermittent therapy with prednisone and cyclophosphamide together with antibiotics was followed by clinical recovery, return of histological appearances of the small intestine to normal, and disappearance of free alpha-chain protein from the serum. Prednisone 26-36 Fc gamma receptor and transporter Homo sapiens 214-225 1259925-2 1976 Two patients with pure red cell aplasia, whose marrow cells were capable of increasing their rate of haem synthesis when incubated in vitro with erythropoietin concentrate, had a complete remission associated with the administration of cyclophosphamide and prednisone. Prednisone 257-267 erythropoietin Homo sapiens 145-159 1122635-0 1975 The behaviour of LDH-3 in patients with malignant diseases during therapy with cytostatic drugs and prednisone, studied by LDH-isoenzyme electrophoresis on cellulose acetate. Prednisone 100-110 lactate dehydrogenase C Homo sapiens 17-22 1232529-3 1975 The group of patients receiving melphalan and prednisone 0.6 mg/kg had significantly improved responses in hemoglobin, lowering of the M-protein concentration, and reduction of azotemia. Prednisone 46-56 myomesin 2 Homo sapiens 135-144 1263838-0 1976 Free and total insulin levels in a patient with insulin-resistant diabetes mellitus and chronic lymphatic leukemia: effect of prednisone therapy. Prednisone 126-136 insulin Homo sapiens 15-22 1263838-2 1976 In response to prednisone therapy, his insulin requirement decreased, but the total and free insulin concentrations increased as insulin antibody measured as the maximal insulin-binding capacity of plasma remained unchanged. Prednisone 15-25 insulin Homo sapiens 39-46 1263838-2 1976 In response to prednisone therapy, his insulin requirement decreased, but the total and free insulin concentrations increased as insulin antibody measured as the maximal insulin-binding capacity of plasma remained unchanged. Prednisone 15-25 insulin Homo sapiens 93-100 1263838-2 1976 In response to prednisone therapy, his insulin requirement decreased, but the total and free insulin concentrations increased as insulin antibody measured as the maximal insulin-binding capacity of plasma remained unchanged. Prednisone 15-25 insulin Homo sapiens 93-100 1263838-2 1976 In response to prednisone therapy, his insulin requirement decreased, but the total and free insulin concentrations increased as insulin antibody measured as the maximal insulin-binding capacity of plasma remained unchanged. Prednisone 15-25 insulin Homo sapiens 93-100 1263838-4 1976 The beneficial effect of prednisone treatment in this patient is discussed, and it is postulated to be the result of either increased availability of free insulin or an increased responsiveness of the tissues to insulin or both. Prednisone 25-35 insulin Homo sapiens 155-162 1263838-4 1976 The beneficial effect of prednisone treatment in this patient is discussed, and it is postulated to be the result of either increased availability of free insulin or an increased responsiveness of the tissues to insulin or both. Prednisone 25-35 insulin Homo sapiens 212-219 183594-2 1976 Resolution of the sarcoidosis disease state or therapeutic control with adequate doses of corticosteroids (15 mg prednisone daily) brought the elevated serum ACE levels down into the normal range. Prednisone 113-123 angiotensin I converting enzyme Homo sapiens 158-161 1026858-2 1976 There was clinical response to COP therapy (cytoxin, oncovin, prednisone). Prednisone 62-72 caspase recruitment domain family member 16 Homo sapiens 31-34 1103758-3 1975 The dosage of prednisone during the first posttransplant year corrected for patient weight showed a significant correlation with the development of PSC during the first posttransplant year. Prednisone 14-24 PSC Homo sapiens 148-151 1103758-4 1975 The severity of the PSC were correlated with time of onset and prednisone dosage. Prednisone 63-73 PSC Homo sapiens 20-23 1159064-10 1975 Thus, prednisone apparently has an early inhibitory effect on the insulin response to glucose. Prednisone 6-16 insulin Homo sapiens 66-73 1131420-1 1975 A patient, CAL, with gamma heavy chain disease is presented who has had a complete remission lasting over 2 yr with combination chemotherapy consisting of pulsatile cyclophosphamide and prednisone. Prednisone 186-196 filamin binding LIM protein 1 Homo sapiens 11-14 4371409-0 1974 Response to LH-RH in women before and after treatment with prednisone. Prednisone 59-69 gonadotropin releasing hormone 1 Homo sapiens 12-17 5078362-0 1972 [Effect of prednisone on variations in the immunoreactive insulin blood level after intravenous injection of glucose in children]. Prednisone 11-21 insulin Homo sapiens 58-65 4186346-0 1969 The effect of alternating prednisone therapy on insulin binding. Prednisone 26-36 insulin Homo sapiens 48-55 4640052-0 1972 Albumin and immunoglobulin turnover in patients with chronic active liver disease treated with prednisone. Prednisone 95-105 albumin Homo sapiens 0-7 5358372-0 1969 [Fibrinolytic activity and fibrinogen level in children with rheumatic fever treated or not treated with prednisone]. Prednisone 105-115 fibrinogen beta chain Homo sapiens 27-37 5284140-1 1971 A supplement to the CSL prednisone trial in cirrhosis. Prednisone 24-34 chorionic somatomammotropin hormone like 1 Homo sapiens 20-23 13842204-0 1960 [Variations of adrenal reactivity to ACTH after arrest of a prolonged treatment by cortisone derivatives (deltacortisone) associated or not with depot ACTH or with testosterone]. Prednisone 106-120 proopiomelanocortin Homo sapiens 37-41 13800053-0 1960 Study of the adrenal response to ACTH after prolonged treatment with prednisone alone or in combination with ACTH or testosterone. Prednisone 69-79 proopiomelanocortin Homo sapiens 33-37 14429291-0 1960 Effect of prednisone on B12 absorption in pernicious anaemia. Prednisone 10-20 NADH:ubiquinone oxidoreductase subunit B3 Homo sapiens 24-27 14429292-0 1959 [Effects of prednisone on B12 absorption in pernicious anemia]. Prednisone 12-22 NADH:ubiquinone oxidoreductase subunit B3 Homo sapiens 26-29 13656630-0 1959 [Observations & remarks on hormone treatment with prednisone & ACTH in cases of pemphigus]. Prednisone 54-64 proopiomelanocortin Homo sapiens 71-75 13639264-0 1959 Serum enzymes (transaminases, phosphoglucomutase, fumarase) in viral hepatitis during prednisone. Prednisone 86-96 fumarate hydratase Homo sapiens 50-58 13579959-0 1958 [Changes of blood transaminase in viral hepatitis in patients with pulmonary tuberculosis treated with prednisone & ACTH]. Prednisone 103-113 proopiomelanocortin Homo sapiens 120-124 13541154-0 1958 [Protein & lipoprotein electrophoretic picture of the serum in nephrotic syndrome of childhood, with special reference to changes observed in the course of treatment with ACTH & prednisone]. Prednisone 186-196 proopiomelanocortin Homo sapiens 175-179 13528599-0 1958 [Reaction of fractionated bilirubin in blood & of alkaline phosphatase in acute hepatitis treated with prednisone & ACTH]. Prednisone 107-117 proopiomelanocortin Homo sapiens 124-128 13532197-0 1958 [Prednisone-ACTH retard therapy in the prevention of adrenal atrophy during prednisone therapy]. Prednisone 1-11 proopiomelanocortin Homo sapiens 12-16 13532197-0 1958 [Prednisone-ACTH retard therapy in the prevention of adrenal atrophy during prednisone therapy]. Prednisone 76-86 proopiomelanocortin Homo sapiens 12-16 13446442-0 1957 A COMPARISON of cortisone and prednisone in treatment of rheumatoid arthritis; a report by the Joint Committee of the Medical Research Council and Nuffield Foundation on Clinical Trials of Cortisone, ACTH and other therapeutic measures in chronic rheumatic diseases. Prednisone 30-40 proopiomelanocortin Homo sapiens 200-204 4301373-0 1968 ACTH drip in prednisone resistant pemphigus. Prednisone 13-23 proopiomelanocortin Homo sapiens 0-4 14432517-0 1960 [The effect of prednisone on the 17-hydroxycorticosteroids in the plasma after ACTH- and pyrexal administration]. Prednisone 15-25 proopiomelanocortin Homo sapiens 79-83 13473128-0 1957 [Clinical observations on burns in children with special reference to ACTH & prednisone]. Prednisone 81-91 proopiomelanocortin Homo sapiens 70-74 13412911-0 1956 [Variations of tryptophan-peroxidase-oxidase (TPO) in liver homogenates of adrenalectomized rats treated with cortisone, prednisone and DOCA]. Prednisone 121-131 thyroid peroxidase Rattus norvegicus 15-44 13384665-0 1956 [Considerations on the association of prednisone with ACTH in the treatment of rheumatoid arthritis]. Prednisone 38-48 proopiomelanocortin Homo sapiens 54-58 13453822-0 1957 [Changes in bone tissue during prolonged treatment with prednisone & ACTH; anatomo-clinical and experimental observations]. Prednisone 56-66 proopiomelanocortin Homo sapiens 73-77 13412911-0 1956 [Variations of tryptophan-peroxidase-oxidase (TPO) in liver homogenates of adrenalectomized rats treated with cortisone, prednisone and DOCA]. Prednisone 121-131 thyroid peroxidase Rattus norvegicus 46-49 13323365-0 1956 [Research on the behavior of the C-reactive protein in blood of patients with rheumatoid arthritis treated with prednisone]. Prednisone 112-122 C-reactive protein Homo sapiens 33-51 33295631-10 2021 Whereas patients taking prednisone showed higher serum levels of PCSK9 [55 ng/ml (95% CI 24, 8), P = 0.001], those under anti-TNF-alpha therapies exhibited lower levels [beta coefficient -26 ng/ml (95% CI -43, -9], P = 0.003]. Prednisone 24-34 proprotein convertase subtilisin/kexin type 9 Homo sapiens 65-70 13242644-0 1955 The comparative effects of metacortandracin, 9-alpha-fluorohydrocortisone and hydrocortisone upon ACTH secretion in man. Prednisone 27-43 proopiomelanocortin Homo sapiens 98-102 34046945-7 2021 After mTOR initiation, 50% of patients were reduced or weaned off tacrolimus and 13.7% off prednisone. Prednisone 91-101 mechanistic target of rapamycin kinase Homo sapiens 6-10 34031890-6 2021 Compared to placebo, use of prednisone was associated with reductions in levels of CRP on days 3, 5, and 7, (mean difference of 46%, p < 0.001 for each time point). Prednisone 28-38 C-reactive protein Homo sapiens 83-86 34022150-2 2021 We aimed to establish the safety and efficacy of rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in patients with DLBCL in Malawi. Prednisone 112-122 DNA damage inducible transcript 3 Homo sapiens 126-130 34021410-10 2022 Most anti-HMGCR-positive patients achieved favorable outcomes following prednisone and additional immunotherapies. Prednisone 72-82 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 10-15 34055544-10 2021 Steroid-sparing anti-interleukin-5 (IL-5) agents and dupilumab should be considered as alternative treatment options for patients, such as ours, with eosinophilic, prednisone-dependent asthma refractory to omalizumab therapy. Prednisone 164-174 interleukin 5 Homo sapiens 36-40 33600264-8 2021 Meanwhile, higher baseline lnc-MEG3 expression was correlated with good prednisone response at day 8 (p = .001) and good bone marrow response at day 15 (p = .046) in cALL patients. Prednisone 72-82 maternally expressed 3 Homo sapiens 31-35 33989279-2 2021 However, the addition of lenalidomide to rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in randomized clinical trials has shown equivocal benefit, despite phase 2 studies that suggested otherwise. Prednisone 104-114 DNA damage inducible transcript 3 Homo sapiens 118-122 33880064-2 2021 In this study, we aimed to evaluate the efficacy of polyethylene glycol recombinant granulocyte colony-stimulating factor (PEG-rhG-CSF) compared with short-acting rhG-CSF in the dose-adjusted etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin (DA-EPOCH) regimen. Prednisone 203-213 colony stimulating factor 3 Homo sapiens 84-121 33864237-4 2021 THP-COP (pirarubicin, cyclophosphamide, vincristine, and prednisone) is sometimes used for elderly patients with non-Hodgkin"s lymphoma in Japan. Prednisone 57-67 caspase recruitment domain family member 16 Homo sapiens 4-7 33987044-11 2021 He was started on azathioprine and prednisone and showed a positive response, indicated by a decreasing erythrocyte sedimentation rate and C-reactive protein. Prednisone 35-45 C-reactive protein Homo sapiens 139-157 33837952-0 2021 Prednisone-induced sustained remission in a patient with familial fibronectin glomerulopathy (GFND). Prednisone 0-10 fibronectin 1 Homo sapiens 66-77 33837952-0 2021 Prednisone-induced sustained remission in a patient with familial fibronectin glomerulopathy (GFND). Prednisone 0-10 fibronectin 1 Homo sapiens 94-98 33837952-3 2021 We present a case of GFND associated with progressive chronic kidney disease (CKD) and nephrotic range proteinuria showing a sustained response to prednisone treatment. Prednisone 147-157 fibronectin 1 Homo sapiens 21-25 33845430-9 2021 The data presented in this study indicates that corticosteroids, like prednisone can have potentially better selectively (Kd ~ 0.38 muM) toward C5a than C3a, suggesting the positive modulatory role of C5a in the general success of the corticosteroid therapy in moderate to severe COVID19. Prednisone 70-80 complement C5a receptor 1 Homo sapiens 144-147 33845430-9 2021 The data presented in this study indicates that corticosteroids, like prednisone can have potentially better selectively (Kd ~ 0.38 muM) toward C5a than C3a, suggesting the positive modulatory role of C5a in the general success of the corticosteroid therapy in moderate to severe COVID19. Prednisone 70-80 complement C3 Homo sapiens 153-156 33845430-9 2021 The data presented in this study indicates that corticosteroids, like prednisone can have potentially better selectively (Kd ~ 0.38 muM) toward C5a than C3a, suggesting the positive modulatory role of C5a in the general success of the corticosteroid therapy in moderate to severe COVID19. Prednisone 70-80 complement C5a receptor 1 Homo sapiens 201-204 33647818-12 2021 CONCLUSION: The combination of FLAG, idarubicin, vincristine, and prednisone (FLAG-VIPR) demonstrated favorable induction responses in a disease state with historically poor outcomes and should be studied in a prospective clinical trial. Prednisone 66-76 vasoactive intestinal peptide receptor 1 Homo sapiens 83-87 33469936-9 2021 DHA alone or in combination with prednisone also reduced the transcription of RORgammat and increased Foxp3 in lymphocytes, as well as IL-17 and TGF-beta levels. Prednisone 33-43 forkhead box P3 Mus musculus 102-107 33469936-9 2021 DHA alone or in combination with prednisone also reduced the transcription of RORgammat and increased Foxp3 in lymphocytes, as well as IL-17 and TGF-beta levels. Prednisone 33-43 interleukin 17A Mus musculus 135-140 33571020-1 2021 OBJECTIVES: To quantify the association between dose reductions of abiraterone acetate plus prednisone (AAP) or enzalutamide and prostate-specific antigen (PSA) progression in patients with metastatic castration-resistant prostate cancer (mCRPC). Prednisone 92-102 kallikrein related peptidase 3 Homo sapiens 129-154 34007370-9 2021 Finally a leukemic DLBCL was diagnosed and immediately treatment with rituximab cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP) was started. Prednisone 127-137 DNA damage inducible transcript 3 Homo sapiens 141-145 33734921-1 2021 BACKGROUND: Treatment with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) is standard of care first line treatment for diffuse large B-cell lymphoma (DLBCL), though outcomes remain suboptimal. Prednisone 86-96 DNA damage inducible transcript 3 Homo sapiens 100-104 33688781-1 2021 Peripheral T-cell lymphoma (PTCL) is a group of aggressive lymphomas commonly treated with cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP). Prednisone 139-149 DNA damage inducible transcript 3 Homo sapiens 151-155 33650292-0 2021 Liquid biopsy reveals KLK3 mRNA as a prognostic marker for progression free survival in patients with metastatic castration-resistant prostate cancer undergoing first-line abiraterone acetate and prednisone treatment. Prednisone 196-206 kallikrein related peptidase 3 Homo sapiens 22-26 33625586-1 2021 BACKGROUND: A combination of rituximab with cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) is the standard first-line therapy for diffuse large B cell lymphoma (DLBCL), the most common aggressive lymphoma in adults. Prednisone 92-102 DNA damage inducible transcript 3 Homo sapiens 106-110 33678483-4 2021 We present a case report of a 39-year-old male, with a medical history of rheumatoid arthritis (RA) for which he uses adalimumab and low-dose prednisone, with idiopathic acute CS of thenar and hypothenar compartments. Prednisone 142-152 citrate synthase Homo sapiens 176-178 33592897-8 2021 INTERVENTIONS: The patient was first treated with the cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) regimen. Prednisone 102-112 DNA damage inducible transcript 3 Homo sapiens 114-118 33728177-5 2021 Rituximab, cyclophosphamide, doxorubicin hydrochloride, vincristine sulfate, and prednisone (R-CHOP) with dexamethasone treatment resulted in significant radiographic regression of his intracranial lesions with dramatic symptomatic improvement. Prednisone 81-91 DNA damage inducible transcript 3 Homo sapiens 95-99 33572634-1 2021 BACKGROUND: The t (2; 5) chromosomal rearrangement of the ALK gene with nucleophosmin 1 gene (NPM1), resulting in an NPM1-ALK fusion, was first demonstrated in 1994 in anaplastic large cell lymphoma, (ALCL), a T-cell lymphoma responsive to cyclophosphamide, abriblastine, vincristine and prednisone in approximately 80% of cases; refractory cases usually respond favorably to brentuximab vedotin. Prednisone 288-298 ALK receptor tyrosine kinase Homo sapiens 58-61 33572634-1 2021 BACKGROUND: The t (2; 5) chromosomal rearrangement of the ALK gene with nucleophosmin 1 gene (NPM1), resulting in an NPM1-ALK fusion, was first demonstrated in 1994 in anaplastic large cell lymphoma, (ALCL), a T-cell lymphoma responsive to cyclophosphamide, abriblastine, vincristine and prednisone in approximately 80% of cases; refractory cases usually respond favorably to brentuximab vedotin. Prednisone 288-298 nucleophosmin 1 Homo sapiens 94-98 33572634-1 2021 BACKGROUND: The t (2; 5) chromosomal rearrangement of the ALK gene with nucleophosmin 1 gene (NPM1), resulting in an NPM1-ALK fusion, was first demonstrated in 1994 in anaplastic large cell lymphoma, (ALCL), a T-cell lymphoma responsive to cyclophosphamide, abriblastine, vincristine and prednisone in approximately 80% of cases; refractory cases usually respond favorably to brentuximab vedotin. Prednisone 288-298 nucleophosmin 1 Homo sapiens 117-121 33572634-1 2021 BACKGROUND: The t (2; 5) chromosomal rearrangement of the ALK gene with nucleophosmin 1 gene (NPM1), resulting in an NPM1-ALK fusion, was first demonstrated in 1994 in anaplastic large cell lymphoma, (ALCL), a T-cell lymphoma responsive to cyclophosphamide, abriblastine, vincristine and prednisone in approximately 80% of cases; refractory cases usually respond favorably to brentuximab vedotin. Prednisone 288-298 ALK receptor tyrosine kinase Homo sapiens 122-125 33274857-10 2021 CONCLUSION: Rituximab +- MMF did not significantly change pulmonary function compared with MMF alone, but it did result in a relative decrease in average daily prednisone dose in a population with recalcitrant CTD-ILD. Prednisone 160-170 CTD Homo sapiens 210-213 33426985-3 2022 Immunosuppressive therapy with prednisone was initially started to eradicate anti-FVIII antibodies, subsequently boosted with cyclophosphamide and rituximab, these medications being also chosen to treat the associated indolent lymphoma. Prednisone 31-41 coagulation factor VIII Homo sapiens 82-87 33404658-8 2021 MMP-12 serum levels were significantly lower in patients with JA (0.18 ng/ml, p< 0.05) and inversely associated with the prednisone daily dose (B-coeff -0.03; r= -0.44; p< 0.01). Prednisone 121-131 matrix metallopeptidase 12 Homo sapiens 0-6 33796235-0 2021 Rituximab in combination with cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in diffuse large B-cell lymphoma. Prednisone 78-88 DNA damage inducible transcript 3 Homo sapiens 92-96